---
document_datetime: 2023-09-21 17:24:27
document_pages: 157
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/roactemra-h-c-955-x-0030-epar-assessment-report-variation_en.pdf
document_name: roactemra-h-c-955-x-0030-epar-assessment-report-variation_en.pdf
version: success
processing_time: 209.3961268
conversion_datetime: 2025-12-20 17:25:35.442964
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 February 2014 EMA/CHMP/606295/2013 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

RoActemra

International non-proprietary name: tocilizumab

Procedure No. EMEA/H/C/000955/X/0030

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Product information

| Name of the medicinal product:         | RoActemra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                             | Roche Registration Ltd 6 Falcon Way Shire Park Welwyn Garden City AL7 3AY UNITED KINGDOM                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Active substance:                      | Tocilizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| International Nonproprietary Name:     | Tocilizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Pharmaco-therapeutic group (ATC Code): | Pharmacotherapeutic group: Immunosupressants, Interleukin inhibitors (L04AC07 )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Therapeutic indication(s):             | RoActemra, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate. |
| Pharmaceutical form(s):                | Solution for injection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Strength(s):                           | 162 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Route(s) of administration:            | Subcutaneous use                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Packaging:                             | Pre-filled syringe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Package size(s):                       | 4 pre-filled syringes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                    | 6                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6       |                                                                                                          |
| 1.2. Manufacturers......................................................................................................7   |                                                                                                          |
| 1.3. Steps taken for the assessment of the product.........................................................7                |                                                                                                          |
| 2. Scientific discussion................................................................................                    | 8                                                                                                        |
| 2.1. Introduction.........................................................................................................8 |                                                                                                          |
| 2.2. Quality aspects                                                                                                        | ....................................................................................................9    |
| 2.2.1. Introduction......................................................................................................9  |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................10      |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                           | ................................................................................11                       |
| 2.2.4. Conclusions on the chemical, pharmaceutical and biological aspects.......................13                          |                                                                                                          |
| 2.2.5. Recommendation(s) for future quality development                                                                     | .............................................13                                                          |
| 2.3. Non-clinical aspects                                                                                                   | ............................................................................................14           |
| 2.3.1. Introduction....................................................................................................14   |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                         | .................................................................................................14      |
| 2.3.3. Pharmacokinetics.............................................................................................15      |                                                                                                          |
| 2.3.4. Toxicology                                                                                                           | ......................................................................................................18 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                            | .........................................................22                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................22           |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................24             |                                                                                                          |
| 2.4. Clinical aspects                                                                                                       | ..................................................................................................24     |
| 2.4.1. Introduction....................................................................................................24   |                                                                                                          |
| 2.4.2. Pharmacokinetics.............................................................................................26      |                                                                                                          |
| 2.4.3. Pharmacodynamics..........................................................................................29         |                                                                                                          |
| 2.4.4. Discussion on clinical pharmacology...................................................................32             |                                                                                                          |
| 2.4.5. Conclusions on clinical pharmacology                                                                                 | .................................................................34                                      |
| 2.5. Clinical efficacy                                                                                                      | ..................................................................................................35     |
| 2.5.1. Dose response studies......................................................................................35        |                                                                                                          |
| 2.5.2. Main studies....................................................................................................35   |                                                                                                          |
| 2.5.3. Discussion on clinical efficacy                                                                                      | ............................................................................98                           |
| 2.5.4. Conclusions on the clinical efficacy...................................................................104           |                                                                                                          |
| 2.6. Clinical safety                                                                                                        | ..................................................................................................105    |
| 2.6.1. Discussion on clinical safety                                                                                        | ............................................................................139                          |
| 2.6.2. Conclusions on the clinical safety.....................................................................142           |                                                                                                          |
| 2.7. Pharmacovigilance............................................................................................          | 143                                                                                                      |
| 2.8. Risk Management Plan ......................................................................................            | 143                                                                                                      |
| 2.9. User consultation                                                                                                      | ............................................................................................. 151        |
| 3. Benefit-Risk Balance...........................................................................                          | 152                                                                                                      |

<div style=\"page-break-after: always\"></div>

List of abbreviations

ACR

American College of Rheumatology

ALT

Alanine aminotransferase

ANC

Absolute neutrophil count

AST

Aspartate aminotransferase

AUC

Area under the serum concentration-time curve

BMI

Body Mass Index

Cavg

Average concentrations

CBR

Cytokine binding region

CDR

Complementarity determining region

CHO

Chinese hamster ovary

CI

Confidence Interval

CIA

Collagen-induced arthritis

CL

Clearance

Cmax

Maximum Concentration

CMH

Cochran-Mantel Haenzsel

Cmin

Concentration at the End of the Dosing Interval (Trough Concentration)

COX

Cyclo-oxigenase enyzme

CPK

Creatine phosphokinase

CRP

C-reactive protein

Ctrough

trough concentrations

CYP450

Cytochrome P450

DAS

Disease Activity Score

DBP

Diastolic Blood Pressure

DC

Dendritic cells

DMARD

Disease modifying anti-rheumatic drug

EBV

Epstein-Barr Virus

ECG

Electrocardiogram

EIA

Enzyme immunoassay

ELISA

Enzyme-Linked Immunosorbent Assay

ESR

Erythrocyte sedimentation rate

EULAR

European League Against Rheumatism

FACIT-F

Functional Assessment of Chronic Illness Therapy - Fatigue

FcRN

Neonatal Fc receptor

FDA

Food and Drug Administration

GCP

Good Clinical Practice

GI

Gastrointestinal

gp130

Glycoprotein 130 (signaling complex)

h

Hour

HAHA

Human Anti-Human Antibodies

HAQ-DI

Health Assessment Questionnaire - Disability Index

HDL

High density lipoprotein

IgG

Immunoglobulin G

IL-1β

Interleukin-1 beta

IL-2

Interleukin-2

IL-6

Interleukin-6

IL-6R

Interleukin-6 receptor

IM

Intra muscular

IR

Inadequate Responder

ITT

Intent-to-Treat

IV

Intravenous

Kd

Dissociation constant

KD

Equilibrium dissociation constant

LDL

Low density lipoprotein

LDL

Low-Density Lipoprotein

LLOQ

Lower Limit of Quantitation

mIL-6R

Membrane bound interleukin-6 receptor

MR16-1

Mouse specific interleukin-6 receptor antibody

MRA

Myeloma receptor antagonist, acronym for tocilizumab

MTX

Methotrexate

NA

Not applicable

ND

Not determined

NOAEL

Non observed adverse effect level

NSAID

NSD

Non-steroidal anti-inflammatory drug

Needle safety device

PBL

Peripheral blood leucocytes

PD

PFS

PFP

Pharmacodynamic(s)

Pre-filled syringe

Pre-filled pen

pJIA

Polyarticular juvenile idiopathic arthritis

PK

Pharmacokinetic(s)

PP

Per Protocol

PPI

Proton Pump Inhibitors

RA

Rheumatoid arthritis

RF

Rheumatoid factor

rh

Recombinant human

SAA

Serum Amyloid A

SBP

Systolic Blood Pressure

SC

Subcutaneous

SCID

Severe combined immunodeficiency disease

SD

Standard deviation

sgp130

Soluble glycoprotein 130

sIL-6R

Soluble interleukin-6 receptor

sJIA

Systemic Juvenile Idiopathic Arthritis

T½ (α)

Initial half-life

T½ (β)

Terminal half-life

TB

Tuberculosis

TCZ

Tocilizumab

tmax

Time to achieve Cmax

TNF

Tumor necrosis factor

ULN

Upper Limit of Normal

Vss

Volume of Distribution at Steady-State

WBC

White blood cell

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Roche Registration Ltd submitted to the European Medicines Agency (EMA) on 20 December 2012 an extension application for the Marketing Authorisation for RoActemra, through the centralised procedure falling within Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I.

Roche  Registration  Ltd  is  the  Marketing  Authorisation  Holder  (MAH)  for  RoActemra  20  mg/ml concentrate for solution for infusion in vials (intravenous use) indicated in the following:

- RoActemra, in  combination  with  methotrexate  (MTX),  is  indicated  for  the  treatment  of moderate to severe active  rheumatoid  arthritis  (RA)  in  adult  patients  who  have  either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying  anti-rheumatic  drugs  (DMARDs)  or  tumour  necrosis  factor  (TNF) antagonists.  In  these  patients,  RoActemra  can  be  given  as  monotherapy  in  case  of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra  has  been  shown  to  reduce  the  rate  of  progression  of  joint  damage  as measured  by  X-ray  and  to  improve  physical  function  when  given  in  combination  with methotrexate.
- RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs  and systemic corticosteroids. RoActemra  can be given as monotherapy  (in case of intolerance to MTX  or where treatment with MTX  is inappropriate) or in combination with MTX.
- RoActemra  in  combination  with  methotrexate  (MTX)  is  indicated  for  the  treatment  of juvenile  idiopathic  polyarthritis  (rheumatoid  factor  positive  or  negative  and  extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous  therapy  with  MTX.  RoActemra  can  be  given  as  monotherapy  in  case  of intolerance to MTX or where continued treatment with MTX is inappropriate.

The MAH applied for a new strength 162 mg solution for injection in a pre-filled syringe and in a pre-filled pen (subcutaneous injection) for the following indication:

RoActemra, in  combination  with  methotrexate  (MTX),  is  indicated  for  the  treatment  of moderate to severe active  rheumatoid  arthritis  (RA)  in  adult  patients  who  have  either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying  anti-rheumatic  drugs  (DMARDs)  or  tumour  necrosis  factor  (TNF) antagonists.  In  these  patients,  RoActemra  can  be  given  as  monotherapy  in  case  of intolerance to MTX or where continued treatment with MTX is inappropriate.

RoActemra  has  been  shown  to  reduce  the  rate  of  progression  of  joint  damage  as measured  by  X-ray  and  to  improve  physical  function  when  given  in  combination  with methotrexate.

<div style=\"page-break-after: always\"></div>

## Information on Paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA Decision P/0179/2012 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0179/2012 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC)  No  847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible similarity  with  authorised  orphan  medicinal  products  because  there  is  no  authorised  orphan medicinal product for a condition related to the proposed indication.

## Scientific Advice

The applicant received Scientific Advice from the CHMP on 24 May 2007, 19 January 2012 and 16 February 2012 (EMEA/CHMP/SAWP206914/2007, EMEA/CHMP/SAWP/9785/2012, EMEA/CHMP/SAWP/9787/2012  and  EMEA/CHMP/SAWP/99262/2012).  The  Scientific  Advices pertained to clinical aspects of the dossier.

## Licensing status

RoActemra  has  been  given  a  Marketing  Authorisation  in  the  European  Union  on  16  January 2009.

## 1.2. Manufacturers

## Manufacturer responsible for batch release

Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Whylen Germany

## 1.3. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Jan Müller-Berghaus Co-Rapporteur: Ágnes Gyurasics

- The application was received by the EMA on 20 December 2012.
- The procedure started on 30 January 2013.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 19 April 2013 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 18 April 2013 (Annex 2).

<div style=\"page-break-after: always\"></div>

- During  the  meeting  on  30  May  2013,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 3 June 2013 (Annex 4).
- The applicant submitted the responses to the CHMP consolidated List of Questions on 22 August 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 26 September 2013 (Annex 5).
- During the CHMP meeting on 24 October 2013, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant (Annex 6).
- The  applicant  submitted  the  responses  to  the  CHMP  List  of  Outstanding  Issues  on  15 November 2013.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 26 November 2013 (Annex 7).
- During  the  meeting  on  19  December  2013,  the  CHMP,  in  the  light  of  the  overall  data submitted and the scientific discussion within the Committee, issued a positive opinion for granting an extension of the Marketing Authorisation for RoActemra.
- On 20 December 2013, the MAH informed EMA of a clogging issue with the new pre-filled syringe presentation. During the meeting on 20-23 January 2014, the CHMP adopted a list of questions to the MAH requesting further information to which the MAH responded on 31 January 2013.
- On 31 January 2014 the MAH informed EMA and the CHMP of an out of specification issue with the new pre-filled pen presentation. On 11 February 2014 the MAH withdrew the new pre-filled pen presentation.
- During the meeting on 17-20 February 2014, the CHMP adopted a revised positive opinion for granting  an  extension  to  the  Marketing  Authorisation  for  RoActemra  162  mg  solution  for injection in a pre-filled syringe on 20 February 2014.

## 2. Scientific discussion

## 2.1. Introduction

## Problem statement

This  extension  of  the  Marketing  Authorisation  for  RoActemra  concerns  a  new  pharmaceutical form  'solution  for  injection',  a  new  strength  162  mg  with  two  new  presentations  pre-filled syringe and pre-filled pen and a new route of administration for subcutaneous use.

Rheumatoid  arthritis  (RA)  is  a  progressive,  systemic  auto-immune  disease  characterised  by synovitis that damages  diarthroidal joints and  is  accompanied  by  fatigue,  anemia,  and osteopenia. RA has a prevalence of 0.5% to 1.0% and a peak incidence between 40 and 60 years of age and affects primarily women.

Non-steroidal  anti-inflammatory  drugs  (NSAIDs)  provide  only  symptomatic  relief.  Diseasemodifying  anti-rheumatic  drugs  (DMARDs),  the  cornerstone  of  RA  treatment  throughout  all

<div style=\"page-break-after: always\"></div>

stages  of  the  disease,  maintain  or  improve  physical  function  and  retard  radiographic  joint damage. More recently, biologic compounds that target tumour necrosis factor alpha (TNF-α), B cells,  or  T  cells  have  been  used  successfully  to  treat  RA,  but  approximately  30%  to  40%  of patients fail to respond to these therapies.

IL-6  is  a  pleiotropic,  pro-inflammatory,  multifunctional  cytokine  produced  by  a  variety  of  cell types, and it has been implicated in the pathogenesis of several inflammatory and autoimmune disorders, including RA. Elevated IL-6 levels have been observed in the serum and synovial fluid of RA patients, and levels correlate with disease activity.

## About the product

TCZ  is  a  recombinant  humanised  anti-human  IgG1  monoclonal  antibody  directed  against  the interleukin-6 receptor (IL-6R) that binds specifically to both soluble and membrane-bound IL-6R, thereby inhibiting IL-6-mediated signalling.

The authorised formulation of TCZ is for  IV administration given over 60 minutes. IV infusion requires  administration  by  a  healthcare  professional  (HCP)  in  a  clinical  setting.  For  the  SC formulation, it is intended that after proper training in injection technique by an HCP, patients may self-inject at home if their physician determines that it is appropriate.

In  several  chronic  conditions,  including  RA,  in  which  patients  are  required  to  self-administer injectable drugs (e.g. diabetes, multiple sclerosis), a preference for an auto injector (AI) over a syringe has been reported (Korytkowski 2003, Summers 2004, Mikol 2005, Kivitz 2006).

## Type of application and aspects on development

This  Extension  Application  as  referred  to  in  Article  19  of  Commission  Regulation  (EC)  No 1234/2008 and Annex I is to register the following:

- A new pharmaceutical form 'solution for injection'
- A new strength 162 mg with two new presentations Pre-filled syringe and pre-filled pen
- A new route of administration for subcutaneous route.

The  development  program  comprises  six  Phase  I  or  Phase  I/II  clinical  pharmacology  studies (studies  WP18097,  BP22065,  NP25539,  BP21894,  MRA227JP  and  NP22623)  and  two  pivotal Phase  III  studies  (studies  WA22762  and  NA25220)  in  patients  with  RA.  The  Phase  III  study MRA229JP, conducted exclusively in Japanese patients with RA, is supportive only of the efficacy and safety of TZC SC when given as monotherapy.

## 2.2. Quality aspects

## 2.2.1. Introduction

The  formulation  development  program  was  to  obtain  a  stable  highly  concentrated  liquid formulation for subcutaneous (SC) administration of tocilizumab (RoActemra SC). A 180 mg/mL concentration was selected for SC administration of 162 mg/0.9 mL of tocilizumab in a single-use prefilled syringe (PFS) mounted with a needle safety device (NSD) or assembled as a single-use prefilled pen (also referred to as an 'auto-injector' (AI)).

<div style=\"page-break-after: always\"></div>

The  RoActemra  SC  finished  product  formulation  consists  of  180  mg/mL  tocilizumab  in  Lhistidine/L-histidine hydrochloride, L-arginine/L-arginine hydrochloride, L-methionine, polysorbate 80, at a pH of approximately 6.0.

Tocilizumab  for  SC  formulation  was  developed  by  modifying  the  latest  tocilizumab  G5  process version at the Chugai Utsunomiya (UT) facility (G5U).

To maintain the Phase III clinical  supply  and  for  future  commercial  supply,  the  manufacturing process for the G5.2 active substance was transferred to Genentech's Oceanside (OCN) facility.

## 2.2.2. Active Substance

Currently global commercial supply of active substance for IV administration is provided by the G5U fifth generation process in UT. For SC administration, active substance derived from the fifth generation  process  at  OCN  will  be  used.  The  initial  G5U  manufacturing  process  approved  for tocilizumab active substance was validated to ensure consistent product quality.

The  manufacturing  process  for  subcutaneous  (SC)  administration  (G5.2)  was  transferred  from the clinical site in Vacaville (VV) to the Oceanside (OCN) facility. The OCN facility is the intended commercial  manufacturing  site  for  SC  Active  substance.  The  G5.2  manufacturing  process  is identical to the manufacturing process for the tocilizumab active substance for IV administration, except  for  higher  bulk  active  substance  concentration.  Additional  validation  was  required  to support the changes, as well as to support the facility and equipment differences between the licensed UT site and the OCN site.

The  process  qualification  (PQ)  of  the  tocilizumab  SC  process  was  performed  to  qualify  the manufacturing process at the OCN site.. The G5.2 qualification runs met the established ranges. Additionally,  in-process  testing  and  Certificate  of  Analysis  (CofA)  results  were  reviewed  to demonstrate that the quality attributes of the qualification runs meet the quality control release criteria. Verification that the process parameters are maintained within the established acceptable  ranges  for  all  steps  in  common  between  the  G5.2  and  IV  formulation  process  was demonstrated.  The  summary  of  the  results  indicate  that  the  tocilizumab  G5.2  manufacturing process is capable of consistently producing active substance that meets the established quality specifications and attributes.

To demonstrate the comparability of the tocilizumab G5.2 active substance manufactured at OCN facility to G5.2 active substance produced at Genentech Vacaville facility, G5.2 Active substance batches produced at the OCN facility (OCN G5.2 active substance batches) were compared to the Reference Standard (RS) and G5.2 active substance batches produced at the VV facility (VV G5.2 active  substance  batches).  In  addition  to  meeting  the  active  substance  specification,  further characterisation  was  performed  with  respect  to  the  primary  structure  of  the  G5.2  active substance and included an assessment of the heterogeneity of the G5.2 active substance with respect to glycosylation, size, and charge-based isoforms. It was demonstrated that, with respect to  the  structure  of  the  tocilizumab  molecule,  the  OCN  G5.2  active  substance  batches  are consistent  with  and  comparable  to  the  VV  G5.2  active  substance  batches  and  the  RS. Comparability data for batches manufactured with the currently approved G5U and the proposed G5.2 OCN process were also provided. Tocilizumab G5.2 batches were evaluated with respect to the removal of process- and product-related impurities. The results demonstrate that the levels of  process-  and  product-related  impurities  are  consistently  removed  to  levels  below  or  at  the level of detection of the respective assay.

<div style=\"page-break-after: always\"></div>

Specifications  contain  standard  criteria  for  the  acceptance  or  rejection  of  batches  based  on features that are important to assure the identity, purity, content, potency, and safety of G5.2 tocilizumab  Active  substance.  The  proposed  specification  is  based  upon  knowledge  from preclinical  development  as  well  as  the  approved  tocilizumab  intravenous  (IV)  active  substance specification.  Furthermore,  the  specification  complies  with  current  regulatory  requirements. Appropriateness of the proposed specification was evaluated based on the results from batches of G5.2 tocilizumab active substance. The batch analysis data demonstrate that the G5.2 process is validated to produce tocilizumab that meets all current release specifications.

The  results  of  the  stability  studies  indicate  consistency  of  tocilizumab  manufactured  at  the commercial scale.  Real-time and accelerated stability studies were initiated in accordance with ICH  guidelines  and  per  protocol  (PP)  to  monitor  the  time-temperature  stability  of  finished product. On the basis of the data provided, the approvable shelf life for the finished product is 30 months at 2-8°C.

## 2.2.3. Finished Medicinal Product

RoActemra (tocilizumab) is supplied as a sterile, colorless to slightly yellowish, preservative-free liquid  solution  in  a  single-use  1  mL  prefilled  syringe  (PFS)  for  subcutaneous  (SC)  injection, delivering 162 mg tocilizumab in a 0.9 mL solution.

## A) Finished product in prefilled syringe (PFS)

Galenical bulk production of RoActemra SC prefilled syringes (PFSs) 162 mg/0.9 mL is performed by  Vetter  Pharma-Fertigung  GmbH  &amp;  Co  KG  Schützenstrasse  87  and  99-101  D-88212 Ravensburg Germany.

RoActemra  (tocilizumab)  active  substance  is  thawed  in  the  primary  container  and  stirred  for homogenization.  The  filtered finished product bulk solution is sterile-filtered in-line  and aseptically  filled  into  1  mL  pre-sterilised  syringes.  Immediately  after  filling,  the  syringes  are stoppered with sterilized plunger stoppers and stored at 2 ° C - 8 ° C prior to visual inspection. After the visual inspection is completed, syringes are bulk packaged and stored at 2 ° C - 8 ° C. Final  automated assembly of the PFS with the plunger rod and needle safety device (NSD) is performed  at  the  Roche  Kaiseraugst  facility  on  a  fully  automated  assembly  line.  The  final assembled  PFS  +  NSD  and  patient  leaflets  are  packaged  together  in  a  printed  carton.  After packaging, the final product is transferred to cold storage (2 ° C - 8 ° C) until final distribution.

Validation activities were conducted to ensure that appropriate process parameters and ranges are defined for the manufacture of the commercial batch sizes.

To  validate  the  sterile  filtration  process,  a  microbial  retention  test  was  performed.  Hold  time study results support the proposed hold times.

In general the specifications are set according to the requirements of the ICH Q6B Guidance. The European Pharmacopoeia monograph 'Monoclonal antibodies for human use' (2031) requires for appearance that liquid preparations are without visible particles, unless otherwise justified. The applicant  was  asked  to  set  the  specifications  according  to  the  monograph  or  to  justify  the proposed specification. The analytical procedures for RoActemra SC prefilled syringes have been established based on the validated analytical procedures previously submitted for RoActemra IV vials. The minor differences and adjustment have no impact on the test performance. The batch analysis data indicate that all acceptance criteria were met. The actual values for the potency

<div style=\"page-break-after: always\"></div>

determination should be provided. The proposed RoActemra SC finished product release and endof-shelf-life  specifications  are  based  upon  knowledge  from  clinical  development  as  well  as  the approved RoActemra IV.

The  materials of the  primary packaging  material are in compliance  with the Ph. Eur. requirements.

A maximum product expiry for the RoActemra PFS + NSD combination product of 30 months at the recommended storage condition of 2°C - 8°C was considered acceptable based on:

- Real-time and accelerated data for the PFS;
- Supportive Real-time and accelerated data for the PFS;
- Real-time and accelerated data for the PFS + NSD;
-  Functionality  data  on  PFS  +  NSDs  assembled  on  the  semi-automated  assembly  line  at recommended storage conditions;

- Supportive container closure integrity (CCI) study of assembled media-filled syringes into the PFS + NSD.

On 20 December 2013, the MAH reported an issue affecting the PFS-NSD device: at the 9-month time point of the long term functionality testing performed in June 2013, one PFS-NSD device out of  60  units  exceeded  the  acceptance  criterion  of  peak  force  before  the  finished  product  is expelled  from  the  syringe.  Testing  of  the  0,  3,  6  and  12  month  time  points  were  successfully completed with all syringes meeting the acceptance criteria. The possible root cause is a clogged needle  due  to  solidified  finished  product  at  the  tip.  The  MAH  already  reported  clogging  as  a possible root cause for a clinical complaint in the submission documentation.

As an immediate action the MAH proposed changes to the product information in sections 6.3 and 6.6 of the SmPC as well as in the Package Leaflet in sections 5 and 6 (Instructions for Use Steps 2 and 5). This is supported by CHMP.

Overall  it  was  concluded  that  that  clogging  incidents,  including  clogging  incidents  prior  to  cap removal, are very rare events. Furthermore, the risk assessment provided by the MAH indicated that if in the very rare event a patient were to attempt to perform an injection using a PSF-NSD or PFP with a clogged needle, it is highly unlikely there would be any impact on clinical efficacy or safety.

It  is  concluded  that  there  is  no  impact  on  clinical  efficacy  or  safety  due  to  clogging  incidents when using the PFS-NSD device.

## B) Finished product in prefilled pen (AI-auto injector)

An  assessment  of  the potential influence of the assembly  process  on  finished product performance was conducted. The degradation behaviour of tocilizumab at 2 ° C -8 ° C and 25 ° C in the bulk PFS and in the AI configurations is considered very similar. Furthermore the results are well within specification limits for the recommended storage condition of 2 ° C -8 ° C.

The AI delivers RoActemra to the patient by a mechanical spring that pushes the plunger stopper towards  the  needle,  initiating  the  injection  of  the  finished  product  solution.  An  additional  risk assessment for  the  AI  was  performed  in  order  to  evaluate  the  influence  of  the  assembly  and

<div style=\"page-break-after: always\"></div>

packaging  process  on  CCI  integrity.  Supporting  microbiological  CCI  testing  on  commercial representative media-filled syringes in the assembled system were additionally performed.

Galenical  bulk  production  of  RoActemra  SC  prefilled  syringes  (PFSs)  162  mg/0.9  mL:  Vetter Pharma-Fertigung  GmbH  &amp;  Co  KG.  The  autoinjector  (AI)  is  composed  of  front  and  rear subassembly parts that are assembled to hold the prefilled syringe (PFS). Final assembly of the PFS into the AI is performed at the Roche Kaiseraugst facility on a fully automated assembly line in a controlled, non-sterile environment.

As part of validation, in-line controls and functionality were checked and the correct assembly of the AIs was demonstrated by a visual and functional test.

The degradation behaviour of tocilizumab at 2 ° C -8 ° C and 25 ° C in the bulk PFS and in the AI configurations  is  considered  very  similar.  Furthermore  the  results  are  well  within  specification limits for the recommended storage condition of 2 ° C -8 ° C. The shelf life for the RoActemra AI combination  product  is  further  supported  by  the  results  from  all  assembled  AI  batches  and available studies for the components and will be assigned to each assembled AI batch based on the component having the shortest remaining shelf life.

On 29 January 2014, the applicant reported several out-of-specification results with the PFP at the 24 month time point of the long-term functionality testing: several examples exceeded the injection  time  limit.  This  acceptance  limit  for  the  injection  time  into  air  is  based  on  the performance  capability  of  the  spring-driven  PFP  auto-injector  to  deliver  the  full  dose  of RoActemra 162 mg/0.9 mL. The possible root cause of these events is not fully understood. As a consequence, on 11 February 2014 the MAH decided to remove the PFP presentation from the scope of this line extension. The MAH also confirmed their ability to ensure commercial supply of the PFS to all rheumatoid arthritis patients once approved and to subjects enrolled in on-going clinical studies.

## C) Adventitious agents safety evaluation

The G5U manufacturing process of tocilizumab was used as the basis for the initial manufacture of  RoActemra  SC.  Modifications  to  the  G5U  purification  process  were  made  to  accommodate facility-related differences, including larger mass produced in Genentech bioreactors relative to those  used  in  the  G5U  process.  No  new  TSE  risk  material  has  been  introduced.  For  all  viral clearance  steps  that  did  not  change  from  G5U  to  G5.2  virus  removal  and  inactivation  studies have not been repeated.

In  summary,  the  virus  safety  for  the  new  G5.2  active  substance  manufacturing  process  is considered sufficiently demonstrated.

## 2.2.4. Conclusions  on  the  chemical,  pharmaceutical  and  biological aspects

The overall Quality of RoActemra in a pre-filled pen syringe equipped with needle safety device (PFS+NSD) is considered acceptable.

## 2.2.5. Recommendation(s) for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Tocilizumab is a recombinant humanized monoclonal antibody of the immunoglobulin G1 (IgG1) class  that  binds  both  soluble  and  membrane-bound  human  interleukin-6  receptor  (IL-6R). Tocilizumab has been shown to be pharmacologically active in cynomolgus monkeys. To support the original marketing authorisation application (MAA), an extensive number of pharmacology, pharmacokinetics  and  toxicities  studies  were  conducted.  Authorisation  of  the  IV  route  of administration was mainly based on pharmacology, pharmacokinetics and toxicology data using this route of exposure in cynomolgus monkeys. Pharmacology, PK and toxicity data (reproductive toxicity  and  juvenile  toxicity  studies)  were  also  provided  using  a  murine  surrogate  antibody MR16-1 with IV infusion in the mouse.

To  bridge  this  comprehensive  dataset  to  the  subcutaneous  (SC)  route  of  administration,  a  PK study was  conducted  in the minipig to assess the absorption behavior from  the high concentration SC formulation of tocilizumab (180 mg/mL) intended for clinical use. An IV dose arm allowed for the estimation of the bioavailability of tocilizumab after SC dosing. The minipig was  selected  for  this  purpose  as  this  species  represents  an  animal  model  with  skin  and subcutaneous tissue texture similar to humans making it appropriate to study the absorption of SC formulations.

Further, the safety of tocilizumab SC with respect to any local reactions at the site of injection, the effects on the draining lymphatic system specific to this site of administration, a comparison of exposure and an assessment of anti-drug antibody formation with this subcutaneous mode of administration  versus  the  IV  route,  the  elimination  phase  of  tocilizumab  and  the  possible reversibility  of  any  observations in  a  treatment-free  phase  of the  study  were  assessed in a 9week  SC  repeat-dose  toxicity  study  in  the  cynomolgus  monkey,  which  included  a  16-week treatment-free observation period.

These studies were conducted with the high concentration preparation of 180 mg/mL tocilizumab that  is  also  used  for  the  human  SC  formulation.  Thus,  these  data  also  bridge  the  non-clinical kinetic and safety data to the human preparation including the excipients used.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

The pharmacodynamics studies performed with tocilizumab in support of the original application showed that tocilizumab specifically binds to the IL-6 binding site of both sIL-6R and mIL-6R with similar affinity. Therefore, tocilizumab is able to block IL-6 from binding to both receptors and thereby blocks the activity of IL-6. In vitro studies demonstrated that tocilizumab can inhibit IL-6 binding to and displace already bound IL-6 from sIL-6R and that tocilizumab has a strong antiIL-6 effect. Tocilizumab is specific to the IL-6R with no binding to other receptors associated with gp130 or to receptors for other cytokines. Pre-clinical studies showed specificity of tocilizumab to the IL-6R with no direct cross-reactive inhibitory effect on TNF-α, IL-1β, IL-15 or IL-2 in vitro .

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacokinetics

A non-GLP PK study (study No 165.001) was conducted in the minipig to assess the absorption behavior  of  the  high  concentration  SC  formulation  of  tocilizumab  (180  mg/mL)  intended  for clinical  use.  An  IV  dose  arm  allowed  for  the  estimation  of  the  relative  bioavailability  of tocilizumab after SC dosing. The bioavailability was estimated at 83.5%, which indicates a very good absorption of tocilizumab SC from this formulation.

No  repeated  dose  PK  studies  have  been  performed  with  tocilizumab  SC.  Information  on  the repeated  dose  PK  of  tocilizumab  SC  was  obtained  in  a  repeated  dose  SC  toxicology  study  in cynomolgus monkeys (study 1029905).

## Method of analysis

## Assay for quantification of tocilizumab in cynomologus monkey plasma

Concentrations  of  tocilizumab  after  repeated  doses  in  cynomolgus  monkey  plasma  were determined with a validated sandwich enzyme-linked immunosorbent assay (ELISA).

The  ELISA  used  for  analysis  of  tocilizumab  concentrations  in  the  single  SC  dose  study  in cynomolgus  monkey  was  already  described  in  the original MAA  for the tocilizumab IV formulation.

## Assay for quantification of tocilizumab in minipig plasma

Concentrations of tocilizumab in minipig plasma were determined with an exploratory sandwich ELISA which was adapted from the assay validated for cynomolgus monkey plasma. The assay closely  followed  the  procedure  for  cynomolgus  monkey  plasma,  with  calibration  and  quality control samples made up in minipig plasma.

## Assay for detection of anti-tocilizumab antibodies in cynomologus monkey plasma

A  validated  sandwich  ELISA  was  used  to  detect  and  confirm  the  presence  of  antitocilizumab antibodies after repeated doses in cynomolgus monkey plasma. This assay uses a mouse antihuman IL-6R monoclonal antibody (mPM- 1) which has the same CDR as tocilizumab. This assay system only detects monkey antibodies that bind to the CDR of tocilizumab.

## Absorption

## Single-dose  intravenous  and  subcutaneous  administration  in  minipigs  (study  No. 165.001)

A  PK  study  was  conducted  with  tocilizumab  SC  in  minipigs  to  explore  the  PK  of  the  high concentration SC formulation of tocilizumab (concentration 180 mg/mL). The study included an IV dosing arm to allow estimation of absolute bioavailability. In additional dose arms, the PK of two  alternative  formulations  was  studied  containing  different  concentrations  of  recombinant human  hyaluronidase  (rHuPH20)  as  a  permeation  enhancer.  The  tocilizumab  SC  formulations containing  rHuPH20  are  not  relevant  for  this  application, as the clinical  tocilizumab  SC formulation  does  not  contain  rHuPH20.  Therefore  the  results  for  the  rHuPH20  containing formulations will not be discussed further.

Female Göttingen minipigs  (n=3  and  5  for  IV  and  SC  administration,  respectively)  received  a single IV dose of tocilizumab at 20.3 mg/kg or a single SC dose at 180 mg/animal (about 20.2 mg/kg). The SC injection volume was 1 mL. Plasma concentrations of tocilizumab were analyzed

<div style=\"page-break-after: always\"></div>

with a specific ELISA. PK analysis was conducted by both non-compartmental and compartmental methods. The figure below shows the average plasma concentration-time profiles after IV and SC dosing.

Figure 1. Time Course of Tocilizumab Plasma Concentrations in Female Göttingen Minipigs  Following  a  Single  iV  (at  20.3  mg/kg)  or  SC  (at  180  mg/animal. Equivalent  to  ca.  20.2  mg/kg)  Administration  of  Tocilizumab  (n  =  3  or  5, respectively) (mean ± SD)

<!-- image -->

After  IV  administration,  the  plasma  concentration-time  curve  showed  a  biphasic  disposition  of TCZ. Non-compartmental PK analysis indicated a terminal half-life of 286 ± 182 hours. Clearance was estimated at 0.00435 ± 0.00179 mL/min/kg (equivalent to 6.26 ± 2.58 mL/day/kg), and the volume of distribution at steady-state (Vss) was estimated to be 84.9 ± 19.2 mL/kg (mean ± SD).

After SC administration, maximum TCZ plasma concentrations were 190 ± 14 µg/mL (mean ± SD).  They  were  reached  after  48  hours  (median  value;  range:  24  to  72  hours).  The  terminal half-life  (262  ±  40  hours;  mean  ±  SD)  was  similar  to  that  after  IV  administration.  The  SC bioavailability  from  non-compartmental  PK  analysis  was  83.5  ±  23.1%.  Compartmental  PK modeling  revealed  a  first  order  absorption  rate  constant  ka  of  0.0359  h-1  and  a  fraction absorbed of 81.2% (population estimates).

## Single-dose  subcutaneous administration in cynomolgus monkeys (study No ADM040014)

This SC PK study in male cynomolgus monkeys was already described in the original MAA for the tocilizumab IV formulation. The results of this study were used to support the planning of the SC GLP  toxicology  study  in  cynomolgus  monkeys.  Therefore,  the  results  of  this  study  are  again briefly summarized.

Male cynomolgus monkeys (n=4/dose group) received a single SC tocilizumab dose at a dose level of 1, 5, or 15 mg/kg. Plasma concentrations of tocilizumab were analyzed with a specific ELISA. PK analysis was conducted by non-compartmental analysis. The figure below shows the average plasma concentration-time profiles.

<div style=\"page-break-after: always\"></div>

Figure 2. Time  Course  of  Tocilizumab  Plasma  Concentrations  in  Cynomolgus Monkeys  Following  a  Single  Subcutaneous  Administration  of  Tocilizumab  at Various Dose levels (n = 4/dose group) (mean ± SD)

<!-- image -->

PK parameters are summarized in the table below.

Table 1. Noncompartimental Pharmacokinetic Parameters for Tocilizumab in Cynomolgus Monkeys Following Single Subcutaneous Administration of Tocilizumab at Various Dose Levels (mean ± SD)

| Parameter          | Dosing Regimen (n=4/dose group)   | Dosing Regimen (n=4/dose group)   | Dosing Regimen (n=4/dose group)   |
|--------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                    | 1 mg/kg                           | 5 mg/kg                           | 15 mg/kg                          |
| Cmax (μg/mL)       | 4.88 ± 1.29                       | 30.1 ± 11.8                       | 145 ± 8                           |
| Tmax (h)           | 50.0 ± 30.2                       | 72.0 ± 19.6                       | 66.0 ± 12.0                       |
| AUC oinf (h·μg/mL) | 737 ± 210                         | 7860 ± 2260                       | 55200 ±10200                      |
| T1/2 (h)           | 68.1 ± 26.1                       | 112±9                             | 229 ± 42                          |
| F (%)              | NC                                | 72.1                              | NC                                |

Cmax: Maximum plasma concentration

Tmax: Time to maximum plasma concentration

AUC: Area under the plasma concentration-time curve

F: Bioavailability

NC: not calculated

Following SC administration maximum tocilizumab plasma concentrations were reached at about 2  to  3  days  post  dose  at  all  dose  levels.  Cmax  and  AUC  values  increased  more  than  doseproportionately,  which  is  in  line  with  the  non-linear  PK  of  tocilizumab  in  cynomolgus  monkeys observed after IV administration. At the 5 mg/kg dose level the SC bioavailability was estimated at 72.1%.

<div style=\"page-break-after: always\"></div>

## Repeated-dose subcutaneous administration

Information  on  the  repeated-dose  PK  of  tocilizumab  SC  was  obtained  in  a  repeated  dose toxicology study (study 1029905). Cynomolgus monkeys (n=5/gender) received weekly doses of tocilizumab  SC  at  100  mg/kg  over  9  weeks.  Average  maximum  plasma  concentrations  of tocilizumab increased from 1110 μg/mL after the first dose to 3280 μg/mL after the 8 th   dose, while average AUC(0-168h) values increased from 151,000 to 478,000 μg·h/mL.

Anti-tocilizumab antibodies were measured in the recovery animals (n=2/gender) during and at the  end  of  the  16-week  recovery  phase.  No  anti-tocilizumab  antibodies  were  detected  in  any cynomolgus monkeys during the recovery phase.

## Metabolism (interspecies comparison)

No  dedicated  studies  on  the  metabolism/catabolism  of  tocilizumab  SC  have  been  performed. Tocilizumab  is  expected  to  undergo  catabolism  similar  to  that  of  other  IgGs.  There  is  broad evidence in the literature that IgG is cleared from the body predominantly via catabolism. The neonatal Fc receptor (FcRn) plays a key role in maintaining IgG homeostasis by protecting IgG from catabolism.

The FcRn mediated protection process is also relevant during the SC absorption process. Studies in mice have shown a marked reduction in SC bioavailability for an IgG in FcRn knockout mice relative to wild-type mice. It is known that most of IgGs given subcutaneously are absorbed into blood flow through lymph.

Dedicated studies to assess the fate of tocilizumab in the subcutaneous interstitial space and the lymphatic system were not considered to be necessary. This was supported by the CHMP. Uptake of IgGs from the interstitial space into the lymphatic system and subsequent back transport into blood circulation also occurs following IV administration as part of the normal distribution and recirculation process of IgGs. Therefore, catabolic processes unique to SC administration are quite unlikely.

Overall, the catabolism processes of tocilizumab administered SC are expected to be similar to those after IV administration.

## Pharmacokinetic drug interactions

No PK drug interaction studies have been performed with tocilizumab SC. The potential for PK drug  interaction  with  tocilizumab  SC  is  not  expected  to  differ  from  that  of  the  tocilizumab  IV formulation,  since  after  having  reached  systemic  circulation  tocilizumab  will  behave  the  same irrespective of the administration route. This was considered acceptable by the CHMP.

## 2.3.4. Toxicology

Tocilizumab has been extensively characterized in the cynomolgus monkey in single and repeatdose toxicity studies with intravenous (IV) administration of this antibody. In order to bridge the IV toxicity study program to the new subcutaneous (SC) formulation program, a single 9-week SC repeat-dose toxicity study followed by a 16-week recovery phase in the cynomolgus monkey was  conducted.  The  treatment  duration  of  this  study  and  the  recovery  phase  was  based  on steady state and elimination expectations.

<div style=\"page-break-after: always\"></div>

Any concerns regarding systemic toxicity of tocilizumab are sufficiently characterized using the IV route  of  exposure  in  cynomolgus  monkey  studies  and  in  studies  using  MR16-1,  a  surrogate antibody blocking the mouse IL-6 receptor. Hence, the toxicology bridging program for the SC route focused on the following objectives:

- any local reactions at the site of injection
- the effects on the draining lymphatic system specific to this site of administration
- a comparison of exposure and an assessment of anti-drug antibody formation with this subcutaneous mode of administration versus the intravenous route
- the elimination phase of tocilizumab and the possible reversibility of any observations in a treatment-free phase of the study.

One high dose of 100 mg/kg weekly was administered subcutaneously for this purpose. This dose was  also  used  as  a  high  dose  in  the  IV  toxicity  program  with  tocilizumab  in  the  cynomolgus monkey with weekly administrations for six months. The exposure and clearance of tocilizumab did  not  substantially  differ  between  the  two  modes  of  administration.  The  somewhat  higher trough values with SC administration are related to a slower absorption with this route compared to the IV route but otherwise the two administration routes had similar elimination kinetics. No evidence for anti-drug antibodies was found in the animals investigated during and at the end of the treatment free phase of the SC study (n=2/gender). The low levels of tocilizumab towards the  end  of  the  treatment-free  period  together  with  the  high  drug  tolerance  of  the  anti-drug antibody  assay  allowed  a  reliable  assessment  of  recovery  animals  for  presence  of  antidrug antibodies.  Hence,  the  formation  of  anti-drug  antibodies did  not  have  an  impact  on  the  study data. There were no specific reactions to the local SC administration of tocilizumab in the area of administration or in the draining lymphatic system, in this 9- week cynomolgus monkey SC study followed  by  a  16-week  recovery  period.  Thus,  this  study  bridges  the  previously  characterized acute and chronic dosing animal safety program of tocilizumab using the IV route with the new intended  route  of  a  SC  administration.  No  new  safety  concerns,  which  can  be  addressed  by animal studies using tocilizumab, have emerged from this change in the route of administration.

## Repeat dose toxicity

## Study 1029905: a 9-week subcutaneous administration toxicity study in the cynomolgus monkey with a 16-week recovery phase

The  objective  of  the  repeat-dose  toxicity  study  was  to  determine  the  toxicity  of  tocilizumab, following  weekly  SC  administrations  to  cynomolgus  monkeys  for  9  weeks  and  to  assess  the reversibility of the adverse effects during a 16-week recovery phase.

Assessment of toxicity was based on observation of mortality, clinical signs, injection sites, and on  measurement  of  body  weight,  testicular  volume,  haematology,  clinical  chemistry,  urine analysis,  toxicokinetics,  and  on  terminal  procedures  (organ  weights,  macroscopic  findings  and histopathology) and on bone marrow evaluation.

The dosing design was as follows in the table below.

<div style=\"page-break-after: always\"></div>

Table 2. Dose and number of animals in the repeat-dose SC toxicity study with tocilizumab

| Group number   | Group description   | Treatment code   | Dose level (mg/kg/week)   | Animals/group   | Animals/group   | Necropsy     | Necropsy         |
|----------------|---------------------|------------------|---------------------------|-----------------|-----------------|--------------|------------------|
| Group number   | Group description   | Treatment code   | Dose level (mg/kg/week)   | Male            | Female          | Main animals | Recovery animals |
| 1              | control             | G1               | 0                         | 5               | 5               | 3M / 3F      | 2 M / 2 F        |
| 2              | dose                | G2               | 100                       | 5               | 5               | 3M / 3F      | 2 M / 2 F        |

Consistent high systemic exposure  to  tocilizumab  was  seen  in  this  study.  Mean  Cmax concentrations  of  3410  and  3140  μg/mL  and  mean  AUC  (0-168h)  of  507000  and  448000 h.μg/mL  were  reached in this study in  males  and females respectively, after the 8 th administration on day 50.

Systemic  exposure  was  characterized  by  a  normal  inter-individual  variability  with  no  relevant gender  differences.  As  expected  from  the  long  plasma  half-life,  exposure  to  tocilizumab, accumulated during the course of the treatment period with an overall average day 50 to day 1 ratio  of  3.16  for  AUC(0-168h)  and  2.96  for  Cmax.  Due  to  the  slow  plasma  clearance  of tocilizumab,  3  of  the  4  animals  were  continuously  exposed  to  tocilizumab  during  the  entire recovery period of 16 weeks, with terminal tocilizumab plasma concentrations between 2.9 and 43.1 μg/mL.

Tocilizumab demonstrated no immunogenic potential in this study. Anti-tocilizumab antibodies, measured under non-GLP conditions were not detected in any sample taken during the treatment period or during the recovery period. Accelerated clearance of tocilizumab was neither observed during the treatment phase nor was it observed during the 16-week treatment free period in the 4 recovery sub-group animals.

Exposure  to  tocilizumab  by  weekly  SC  injections  did  not  induce  any  noteworthy  or  significant adverse effects. Similar to the repeat-dose studies with IV administration, there was in particular no effect  on  absolute  neutrophil  counts  or  any  other  hematological  dyscrasia  observed  at  any phase of the study. A slight decrease in serum fibrinogen as the only potential treatment-related observation was considered to be of minor physiological relevance. All values were within or close to normal ranges.

The  histological  examination  of  organs  and  tissues,  including  the  axillary  lymph  node  as  the injection site draining lymph node, did not reveal any histopathological differences between the control and treated animals.

Local reactions at the injection sites were clinically insignificant and macroscopically comparable between control and dosed animals. The injection site reactions were histologically seen as mild focal  and  predominantly  mononuclear  and  perivascular  inflammatory  reactions.  Such  reactions were  found  in  control  and  treated  animals  of  both  sexes  with  insignificant  differences  in  the severity between the two groups. Control animals were injected with physiological saline.

## Toxicokinetic data

Consistent  high  systemic  exposure  to  tocilizumab  was  seen  in  the  9-week  SC  toxicity  study. Mean Cmax concentrations of 3410 and 3140 μg/mL and mean AUC  (0-168h) of 507000 and

<div style=\"page-break-after: always\"></div>

448000  h.μg/mL  were  reached  in  this  study  in  males  and  females  respectively,  after  the  8 th administration on day 50.

As expected from the long plasma half-life, tocilizumab accumulated over time with an overall average day 50 to day 1 ratio of 3.16 for AUC(0-168h) and 2.96 for Cmax, respectively. Due to the  slow  plasma  clearance  of  tocilizumab,  3  of  the  4  animals  were  continuously  exposed  to tocilizumab  during  the  entire  recovery  period  of  16  weeks,  with  terminal  tocilizumab  plasma concentrations between 2.9 and 43.1 μg/mL.

## Comparison of different administration routes

The dose level of 100 mg/kg chosen for the 9-week SC study was equivalent to that was used previously in a 6-month repeat-dose IV toxicity study. Cmin exposure at 168 h (7 days) after the eighth weekly dose in the SC study is approximately 40 % higher than the exposure at 168 h (7 days) after the eighth weekly dose in the 6-month IV study.

Table 3. Cmin exposures attained at 100 mg/kg tocilizumab given intravenously or subcutaneously in monkey toxicity studies

| Study                                                     | Time point                                                          |   Dose (mg/kg) | No. of animals    | C min (µg/mL)   | CV 1 or SD 2   |
|-----------------------------------------------------------|---------------------------------------------------------------------|----------------|-------------------|-----------------|----------------|
| 9-week monkey subcutaneous study (Report No.1029905)      | 168h after 8 th weekly dose (samples taken before 9 th weekly dose) |            100 | 5 males 5 females | 2580 2230       | 18% 17.7%      |
| 6-month monkey intravenous study (Report No. TOX02- 0169) | 168h after 8 th weekly dose (samples taken before 9 th weekly dose) |            100 | 5 males 5 females | 1436.2 1594.9   | 135.8 87.7     |

1 CV - coefficient of variation used as the parameter in the SC study;

2  SD - standard deviation used as the parameter in the IV study.

## Local Tolerance

The local tolerance of the SC formulation was assessed as part of the repeat-dose toxicity study in  the  cynomolgus  monkey  carried  out  to  bridge  the  previous  IV  animal  toxicity  program  to support a SC administration of tocilizumab.

Local reactions at the injection sites were clinically insignificant and macroscopically comparable between control and treated animals. The histological findings were mild focal and predominantly mononuclear and perivascular inflammatory reactions.

The SC  formulation of tocilizumab was  well tolerated, so this result supports the  SC administration of tocilizumab.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Ecotoxicity/environmental risk assessment

No  dedicated  ecotoxicity/environmental  risk  assessment  was  performed  for  this  medicinal product, which is in accordance with the applicable guidance. The active substance is a protein, the use of which is unlikely to result in significant risk to the environment. Therefore, tocilizumab is not expected to pose a risk to the environment.

## 2.3.6. Discussion on non-clinical aspects

## Pharmacokinetics

The PK of tocilizumab after SC administration was studied in minipigs and cynomolgus monkeys. The studies focused on the absorption behavior of tocilizumab after SC administration, since the disposition  PK  of  tocilizumab  after  IV  administration  has  been  well  characterized  previously during the development of tocilizumab for IV administration.

The species selection served the needs of the non-clinical SC development program.

The SC PK data in cynomolgus monkeys supported the planning of the GLP cynomolgus monkey toxicology study.

Minipigs  were  used  to  assess  the  absorption  behavior  of  the  high  concentration  tocilizumab formulation. The minipig was chosen for this study because its skin and the texture of the SC tissue are considered to be similar to those of humans with a fibrous tissue network connecting dermis and deep fascia/muscle. It was not assessed whether the minipig is a responder species to tocilizumab. This was considered irrelevant for the interpretation of the present study, as this focused on the absorption behavior rather than on the general disposition PK of tocilizumab.

Tocilizumab showed high SC bioavailability in both species, i.e. 83.5 and 72.1% in minipigs and cynomolgus  monkeys,  respectively,  estimated  by  non-compartmental  PK  analysis.  Time  to maximum plasma concentration was in the expected range for SC administration of IgGs .

As a result of above  studies, the PK  of tocilizumab were  well characterized after  SC administration to animals. The data provided a basis for planning of the SC toxicology study and gave support for the clinical development program of tocilizumab SC.

## Toxicology

The evaluation of the potential toxicity of tocilizumab SC extends previous evaluations following an IV administration. The bridging strategy to non-clinical safety data focused on the elements specific to the SC route of administration versus the IV route, i.e. local tolerance at the injection site,  effects  on  the  local  and  draining  immune  system  via  assessment  of  the  draining  lymph nodes,  an  assessment  of  the  exposure,  and  possible  formation  of  anti-drug  antibodies  in relationship to the IV route at the same dose.

Furthermore, the reversibility of any changes, if observed, was assessed.

One high dose level of 100 mg/kg weekly given subcutaneously was chosen for this purpose. This is the same high dose that was used previously in a 6-month repeat-dose toxicity study using the IV route of administration in cynomolgus monkeys. Cmin exposure at 168 h (7 days) after the eighth weekly dose in the 9-week cynomolgus monkey SC study (100 mg/kg) is approximately

<div style=\"page-break-after: always\"></div>

40% higher than the exposure at 168 h (7 days) after the eighth weekly dose in the 6-month cynomolgus monkey IV study (100 mg/kg).

Hence,  taking  into  account  the  high  subcutaneous  bioavailability  and  the  generally  slower absorption phase for SC mode of administration compared to the IV route, the somewhat higher Cmin  values  for  the  SC  dose  in  this  sub-chronic  study  are  to  be  expected.  Overall,  taking variability into account, comparable exposures between the same nominal doses used for IV and SC  administration  to  cynomolgus  monkeys  have  been  observed.  This  justifies  a  complete bridging of systemic effects observed between these two modes of administration.

As local reactions and effects on the draining lymphatic system specific to the SC administration of  tocilizumab  were  not  apparent  from  the  study  with  SC  administration,  no  additional  safety concerns  have  emerged  from  this  administration  mode  of  tocilizumab.  Further,  there  was  no evidence of formation of anti-drug antibodies in the animals of the 16 weeks recovery phase of the study.

In the submitted 9-week subcutaneous administration toxicity study in the cynomolgus monkey with a 16-week recovery phase, only a very rough reference to the IV study was made. Higher trough values for the subcutaneous dose were observed with comparable elimination kinetics in a sub-chronic  study.  Since  a  lot  of  data  from  clinical  studies  using  the  SC  administration  are available  no  further  animal  studies  are  considered  required.  Nevertheless  the  applicant  was requested  during  the  evaluation  to  review  the  PK  data  from  IV  and  SC  administration  in cynomolgus monkeys.

The MAH argued that comparable exposures between the same nominal doses used for IV and SC administration to cynomolgus monkeys in repeat dose toxicity studies cannot be concluded from the measured data alone. This is mainly due to the fact that the chronic IV toxicity study included  trough  sampling  only  for  toxicokinetic  (TK)  assessment  and  hence  no  full  profile  is available for this study. Full profiles are available for the (newer) 9 week SC toxicity study. To bridge these two data sets, the MAH simulated the full profile for the 6 month IV toxicity study and compared it with the measured values in the 9 week SC toxicity study. The simulation of IV PK profiles was done using a non-linear PK model. The non-linear PK model was fitted to data from a single dose PK study in cynomolgus monkeys (IV dose levels of 0.5, 5, and 50 mg/kg) and from the 6 months IV toxicity study. Contrary to the 6 months IV toxicity study, in the single dose IV PK study, the full PK profiles were available.

The simulated PK after weekly IV dosing of 100 mg/kg tocilizumab to cynomolgus monkeys over 26 weeks were in agreement with both the observed trough levels and levels in the recovery phase  from  the  6  months  IV  toxicity  study.  This  match  between  PK  model-projected  plasma levels and measured levels indicates that the PK model captures tocilizumab levels during the 6 months  IV  toxicity  study  in  an  adequate  manner.  A  comparison  of  the  average  post-hoc estimated clearance and population clearance indicates a maximal mismatch of 20%.

AUC(0-168h) values are nearly identical after IV and SC administration at 100 mg/kg/week for each dosing route. As expected both Cmax and Cmin data differ between both dosing routes. Cmax levels are slightly lower after SC administration, while Cmin values tended to be higher after SC administration. These differences are consistent with the relatively slow SC absorption of immunoglobulins,  as  was  also  evident  in  the  9  week  SC  toxicity  study.  This  was  indicated  by times to maximum plasma concentrations ranging from 24 to 72 h. The justification provided by the  MAH  was  considered  acceptable  by  the  CHMP.  The  data  provided  indicate  a  comparable

<div style=\"page-break-after: always\"></div>

exposure to tocilizumab in terms of AUC after SC and IV administration at the dose level of 100 mg/kg/week used in both the SC and IV toxicity studies.

## 2.3.7. Conclusion on the non-clinical aspects

Tocilizumab and its murine surrogate antibody MR16-1 have been extensively characterized in the cynomolgus monkey and in the mouse in pharmacology, PK and toxicity studies using the IV route of administration. These data have been the basis for approval of the IV formulation.

In  order  to  bridge  the  IV  non-clinical  study  program  to  the  new  SC  formulation  program,  a bridging program consisting of a single-dose SC PK study in the minipig and a 9-week SC repeatdose  toxicity  study  followed  by  a  16-week  recovery  phase  in  the  cynomolgus  monkey  was conducted.  These  studies  were  conducted  using  the  same  dose  strength  (180  mg/mL) formulations as in humans containing the same excipients.

The bridging strategy to non-clinical safety data focused on the safety elements specific to the SC route of administration versus the IV route, i.e. local tolerance at the injection site, effects on the  local  and  draining  immune  system  via  assessment  of  the  draining  lymph  nodes  and  an assessment of the exposure, and possible formation of anti-drug antibodies in relationship to the IV  route  at  the  same  dose.  Furthermore,  the  reversibility  of  any  changes,  if  observed,  was assessed.

One high dose level of 100 mg/kg weekly given subcutaneously was chosen for this purpose. This was the same high dose used previously in a 6-month repeat-dose toxicity study using the IV route of administration in cynomolgus monkeys. SC weekly dosing of tocilizumab to cynomolgus monkeys  at  100  mg/kg  for  nine  weeks  was  well  tolerated,  without  any  relevant  tocilizumabinduced finding. The NOAEL was considered to be at the dose of 100 mg/kg. Exposure at 168 h (7 days) after the eighth weekly dose in the 9-week cynomolgus monkey SC study (100 mg/kg) was approximately 40% higher than the exposure at 168 h (7 days) after the eighth weekly dose in the 6 month cynomolgus monkey IV study (100 mg/kg). Hence, taking into account the high subcutaneous  bioavailability  and  the  generally  slower  absorption  phase  for  the  subcutaneous route of administration compared to the intravenous route, the slightly higher trough values for the subcutaneous dose are to be expected with comparable elimination kinetics in a sub-chronic study. Overall, taking variability into account, comparable exposures between the same nominal doses  used  for  IV  and  SC  administration  to  cynomolgus  monkeys  have  been  observed.  This justifies  a  complete  bridging  of  systemic  effects  observed  between  these  two  modes  of administration.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH. The MAH has provided a statement to the effect that clinical trials conducted outside the Union were carried out in accordance with the ethical standards of Directive 2001/20/EC.

In  study  WA22762,  critical  GCP  issues  were  identified  in  one  centre  in  Lithuania  following  an unscheduled Health Authority and Ethics Committee inspection. These included: 1) late reporting

<div style=\"page-break-after: always\"></div>

of serious adverse events (SAEs) and adverse events of special interest (AESI) for one patient, and 2) instances of non-compliance with the study protocol requirements (failure to use the 24hour medical line for support, failure  to  examine  the  patient  and  perform  necessary  tests  per protocol requirements, and failure to include an unscheduled visit). Corrective and preventative actions were undertaken, including the appointment of a new site principal investigator. This was considered acceptable by the CHMP.

The  clinical  development  program  comprises  six  Phase  I  or  Phase  I/II  clinical  pharmacology studies  (studies  WP18097,  BP22065,  NP25539,  BP21894,  MRA227JP  and  NP22623)  and  two pivotal  Phase  III  studies  (studies  WA22762  and  NA25220)  in  patients  with  RA.  The  Phase  III study MRA229JP, conducted exclusively in Japanese patients with RA, is supportive only of the efficacy and safety of TZC SC when given as monotherapy.

Table 4. Tabular overview of clinical studies

| Protocol               | Study Design                                                                                                                                                           | Patient Population                                                                                                                                                                        | Dose, Route, Regimen                                                                                                                                                                                                                           | Number of Patients                                                                                                                                   |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| PivotalPhaseIllStudies | PivotalPhaseIllStudies                                                                                                                                                 | PivotalPhaseIllStudies                                                                                                                                                                    | PivotalPhaseIllStudies                                                                                                                                                                                                                         | PivotalPhaseIllStudies                                                                                                                               |
| WA22762                | parallel-group non-inferiority study of TCZ + DMARD 24-week double-blind period followed by 72-week open- label extension                                              | Randomized, active-controlled, Adult patients with moderate to severe active RA who had an inadequate response to current DMARD therapy that mayhave included one or more TNF antagonists | First 24 weeks: 162 mg SC TCZ qw (via PFS) SC TCZ qw: n=631 + placebo IV q4w or Placebo SC qw (via PFS) + 8 mg/kg IV TCZ q4w Open-label extension: 162 mg SC TCZ qw (via PFS) SC TCZ qw: n=524 or 8 mg/kg IV TCZ q4w                           | N=1262 IV TCZ q4w: n=631 IV TCZ q4w: n=377 IV TCZ q4w>SC qw: n=186                                                                                   |
| NA25220                | Randomized, placebo controlled, parallel-group study severe active RA who had an of TCZ + DMARD 24-week, double-blind period followed by 72-week open- label extension | Adult patients with moderate to inadequate response to current DMARD therapythat mayhave included one or more TNF antagonists                                                             | First 24 weeks: 162 mg SC TCZ q2w (via PFS) SC TCZ q2w PFS: n=438 or Placebo SC q2w (via PFS) Open-label extension: 162 mg SC TCZ q2w (PFS) or 162 mg SC TCZ q2w (Al) Escape therapy (from Week 12): 162 mg SC TCZ qw patients before week 24) | N=656 PISC q2w PFS: n=218 TCZ PFS q2w: n=167 TCZ PFSq2w →Al q2w: n=167 PIPFSq2w→TCZPFSq2w:n=60 PIPFS q2w→TCZ Alq2w: n=59 n=162 (including 90 placebo |

<div style=\"page-break-after: always\"></div>

Al=autoinjector,DMARDs=disease-modifying anti-rheumaticdrugs;IV=intravenous;MTX=methotrexate;PD=pharmacodynamics; PFS=prefilledsyringe;PK=pharmacokinetics;PI:Placebo;PO=orally.q2w=everytwoweeks;q4w=everyfourweeks;qw=everyweek; RA=rheumatoidarthritis;rHuPH20=recombinanthumanhyaluronidase;SC=Subcutaneous;TCZ=Tocilizumab;TNF=tumornecrosisfactor

<!-- image -->

| Protocol           | Study Design                                                                                         | Patient Population                                                                | Dose,Route,Regimen                                                                                                       | No.of Patients     |
|--------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------|
| Supportive Studies | Supportive Studies                                                                                   | Supportive Studies                                                                | Supportive Studies                                                                                                       | Supportive Studies |
|                    | MRA229JPRandomized,double-blind,parallel (Phasell)group comparative studyofSCTCZ monotherapy         | Adult patientswith RA withinadequateresponse8 toDMARDs(including TNF antagonists) | 162mgSCTCZq2w+placeboIVq4wvs 8mg/kgIVTCZq4w+placeboSCq2wfor24 weeksfollowedbyopen-labelSCTCZforupto 84weeks              | N=348              |
| (PhaseI/Il)        | MRA227JPRandomized,open-label,multiple-dose, inter-individual doseescalationstudyof SCTCZmonotherapy | Adult patients with RA                                                            | 81mgSCTCZq2wfor35weeksvs 162mgSCTCZq2wfor35weeksvs 162mgSCTCZqwfor28weeks                                                | N=32               |
| NP22623 (Phase Ib) | Open-label,randomized,parallel-groupAdultpatientswithRA                                              |                                                                                   | Part 1:7.5-25mgMTX（POorIV)plus 162mgSCTCZqworq2wfor12weeks Part 2:(optionalpost-studyphase) 8mg/kgIVTCZqiwforuptooneyear | N=29               |
| WP18097 (Phasel)   | Single-dose,single-blind,randomized, double dummy                                                    | Adult healthyvolunteers                                                           | 160mgSCTCZ+IVplacebovs 160mgIVTCZ+SCplacebo                                                                              | N=20               |
| BP22065 (Phasel)   | Single-dose,open-label,single-center, parallelfour-groupstudyofPK,PD safetyofSCTCZvsIV               | Adult healthyvolunteers                                                           | 81or162mgSCTCZ,or81or162mgIVTCZ                                                                                          | N=48               |
| NP25539 (Phasel)   | Single-dose,randomized,open-label, parallel2-group,2-centerrelative bioavailability study(PFSvsAl)   | Adult healthyvolunteers                                                           | 162mgSCTCZviaPFSvs 162mgSCTCZviaAl                                                                                       | N=261              |
| BP21894 (Phasel)   | Single-dose,open-label,parallel-group studyof PK,PD,safety of SCTCZ                                  | Adulthealthyvolunteers                                                            | singledoseof162,324,or648mgwithor withoutrHuPH20                                                                         | N=48               |

## 2.4.2. Pharmacokinetics

The clinical pharmacology program was designed to characterize the PK and PD profiles of TCZ following IV and SC  administration and to evaluate the  immunogenicity  of  TCZ  when administered subcutaneously.

## PK characteristics of TCZ SC

The PK of TCZ following multiple IV and SC administration in RA patients was best described by a two-compartment PK model with first-order absorption (following SC administration) and parallel linear and Michaelis-Menten (non-linear) eliminations. The population estimate of bioavailability following SC administration of TCZ was 79.5%, and the absorption half-life was approximately 4 days.

The  total  clearance  of  tocilizumab  was  concentration-dependent  and  is  the  sum  of  linear clearance and non-linear clearance. Exposure following the administration of a single dose of TCZ to  healthy  volunteers increased in  a  greater than  proportional  manner  when  the  SC  dose  was increased from 81 mg to 162 mg; AUCinf increased 6.4-fold and Cmax increased 4-fold as the dose was doubled.

For both the 162 mg qw SC and 8 mg/kg q4w IV regimens, nearly complete target saturation was achieved at steady state during the entire dosing interval. The contribution of non-linear CL to  total  CL  was  small,  and  the  average  steady-state  concentration  (AUC/dosing  interval)  was similar  for  both  dose  regimens.  By  virtue  of  the  different  routes  of  administration  and  the extended absorption following SC dosing, Cmax was higher following IV dosing, whereas Ctrough was higher following SC administration.

For  the  162  mg  q2w  SC  dosing  regimen,  the  target-mediated  elimination  pathway  was  not saturated at steady state, which led to high total clearance and high fluctuation of clearance over

<div style=\"page-break-after: always\"></div>

the  dosing  interval.  The  nonlinear  clearance  led  to  a  more  than  dose-proportional  increase  in exposure following the 162 mg qw dosing regimen compared with the q2w SC dosing regimen.

After  multiple  dosing  with  162  mg  qw  and  q2w  SC,  steady-state  for  AUC  and  Ctrough  was achieved after the 12 th  injection for the qw regimen and the 6 th  injection for the q2w regimen. For 162 mg qw SC, the accumulation ratio was high for AUC, Cmax, and Ctrough (6.83, 5.47, and 6.37 respectively).Ffor 162 mg q2w SC, the accumulation was small for AUC and Cmax (2.67 and 2.12 respectively) but higher for Ctrough (5.6).

Based on parameter estimates from the population PK model, the effective t1/2  at steady-state ranged from 12.1 to 13.0 days for 162 mg qw SC and from 1.8 to 4.9 days for 162 mg q2w SC.

## Comparison of the pharmacokinetics of PK of TCZ following IV and SC administration

The  PK  profile  of  TCZ  following  SC  and  IV  dosing  differed  as  expected  on  the  basis  of  the different route of administration and dosing frequency. IV administration of TCZ is infused over a short period of time (i.e. over 1 hour) directly into the venous system, which leads to a high Cmax followed by the disposition phase. After SC  administration, TCZ  is absorbed from the subcutaneous tissue into the venous system, resulting in lower bioavailability, lower Cmax, and longer  Tmax compared  with  IV  administration.  At  steady-state  after  multiple  dosing,  the fluctuation of TCZ concentration for SC regimens is small over the dosing interval and the peakto-trough TCZ ratios of SC regimens are much lower than those of corresponding IV regimens. IV dosing  was  also  based  on  body  weight -adjusted  dosing  regimens,  whereas  SC  administration applied flat dosing regimens.

In study WA22762, the average steady-state concentration (Cmean) was similar for the 162 mg SC qw and IV 8 mg/kg q4w regimens. However, Cmax was three times lower for the SC regimen compared with the IV regimen, whereas Ctrough was 2.4 times higher with the SC regimen (see table  below).  The  exposure  level  of  the  IV  8  mg/kg  regimen  in  this  study  is  comparable  to historical  IV  8  mg/kg  data,  with  the  exception  of  a  2-fold  higher  Ctrough  value  that  was  highly variable (CV% of approximately 80%).

In  study  NA25220,  the  average  steady-state  concentration  (Cmean)  following  TCZ  SC  q2w administration was 1.9 times lower than historical IV 4 mg/kg q4w data (see table below). The Cmax values for the SC q2w regimen were 6.8 times lower than the IV 4 mg/kg regimen, but Ctrough values were four times higher with SC q2w.

In study MRA229JP, the observed Ctrough was comparable between the SC q2w and 8 mg/kg IV q4w groups from Week 4 onwards (~11 -12 μg/mL at Week 24). The observed Ctrough levels at Week 24 in these Japanese patients following SC q2w dosing were higher than those observed in similarly  treated,  but  comparatively  heavier,  patients  (54  kg  vs.  70  kg)  from  study  NA25220 (approximately 11 μg/mL vs. approximately 7 μg/mL).

<div style=\"page-break-after: always\"></div>

Table 5. Summary  Statistics  -  Mean  (SD)  of  Predicted  Steady-State  Exposure Parameters for Different SC and IV Dose Regimens

| DoseRegimen               | N   | AUC, (μg/mL·h) over 4 weeks   | Cmean (μg/mL)   | Cmax (μg/mL)   | Tmax (days)   | Ctrough (μg/mL)   |
|---------------------------|-----|-------------------------------|-----------------|----------------|---------------|-------------------|
| WA22762 162 mg SC qw      | 621 | 33000 (15320)                 | 49.1 (22.8)     | 51.3 (23.2)    | 2.8 (0.2)     | 45.3 (22.2)       |
| WA22762 8 mg/kg IV q4w    | 629 | 39500 (14500)                 | 58.7 (21.6)     | 152.7 (42.1)   |               | 18.8 (14.8)       |
| Historical 8 mg/kg IV q4w |     | 35000                         | 52.1 (23.1)     | 183 (85.6)     |               | 9.74              |
| NA25220                   | a   | (15500)                       |                 |                |               | (10.5)            |
|                           |     | 6920                          | 10.3            | 13.0           | 4.7           | 5.9               |
| 162 mg SC q2w             | 509 | (5060)                        | (7.5)           | (8.3)          | (0.5)         | (6.3)             |
| Historical                |     | 13000                         |                 | 88.3           |               |                   |
|                           |     |                               | 19.3            |                |               | 1.49              |
| 4 mg/kg IV q4w            | a   | (5800)                        | (8.6)           | (41.4)         |               | (2.13)            |

a

simulation performed with 48 weeks of treatment and the two doses tested in

Phase Ill (4 and 8 mg/kg q4w) with 10 studies (replicates) (n=1793 patients per replicate).

## Effect of intrinsic factors on the pharmacokinetics of TCZ

The following intrinsic covariates were found to have a statistically significant influence on the PK parameters of TCZ:

- Body weight and HDL cholesterol on CL
- Body weight, total protein, and albumin on central and peripheral volume of distribution
- Normalized  creatinine  clearance  on  the  maximum  elimination  rate,  and  age  on  the absorption rate constant.

Among  all  identified  covariate  relationships,  the  only  strong  covariate  dependence  was  the influence  of  body  size  on  TCZ  clearance  and  volume  parameters.  No other  covariate influence had a clinically relevant effect on TCZ PK.

Body  weight  was  identified  as  the  best  predictor  among  three  body  size  parameters  (body weight,  body  surface  area,  and  body  mass  index).  TCZ  clearance  and  volumes  increased  with increasing body weight. For IV administration, the effect of body weight was accounted for with a body weight -adjusted dosing regimen (maximum of 800 mg for patients with a body weight of ε 100 kg); however, this body-weight adjustment resulted in a higher exposure for patients of high body weight. For SC administration, flat dosing regimens were applied and TCZ exposure decreased with increasing body weight. For the 162 mg SC qw and q2w regimens, steady-state exposure was consistently low for patients of ε 100 kg and higher for patients of &lt; 60 kg compared with the majority of patients with body weight of 60 to &lt; 100 kg. In study WA22762, the steadystate Cmean for the 162 mg SC qw regimen was slightly lower for patients with body weight of 60 to  100  kg  compared  with  the  8  mg/kg  IV  regimen,  whereas  Ctrough  was  2.3-fold  higher.  For patients of ε 100kg, steady-state Cmean and Ctrough for 162 mg SC qw were 3-fold and 30% lower than those of 8 mg/kg IV, respectively; whereas steady-state Cmean and Ctrough for 162 mg SC qw were 30% and 4.7-fold higher than those of 8 mg/kg IV for patients of &lt; 60kg, respectively.

<div style=\"page-break-after: always\"></div>

## Effect of extrinsic factors on the pharmacokinetics of TCZ

Neither  smoking  nor  the  route  of  administration  had  a  noticeable  effect  on  the  TCZ  PK parameters and thus were not included in the final PK model. Among three tested injection sites for  SC  regimens  (arm,  abdomen,  and  thigh),  the  effect  of  administration  into  the  thigh  on bioavailability was greater than those of arm and abdomen. However, the difference was small (11%) and not clinically relevant.

## Pharmacokinetics of TCZ following administration with an autoinjector or prefilled syringe

## Study NP25539

The  relative  bioavailability  of  TCZ  in  healthy  subjects  following  a  single  SC  dose  of  162  mg administered via a disposable AI or PFS was assessed in study NP25539.

The data showed similar PK parameters of TCZ following administration via PFS and AI. Although the bioequivalence criterion was met for the secondary PK parameter, AUCinf, the bioequivalence of the AI compared with the PFS could not be claimed because the upper 90% CIs for geometric mean ratios (GMRs) for the primary PK parameters Cmax and AUClast (1.27 for both) fell slightly above the prospectively defined upper bound of the bioequivalence range (0.80, 1.25).

Although  the  primary  analyses  did  not  show  the  two  devices  to  be  bioequivalent,  the  results showed that the time course for TCZ was very similar following administration of TCZ via the PFS and  AI.  The  estimated  GMRs  (AI  compared  to  PFS)  for  Cmax,  AUClast,  and  AUCinf  were approximately  1.09,  1.07,  and  1.04,  respectively.  These  values,  along  with  the  90%  CIs  for GMRs, indicated slightly higher average exposure to TCZ following administration via the AI. It was noted, however, that all individual exposure values following AI administration were within the range of values observed with PFS, with the exception of the maximal Cmax value following AI (33.1 μg/mL, compared with 29.2 μg/mL following PFS). Furthermore, safety results from both treatment groups were comparable.

## Study NA25220

Study NA25220 also evaluated administration of TCZ SC via a PFS or AI in the LTE phase (i.e. from Week 24 onwards). Regardless of treatment up to Week 24, Ctrough levels were comparable between the PFS and AI  from Weeks 24 through  36, indicating  that  both  devices  delivered  a comparable dose of TCZ with each injection up to that point. Compared with the PFS, the Week 40 and Week 48 Ctrough values for the AI were lower in patients who switched from placebo and higher  in  those  who  switched  from  active  TCZ  treatment.  Interpretation  of  this  finding  was limited by the low numbers of evaluable patients compared with available data up to Week 36.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). Tocilizumab has been shown to inhibit sIL-6R and mIL-6R-mediated signalling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes  and  fibroblasts.  IL-6  is  involved  in  diverse  physiological  processes  such  as  T-cell

<div style=\"page-break-after: always\"></div>

activation,  induction  of  immunoglobulin  secretion,  induction  of  hepatic  acute  phase  protein synthesis  and  stimulation  of  haemopoiesis.  IL-6  has  been  implicated  in  the  pathogenesis  of diseases including inflammatory diseases, osteoporosis and neoplasia.

## Primary pharmacology

In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed. Consistent with the effect on acute phase reactants, treatment  with  tocilizumab  was  associated  with  reduction  in  platelet  count  within  the  normal range. Increases in haemoglobin levels were observed, through tocilizumab decreasing the IL-6 driven effects on hepcidin production to increase iron availability. In tocilizumab-treated patients, decreases  in  the  levels  of  CRP  to  within  normal  ranges  were  seen  as  early  as  week  2,  with decreases maintained while on treatment.

## Effect of TCZ SC on CRP and sIL-6R Levels

The  sIL-6R-bound  TCZ  complex  and  CRP  are  two  key  PD  markers  for  the  TCZ  mechanism  of action. Greater increases in sIL-6R levels suggest more binding of TCZ to sIL-6R. CRP levels are suppressed after blockade of the IL-6 pathway by TCZ.

The profiles of sIL-6R (see figure below) and CRP (see figure below) for RA patients receiving TCZ 162 mg SC qw closely mirrored those receiving TCZ 8 mg/kg IV, with respect to both the rate and magnitude of change. For patients on the TCZ SC qw regimen, there was a substantial increase  in  sIL-6R  levels  which  were  comparable  to  those  achieved  with  the  8  mg/kg  IV  q4w regimen  (study  WA22762).  An  increase  in  sIL-6R  levels  was  also  observed  with  the  SC  q2w regimen, but to a lesser extent than was observed with the SC qw regimen. However, sIL-6R levels were notably higher for TCZ SC q2w compared with historical TCZ 4 mg/kg IV q4w data.

The SC qw regimen provided complete suppression of CRP from Week 2 onwards, with mean CRP levels slightly lower than those achieved with 8 mg/kg IV from Weeks 4 to 24, consistent with higher  trough  TCZ  concentrations  in  this  group  (see  figure  below).  The  SC  q2w  regimen  also provided suppression of CRP from Week 2 onwards, but CRP levels remained higher than those achieved with SC qw or 8 mg/kg IV, but lower than those seen with historical 4 mg/kg IV data. These results indicate that the SC q2w regimen provides adequate suppression of CRP, but to a lesser extent than with the qw regimen.

<div style=\"page-break-after: always\"></div>

Figure 3. Studies WA2762, NA25220, and Historical 4 and 8 mg/kg IV Data: Mean (± SEM) sIL-6R Levels over Time

<!-- image -->

Figure 4. Studies WA22762, NA25220 and Historical 4 and 8 mg/kg IV Data: Mean (± SEM) CRP Levels over time

<!-- image -->

Pharmacodynamic  effects  following  administration  of  TCZ  with  an autoinjector or prefilled syringe in study NA25220

In study NA25220, following re-randomization, and irrespective of treatment up to Week 24, the levels of the various PD markers (sIL-6R, CRP, and ESR) were comparable between the PFS and AI  from  Weeks  24  through  48.  This  indicates  that  the  differences  in  TCZ  exposure  noted  at

<div style=\"page-break-after: always\"></div>

Weeks 40 and 48 did not translate into a discernible difference in PD effect. However, the low numbers of patients at Weeks 40 and 48 limits this analysis.

## Immunogenicity

The overall immunogenicity rate (defined as the development of a confirmed postbaseline antiTCZ antibody response) with TCZ SC was low and comparable to that previously reported for TCZ IV.

At Week 24, the proportion of patients who developed anti-TCZ antibodies was 0.8% with the SC qw  regimen,  0.8%  with  the  8  mg/kg  IV  regimen,  and  1.6%  with  the  SC  q2w  regimen.  The proportion of patients who developed neutralizing anti-TCZ antibodies was 0.8% with both the SC qw and 8 mg/kg IV regimens, and 1.4% with the SC q2w regimen. These rates are consistent with those previously reported for TCZ IV (0.6% and 1.0%, respectively).

In the SC qw and q2w studies, data from the LTE phase showed that the proportion of patients who developed anti-TCZ antibodies was consistent with the Week 24 results.

It should be noted with the 162 mg TCZ SC qw regimen used in study WA22762, there was the possibility for interference with the immunogenicity assay (because of high Ctrough TCZ levels); this could potentially have led to an underestimation of the incidence of immunogenicity. As a consequence,  the  protocol  for  study  WA22762  was  amended  (amendment  C),  to  allow  the collection  of  an  additional  serum  sample  to  analyze  anti-TCZ  antibodies  in  patients  who  had prematurely withdrawn from the study, completed the study, or missed TCZ treatment during the study. The data for the 162 mg TCZ SC q2w regimen used in study NA25220 are considered robust,  as  the  TCZ  Ctrough  levels  were  lower  and  were  not  expected  to  interfere  with  the immunogenicity assay.

## Effect of anti-TCZ antibodies on the pharmacokinetics of TCZ

Anti-TCZ antibodies had no impact on the PK profiles of TCZ, except for one patient in study NA25220 for whom anti-TCZ antibodies may be related to the change in PK/PD profile for this particular patient.

In  the  population  PK  covariate  analysis,  anti-TCZ  antibodies  were  not  identified  as  a  covariate influencing  the  PK  of  TCZ.  Neutralizing  anti-TCZ  antibodies  did  not  affect  the  evaluated exposure-safety and exposure-efficacy relationships.

## 2.4.4. Discussion on clinical pharmacology

Central to the PK/PD assessment are the two pivotal studies (studies WA22762 and NA25220), which  provide  data  on  SC  dosing  at  the  fixed  dose  of  162  mg  administered  via  the  prefilled syringe (PFS). The dose regimen proposed by the MAH i.e. q1w was studied in WA22762 only. In study NA25220 a q2w regimen was investigated.

The use of single-use auto-injector (AI) was investigated in study NA25220 open-label extension part (q2w). Additional data on the comparison of PFS versus AI are derived from the single dose study NP25539 in healthy volunteers.

Study WA22762 directly compared the already approved IV posology (8 mg/kg q4w) with the 162 mg SC fixed q1w dose that the MAH applied for as part of this extension application.

<div style=\"page-break-after: always\"></div>

Of note, the observed Ctrough level was approximately 18 μg/mL in the IV arm which is nearly twice as high as the historical value (9.74 μg/mL) currently reflected in the SmPC. The MAH shall submit a variation to align section 5.2 of the SmPC for the IV and the SC route of administration with the corrected Ctrough value.

For both the IV and SC route of administrations steady state was reached around week 12. The increase from baseline was in the SC group 5-fold and in the IV group 2-fold. Ctrough level were approximately 40 μg/mL in the SC qw arm and approximately 18 μg/mL in the IV  q4w arm. With a KD value of about 1nM (corresponding to 0.15 μg/ml) for the binding of tocilizumab to IL-6R, this corresponds to 267 and 120 times the KD value respectively.

Ctrough is highest at low body weight and decreases with body weight. This is mainly due to the flat dose in contrast to the weight adjusted IV dose, which led to a relative increase in exposure in  patients  with  low  body  weight.  In  comparison  to  IV  dosing  at  comparable  body  weight, Ctrough after SC administration in the low body weight category is 4-fold higher, in the mid body weight group 2-fold higher and about equal in patients with high body weight. This means that, in  patients  with  a  body  weight  below  100  kg,  steady  state  exposure  to  tocilizumab  is  at  least twice as high as with the approved IV posology. Even in patients with body weight &gt; 100 kg, the Ctrough at week 24 after q1w SC application is as high as in the IV group corresponding to 120 times the KD value.

The results indicate that for patients &gt;100 kg, the SC qw dose is required to achieve an adequate response  to  therapy.  Study  NA25220  demonstrated  that  as  expected  lower  Ctrough  level  are observed with the q2w SC dose regimen compared to weekly SC dosing. Steady state is reached later at week 20 with a 3.9-fold increase around week 24. The mean steady-state predose TCZ concentration at Week 24 was approximately 7.4 μg/mL following SC dosing q2w (higher than previously reported in the small sized study NP22623). This corresponds to 49 times KD value for the binding of tocilizumab to IL6-R.

Similar  to  the  q1w  SC  regimen,  increasing  exposure  with  decreasing  body  weight  is  also observed  with  the  SC  q1w  162  fixed  dose.  Ctrough  increases  by  2-fold  in  patients  &lt;60kg compared  to  patients  with  average  body  weight  (60-100kg).  In  contrast  to  the  weekly  dose regimen, however, the results indicate a steeper decline of Ctrough in patients &gt;100kg. Given the low number of patients in this body weight category (5.8%), the results may be interpreted with cautions. However, they could also be related to the low serum concentration level, where non-linear  clearance  manifests,  and  thus  indicate  that  the  q2w  SC  dose  regimen  may  not  be appropriate for obese patients in providing reliably a sufficient Ctrough level for target saturation.

In  patients  with  body  weight  &gt;  100  kg,  the  variability  of  Ctrough  was  also  high,  which  may further  explain  why  despite  a  mean  Ctrough  at  wk24  after  q2w  SC  application  of  2.0  μg/mL corresponding to 13 times the KD value.

A similar pattern arises with the q2w dosing as seen with q1w or IV dosing with regard to CRP, sIL-6R and ESR response. The drop in CRP below the ULN is observed also at wk2. A level below the ULN is maintained throughout treatment, which is only slightly higher than after IV or 2wq SC administration.

SC bioavailability derived by population PK modelling (79.5%) is higher than previously reported from single dose studies (48.8% and 56.5% for the respective dose range of 162 mg). However, the CHMP is of the view that the most reliable assessment of bioavailability, which is affected by

<div style=\"page-break-after: always\"></div>

clearance, is the population PK approach, since it takes the concentration-dependent variability of the clearance into account. When applying compartmental modelling to the single dose study results  to  address  clearance  more  properly,  the  bioavailability  is  estimated  as  77%  (95%  CI: 69% to 85%).

With  regard  to  Ka  and  elimination  half-life,  since  it  could  not  be  determined  what  definitely caused  the  discrepancy  (of  ~2  days)  between  the  two  pivotal  studies  (sampling  intervals, differences in elimination between the dose regimens), Tmax instead of absorption half-life has been included in section 5.2 of the SC SmPC and also the bioavailability is expressed in %.

While there was no clear correlation between Ctrough and incidence of AEs there is a reduction of overall AEs and of infection/infestations in the q2w SC dose group compared to the q1w SC dose regimen and IV dosing. This could be related to the reduced incidence of grade 1-2 neutropenia observed with SC q2w dosing. These data suggest a trend towards reduced infection/infestation risk  with  162  mg  q2w  SC  dos  regimen.  There  was no apparent association  between concentrations of tocilizumab and the occurrence of SAEs. This observation is consistent with the analysis  of  pooled  IV  data  from  four  Phase  III  studies.  The  incidence  of  SAE  was  comparable between the treatment regimens

In general, the model parameters are similar to the estimates obtained earlier with the IV data suggesting  that  there  are  no  major  differences  between  exposure-response  relationships between the IV and SC formulations.

There was a slight covariate effect of the injection site (arm, abdomen, thigh or 'unknown') on bioavailability with an increase in Fsc after injection into the thigh by 11%. There are however differences in the covariate effects. Previously identified influences on the population PK-safety analysis  were  only  partially  confirmed  (CRP,  PCOR,  gender,  IL-6  level).  Age  was  a  newly identified effect on Kout in the current model, resulting in increased neutrophil reduction rate in older patients. Nevertheless, in none of the dose regimens did this result in a clinical meaningful difference.

Overall, the influence of covariates on neutrophil counts over time depicted in simulations was small and clinically not significant.

With  regard  to  immunogenicity,  albeit  the  same  DP  was  used  in  all  three  phase  III  studies (WA22762, NA25220, MRA229JP), there is discrepancy between the studies in the incidence of ADA development after SC (0.8(q1w), 1.6(q2w), 15% (q2w)) as well as after IV dosing (0.8, na., 5%  respectively).  The  MAH  clarified  that  the  differences  observed  were  due  to  different immunogenicity assay strategies, and were not related to assay methodology or other influences. This was considered acceptable by the CHMP.

## 2.4.5. Conclusions on clinical pharmacology

The  pharmacokinetics  of  TCZ  following  single  multiple  SC  administrations  were  studied  in  six Phase  I  and  II  studies  in  healthy  volunteers  and  RA  patients.  In  addition  PK  data  have  been collected from the two pivotal phase III studies (studies NA25220 and WA22762) for population PK modelling.

The  PK  profile  of  TCZ  following  SC  and  IV  administration  differed  as  expected  based  on  the different route of administration and dosing regimen. IV administration of TCZ is infused over a short  period  of  time  leading  to  a  high  Cmax  followed  by  a  disposition  phase.  After  SC

<div style=\"page-break-after: always\"></div>

administration, TCZ is absorbed through the lymphatic system into the venous system resulting in  a  lower  bioavailability,  lower  Cmax  and  longer  Tmax  compared  with  IV  administration.  The inter-subject  variability  of  plasma  levels  significantly  increased  but  is  more  pronounced  after single  administration  than  at  steady-state.  Steady  state  was  reached  after  12  weeks  for  AUC, Cmin, and Cmax like with the IV route of administration.

After a single dose, the mean AUCinf for the 162-mg SC dose was approximately 6.4-fold higher than the AUCinf for the 81 mg SC dose while the corresponding ratio for Cmax was 4. The nonlinear clearance of TZC was more marked in the SC route than in the IV route.

In conclusion, though the predefined margins for bioequivalence between the AI and PFS were not met for primary PK parameters (AUClast and Cmax), the bioequivalence criterion was met for the secondary PK parameter (AUCinf). In addition, the mean TCZ concentration -time profiles of PFS and AI were near superimposable, which indicated that the rate and extent of absorption are comparable following AI and PFS administrations. Considering the variability in PK parameters, the fact that the pre-specified margins for the upper 90% CIs for AUClast and Cmax were exceeded by 2%, this is not considered to be clinically relevant.

In the population PK, among all identified covariate relationships, the only strong covariate was body size impacting on TCZ clearance and volume parameters. No other covariate influence had a clinically relevant effect on TCZ PK. The strong influence of body weight was already observed with the IV route hence the dosing regimen is expressed per body weight. In contrast, the TZC dose is a flat one at 162 mg for the SC route.

The mechanism of action of TCZ administered via the SC route is not expected to differ from TCZ administered via the IV route. Therefore no new PD studies were submitted by the MAH with this extension  application  which  is  considered  acceptable  by  the  CHMP.  The  relationships  between concentration and effect and also concentration and safety have been satisfactorily discussed by the MAH for the new SC route of administration.

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies

No formal exposure-response evaluation has been performed by the MAH to register the SC route of administration. This was considered acceptable by the CHMP.

## 2.5.2. Main studies

## Study NA25220

Study  NA25220  was  a  phase  III,  two  arms,  two  years,  randomized,  double-blind,  placebo controlled, parallel-group, multi-center study in patients with moderate to severe active RA who had  an  inadequate  response  to  DMARD(s)  that  may  have  included  one  or  more  anti -TNFα agents  (with  the  percentage  of  patients  who  had  failed  one  or  more  anti -TNF  biologic  agents being capped at approximately 20%). The primary endpoint was evaluated at 24 weeks.

The overall study design is shown in the figure below.

<div style=\"page-break-after: always\"></div>

Figure 5. Study Design

<!-- image -->

Al=autoinjector; IV=intravenous; q2w=every 2 weeks; qw=once weekly; PFS=pre-filled syringe; SC =subcutaneous; SJC =swollen joint count; TCZ=tocilizumab; TJC =tender joint count.

## Methods

## Study participants

The  target  population  for  this  study  was  patients  with  moderate  to  severe  RA  who  were inadequate responders to DMARDs that may include one or more anti -TNFα agents.

The  percentage  of  patients  who  had  failed  one  or  more  anti-TNFα agents  was  capped  at approximately 20%.

## Inclusion criteria

Patients were eligible for the study if they met all of the following criteria:

1. Able and willing to give written informed consent and comply with the requirements of the study protocol (e.g. willing to take oral folate at a minimum dose of 5 mg/wk if on methotrexate [MTX] treatment.)
2. Age ≥ 18 years

<div style=\"page-break-after: always\"></div>

3. RA  of ≥ 6  months  duration,  diagnosed  according  to  the  revised  1987  ACR  (formerly American Rheumatism Association criteria)
4. Receiving treatment on an outpatient basis
5. SJC ≥ 6 (66 joint count) and TJC ≥ 8 (68 joint count) at screening and baseline
6. Prior to randomization, had discontinued etanercept for ≥ 2 weeks, infliximab, certolizumab, golimumab, abatacept or adalimumab for ≥ 8 weeks, anakinra for ≥ 1 week
7. Had to be on permitted DMARD(s) (see Section 4.4.2 of the protocol), at a stable dose for at least 8 weeks prior to baseline
8. At  screening,  either  C-reactive  protein  (CRP) ≥ 1  mg/dL  (10  mg/L)  or  erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr
9. At  screening,  radiographic  evidence  of  at  least  one  joint  with  a  definite  erosion attributable to rheumatoid arthritis, as determined by the central reading site. Any joint of the hands, wrist, or feet was considered, with the exception of the DIP joints of the hands
10. Oral  corticosteroids  ( ≤ 10  mg/day  prednisone  or  equivalent)  and  NSAIDs  (up  to  the maximum recommended dose) were permitted if on a stable dose regimen for ≥ 4 weeks prior to baseline
11. Females  of  childbearing  potential  and  males  with  female  partners  of  childbearing potential participated  in  this  trial  only  if  using  a  reliable  means  of  contraception  (e.g., physical barrier [patient or partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device)
12. If female of childbearing potential, the patient had to have a negative pregnancy test at screening and baseline visit.

## Exclusion criteria

Patients were ineligible for the study if they met any of the following criteria:

## General

1. Major  surgery  (including  joint  surgery)  within  8  weeks  prior  to  screening  or  planned major surgery within 6 months following randomization
2. Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus, mixed  connective  tissue  disease,  scleroderma,  polymyositis,  or  significant  systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty syndrome).
3. Secondary Sjögren syndrome with RA was allowed.
4. Functional  class  IV  as defined  by  the  ACR  Classification  of  Functional  Status  in Rheumatoid Arthritis
5. Diagnosed with JIA or juvenile RA and/or RA before the age of 16

<div style=\"page-break-after: always\"></div>

6. History of or current inflammatory joint disease other than RA (e.g., gout, Lyme disease, seronegative spondyloarthropathy, including reactive arthritis, psoriatic arthritis, arthropathy of inflammatory bowel disease).

## Excluded Previous or Concomitant Therapy

1. Treatment  with  any  investigational  agent  within  4  weeks  (or  5  half-lives  of  the investigational drug, whichever was longer) of screening
2. Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies,  some  examples  of  which  are  CAMPATH,  anti-CD4,  anti-CD5,  antiCD3, anti-CD19, and anti-CD20
3. Treatment with IV gamma globulin, plasmapheresis within 6 months of baseline
4. Intra-articular (IA) or parenteral corticosteroids within 4 weeks prior to baseline
5. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline
6. Previous treatment with TCZ (an exception to this criterion could have been granted for single-dose exposure upon application to the Sponsor on a case-by-case basis)
7. Any  previous  treatment  with  alkylating  agents  such  as  chlorambucil  or  with  total lymphoid irradiation.

## Treatments

During  the  double-blind  period,  a  fixed  dose  of  162  mg  TCZ  or  matching  placebo  was administered by SC injection q2w until Week 24. The open-label period began at Week 24, when all patients who did not initiate escape therapy received a fixed dose of 162 mg of SC TCZ q2w.

Escape therapy:

- From Weeks 12 to 48, patients initially randomized to receive either TCZ or placebo could move to escape therapy with TCZ 162 mg SC qw if there was &lt; 20% improvement in SJC and  TJC  from  baseline.  Such  patients  could  receive  open  label  treatment  until  the completion of the trial.
- After Week 48, if a ≥ 70% improvement from baseline in SJC and TJC was not reached, patients could be switched to treatment with TCZ 162 mg SC qw.

If  a  patient  discontinued  for  any  reason  from  the  study  prior  to  Week  12,  he  or  she  was  not eligible  to  receive  escape  therapy.  All  patients  who  received  escape  therapy  had  radiographic assessments scheduled at Weeks 24 and 48.

Study drug was supplied in a 1-mL ready-to-use, single-use PFS, with a needle safety device, delivering  either  162  mg/0.9  mL  solution  of  TCZ  or  matching  placebo  and  stored  at  2ºC -8ºC.

One PFS was used for each SC administration that was warmed to room temperature before use.

<div style=\"page-break-after: always\"></div>

## Objectives

The primary objectives of the study were to assess the following:

- The efficacy of treatment with TCZ 162 mg SC given every other week versus placebo, in combination with DMARDs, at Week 24 using American College of Rheumatology (ACR) 20
- The safety of treatment with TCZ 162 mg SC given every other week versus placebo, in combination with DMARDs, with regard to adverse events and laboratory assessments.

The secondary objectives of the study were to assess the following:

- Prevention of progression of structural joint damage at Week 24 and Week 48 (addressed in the Open-label Extension Report 105275)
- Improvement of physical function
- Long-term safety and efficacy (addressed in the Open-label Extension Report 105275)
- Pharmacokinetics and pharmacodynamics of TCZ following SC administration
- Immunogenicity of TCZ following SC administration
- Specimens stored in the Roche Clinical Repository (RCR) are to be used to:
- o Study  the association of biomarkers  with efficacy and/or adverse events associated with medicinal products; and/ or
- o Increase our knowledge and understanding of disease biology; and/or
- o Develop biomarker or diagnostic assays; establish the performance characteristics of these assays TCZ pharmacokinetic (PK) -safety and PK -efficacy relationships were also explored.

## Outcome/endpoints

## Primary endpoint

The primary endpoint was identified as the percentage of patients with an ACR20 response at Week 24. The primary comparison was between the group of patients who received TCZ 162 mg SC q2w (Group A) and the group who received placebo SC q2w (Group B).

## Main efficacy secondary endpoints

The main secondary efficacy endpoints were the following:

1. Proportion of patients with ACR50 response at Week 24
2. Proportion of patients with ACR70 response at Week 24
3. Change in Disease Activity Score 28 (DAS28) from baseline at Week 24
4. Proportion of patients with DAS28 &lt; 2.6 (DAS28 remission) at Week 24

<div style=\"page-break-after: always\"></div>

## Sample size

The  primary  analysis  was  based  on  the  intent-to-treat  (ITT)  population.  Based  on  previous ACR20 response rates of patients in the placebo and 4-mg/kg groups in the Phase III TCZ IV studies,  OPTION  (study  WA17822),  LITHE  (study  WA17823),  and  RADIATE  (study  WA18062), the expected ACR20 response was 23% in the placebo arm and 46% in patients treated with IV TCZ. These assumptions were used to generate the sample size for this trial. A sample size of 600 patients, randomized at a ratio 2:1 (400:200 patients), would ensure at least 90% power to detect this difference with a significance level of 5%.

The analysis of the progression of structural damage was a critical secondary objective.

Assuming that patients treated with TCZ 162 mg SC q2w showed the same response as patients treated with TCZ 4 mg/kg IV in the LITHE study, and the response of the placebo SC arm was identical to the placebo IV arm in the LITHE study, then 600 patients randomized in a 2:1 ratio provided a power &gt; 90% to detect a treatment difference between both arms.

The  power  calculation  of  the  radiographic  analysis  was  based  on  simulations  of  the  Week  24 LITHE data followed by  analysis  with  the  van  Elteren  test.  This  non-parametric  statistical  test provides a p-value but not an estimate of the treatment effect.

## Randomisation

Eligible  patients  who  fulfilled  the  inclusion  and  exclusion  criteria  were  randomly  assigned  at  a ratio  of  2:1  to  either  162  mg  SC  q2w  or  placebo  at  baseline  for  the  double-blind  period  and subsequently re -randomized at a 1:1 ratio within each treatment group at Week 24 for the openlabel period, utilizing an interactive voice response system (IVRS).

The two sets of randomization numbers were generated by Perceptive Informatics, Inc. and were linked  to  a  unique  patient  identification  number  through  the  IVRS.  At  baseline,  randomization was  by  minimization,  stratified  by  geographic  region  (Europe,  North  America,  South  America, and  rest  of  world)  and  body  weight  category  ( &lt; 60  kg,  60  to &lt; 100  kg,  and ≥ 100  kg).  The minimization procedure was implemented by Perceptive Informatics. This involved maintaining an updated record of treatment assignments by stratification factors and was used to determine the treatment of choice for a newly recruited patient. The minimization procedure was based on an  80:20  random  element  (i.e.  a  patient  was  assigned  to  the  treatment  of  choice  with  a probability of 0.8).Randomization at Week 24 was implemented by permuted block.

## Blinding (masking)

This study was blinded during the first 24 weeks and a 'dual assessor' approach was used to evaluate first efficacy and then safety data to prevent potential unblinding because of observed efficacy  or  laboratory  changes.  The  efficacy  assessor  was  a  rheumatologist  or  other  skilled arthritis  assessor  but  could  not  be  the  Principal  Investigator.  The  efficacy  assessor  was responsible  for  assessing  the  joint  counts  and  the  Physician's  Global  Assessment  of  Disease visual  analog  scale  (VAS)  components  but  was  not  allowed  access  to  other  patient  data.  The safety  assessor  was  a  rheumatologist  or  medically  qualified  physician  with  access  to  both  the safety and efficacy data and was permitted to be the Principal Investigator.

<div style=\"page-break-after: always\"></div>

Assessments completed by the patient and by the efficacy assessor were to be made before the assessments by the safety assessor.

The study centers, Roche monitors, project statisticians, and the project team were blinded to specific laboratory data (i.e., TCZ, IL-6, sIL-6R, and CRP) before the primary analysis.

Blinding  of  the  treatment  received  was  maintained  for  patients  and  site  personnel  until  all patients completed Week 48 and all data for all patients up to that time point had been collected and reported. Unblinding by the Sponsor occurred at the time of the Week 24 primary analysis.

Per  regulatory  requirements,  study  treatment  was  to  be  unblinded  for  all  unexpected  serious adverse events that were considered by the investigator to be related to study drug. There were no cases of treatment code breaks during the double-blind period of the study.

After  the  Week  48  data  analysis  and  following  specific  instructions  from  the  Sponsor,  a  single assessor approach (using a qualified physician to perform all efficacy and safety assessments) could be used for subsequent visits during the open-label part of the study.

## Statistical methods

The primary analysis tested the null hypothesis that the percentage of patients with an ACR20 response  at  Week  24  in  Group  A  (TCZ  162  mg  SC  q2w)  was  the  same  as  the  percentage  of patients with an ACR20 response at Week 24 in Group B (placebo SC q2w). The null hypothesis was rejected if the percentage of ACR20 responders in Group A differed from Group B.

To test whether treatment assignment by minimization did not affect the outcome of the study, the primary and secondary analyses were re-analyzed by the re-randomization or permutation

## Results

## Participants flow

Of the 1034 patients screened, a total of 656 patients were randomized into the study. The main reason for screen failure was a lack of radiographic evidence of at least one joint with a definite erosion attributable to RA, as determined by the central reading site.

Of the 656 patients enrolled into the study, 437 patients were randomized to receive TCZ and 219 patients were randomized to receive placebo (see figure below).

All patients received at least one dose of study drug. However, 1 patient inadvertently received the wrong treatment. Patient 12001 received TCZ instead of placebo at baseline.

<div style=\"page-break-after: always\"></div>

Figure 6. Overview of Patient Disposition

<!-- image -->

Note: Percentages are based on the number of randomized patients.

All patients received at least one dose of study drug; however, 1 patient (12001) inadvertently received the wrong treatment. Patient 12001 received TCZ instead of placebo at baseline.

Patients who withdrew after Escape

Source: Table 5, Table 6, Table 7, page 276.

## Recruitment

Patients  were  enrolled  at  124  active  centres  in  21  countries  including  South  America,  Europe, and North America.

The first patient was screened on 23 February 2011, and the first patient was randomized on 14 March 2011. The last patient was randomized on 28 November 2011, and the clinical cut-off for the 24-week analysis was 28 May 2012.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

There were two amendments of the protocol.

## Amendment B (24 February 2011):

- A TCZ AI was made available for use in the open-label portion of the study.
- Additional details for the analyses of the radiographic endpoint were included.
- The required tests for the liver profile were clarified, liver profile testing was added at Week 36, and vital sign measurements were added at Weeks 10 and 36.
- The adjustment of the random element used to ensure a baseline randomization ratio of 2:1 was clarified.
- To  prevent  any  potential  unblinding,  a  dual  assessor  approach  was  used  until  the completion of Week 48 data analysis.
- The  reporting  period  for  AESI,  including  nonserious  AESI  to  Roche  Drug  Safety  was clarified (i.e. within 24 hours of learning of the event).
- The requirement for an X-ray image at the initiation of escape therapy was clarified.

## Amendment C (26 April 2011)

- An  optional  ease-of-use  substudy  was  added  to  the  open-label  period  for  the  sites  in Canada and the United States in order to evaluate the ability of patients, caregivers and healthcare professionals to handle and use the PFS or AI.

These two amendments of the protocol did not impact on the safety and efficacy analysis of the study.

The change in the planed analysis (sensitivity analyses) was implemented prior to the unblinding, and had no impact on the efficacy and safety analysis.

## Baseline data

## Demographic data

The  study  population  comprised  predominantly  Caucasian  (72.1%)  females  (84.7%),  with  a mean age of approximately 52 years (range 18 -82 years, see table below). The two treatment arms  were  balanced  with  respect  to  all  baseline  demographic  characteristics  recorded.  The majority of the patients (67%) weighed between 60 and &lt; 100 kg, with 27% weighing &lt; 60 kg and 5.6% weighing ≥ 100 kg. The maximum weight was capped at 150 kg (per the exclusion criterion).

The baseline demographic characteristics of patients in the ITT population were consistent with those observed in the safety population. A listing of baseline demographic characteristics for all patients randomized is provided.

<div style=\"page-break-after: always\"></div>

## Table 6. General Demographic Variables (Safety Population)

|                                                       | ICZ PFS q2w N = 437   | Placebo PFS q2w N = 218   |
|-------------------------------------------------------|-----------------------|---------------------------|
| Sex                                                   |                       |                           |
| MALE                                                  | 62 (14.28)            | 38 (17.4%)                |
| FEMALE                                                | 375 (85.88)           | 180 (82.68)               |
| n                                                     | 437                   | 218                       |
| Race                                                  |                       |                           |
| AMERICAN INDIAN /                                     |                       | 1 ( 0.58)                 |
| ALASRA NATIVE, WHITE AMERICAN INDIAN / ALASKA NATIVE  | 3 (0.78)              | 1 ( 0.58)                 |
| WHITE                                                 | 321 (73.58)           | 151 (69.38)               |
| AMERICAN INDIAN /                                     | 1 (0.28)              |                           |
| ALASKA NATIVE, BLACK ASIAN-INDIAN                     | 1 ( 0.28)             |                           |
| SUBCONTINENT ASIAN-OTHER THAN INDIAN SUBCONTINENT     | 19 ( 4.38)            | 13 ( 6.08)                |
| ASIAN-OTHER THAN INDIAN SUBCONTINENT, BLACK / AFRICAN | 1 ( 0.28) 22 ( 5.0%)  | 13 (6.0)                  |
| AMERICAN OTHER RACE                                   | 66 (15.18)            | 38 (17.4%)                |
| WHITE, OTHER RACE n                                   | 3 3(0.7%) 437         | 1 (0.58) 218              |
| Age in years                                          |                       |                           |
| Mean                                                  | 52.1                  | 52.0                      |
| SD                                                    | 11.49                 | 11.67                     |
| SEM                                                   | 0.55                  | 0.79 54.0                 |
| Median                                                | 53.0                  |                           |
| Min-Max n                                             | 18 - 82 437           | 18 - 76 218               |
| Weight in kg                                          |                       |                           |
| Mean                                                  | 70.33                 | 70.04                     |
| SD                                                    | 16.623                | 15.800                    |
| SEM                                                   | 0.795                 | 1.070                     |
| Median                                                | 67.00                 | 68.80                     |
| Min-Max                                               | 37.1-130.9            | 40.0-129.0                |
| n                                                     | 437                   | 218                       |
| Height in cm                                          |                       |                           |
| Mean                                                  | 161.116               | 161.740                   |
| SD                                                    | 8.9256                | 9.4313                    |
| SEM                                                   | 0.4284                | 0.6388                    |
| Median                                                | 160.000               | 161.000                   |
| Min-Max                                               | 132.00-200.00         | 124.00 - 193.00           |
| n                                                     |                       |                           |
|                                                       |                       | 218                       |
|                                                       | 434                   |                           |
| Baseline Weight Category  (kg)                        |                       |                           |
|                                                       | 119 27.28)            | 58 (26.68) 149 (68.38)    |
| <60 60-100                                            | 292 (66.8%) 26 (5.98) | 11 (5.08)                 |
| >=100 n                                               | 437                   | 218                       |

<!-- image -->

<div style=\"page-break-after: always\"></div>

```
ICZ PFS q2w Placebo PFS q2w N = 437 N = 218 Ethnicity HISPANIC 165 (37.8%) 90 (41.38) NON-HISPANIC 272 (62.2%) 128 (58.78) n 437 218 Geographic Region Europe 101 (23.1号) 49 (22.58) North America 88 (20.1号) 45 (20.6%) South America 177 (40.58) 88 (40.4%) Rest of World 71 (16.2%) 36 (16.58) n 437 218 Female Reproductive status CHILDBEARING 98 (26.18) 42(23.38) POTENTIAL WITH CONTRACEPTIVE PROTECTION CHILDBEARING 1 ( 0.38) 2 ( 1.1%) POTENTIAL WITHOUT CONTRACEPTIVE PROTECTION NON CHILDBEARING 13 ( 3.5%) 8(4.4%) POTENTIAL POSTMENOPAUSAL 190 (50.78) 98 (54.48) PRE-MENARCHAL 1 (0.68) SURGICALLY 73 (19.58) 29( (16.18) STERILIZED n 375 180 Smoking status CURRENT 71 (16.28) 32 (14.78) NEVER. 286(65.4%) 149(68.38) PREVIOUS 80(18.38) 37(17.0%) n 437 218 Family history of Chronic Heart Disease YES 52 (12.0%) 26 (11.98) NO 351(80.9%) 177 (81.28) UNK 31 (7.18) 15 (6.98) n 434 218 n represents number of patients contributing to summary statistics. Percentages are based on n (number of valid values) . Percentages not calculated if n < 10. For reproductive status, NA stands for Not Applicable and Con. Prot. stands for Contraceptive Protection. Escape patients are included. Output : sMAR50uT/crl1935a/r25220a/stdmll_gen.dat DM11 20JUL2012:16:14:49 (2 of 2)
```

## Baseline RA disease characteristics

Overall, the treatment arms were balanced with respect to RA disease characteristics.

The duration of RA was 11.1 years in both arms (see table below).

As  part  of  the  study  eligibility  criteria,  patients  were  required  to  take  DMARDs  (only  those permitted) at a stable dose for at least 8 weeks prior to baseline. Oral NSAIDs were permitted if a patient was on a stable dose regimen for ≥ 4 weeks prior to baseline.

Patients enrolled in the study had been on a mean of 1.3 and 1.4 previous DMARDs in the TCZ and placebo arms, respectively, prior to baseline. Patients had been on a mean of 1.1 and 1.2 previous NSAIDs, respectively. Approximately 20% of the patients in each treatment arm had failed prior anti-TNF treatment.

Approximately 65% of patients in the TCZ arm and 56% of patients in the placebo arm were treated with oral corticosteroids at baseline, for which the dose was similar (median dose of 5 mg/day in both arms). The majority of patients tested positive for rheumatoid factor (81% in the

<div style=\"page-break-after: always\"></div>

TCZ  arm  and  82%  in  the  placebo  arm)  and  were  anti -cyclic  citrullinated  peptide  positive  at baseline (84% TCZ arm vs. 83% placebo arm).

The percentage of the patients who failed prior anti-TNF treatment was 20.4% and 21.6% in the TCZ  and  placebo  arms,  respectively,  which  was  reflective  of  the  capping  rule  (the  protocol stipulated the percentage of patients who failed one or more anti -TNFs should be approximately 20%). The baseline RA disease characteristics of the ITT population were consistent with those observed in the safety population.

Table 7. RA Disease Characteristics at Baseline (Safety Population)

|                                             | ICZ PFS q2w N = 437   | Placebo PFS q2w N = 218   |
|---------------------------------------------|-----------------------|---------------------------|
| Duration of RA (years)                      |                       |                           |
| Mean                                        | 11.1                  | 11.1                      |
| SD                                          | 8.23                  | 8.41                      |
| SEM                                         | 0.39                  | 0.57                      |
| Median                                      | 9.3                   | 9.7                       |
| Min-Max                                     | 1 - 43                | 1 - 49                    |
| n                                           | 437                   | 217citru                  |
| No. of previous IMARDS                      |                       |                           |
| Mean                                        | 1.3                   | 1.4                       |
| SD                                          | 0.70                  | 0.76                      |
| SEM                                         | 0.03                  | 0.05                      |
| Median                                      | 1.0                   | 1.0                       |
| Min-Max                                     | 1 - 6                 | 0-4                       |
| n                                           | 437                   | 218                       |
| Baseline Oral Corticosteroid Use (y/n)      |                       |                           |
| NO                                          | 153 (35.08)           | 95 (43.6)                 |
| YES                                         | 284 (65.0号)           | 123 (56.4%)               |
| n                                           | 437                   | 218                       |
| Baseline Oral Corticosteroid Dose _(mg/day) |                       |                           |
| Mean                                        | 6.50                  | 6.31                      |
| SD                                          | 2.879                 | 3.835                     |
| SEM                                         | 0.171                 | 0.347                     |
| Median                                      | 5.00                  | 5.00                      |
| Min-Max                                     | 0.0- 25.0             | 0.0-40.0                  |
| n                                           | 282                   | 122                       |
| Baseline RF Positivity                      |                       |                           |
| NO                                          | 83 (19.28)            | 40 (18.48)                |
| YES                                         | 349 (80.8%)           | 177 (81.68)               |
| n                                           | 432                   | 217                       |
| Baseline Anti-CcP Positivity                |                       |                           |
| NO                                          | 69 (16.18)            | 37 (17.1)                 |
| YES                                         | 360 (83.98)           | 179(82.98)                |
| n                                           | 429                   | 216                       |
| IVRS Failed Prior anti-TNF Ireatment?       |                       |                           |
| NO                                          | 348(79.68)            | 171 (78.48)               |
| YES                                         | 89(20.48)             | 47(21.6%)                 |
| n                                           | 437                   | 218                       |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Numbers analysed

All patients who received at least one dose of study drug were included in the ITT population and safety population.

Table 8. Analysis population

| Population                                | TCZ PFS q2w   |   PlaceboPFS q2w |
|-------------------------------------------|---------------|------------------|
| Randomized                                | 437           |              219 |
| Randomized treatment received at baseline | 438           |              218 |
| ITT b                                     | 437           |              219 |
| Completed                                 | 410           |              209 |
| Completer d                               | 347           |              124 |
| Safety                                    | 437 f         |              218 |

ITT = intent-to-treat; PFS = pre-filled syringe; q2w = every 2 weeks; TCZ = tocilizumab.

- Patient 12001 inadvertently received TCZ instead of placebo as the first study drug dose; the patient had been randomized to receive placebo.
- For analysis purposes, patients were assigned to the ITT population as randomized, irrespective of the treatment actually received (escape patients are included).
- Total completing treatment is up to Week 24 (escape patients are excluded).
- Completer population includes patients with a valid efficacy assessment at Week 24 (escape patients are excluded)..
- treatment they received at baseline.
- Patient 58201 had no post-baseline safety data and, consequently, was excluded from the safety population (escape patients are included).

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Table 9. Primary  efficacy  endpoint:  ACR  20  response  rate  at  Week  24  and secondary endpoints presented as per hierarchical testing

|                                                            | TCZ162mg SC q2w +DMARD (n=437)                             | Placebo + DMARD (n=219)                                    |                                                            |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Primary Endpoint:Percentage of ACR20 Responders at Week 24 | Primary Endpoint:Percentage of ACR20 Responders at Week 24 | Primary Endpoint:Percentage of ACR20 Responders at Week 24 | Primary Endpoint:Percentage of ACR20 Responders at Week 24 |
| Percentage of ACR20 responders                             | n=437 60.9%                                                | n=219 31.5%                                                |                                                            |
| Weighted difference (95% Cl)                               | 29.5 (22.0, 37.0)                                          | 29.5 (22.0, 37.0)                                          | p<0.0001                                                   |
| Sensitivity analysis: completer population                 | n=347                                                      | n=124                                                      |                                                            |
| Percentage of ACR20 Responders                             | 76.7%                                                      | 55.6%                                                      |                                                            |
| Weighted difference (95% Cl)                               | 22.4 (12.8, 31.9)                                          | 22.4 (12.8, 31.9)                                          | p<0.0001                                                   |
| Secondary Endpoints at Week 24                             |                                                            |                                                            |                                                            |
| Secondary endpoints presented as per hierarchical testing  | Secondary endpoints presented as per hierarchical testing  | Secondary endpoints presented as per hierarchical testing  |                                                            |
| 1. ACR50 responders                                        | n=437                                                      | n=219                                                      |                                                            |
| Weighted difference (95% Cl)                               | 27.9 (21.5, 34.4)                                          | 27.9 (21.5, 34.4)                                          | p<0.0001                                                   |
| 2. ACR70 responders                                        | n=437 19.7%                                                | n=219 5.0%                                                 |                                                            |
| Weighted difference (95% Cl)                               | 14.8 (9.8, 19.9)                                           | 14.8 (9.8, 19.9)                                           | p<0.0001                                                   |
| 3. Change in DAS28, mean                                   | n=344 -3.1                                                 | n=123 -1.7                                                 |                                                            |
| Weighted difference (95% Cl)                               | -1.4 (-1.7, -14.1)                                         | -1.4 (-1.7, -14.1)                                         | p<0.0001                                                   |
| 4. DAS28 <2.6 (DAS28 remission), %                         | n=347 32%                                                  | n=124 4%                                                   |                                                            |
| Weighted difference (95% Cl)                               | 28.6 (22.0, 35.2)                                          | 28.6 (22.0, 35.2)                                          | p<0.0001                                                   |
| 5. Change in TJC, mean                                     | n=432 -14.2                                                | n=219 -7.8                                                 |                                                            |
| Weighted difference (95% Cl)                               | -6.4 (-8.5,-4.3)                                           | -6.4 (-8.5,-4.3)                                           | p <0.0001                                                  |

<div style=\"page-break-after: always\"></div>

|                                                                           | TCZ162mgSCq2w +DMARD (n=437)                                              | Placebo +DMARD (n=219)                                                    |                                                                           |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Secondary Endpoints at Week 24 (cont.)                                    |                                                                           |                                                                           |                                                                           |
| 6. Change in SJC, mean                                                    | n=432 -9.3                                                                | n=219 -5.6                                                                |                                                                           |
| Weighted difference (95% Cl)                                              | -3.7 (-5.1, -2.3)                                                         | -3.7 (-5.1, -2.3)                                                         | p<0.0001                                                                  |
| 7. Change in CRP, mean                                                    | n=345 -1.6                                                                | n=124 -0.4                                                                |                                                                           |
| Weighted difference (95% Cl)                                              | -1.2 (-1.4, -1.0)                                                         | -1.2 (-1.4, -1.0)                                                         | p<0.0001                                                                  |
| 8. Change in ESR, mean                                                    | n=347 -35.6                                                               | n=124 -12.0                                                               |                                                                           |
| Weighted difference (95% Cl)                                              | -23.6 (-26.7, -20.5)                                                      | -23.6 (-26.7, -20.5)                                                      | p<0.0001                                                                  |
| 9. DAS LDA (≤3.2)                                                         | n=347,45.2% n=124, 15.3%                                                  | n=347,45.2% n=124, 15.3%                                                  |                                                                           |
| Weighted difference (95% Cl)                                              | 30.3 (22.0, 38.6)                                                         | 30.3 (22.0, 38.6)                                                         | p<0.0001                                                                  |
| 10. DAS Categorical Responders (good), %                                  | n=374 41.7%                                                               | n=138 13.8%                                                               | p<0.0001                                                                  |
| 11. Change in van der Heijde modified Sharp radiographic score to Week 24 | 11. Change in van der Heijde modified Sharp radiographic score to Week 24 | 11. Change in van der Heijde modified Sharp radiographic score to Week 24 | 11. Change in van der Heijde modified Sharp radiographic score to Week 24 |
| Mean change mTSS (SD) linear extrapolation method                         | n=391 0.62 (2.692)                                                        | n=186 1.23 (2.816)                                                        | p=0.0149 9 p=0.0145                                                       |
| 12. Median time to onset of ACR20                                         | 57 Days                                                                   | 86 Days                                                                   | p<0.0001                                                                  |
| 13. Change in hemoglobin, mean                                            | n=344 8.7                                                                 | n=123 0.2                                                                 |                                                                           |
| Difference (95% Cl)                                                       | 8.5 (6.6, 10.3)                                                           | 8.5 (6.6, 10.3)                                                           | p<0.0001                                                                  |
| 14. Change in Patient's Global VAS, mean                                  | n=346 -29.3                                                               | n=123 -19.8                                                               |                                                                           |
| Weighted difference (95% Cl)                                              | -9.4 (-14.0,-4.9)                                                         | -9.4 (-14.0,-4.9)                                                         | p<0.0001                                                                  |
| 15. Mean change in Pain VAS                                               | n=346 -24.9                                                               | n=123 -13.6                                                               |                                                                           |
| Weighted difference (95% Cl)                                              | -11.2(-15.6,-6.9)                                                         | -11.2(-15.6,-6.9)                                                         | p<0.0001                                                                  |
| 16. Change in Physician's Global VAS, mean                                | n=348 -34.3                                                               | n=124 -28.7                                                               |                                                                           |
| Weighted difference (95% Cl)                                              | -5.6 (-9.4, -1.7)                                                         | -5.6 (-9.4, -1.7)                                                         | p=0.0048                                                                  |
| 17. Change in HAQ-Dl, mean                                                | n=348 -0.4                                                                | n=124 -0.3                                                                |                                                                           |
| Weighted difference (95% Cl)                                              | -0.2(-0.3, 0.0)                                                           | -0.2(-0.3, 0.0)                                                           | p=0.0054                                                                  |

<div style=\"page-break-after: always\"></div>

|                                        | TCZ 162mg SC q2w + DMARD (n=437)   | Placebo + DMARD (n=219)   |            |
|----------------------------------------|------------------------------------|---------------------------|------------|
| Secondary Endpoints at Week 24 (cont.) |                                    |                           |            |
| 18.Decrease ≥0.3 in HAQ                | n =348 58.0%                       | n =124 46.8%              |            |
| Weighted difference (95% Cl)           | 12.1 (2.2, 22.0)                   |                           | p = 0.0170 |
| 19. Change in SF-36 (Physical), mean   | n=347 5.3                          | n=123 2.9                 |            |
| Difference (95% Cl)                    | 2.4 (1.0, 3.8)                     | 2.4 (1.0, 3.8)            | p=0.0006   |
| 20. Change in SF-36 (Mental), mean     | n=347 6.5                          | n=123 3.8                 |            |
| Difference (95% CI)                    | 2.7 (0.7, 4.6)                     | 2.7 (0.7, 4.6)            | p=0.0068   |
| 21. Median time to onset of ACR50      | 115 days                           | Not computable *          | p<0.0001   |
| 22. Median time to onset of ACR70      | 174 days                           | 174 days                  | p<0.0001   |

DAS = disease activity score; DMARD=disease-modifying anti-rheumatic drug; HAQ-Dl = Health Assessment Questionnaire Disability Index; ITT = intent-to=treat; IV = intravenous; LOCF = last observation carried forward; mTSS = modification of the Sharp score; SC = subcutaneous; SF36 = Short Form 36; VAS = visual analog scale.

## Van der Heijde modified total sharp radiographic score (mTSS)

The mean change from baseline in the van der Heijde modified total Sharp radiographic score at Week 24 was less for TCZ (0.62 ± 2.692) than with placebo (1.23 ± 2.816), suggesting there was less joint damage following TCZ treatment.

<div style=\"page-break-after: always\"></div>

Table 10. Change  from  baseline  in  TSS  at  week  24  linear  extrapolation  method using van Elteren analysis and ANOVA analysis (ITT population)

<!-- image -->

## Escape data

During the 24-week double-blind treatment period, patients who experienced less than a 20% improvement in their SJC and TJC from baseline could receive open-label escape therapy from Week 12 with TCZ 162 mg SC qw using the PFS, if requested and deemed necessary by the investigator. A total of 90 (41.1%) patients in the placebo arm and 72 (16.4%) in the TCZ arm received escape therapy.

<div style=\"page-break-after: always\"></div>

Table 11. ACR response following escape therapy

|                       | TCZ 162 mg SC q2w →TCZ 162 mg SC qw +DMARD N=72   | Placebo SC q2w >TCZ162mgSCqw +DMARD N=90   |
|-----------------------|---------------------------------------------------|--------------------------------------------|
| 12 weeks after escape | n=67                                              | n=79                                       |
| ACR20                 | 39 ( 58.2%)                                       | 57 (72.2%)                                 |
| ACR50                 | 12 ( 17.9%)                                       | 30 ( 38.0%)                                |
| ACR70                 | 4 (6.0%)                                          | 12 ( 15.2%)                                |
| 24weeks afterescape   | n=31                                              | n=32                                       |
| ACR20                 | 18 ( 58.1%)                                       | 25 ( 78.1%)                                |
| ACR50                 | 9 ( 29.0%)                                        | 14 ( 43.8%)                                |
| ACR70                 | 4 ( 12.9%)                                        | 8 ( 25.0%)                                 |

ACR = American College of Rheumatology; TCZ = tocilizumab; SC = subcutaneous; DMARD = disease modifying anti-rheumatic drug; qw = once weekly.

Source: NA25220-LTE:eteprsp01\\_pstesc\\_acrsp\\_wk24\\_10

## Ancillary analyses

## Subgroup analysis

Table 12. ACR 20, ACR 50 and ACR 70 response rates at week 24 by body weight (ITT population)

|                             | No. of Patients (%)                            | No. of Patients (%)                                |
|-----------------------------|------------------------------------------------|----------------------------------------------------|
| ACR Response by Body Weight | TCZ PFS q2w (n=437) Number of Responders/n (%) | Placebo PFS q2w (n=219) Number of Responders/n (%) |
| ACR20response               |                                                |                                                    |
| All patients                | 266/437 (60.9)                                 | 69/219 (31.5)                                      |
| <60 kg                      | 75/119 (63.0)                                  | 17/58 (29.3)                                       |
| 60 to < 100 kg              | 181/292 (62.0)                                 | 49/150 (32.7)                                      |
| ≥100 kg                     | 10/26 (38.5)                                   | 3/11 (27.3)                                        |
| ACR50response               |                                                |                                                    |
| All patients                | 174/437 (39.8)                                 | 27/219 (12.3)                                      |
| <60 kg                      | 52/119 (43.7)                                  | 6/58 (10.3)                                        |
| 60 to < 100 kg              | 119/292 (40.8)                                 | 19/150 (12.7)                                      |
| ≥100 kg                     | 3/26 (11.5)                                    | 2/11 (18.2)                                        |
| ACR70response               |                                                |                                                    |
| All patients                | 86/437 (19.7)                                  | 11/219 (5.0)                                       |
| <60 kg                      | 28/119 (23.5)                                  | 2/58 (3.4)                                         |
| 60 to < 100 kg              | 57/292 (19.5)                                  | 8/150 (5.3)                                        |
| ≥100 kg                     | 1/26 (3.8)                                     | 1/11 (9.1)                                         |

ACR=American College of Rheumatology; ITT =intent to treat; PFS = pre-flled syringe; q2w=every 2 weeks; TCZ=tocilizumab.

<div style=\"page-break-after: always\"></div>

## Region

Table 13. ACR 20, ACR 50 and ACR 70 response rates at week 24 by region (ITT population)

|                        | Number of Patients (%)                         | Number of Patients (%)                             |
|------------------------|------------------------------------------------|----------------------------------------------------|
| ACR Response by Region | TCZ PFS q2w (n=437) Number of Responders/n (%) | Placebo PFS q2w (n=219) Number of Responders/n (%) |
| ACR20response          |                                                |                                                    |
| All patients           | 266/437 (60.9)                                 | 69/219 (31.5)                                      |
| Europe                 | 71/101 (70.3)                                  | 21/49 (42.9)                                       |
| Rest of world          | 46/71 (64.8)                                   | 9/36 (25.0)                                        |
| North America          | 34/89 (38.2)                                   | 7/45 (15.6)                                        |
| South America          | 115/176 (65.3)                                 | 32/89 (36.0)                                       |
| ACR50 response         |                                                |                                                    |
| All patients           | 174/437 (39.8)                                 | 27/219 (12.3)                                      |
| Europe                 | 45/101 (44.6)                                  | 7/49 (14.3)                                        |
| Rest of world          | 28/71 (39.4)                                   | 1/36 (2.8)                                         |
| North America          | 21/89 (23.6)                                   | 4/45 (8.9)                                         |
| South America          | 80/176 (45.5)                                  | 15/89 (16.9)                                       |
| ACR70 response         |                                                |                                                    |
| All patients           | 86/437 (19.7)                                  | 11/219 (5.0)                                       |
| Europe                 | 21/101 (20.8)                                  | 2/49 (4.1)                                         |
| Rest of world          | 15/71 (21.1)                                   | 1/36 (2.8)                                         |
| North America          | 11/89 (12.4)                                   | 1/45 (2.2)                                         |
| South America          | 39/176 (22.2)                                  | 7/89 (7.9)                                         |

ACR =American College of Rheumatology; ITT =intent to treat; PFS = pre-filled syringe;

q2w=every 2 weeks; TCZ=tocilizumab.

## Study NA25220 LTE

## Results

## Participant flow

A total of 410 patients in the TCZ arm and 209 patients in the placebo arm (including 70 and 88 of the patients, respectively, who received escape therapy prior to Week 24) completed the 24week treatment period. As specified in the protocol, patients who withdrew prior to Week 24 and those who received escape therapy prior to Week 24 were not re-randomized at Week 24.

An additional 7 patients received open-label treatment in the extension, although they had no rerandomized dates in IVRS.

<div style=\"page-break-after: always\"></div>

As of the clinical cut-off date (28 May 2012), a total of 11 patients withdrew from the study after Week 24, including 3 (1.8%) patients from the TCZ PFS arm, 6 (3.6%) patients from the TCZ PFS-to-AI switch arm and 2 (3.3%) patients from the placebo to TCZ PFS switch arm. The most common reasons for withdrawal were AEs (5 patients overall).

Among  the  escape  patients  who  received  escape  therapy  as  early  as  Week  12,  14  patients withdrew from the study: 3 were assigned to the TCZ q2w arm at baseline and 11 were assigned to the placebo arm at baseline. The most common reasons for withdrawal among escape patients were withdrawn consent (5 patients overall) and AEs (4 patients overall).

Figure 1. Overview of Patient Disposition

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Baseline data

## Safety Population

The study population was comprised predominantly of Caucasian (&gt;70%) females (&gt;80%) with a mean age of approximately 52 years (range 18-82 years). The four re-randomization treatment arms  were  balanced  with  respect  to  all  baseline  demographic  characteristics.  The  majority  of patients  (&gt;65%)  weighed  between  60  and  100  kg,  with  &lt;30%  weighing  60  kg  and  less,  and &lt;5% of patients weighing 100 kg or more. The maximum weight was capped at 150 kg (per the exclusion criterion).

Generally, the four treatment arms were balanced with respect to RA disease characteristics. The mean duration  of  RA  disease  was  approximately  11  years  in  all  treatment  arms.  Median  oral corticosteroid  dose  at  baseline  was  5.0  mg/day  for  each  arm.  The  majority  of  patients  were positive  for  rheumatoid  factor  (ranging  from  78%  to  81%  in  the  treatment  arms),  and  the proportion of patients with a positive baseline for anti-cyclic citrullinated peptide (CCP) ranged from 76% to 85% in the treatment arms.

Consistent  with  the  capping  rule  imposed  in  the  protocol,  the  proportion  of  the  patients  with inadequate response to anti-TNFs prior to study participation was 20.3% for the placebo to TCZ AI switchers treatment arm and was &lt;20% in all other treatment arms.

There were no noteworthy differences between the treatment arms with respect to the ACR core set  (the  number  of  swollen  and  tender  joints,  the  functional  status  [HAQ-DI]  at  baseline,  the patient and physician's assessment of global disease status and patient pain rating, and CRP and ESR levels). The study population had moderate to severe RA disease, as reflected by the mean DAS28 ranging from 6.3 to 6.7 in the treatment arms.

## Escape Patients

As mentioned previously, only those patients who initiated escape therapy between Week 12 and Week 24 are summarized and described in this report. Data for the seven patients who initiated escape therapy after Week 24 are included only in the listings.

The baseline demographics of patients who received escape therapy were generally consistent with  that  of  the  overall  safety  population.  The  proportion  of  patients  in  each  body  weight category was similar in the prior TCZ and placebo arms. Approximately 68% of patients in each treatment  arm  weighed  between  60  and  100  kg;  &lt;30%  weighed  less  than  60  kg;  and approximately 6% of patients weighed more than 100 kg. More patients from North America and Rest of World received escape therapy compared with patients from Europe.

The RA disease characteristics of the escape patients showed that the proportion of patients who were RF positive, anti-CCP positive, and who had failed one or more previous anti-TNF therapies was  higher  among  patients  who  received  escape  therapy  as  compared  to  the  overall  safety population. The ACR core set and DAS28 characteristics for escape patients at the initiation of escape therapy were generally unchanged from baseline (with the exception of ESR and CRP in the prior TCZ arm) and reflected the inadequate response in these patients.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 14. Summary of analysis Population

|        | TCZ PFS   | TCZ PFS to TCZAISwitch   | Placebo to TCZ PFS Switch   |   Placebo to TCZAI Switch | Placebo (provided as reference)   |
|--------|-----------|--------------------------|-----------------------------|---------------------------|-----------------------------------|
| Safety | 437a      | 168°                     | 61d                         |                        59 | 218                               |
| 11I    | 167       | 167                      | 60                          |                        59 | N/A                               |

AEs = adverse events; Al = autoinjector; PFS = prefilled syringe

- The TCZ-PFS arm included all patients who were treated with TCZ 162 mg SC by PFS for their first dose. AE and immunogenicity data include all data up to Week 24 and data for patients re-randomized to TCZ PFS from the open-label period up to the date of the data cut.
- Placebo data from baseline to re-randomization at Week 24 provided as reference for safety analyses.
- Patient 57451 received TCZ PFS and then received Al but had no re-randomization date; hence is not included in lab outputs, but is in AE outputs (ie n=167 for labs and 168 for AEs)
- Patient 37310 received placebo and then received TCZ PFS but had no re-randomization date; hence not included in lab outputs, but is in AE outputs (ie n= 60 for labs and 61 for AEs)

Efficacy data are also summarized for a population of escape patients who met escape criteria from Week 12 up to Week 24 (per protocol) and are receiving weekly injections of TCZ. These escape  patients  (n=72  in  the  prior  TCZ  arm  and  90  in  the  prior  placebo  arm)  are  analysed separately from the ITT and safety populations.

Data for the 7 patients who initiated escape therapy after Week 24 are presented only in the listings.

## Outcomes and estimation

The data presented are based on the analysis of data up to the clinical cut-off date of 28 May 2012.

<div style=\"page-break-after: always\"></div>

Table 15. Summary of efficacy at weeks 24, to 48 (ITT population)

|                                    | Study Week                         | Study Week                         | Study Week                         | Study Week                         | Study Week                         | Study Week                         |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                    | 24                                 | 28                                 | 32                                 | 36                                 | 40                                 | 48                                 |
| ACR20 Responder (%)                |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZ PFS-→TCZ PFS                   | 79.0 (n=167)                       | 80.0 (n=165)                       | 73.7 (n=114)                       | 81.1 (n=74)                        | 70.5 (n=44)                        | 78.9 (n=19)                        |
| TCZPFS→TCZAI                       | 77.2 (n=167)                       | 75.9 (n=166)                       | 72.8 (n=114)                       | 67.5 (n=77)                        | 69.8 (n=43)                        | 73.7 (n=19)                        |
| ACR50 Responder (%)                |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZ PFS -→TCZ PFS                  | 53.9 (n=167) 49.1                  | 51.5 (n=165) 49.4                  | 56.1 (n=114) 50.0                  | 51.4 (n=74) 48.1                   | 50.0 (n=44) 53.5                   | 52.6 (n=19) 57.9                   |
| TCZPFS→TCZAI                       | (n=167)                            | (n=166)                            | (n=114)                            | (n=77)                             | (n=43)                             | (n=19)                             |
| ACR70 Responder (%)                |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZ PFS → TCZ PFS                  | 25.7 (n=167)                       | 29.7 (n=165)                       | 30.7 (n=114)                       | 39.2 (n=74)                        | 36.4 (n=44)                        | 31.6 (n=19)                        |
| TCZPFS→TCZAI                       | 24.6 (n=167)                       | 25.9 (n=166)                       | 28.9 (n=114)                       | 28.6 (n=77)                        | 23.3 (n=43)                        | 10.5 (n=19)                        |
| Mean DAS28                         |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZPFS→→TCZPFS                     | 3.41 (n=167) 3.31                  | 3.29 (n=162) 3.32                  | 3.23 (n=106) 3.28                  | 3.20 (n=69) 3.10                   | 3.10 (n=39) 2.74                   | 2.85 (n=16) 3.08                   |
| TCZPFS→→TCZAI                      | (n=167)                            | (n=161)                            | (n=104)                            | (n=71)                             | (n=36)                             | (n=18)                             |
| Mean change in DAS28 from baseline | Mean change in DAS28 from baseline | Mean change in DAS28 from baseline | Mean change in DAS28 from baseline | Mean change in DAS28 from baseline | Mean change in DAS28 from baseline | Mean change in DAS28 from baseline |
| TCZ PFS-TCZ PFS                    | -3.34 (n=165)                      | -3.48 (n=160)                      | -3.46 (n=105)                      | -3.52 (n=68)                       | -3.57 (n=38)                       | -3.78 (n=16)                       |
| TCZPFS-→TCZAI                      | -3.24 (n=116)                      | -3.27 (n=160)                      | -3.36 (n=105)                      | -3.53 (n=71)                       | -3.84 (n=36)                       | -3.42 (n=18)                       |
| DAS28<2.6 (%)                      |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZ PFS→→TCZ PFS                   | 29.3 (n=167) 36.5                  | 35.2 (n=162) 34.8                  | 39.6 (n=106) 36.5                  | 36.2 (n=69) 47.9                   | 41.0 (n=39) 52.8                   | 62.5 (n=16) 44.4                   |
| TCZPFS→→TCZAI                      | (n=167)                            | (n=161)                            | (n=104)                            | (n=71)                             | (n=36)                             | (n=18)                             |
| Mean change in HAQ-DI              |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZ PFS→→TCZ PFS                   | -0.58 (n=166)                      | -0.59 (n=163)                      | -0.65 (n=107)                      | -0.69 (n=69)                       | -0.84 (n=39)                       | -0.52 (n=16)                       |
| TCZPFS-→TCZAI                      | -0.43 (n=167)                      | -0.43 (n=165)                      | -0.52 (n=108)                      | -0.45 (n=72)                       | -0.52 (n=36)                       | -0.40 (n=18)                       |
| HAQ-Dl decrease ≥ 0.3 (%)          |                                    |                                    |                                    |                                    |                                    |                                    |
| TCZ PFS-→TCZ PFS                   | 63.3 (n=166)                       | 62.6 (n=163)                       | 68.2 (n=107)                       | 69.6 (n=69)                        | 79.5 (n=39)                        | 62.5 (n=16)                        |
| TCZ PFS → TCZAI                    | 53.9 (n=167)                       | 51.5 (n=165)                       | 54.6 (n=108)                       | 52.8 (n=72)                        | 61.1 (n=36)                        | 38.9 (n=18)                        |

Assessment Questionnaire Disability Index; TCZ = tocilizumab; PFS = pre-filled syringe; Al autoiniector.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analysis

Table 16. ACR20, ACR 50 and ACR 70 response rates at week 36 by bodyweight (ITT population)

|                             | No. (%) of Patients                         | No. (%) of Patients                                | No. (%) of Patients                                          | No. (%) of Patients                                          |
|-----------------------------|---------------------------------------------|----------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| ACR Response by Body Weight | TCZ PFS q2w (N=167) No. of Responders/n (%) | TCZPFSq2w→ TCZ AI q2w (N=167) No.ofResponders/n(%) | Placebo PFS q2w→ TCZ PFS q2w (N =60) No. of Responders/n (%) | Placebo PFS q2w→ TCZ Al q2w (N = 59) No. of Responders/n (%) |
| ACR20 response              |                                             |                                                    |                                                              |                                                              |
| <60 kg                      | 12/15 (80.0)                                | 15/20 (75.0)                                       | 7/8 (87.5)                                                   | 5/6 (83.3)                                                   |
| 60 to<100 kg                | 46/56 (82.1)                                | 33/50 (66.0)                                       | 10/17 (58.8)                                                 | 16/21 (76.2)                                                 |
| ≥100 kg                     | 2/3 (66.7)                                  | 4/7 (57.1)                                         | 3/3 (100)                                                    | 1/1 (100.0)                                                  |
| ACR50response               |                                             |                                                    |                                                              |                                                              |
| <60 kg                      | 9/15 (60.0)                                 | 13/20 (65.0)                                       | 6/8 (75.0)                                                   | 3/6 (50.0)                                                   |
| 60 to <100 kg               | 29/56 (51.8)                                | 23/50 (46.0)                                       | 8/17 (47.1)                                                  | 7/21 (33.3)                                                  |
| ≥100 kg                     | 0/3 (0.0)                                   | 1/7 (14.3)                                         | 2/3 (66.7)                                                   | 1/1 (100.0)                                                  |
| ACR70 response              |                                             |                                                    |                                                              |                                                              |
| <60 kg                      | 6/15 (40.0)                                 | 9/20 (45.0)                                        | 2/8 (25.0)                                                   | 2/6 (33.3)                                                   |
| 60 to<100 kg                | 23/56 (41.1)                                | 13/50 (26.0)                                       | 4/17 (23.5)                                                  | 2/21 (9.5)                                                   |
| ≥100 kg                     | 0/3 (0.0)                                   | 0/7 (0.0)                                          | 2/3 (66.7)                                                   | 1/1 (100.0)                                                  |

ACR20=American College of Rheumatology 20% response; ACR50=American College of Rheumatology 50% response; ACR70=American College of Rheumatology70% response; Al=Autoinjector; CRP=C-reactive protein; PFS=Pre filled syringe; q2w=Every 2 weeks.

Source: page 450.

Table 17. Summary of efficacy at 8 and 12 weeks following escape therapy

|                                      | No. of Patients (%)             | No. of Patients (%)                  |
|--------------------------------------|---------------------------------|--------------------------------------|
| Efficacy Endpoint Study Week         | TCZ PFS qw (prior TCZ q2w) N=72 | TCZ PFS qw (prior Placebo q2w) N= 90 |
| ACR20responserate                    |                                 |                                      |
| 8 Weeks after Escape                 | 37/69 (53.6)                    | 54/87 (62.1)                         |
| 12 Weeks after Escape                | 39/67 (58.2)                    | 57/79 (72.2)                         |
| ACR50 response rate                  |                                 |                                      |
| 8 Weeks after Escape                 | 10/69 (14.5)                    | 27/87 (31.0)                         |
| 12 Weeks after Escape                | 12/67 (17.9)                    | 30/79 (38.0)                         |
| ACR70responserate                    |                                 |                                      |
| 8 Weeks after Escape                 | 4/69 (5.8)                      | 12/87 (13.8)                         |
| 12 Weeks after Escape                | 4/67 (6.0)                      | 12/79 (15.2)                         |
| DAS LDA(<3.2)                        |                                 |                                      |
| 8 Weeks after Escape                 | 21/66 (31.8)                    | 32/79 (40.5)                         |
| 12WeeksafterEscape                   | 19/60 (31.7)                    | 33/76 (43.4)                         |
| DAS responders (good EULAR response) |                                 |                                      |
| 8 Weeks after Escape                 | 18/66 (27.3)                    | 32/79 (40.5)                         |
| 12 Weeks after Escape                | 18/60 (30.0)                    | 33/76 (43.4)                         |

ACR20=American College of Rheumatology 20%response; ACR50=American College of Rheumatology50%response;ACR70=AmericanCollegeofRheumatology70%response; DAS = Disease Activity Score; LDA=Low disease activity; PFS =Pre filled syringe; qw=Every week; q2w=Every 2 weeks; TCZ=Tocilizumab.

<div style=\"page-break-after: always\"></div>

## Study WA22762

## Methods

Study WA22762,  otherwise known  as SUMMACTA,  was  a  Phase III, two-arm, 2-year, randomized,  double-blind,  double-dummy,  active-controlled,  parallel-group,  multicentre  trial  in patients with moderate to severe active RA who had an inadequate response to a stable dose of DMARDs that may have included one or more anti-TNF biologic agents (with the percentage of patients who had failed one or more anti-TNF biologic agents capped at approximately 20%). The primary endpoint was evaluated at 24 weeks.

Figure 7. Study Design

<!-- image -->

IV=intravenous; q4w=every 4 weeks; qw=once weekly; SC =subcutaneous; TCZ=tocilizumab.

## Study participants

## Inclusion criteria

Patients were eligible for the study if they met all of the following criteria:

1. Able and willing to give written informed consent and comply with the requirements of the study protocol (e.g., willing to take oral folate at a minimum dose of 5 mg/wk if on methotrexate [MTX] treatment)
2. Age ≥ 18 years
3. RA of ≥ 6 months' duration, diagnosed according to the revised 1987 ACR (formerly, the American Rheumatism Association) criteria

<div style=\"page-break-after: always\"></div>

4. Received treatment on an outpatient basis
5. Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline
6. Prior to randomization, had discontinued etanercept for ≥ 2 weeks, infliximab, certolizumab, golimumab, abatacept, or adalimumab for ≥ 8 weeks, or anakinra for ≥ 1 week
7. Had to be on at least one permitted DMARD (see Section 4.4.2 of the protocol, which had been at a stable dose for at least 8 weeks prior to baseline
8. At screening, either C-reactive protein (CRP) ≥ 10 mg/L ( ≥ 1 mg/dL) and/or erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr
9. Oral  corticosteroids  ( ≤ 10  mg/day  prednisone  or  equivalent)  and  NSAIDs  (up  to  the maximum recommended dose) were permitted if on a stable dose regimen for ≥ 4 weeks prior to baseline
10. Females of childbearing potential and males with female partners of childbearing
11. potential participated  in  this  trial  only  if  using  a  reliable  means  of  contraception  (e.g., physical barrier [patient or partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device)
12. If female of childbearing potential, the patient had to have a negative pregnancy test at screening and baseline visit.

## Exclusion criteria

Patients were ineligible for the study if they met any of the following criteria:

## General

1. Major  surgery  (including  joint  surgery)  within  8  weeks  prior  to  screening  or  planned major surgery within 6 months following randomization
2. Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus, mixed  connective  tissue  disease,  scleroderma,  polymyositis,  or  significant  systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty syndrome).

Secondary Sjögren syndrome with RA was allowed.

3. Functional  class  IV  as defined  by  the  ACR  Classification  of  Functional  Status  in Rheumatoid Arthritis
4. Diagnosed with JIA or juvenile RA and/or RA before the age of 16
5. History of or current inflammatory joint disease other than RA (e.g., gout, Lyme disease, sero-negative spondyloarthropathy, including reactive arthritis, psoriatic arthritis, arthropathy of inflammatory bowel disease).

<div style=\"page-break-after: always\"></div>

## Excluded Previous or Concomitant Therapy

6. Treatment  with  any  investigational  agent  within  4  weeks  (or  5  half-lives  of  the investigational drug, whichever was longer) of screening
7. Previous treatment with any cell-depleting therapies, including investigational agents or approved  therapies,  some  examples  of  which  are  Campath,  anti-CD4,  anti-CD5,  antiCD3, anti-CD19, and anti-CD20
8. Treatment with IV gamma globulin, plasmapheresis within 6 months of baseline
9. Intra-articular (IA) or parenteral corticosteroids within 4 weeks prior to baseline
10. Immunization with a live/attenuated vaccine within 4 weeks prior to baseline
11. Previous treatment with TCZ (an exception to this criterion could have been granted for single-dose exposure upon application to the Sponsor on a case-by-case basis)
12. Any  previous  treatment  with  alkylating  agents  such  as  chlorambucil  or  with  total lymphoid irradiation.

## Treatments

## IV Tocilizumab/Placebo

During the double-blind period, patients received an IV infusion of 8 mg/kg of TCZ or placebo q4w on an outpatient basis for a total of six infusions (baseline [Week 0, Day 1], Weeks 4, 8, 12, 16, and 20). The last recorded body weight of a patient was used for calculating the TCZ dose for each  infusion.  No  study  treatment  was  scheduled  at  Week  24.  All  patients  were  to  be  rerandomized for the open-label period at Week 24.

After a 1-week dose interruption, patients assigned to receive 8 mg/kg of IV TCZ were to receive this  dose  q4w,  starting  at  Week  25  until  Week  93.  Infusions  were  administered  under  close supervision  of  the  investigator  in  a  setting  where  medications  and  resuscitation  facilities  were available.

## SC Tocilizumab/Placebo

During  the  double-blind  period,  a  fixed  dose  of  162  mg  of  TCZ  or  matching  placebo  was administered by SC injection qw until Week 23. No study treatment was scheduled at Week 24. SC injections of study drug (TCZ or placebo) were given using a pre-filled syringe (PFS) with a needle safety device. The recommended injection sites were the front of the middle part of the thigh and the lower part of the abdomen below the navel (belly button), except for the 2-inch area directly around the navel. If a caregiver was giving the injection, the outer area of the upper arms could also be used. Injections were not to be made into areas where the skin was not intact or was tender, bruised, red, or hard. All patients were re-randomized for the open-label period at Week 24. After a 1-week dose interruption, patients assigned to receive 162 mg of SC TCZ were to receive this dose qw, starting at Week 25 until Week 96.

<div style=\"page-break-after: always\"></div>

## Objectives

The primary objectives of the study were to assess:

- The efficacy of treatment with 162 mg TCZ given subcutaneously weekly versus 8 mg/kg TCZ given intravenously every 4 weeks with regard to non-inferiority of the proportion of patients who achieved American College of Rheumatology (ACR) 20 response at Week 24
- The safety of treatment with 162 mg TCZ given subcutaneously weekly versus 8 mg/kg TCZ  given  intravenously  every  4  weeks,  with  regard  to  adverse  events  (AEs)  and laboratory assessments.

The secondary objectives of the study were to assess:

- Long-term safety and efficacy
- Pharmacokinetics and pharmacodynamics of TCZ following SC administration
- Immunogenicity of TCZ following SC administration
- Effect of IV to SC switch on the safety, efficacy, pharmacokinetics, and pharmacodynamics of TCZ.

Specimens stored in the Roche Clinical Repository (RCR) were to be used to:

- Study the association of biomarkers with efficacy and/or AEs associated with medicinal products; and/or
- Increase the knowledge and understanding of disease biology; and/or
- Develop  biomarker  or  diagnostic  assays;  establish  the  performance  characteristics  of these  assays  TCZ  pharmacokinetic  (PK) -safety  and  PK -efficacy  relationships  were  also explored.

## Outcome/endpoint

The primary efficacy endpoint was the ACR20 response rate at Week 24.

For  the  ACR20  response  to  be  considered  positive,  a ≥ 20%  improvement  (i.e.  reduction) compared  with  baseline  was  required  for  both  TJC68  and  SJC66,  as  well  as  for  three  of  the additional five ACR core set variables: patient's assessment of pain, patient's global assessment of  disease  activity,  physician's  global  assessment  of  disease  activity,  Health  Assessment Questionnaire (HAQ), and acute-phase reactant (either CRP or ESR).

The secondary efficacy endpoints were the following:

- Proportion of patients with an ACR50 response at Week 24
- Proportion of patients with an ACR70 response at Week 24
- Proportion of patients with a Disease Activity Score 28 (DAS28) &lt; 2.6 (DAS remission) at Week 24
- Proportion of patients achieving a decrease of ≥ 0.3 in the HAQ-DI from baseline to Week 24

<div style=\"page-break-after: always\"></div>

- Proportion of patients who withdrew because of lack of therapeutic response at Week 24.

## Sample size

The primary analysis was based on the PP population. Data from the initial three pivotal Phase III studies (studies WA17823, WA17822, and WA18063), evaluating 8 mg/kg of TCZ in combination with  MTX  versus  placebo  in  combination  with  MTX  in  DMARD -inadequate  responders  (-IRs), showed ACR20 response rates for the PP population at Week 24 of 58.5% (study WA17823), 63.3% (study  WA17822),  and  64.3%  (study  WA18063).  The  pooled  ACR20  response  rate  for these three studies was 62.5%.

Assuming that Group B had an ACR20 response rate of 62.5%, 450 patients per treatment arm would be required to provide 90% power to demonstrate that Group A was non-inferior to Group B using a 12-percentage point non-inferiority margin and assuming that Group A was 1% worse than Group B. Based on the Phase III IV TCZ studies described above, it was estimated that approximately  25%  of  patients  would  not  be  eligible  for  the  PP  population.  Therefore,  a  total sample size  of  600  patients  per  arm  was  planned  to  be  randomized  into  the  study  to  ensure adequate patient numbers for the primary analysis.

In addition, a sample size of 600 patients per arm also allowed a 95% chance of observing at least 1 patient with a specific AE, if the AE had an event rate of at least 0.5%.

## Randomisation

Eligible patients who fulfilled the inclusion and exclusion criteria were randomly assigned to two treatment groups at baseline for the double-blind period and subsequently re-randomized within each  treatment  group  at  Week  24  for  the  open-label  period,  utilizing  an  interactive  voice response  system  (IVRS).  These  two  sets  of  randomization  numbers  were  generated  by Perceptive Informatics, Inc. and were linked to a unique patient identification number through the  IVRS.  At  baseline,  randomization  was  by  minimization  and  stratified  by  geographic  region (Europe, North America, South America, rest of world) and body weight category ( &lt; 60 kg, 60 to 100 kg, ≥ 100 kg). The minimization procedure was implemented by Perceptive. This involved maintaining an updated record of treatment assignments by stratification factors and was used to determine the treatment of choice for a newly recruited patient. The minimization procedure was based on an 80:20 random element, i.e., a patient was assigned to the treatment of choice with a probability of 0.8.

Randomization at Week 24 was implemented by permuted block.

## Blinding (masking)

This study was blinded during the first 24 weeks, and a 'dual assessor' approach was used to evaluate first efficacy and then safety data to prevent potential unblinding because of observed efficacy  or  laboratory  changes.  The  efficacy  assessor  was  a  rheumatologist  or  other  skilled arthritis  assessor  but  could  not  be  the  principal  investigator.  The  efficacy  assessor  was responsible for assessing the joint counts and the Physician's Global Assessment of Disease VAS components  but  was  not  allowed  access  to  other  patient  data.  The  safety  assessor  was  a rheumatologist or medically qualified physician with access to both the safety and efficacy data and was permitted to be the principal investigator. The study centres, Roche monitors, and study

<div style=\"page-break-after: always\"></div>

team members were blinded to some laboratory data (i.e. TCZ, CRP, IL-6, and sIL-6R) before the primary analysis.

Blinding  of  the  treatment  received  was  maintained  for  patients,  investigators,  and  Roche personnel until  after  completion of  the  last  patient  visit  at  Week  24  and  subsequent  database lock. The initial randomization for the double-blind treatment will be unblended to investigators and patients after the primary analysis result is reported.

Per regulatory requirements, study treatment was to be unblinded for all unexpected SAEs that were considered by the investigator to be related to study drug.

After  the  Week  24  data  analysis  and  following  specific  instructions  from  the  Sponsor,  a  single assessor approach (using a qualified physician to perform all efficacy and safety assessments) could be used for subsequent visits in the open-label part of the study.

## Statistical methods

Non-inferiority of 162 mg SC TCZ qw (group A) compared to 8 mg/kg IV TCZ q4w (group B) with regard to ACR20 response at week 24 was to be concluded if the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of ACR20 responders on group A minus group B was not less than -12%. The primary analysis was performed on the PP population,  excluding  all  patients  with  pre-defined  major  protocol  violations.  Patients  in  whom week 24 ACR20 was not available, were considered non-responder in the primary analysis. In case the null-hypothesis of inferiority of group A compared to group B was rejected, the analysis was to be repeated with a non-inferiority margin of -10%.

As a sensitivity  analysis,  the  primary  analysis  was  repeated  for  the  ITT  population.  To  assess homogeneity of treatment effect, explorative analyses on the primary endpoint were performed, if  appropriate,  in  patient  subgroups  defined  by  region,  weight  at  baseline,  or  any  relevant clinically meaningful characteristics at baseline. All exploratory efficacy subgroup analyses were based on the PP population.

To investigate whether treatment assignment by dynamic randomisation did affect the outcome of the study, the primary analysis was re-analysed using a re-randomization test.

For secondary endpoints treatment effects at week 24 were characterised by point estimates and the  corresponding  95% CI. The analyses  were carried out using the PP population. No formal tests for non-inferiority were performed given that a non-inferiority margin was only defined for the primary endpoint.

No  formal  statistical  analyses  of  exploratory  efficacy  endpoints  were  performed  to  compare treatment arms at week 24.

## Results

## Participant flow

Of the 2157 patients screened, a total of 1262 patients were randomized into the study.

The main reason for screening failure was CRP &lt; 10 mg/L (1 mg/dL) and ESR &lt; 28 mm/hr prior to baseline (unvalidated data obtained from the IVRS).

<div style=\"page-break-after: always\"></div>

Of  the  1262  patients  enrolled  into  the  study,  631  patients  were  randomized  into  each  of  the study arms (see figure below). All patients received at least one dose of study drug.

Figure 8. Overview of Patient Disposition

<!-- image -->

Note: Percentages were based on the number of randomized patients.

## Recruitment

Patients  were  enrolled  at  209  centres  in  25  countries.  The  highest  recruiting  centres  were  in Bulgaria, which enrolled 1.9% of the total number of patients, and Poland, Brazil, and Mexico, each of which enrolled 1.7%.

The first  patient  was  screened on 18 August 2010, and the first patient was randomized on 1 September 2010. The last patient was randomized on 1 August 2011, and the date of the clinical cut-off for the 24-week analysis was 16 January 2012.

## Conduct of the study

The protocol was amended twice: on 19 November 2010 (Amendment B) and on 2 December 2011  (Amendment  C).  The  final  protocol  used  for  the  double-blind  period  of  the  study  was Amendment C.

<div style=\"page-break-after: always\"></div>

## Amendment B (19 November 2010)

- Following one case of a fatal hypersensitivity reaction in an IV TCZ-treated patient that occurred in the post-marketing setting, additional guidance was added to the protocol.
- Event-driven blood sample collection for the analysis of anti-TCZ antibodies was included in  the  amendment  for  patients  who  withdrew  because  of  anaphylaxis  or  serious hypersensitivity

## Amendment C (2 December 2011)

- Additional serum sample collection for the analysis of anti-TCZ antibodies from patients who had terminated from the study early, completed the study, or missed TCZ treatment during  the  study  in  order  to  adjust  for  the  higher  than  expected  mean  TCZ  trough concentration in the TCZ SC group. A longer washout period was required.

These two amendments of the protocol did no impact on the safety and efficacy analysis of the study.

There were no key changes to the analysis of the primary efficacy endpoint or key secondary endpoints after database lock.

## Baseline data

## Demographic Data

The study population comprised predominantly Caucasian (76%) females (83%), at a mean age of  approximately  53  years  (range:  18-86;  see  table  below).  The  two  treatment  arms  were balanced with respect to all baseline demographic characteristics recorded.

Geographic region and body weight category were baseline stratification factors at randomization. The majority of the patients (67%) weighed between 60 and 100 kg, with 23% weighing &lt; 60 kg and 10% weighing ≥ 100 kg. The maximum weight was capped at 150 kg (per an exclusion criterion).

The baseline demographic characteristics of patients in the PP population were consistent with of the safety population.

<div style=\"page-break-after: always\"></div>

Table 18. Baseline Demographic Characteristics (Safety Population)

stdml1\\_gen\\_saf General Demographic Variables at Baseline (Safety Population) Protoco1 (s): WA22762  (R22762A) Analysis: SAFETY Center: ALL CENTERS

|                                     | 162mg SC qw + DMARD N= 631   | 162mg SC qw + DMARD N= 631   | Mb AI bx/bug + DMARD N= 631   | Mb AI bx/bug + DMARD N= 631   |
|-------------------------------------|------------------------------|------------------------------|-------------------------------|-------------------------------|
| Sex                                 |                              |                              |                               |                               |
| MALE                                | 111                          | (17.6%)                      | 110                           | (17.4%)                       |
| FEMALE                              | 520                          | (82.4%)                      | 521                           | (82.6%)                       |
| n                                   | 631                          |                              | 631                           |                               |
| Race                                |                              |                              |                               |                               |
| ASIAN                               | 41                           | (6.5%)                       | 43                            | (6.8%)                        |
| AMERICAN INDIAN/                    |                              |                              | 1                             | (0.2%)                        |
| ALASKA NATIVE,WHITE AMERICANINDIAN/ |                              | 24(3.8%)                     |                               | 26 (4.1%)                     |
| ALASKA NATIVE BLACK                 | 32                           | 5.1%)                        | 27                            | (4.3%)                        |
| NATIVE HAWAIIAN                     | 2                            | 0.3%)                        | 1                             | (0.2%)                        |
| OTHER PACIFIC ISLANDER              |                              |                              |                               | 479 (75.9%)                   |
| WHITE NOT AVAILABLE                 | 46(                          | (7.3%)                       |                               | 54(8.6%)                      |
| n                                   | 631                          | 486 (77.0%)                  |                               |                               |
|                                     |                              |                              |                               | 631                           |
| Age in years                        |                              |                              |                               |                               |
| Mean                                | 52.7                         |                              | 52.8                          |                               |
| SD                                  | 12.35                        |                              |                               | 12.53                         |
| SEM                                 | 0.49                         |                              | 54.0                          | 0.50                          |
|                                     | 54.0                         |                              |                               |                               |
| Median Min-Max                      | 18 - 83                      |                              | 18 -86                        |                               |
| n                                   | 631                          |                              | 631                           |                               |
| Weight in kg                        |                              |                              |                               |                               |
| Mean                                | 74.591                       |                              | 74.406                        |                               |
| SD                                  | 19.1310                      |                              |                               | 19.0081                       |
| SEM                                 |                              | 0.7616                       | 72.000                        | 0.7567                        |
| Median                              |                              | 72.300                       |                               |                               |
| Min-Max                             | 38.00 - 150.00               |                              | 32.40 - 149.90                |                               |
| n                                   | 631                          |                              | 631                           |                               |
| Height in cm                        |                              |                              |                               |                               |
| Mean                                | 162.259                      |                              | 162.275                       |                               |
| SD                                  |                              | 9.6688                       |                               | 8.9760                        |
| SEM                                 |                              | 0.3852                       |                               | 0.3582                        |
| Median                              | 161.000                      |                              | 162.000                       |                               |
| Min-Max                             | 129.50 - 198.00              |                              | 124.00 -192.00                |                               |
| n                                   | 630                          |                              | 628                           |                               |
| Baseline Weight Category (kg)       |                              |                              |                               |                               |
| <60                                 | 144                          | (22.8%)                      | 146                           | (23.1%)                       |
| 60-100                              | 425                          | (67.4%)                      | 422                           | (66.9%)                       |
| >=100                               | 62                           | ($8'6)                       | 63                            | (10.0%)                       |
| n                                   | 631                          |                              | 631                           |                               |
| Ethnicity                           |                              |                              |                               |                               |
| HISPANIC                            | 186                          | (29.5%)                      | 194                           | (30.7%)                       |
| NON-HISPANIC                        | 440                          | (69.7%)                      | 428                           | (67.8%)                       |
| NA.                                 | 5                            | (0.8%)                       | 9                             | (1.4%)                        |
| n                                   | 631                          |                              | 631                           |                               |
| Geographic Region                   |                              |                              |                               |                               |
| Europe                              | 199                          | (31.5%)                      | 198                           | (31.4%)                       |
| North America                       | 180                          | (28.5%)                      | 181                           | (28.7%)                       |
| Rest of World                       | 97                           | (15.4%)                      | 97                            | (15.4%)                       |
| South America n                     | 155 631                      | (24.6%)                      | 155 631                       | (24.6%)                       |

n represents number of patients contributing to summary statistics. Percentages are based on n (number of valid values).Percentages not calculated if n &lt; 10. For reproductive status, NA stands for Not Applicable and Con. Prot. stands for Contraceptive Protection.

DM11 14MAY2012:15:04:04

(1 of 2)

<div style=\"page-break-after: always\"></div>

Protocol(s): WA22762 (R22762A)

Analysis: SAFETY

Center: ALL CENTERS

|                                              | 162mg SC cw + DMARD N = 631   | 162mg SC cw + DMARD N = 631   | 8mg/kg IV q4w + DMARD N = 631   | 8mg/kg IV q4w + DMARD N = 631   |
|----------------------------------------------|-------------------------------|-------------------------------|---------------------------------|---------------------------------|
| Female reproductive status HYSTERECTOMY      | 48                            | (9.2%)                        | 58 (11.1%)                      |                                 |
| HYSTERECTOMY/TUBAL LIGATION                  |                               |                               | 3(0.6%)                         |                                 |
| POST-MENOPAUSAL                              |                               | 240 (46.2%)                   | 232 (44.5%)                     |                                 |
| POST-MENOPAUSAL HYSTERECTOMY                 |                               | 15 (2.9%)                     | 12(2.38)                        |                                 |
| POST-MENOPAUSAL/ HYSTERECTOMY/TUBAL LIGATION |                               | 3(0.6%)                       | 1(0.2%)                         |                                 |
| POST-MENOPAUSAL TUBAL LIGATION               |                               | 20( 3.8%)                     | 22(4.2%)                        |                                 |
| PRE-MENOPAUSAL                               |                               | 158 (30.4%)                   | 155( (29.8%)                    |                                 |
| PRE-MENOPAUSAL TUBALLIGATION                 | 8                             | (1.5%)                        | (0.8%)                          |                                 |
| TUBAL LIGATION                               | 28                            | (5.4%)                        | 34(6.5%)                        |                                 |
| n                                            | 520                           |                               | 521                             |                                 |
| Smoking status                               |                               |                               |                                 |                                 |
| CURRENT                                      |                               | 106 (16.8%)                   | 115 (18.2%)                     |                                 |
| NEVER                                        |                               | 401 (63.5%)                   | 392 (62.1%)                     |                                 |
| PREVIOUS                                     |                               | 124 (19.7%)                   | 124 (19.7%)                     |                                 |
| n                                            | 631                           |                               | 631                             |                                 |
| Family history of Chronic Heart Disease      |                               |                               |                                 |                                 |
| YES                                          |                               | 105 (16.6%)                   | 85 (13.5%)                      |                                 |
| NO                                           |                               | 491 (77.8%)                   | 508 (80.5%)                     |                                 |
| UNK                                          |                               | 35 ( 5.5%)                    | 38(6.0%)                        |                                 |
| n                                            | 631                           |                               | 631                             |                                 |

n represents number of patients contributing to summary statistics.

For reproductive status, NA stands for Not Applicable and Con. Prot. stands for Contraceptive

Percentages are based on n (number of valid values) . Percentages not calculated if n &lt; 10.

Protection.

DM11 14MAY2012:15:04:04

pagination modified

## Baseline RA Disease Characteristics

Overall,  the  treatment  arms  were  balanced  with  respect  to  RA  disease  characteristics.  The duration of RA was 8.7 years for patients in the SC arm and 8.6 years in the IV arm (see table below).

From 6 months prior to screening to baseline, patients enrolled in the study in each arm had been treated with a mean of 1.4 of DMARDs (see table below). Approximately 55% of patients in the SC arm and 54% of patients in the IV arm were treated with oral corticosteroids at baseline for which the dose was similar (mean of 7 mg/day). The majority of patients were positive for rheumatoid  factor  (74%  in  each  arm)  and  anti -cyclic  citrullinated  peptide  positive  at  baseline (72% SC arm vs. 76% IV arm). The study population had moderate to severe RA disease, as reflected by the mean DAS28 score of 6.6 (range: 3 -9) for the SC arm and 6.7 (range: 4 -9) for the IV arm.

The proportion of the patients who were anti -TNF-IRs was 22.5% in the SC arm and 21.6% in the IV arm, reflecting the capping rule (the protocol stipulated the proportion of patients who failed one or more anti-TNF agents should be approximately 20%).

The baseline RA disease characteristics of the PP population were consistent with those observed in the safety population.

(2 of 2)

<div style=\"page-break-after: always\"></div>

Table 19. Baseline RA Disease Characteristics (Safety Population)

Protocol(s):WA22762 (R22762A)

Analysis: SAFETY

Center: ALL CENTERS

|                                            | 162mg SC qw + DMARD N = 631   | Mb AI bx/bug + DMARD N = 631   |
|--------------------------------------------|-------------------------------|--------------------------------|
| Duration of RA (years)                     |                               |                                |
| Mean                                       | 8.7                           | 8.6                            |
| SD                                         | 8.26                          | 8.05                           |
| SEM                                        | 0.33                          | 0.32                           |
| Median                                     | 5.8                           | 6.2                            |
| Min-Max                                    | 0-47                          | 1 -44                          |
| n                                          | 631                           | 631                            |
| No. of previous DMARDS                     |                               |                                |
| Mean                                       | 1.4                           | 1.4                            |
| SD                                         | 0.72                          | 0.70                           |
| SEM                                        | 0.03                          | 0.03                           |
| Median                                     | 1.0                           | 1.0                            |
| Min-Max                                    | 0-6                           | 0-5                            |
| n                                          | 631                           | 631                            |
| Baseline Oral Corticosteroid Use           | (y/n)                         |                                |
| NO                                         | 287 (45.5%)                   | 293 (46.4%)                    |
| YES                                        | 344 (54.5%)                   | 338 (53.6%)                    |
| n                                          | 631                           | 631                            |
| Baseline Oral Corticosteroid Dose (mg/day) |                               |                                |
| Mean                                       | 6.92                          | 6.76                           |
| SD                                         | 2.607                         | 2.548                          |
| SEM                                        | 0.141                         | 0.139                          |
| Median                                     | 5.00                          | 5.00                           |
| Min-Max                                    | 0.0 - 20.0                    | 0.0 - 10.0                     |
| n                                          | 341                           | 337                            |
| Baseline RF Positivity                     | (26.5%)                       |                                |
| NO                                         | 164                           | 160 (25.6%)                    |
| YES                                        | 456( (73.5%)                  | 465 (74.4%)                    |
| n                                          | 620                           | 625                            |
| Baseline Anti-CCP Positivity               |                               |                                |
| NO                                         | 167 (27.8%)                   | 150 (24.2%)                    |
| YES                                        | 434 (72.2%)                   | 471 (75.8%)                    |
| n                                          | 601                           | 621                            |

n represents number of patients contributing to summary statistics. Percentages are based on n (number of valid values). Percentages not calculated if n &lt; 10. Previous DMARDs included those that were ongoing at baseline). DM11 14SEP2012:01:43:16 footnoteadded (1 of 2)

<div style=\"page-break-after: always\"></div>

<!-- formula-not-decoded -->

|                                       | 162mg SC qw + DMARD N= 631   | Mb AI bx/bug + DMARD N = 631   |
|---------------------------------------|------------------------------|--------------------------------|
| Baseline DAS28                        |                              |                                |
| Mean                                  | 6.6                          | 6.7                            |
| SD                                    | 1.00                         | 1.02                           |
| SEM                                   | 0.04                         | 0.04                           |
| Median                                | 6.6                          | 6.7                            |
| Min-Max                               | 3-9                          | 4-9                            |
| n                                     | 623                          | 626                            |
| IVRS Failed Prior anti-TNF Treatment? |                              |                                |
| N                                     | 489(77.5%)                   | 495 (78.4%)                    |
|                                       | 142 (22.5%)                  | 136 (21.6%)                    |
| n                                     | 631                          | 631                            |

n represents number of patients contributing to summary statistics. Percentages are based on n (number of valid values). Percentages not calculated if n &lt; 10. Previous DMARDs included those that were ongoing at baseline. DM11 14SEP2012:01:43:16 footnote addled (2 of 2)

## Numbers analysed

Of the 1262 patients enrolled into the study (631 in each of the treatment arms), all patients received study treatment and were eligible for inclusion in the ITT and safety populations.

The PP population comprised 1095 patients (558 SC arm, 537 IV arm), with approximately 13% of  the  overall population  being  excluded from the PP population for one or more reasons (see table below).

More patients in the IV arm (15%) compared with the SC arm (12%) were excluded from the PP population.  The  most  common  reason  for  exclusion  from  the  PP  population  in  both  arms  was because of the background DMARD not remaining at a stable dose (38 patients in the SC arm vs. 37 patients in the IV arm).

There was an imbalance in the number of patients excluded for receiving less than two-thirds or more than four-thirds of the total allocated SC treatment of TCZ or placebo (6 patients SC arm vs. 19 patients IV arm), and this was the second most common reason for exclusion from the PP population  in  the  IV  arm.  In  addition,  more  patients  in  the  IV  arm  than  in  the  SC  arm  were excluded because they received less than the two-thirds or more than four-thirds of the total allocated IV TCZ or placebo (5 patients SC arm vs. 9 patients IV arm).

In the SC arm, the third most common reason for exclusion was 'patients do not have at least one permitted DMARD with a stable dose for at least 8 weeks prior to baseline.'

Eight  patients  were  excluded  despite  this  being  an  inclusion  criterion.  A  similar  number  of patients (7) were excluded from the IV arm for this reason.

All patients who reached Week 24 (a total of 1136 patients: 572 in the SC arm, 564 in the IV arm) were re-randomized to the 72-week open-label treatment period. Of note, 1 patient in the SC arm who completed the double-blind period died after re-randomization and did not receive any open-label drug.

<div style=\"page-break-after: always\"></div>

Table 20. Analysis Population

| (uotaetndog sauetaea ttt) auawneeti Tetai peztwopuey Aq suotaetndoa stettouy tte Ttoens Prot0c61(s): WA22762 (R22762A) AnalySis: ALL PATIENIS Center: ALL CENTERS   |                  |                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------|
|                                                                                                                                                                     | 162mgSCqw +DMARD | 8mg/kg 1V q4w + DMARD |
| No. of Patients Randomized                                                                                                                                          | 631              | 631                   |
| No. Inciuded in INTENT TO TREAT No.Excluded frcm INTENT TO TREAT                                                                                                    | 631              | 631                   |
| No. Included in SAFEIY No. Excluded frcm SAFETY                                                                                                                     | 631              | 631                   |
| No. Included in PER PROTOCOL No.Excluded frcmPERPROIOCOL                                                                                                            | 558 73           | 537 94                |
| EC11 14JUN2012:14:24:23                                                                                                                                             |                  | (1 of 2)              |

More patients in the IV arm (15%) compared with the SC arm (12%) were excluded from the PP population.  The  most  common  reason  for  exclusion  from  the  PP  population  in  both  arms  was because of the background DMARD not remaining at a stable dose (38 patients in the SC arm vs. 37 patients in the IV arm).

Six  patients  (2  patients  in  the  SC  arm;  4  patients  in  the  IV  arm)  were  excluded  from  the  PP population because of a treatment code break.

In  2011 an unscheduled health authority/ethics committee inspection occurred at a Lithuanian center. As a result of this inspection, critical findings related to GCP were reported. Nine of the 12  patients  randomised  at  the  site  were  eligible  to  be  included  in  the  per-protocol  (PP) population, 6 in the SC arm and 3 in the IV arm. An ACR20 response at Week 24 was achieved in 2 of the 6 patients (33%) in the SC arm compared with 3 of 3 patients (100%) in the IV arm. Since  removal  of  these  patients  would  favor  the  efficacy  of  the  SC  arm,  it  was  decided  to maintain  patients  randomized  to  this  site  in  the  analysis  in  order  to  be  conservative  in  the primary analysis, which was based on the PP population. No sensitivity analysis was performed on the data. All 12 patients were included in the intent-to-treat (ITT) population. Data from the 12 patients were also included in the safety population as a conservative approach.

## Outcomes and estimation

The data presented are based on the primary analysis, which was conducted after all patients had  completed  the  double-blind  treatment  period,  i.e.  24  weeks  of  study  treatment  unless prematurely withdrawn.

The  population  used  for  the  primary  and  secondary  analyses  was  the  PP  population.  The  ITT population was used for sensitivity analysis of the primary endpoint.

<div style=\"page-break-after: always\"></div>

Table 21. Overview of efficacy (PP population)

|                                                             | 162 mg SC qw+ DMARD n=558                                   | 8 mg/kg IV q4w+DMARD n=537                                  |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Primary endpoint: percentage of ACR20 responders at Week 24 | Primary endpoint: percentage of ACR20 responders at Week 24 | Primary endpoint: percentage of ACR20 responders at Week 24 |
| Percentage of ACR20 responders                              | 69.4%                                                       | 73.4%                                                       |
| Weighted difference (95% Cl)                                | -4.0 (-9.2, 1.2)                                            | -4.0 (-9.2, 1.2)                                            |
| Sensitivity analysis, ITT population                        | n=631                                                       | n=631                                                       |
| Percentage of ACR20 responders                              | 67.7%                                                       | 70.2%                                                       |
| Weighted difference (95% Cl)                                | -2.7 (-7.6, 2.2)                                            | -2.7 (-7.6, 2.2)                                            |
| Secondary endpoints at Week 24                              |                                                             |                                                             |
| ACR50 responders, n (%)                                     | 262 (47.0)                                                  | 261 (48.6)                                                  |
| Weighted difference (95% Cl)                                | -1.8 (-7.5, 4.0)                                            | -1.8 (-7.5, 4.0)                                            |
| ACR70 responders, n (%)                                     | 134 (24.0)                                                  | 150 (27.9)                                                  |
| Weighted difference (95% Cl)                                | -3.8 (-9.0, 1.3)                                            | -3.8 (-9.0, 1.3)                                            |
| DAS remission (<2.6), n (%)                                 | 198 (38.4)                                                  | 184 (36.9)                                                  |
| Weighted difference (95% Cl)                                | 0.9 (-5.0, 6.8)                                             | 0.9 (-5.0, 6.8)                                             |
| Decrease in HAQ-DI ≥0.3, n (%)                              | 336 (65.2)                                                  | 337 (67.4)                                                  |
| Weighted difference (95% Cl)                                | -2.3 (-8.1, 3.4)                                            | -2.3 (-8.1, 3.4)                                            |
| Withdrawal due to lack of                                   | 10 (1.8)                                                    | 5 (0.9)                                                     |
| therapeutic response, n (%)                                 |                                                             |                                                             |
| Weighted difference (95% Cl)                                | 0.9 (-0.9, 2.7)                                             | 0.9 (-0.9, 2.7)                                             |

ACR=American College of Rheumatology; Cl=confidence interval; DAS =disease activity score; DMARD =disease-modifying anti-rheumatic drug; HAQ-Dl=Health Assessment Questionnaire-Disability Index; ITT =intent to treat; IV=intravenous; LOCF =last observation carried forward; PP =per protocol: SC=subcutaneous.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Subgroup analysis

Table 22. ACR20, ACR 50 and ACR 70 response rates at week 24 by bodyweight (PP population)

|                                      | No. of Patients (%)        | No. of Patients (%)          |
|--------------------------------------|----------------------------|------------------------------|
| ACR Response by BodyWeightatBaseline | 162 mg SC qw+DMARD (n=558) | 8 mg/kg IV q4w+DMARD (n=537) |
| ACR20response                        |                            |                              |
| <60 kg                               | 99/131 (75.6)              | 100/129 (77.5)               |
| 60-100 kg                            | 260/374 (69.5)             | 264 358 (73.7)               |
| ≥100 kg                              | 28/53 (52.8)               | 30/50 (60.0)                 |
| ACR50response                        |                            |                              |
| <60 kg                               | 66/131 (50.4)              | 71/129 (55.0)                |
| 60-100 kg                            | 176/374 (47.1)             | 177 358 (49.4)               |
| ≥100 kg                              | 20/53 (37.7)               | 13/50 (26.0)                 |
| ACR70 response                       |                            |                              |
| <60 kg                               | 31/131 (23.7)              | 47/129 (36.4)                |
| 60-100 kg                            | 96/374 (25.7)              | 100/358 (27.9)               |
| ≥100 kg                              | 7/53 (13.2)                | 3/50 (6.0)                   |

ACR=American College of Rheumatology; DMARD =disease-modifying anti-rheumatic drug; IV=intravenous; pp =per protocol; q4w=every 4 weeks; qw=once weekly; SC =subcutaneous.

Table 23. ACR20, ACR 50 and ACR 70 response rates at week 24 by region (PP population)

|                        | No. of Patients (%)     | No. of Patients (%)          |
|------------------------|-------------------------|------------------------------|
| ACR Response by Region | 162mgSCqW+DMARD (n=558) | 8 mg/kg IV q4w+DMARD (n=537) |
| ACR20 response         |                         |                              |
| Europe                 | 135/180 (75.0)          | 125/170 (73.5)               |
| Rest of world          | 68/84 (81.0)            | 68/80 (85.0)                 |
| North America          | 78/152 (51.3)           | 86/147 (58.5)                |
| South America          | 106/142 (74.6)          | 115/140 (82.1)               |
| ACR50response          |                         |                              |
| Europe                 | 86/180 (47.8)           | 78/170 (45.9)                |
| Rest of world          | 48/84 (57.1)            | 54/80 (67.5)                 |
| North America          | 49/152 (32.2)           | 43/147 (29.3)                |
| South America          | 79/142 (55.6)           | 86/140 (61.4)                |
| ACR70response          |                         |                              |
| Europe                 | 37/180 (20.6)           | 50/170 (29.4)                |
| Rest of world          | 27/84 (32.1)            | 25/80 (31.3)                 |
| North America          | 23/152 (15.1)           | 23/147 (15.6)                |
| South America          | 47/142 (33.1)           | 52/140 (37.1)                |

ACR=American College of Rheumatology; DMARD=disease-modifying anti-rheumatic drug;

IV=intravenous; pp=per protocol; q4w=every 4 weeks; qw=once weekly; SC =subcutaneous.

Source: page 555.

<div style=\"page-break-after: always\"></div>

## Study WA22762 LTE

## Results

## Participant flow

The first  patient  was  screened  on  18  August  2010  and  the  first  patient  was  randomized  on  1 September 2010. The last patient was randomized on 1 August 2011 and the date of the clinical cut-off was 16 January 2012.

From  2157  patients  screened,  a  total  of  1262  patients  at  209  centers  in  25  countries  were randomized into the study: 631 to TCZ SC and 631 to TCZ IV. The main reason for screen failure was CRP &lt; 10 mg/L (1 mg/dL) and ESR &lt; 28 mm/h prior to baseline.

All of the 1262 patients received at least one dose of study medication. Of the 1262 patients, 572 patients (91%) in the TCZ SC arm and 564 (89%) in the TCZ IV arm completed the double-blind phase  to  Week  24;  59  patients  (9%)  in  the  SC  arm  and  67  patients  (11%)  in  the  IV  arm withdrew from the study before reaching Week 24. One patient in the IV arm completed Week 24 but subsequently withdrew before re-randomization due to lack of therapeutic response.

At  Week  24,  patients  from  the  SC  arm  were  re-randomized  in  a  ratio  of  11:1  to  SC  and  IV, respectively, whilst patients from the IV arm were re-randomized in a ratio of 2:1 to IV and SC, respectively. The re-randomization resulted in 48 patients in the SC arm being re-randomized to IV (SC-IV switch arm) and 524 patients continuing with SC (SC arm).

In the IV arm, the re-randomization resulted in 186 patients being re-randomized to SC (IV-SC switch arm) and 377 patients continuing with IV (IV arm).

As of the clinical cut-off date of 16 January 2012, 21/524 (4.0%) patients in the SC arm and 17/377 (4.5%) patients in the IV arm had withdrawn prematurely since re-randomization (i.e. during  the  open-label  period).  Thus,  overall,  including  the  59  patients  who  were  withdrawn during the double-blind period from the SC arm and the 68 patients who were withdrawn from the IV arm, a total of 80/583 (13.7%) patients in the SC arm and 85/445 (19.1%) patients in the IV arm had withdrawn prematurely from the study by the time of the clinical cut-off. In the SC-IV  and  IV-SC  switch  arms,  there  were  1/48  (2.1%)  and  7/186  (3.8%)  withdrawals, respectively, between re-randomization and the clinical cut-off date.

## Baseline data

Overall, the baseline demographic characteristics were well balanced across the treatment arms. The majority of patients in each treatment arm were female (75% to 84% across arms), white (74% to 83% across arms), and of non-hispanic ethnicity (65% to 70% across arms). The mean age ranged from 52.2 to 54.7 years across arms. The majority of patients weighed between 60 and &lt;100 kg (67% to 69% across arms), with 22% to 25% weighing &lt; 60 kg and 6% to 10% weighing ≥ 100 kg. The maximum weight was capped at 150 kg (per the exclusion criterion). The majority of patients in all arms had never smoked (60% to 65% across arms) and had no known family history of chronic heart disease (73% to 82% across arms).

The SC and IV treatment arms were well balanced with respect to RA disease characteristics at baseline. Baseline RA disease characteristics in the smaller IV-SC and SC-IV switch arms were

<div style=\"page-break-after: always\"></div>

comparable with those in the IV and SC arms, respectively. Some differences between arms were observed for baseline anti-CCP positivity, RF positivity, and certain ACR core set parameters.

## Numbers analysed

Table 24. Overview of analysis population (all patients)

|                            | 162mg SC qw+DMARD   | 8mg/kg IV q4w+DMARD   |   IV-SC |   SC-IV |
|----------------------------|---------------------|-----------------------|---------|---------|
| PPpopulation,n             | 473                 | 338                   |     161 |      44 |
| ITTpopulation, n           | 524                 | 377                   |     186 |      48 |
| PK evaluable population, n | 583a                | 445a                  |     186 |      48 |
| Safety population, n       | 631b                | 631b                  |     186 |      48 |

a Includes patients who were withdrawn during the double-blind period.

b Safety data from patients who switched treatment at Week 25 are included in the SC and IV arms up to the point of switch but in the SC-IV and IV-SC arms, respectively, after switch.

Source:page203.

Based on the original randomized SC and IV populations, 110/583 (18.9%) patients in the SC arm and 107/445 (24.0%) patients in the IV arm were excluded from the PP population; the most common reason for exclusion in these arms was not being re-randomized at Week 24 due to withdrawal during the double-blind period. The next most common reason was the background DMARD not remaining at a stable dose.

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Table 25. Overview of efficacy results up to week 49 (PP population)

|                                                              | No. Patients (%)                                             | No. Patients (%)                                             | No. Patients (%)                                             | No. Patients (%)                                             |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                                              | 162mg SC qw +DMARD n=473                                     | 8mg/kg IVq4w +DMARD n=338                                    | IV-SC n =161                                                 | SC-IV n = 44                                                 |
| ACR20 response rate[Section 5.2.1]                           | ACR20 response rate[Section 5.2.1]                           | ACR20 response rate[Section 5.2.1]                           | ACR20 response rate[Section 5.2.1]                           | ACR20 response rate[Section 5.2.1]                           |
| Week24                                                       | 355/473 (75%)                                                | 263/338 (78%)                                                | 130/161 (81%)                                                | 29/44 (66%)                                                  |
| Week 37                                                      | 203/274 (74%)                                                | 155/203 (76%)                                                | 71/97 (73%)                                                  | 21/28 (75%)                                                  |
| Week 49                                                      | 84/115 (73%)                                                 | 63/92 (69%)                                                  | 28/41 (68%)                                                  | 8/12 (67%)                                                   |
| ACR50 response rate [Section 5.2.2]                          | ACR50 response rate [Section 5.2.2]                          | ACR50 response rate [Section 5.2.2]                          | ACR50 response rate [Section 5.2.2]                          | ACR50 response rate [Section 5.2.2]                          |
| Week 24                                                      | 238/473 (50%)                                                | 176/338 (52%)                                                | 85/161 (53%)                                                 | 22/44 (50%)                                                  |
| Week 37                                                      | 146/274 (53%)                                                | 96/203 (47%)                                                 | 49/97 (51%)                                                  | 14/28 (50%)                                                  |
| Week 49                                                      | 59/115 (51%)                                                 | 38/92 (41%)                                                  | 14/41 (34%)                                                  | 5/12 (42%)                                                   |
| ACR70 response rate[Section 5.2.3]                           | ACR70 response rate[Section 5.2.3]                           | ACR70 response rate[Section 5.2.3]                           | ACR70 response rate[Section 5.2.3]                           | ACR70 response rate[Section 5.2.3]                           |
| Week 24                                                      | 127/473 (27%)                                                | 105/338 (31%)                                                | 45/161 (28%)                                                 | 7/44 (16%)                                                   |
| Week 37                                                      | 80/274 (29%)                                                 | 60/203 (30%)                                                 | 26/97 (27%)                                                  | 10/28 (36%)                                                  |
| Week 49                                                      | 39/115 (34%)                                                 | 27/92 (29%)                                                  | 7/41 (17%)                                                   | 4/12 (33%)                                                   |
| Decrease in HAQ-Dl≥0.22 [Section 5.4]                        | Decrease in HAQ-Dl≥0.22 [Section 5.4]                        | Decrease in HAQ-Dl≥0.22 [Section 5.4]                        | Decrease in HAQ-Dl≥0.22 [Section 5.4]                        | Decrease in HAQ-Dl≥0.22 [Section 5.4]                        |
| Week 24                                                      | 343/468 (73%)                                                | 249/337 (74%)                                                | 123/161 (76%)                                                | 30/43 (70%)                                                  |
| Week 37                                                      | 209/267 (78%)                                                | 142/196 (72%)                                                | 63/92 (69%)                                                  | 18/25 (72%)                                                  |
| Week 49                                                      | 84/107 (79%)                                                 | 62/88 (71%)                                                  | 29/38 (76%)                                                  | 5/9 (56%)                                                    |
| Decrease in HAQ-Dl ≥0.30 [Section 5.4]                       | Decrease in HAQ-Dl ≥0.30 [Section 5.4]                       | Decrease in HAQ-Dl ≥0.30 [Section 5.4]                       | Decrease in HAQ-Dl ≥0.30 [Section 5.4]                       | Decrease in HAQ-Dl ≥0.30 [Section 5.4]                       |
| Week 24                                                      | 307/468 (66%)                                                | 229/337 (68%)                                                | 107/161 (67%)                                                | 26/43 (61%)                                                  |
| Week 37                                                      | 176/267 (66%)                                                | 129/196 (66%)                                                | 56/92 (61%)                                                  | 16/25 (64%)                                                  |
| Week 49                                                      | 76/107 (71%)                                                 | 58/88 (66%)                                                  | 25/38 (66%)                                                  | 5/9 (56%)                                                    |
| DAS-ESR remission (<2.6) [Section 5.6]                       | DAS-ESR remission (<2.6) [Section 5.6]                       | DAS-ESR remission (<2.6) [Section 5.6]                       | DAS-ESR remission (<2.6) [Section 5.6]                       | DAS-ESR remission (<2.6) [Section 5.6]                       |
| Week 24                                                      | 180/467 (39%)                                                | 122/335 (36%)                                                | 61/160 (38%)                                                 | 16/43 (37%)                                                  |
| Week 37                                                      | 110/260 (42%)                                                | 77/193 (40%)                                                 | 37/90 (41%)                                                  | 13/26 (50%)                                                  |
| Week 49                                                      | 47/105 (45%)                                                 | 30/87 (35%)                                                  | 18/37 (49%)                                                  | 8/10 (80%)                                                   |
| Withdrawal due to lack of therapeutic response [Section 5.7] | Withdrawal due to lack of therapeutic response [Section 5.7] | Withdrawal due to lack of therapeutic response [Section 5.7] | Withdrawal due to lack of therapeutic response [Section 5.7] | Withdrawal due to lack of therapeutic response [Section 5.7] |
|                                                              | 3/473 (0.6%)                                                 | 3/338 (0.9%)                                                 | 1/161 (0.6%)                                                 | 0/44 (0%)                                                    |

ACR=American College of Rheumatology; DAS= disease activity score; DMARD=diseasemodifying antirheumatic drug; HAQ-Dl= Health Assessment Questionnaire-Disability Index; IV =intravenous; PP =per protocol; SC=subcutaneous.

a Based on data collected during the double blind and open label phases up to the clinical cut off.

<div style=\"page-break-after: always\"></div>

Figure 9. Plot of the percentage with ACR 20 response by visit (PP population)

Iplot01\\_acr203 Plot of the Percentage of Patients with; ACR20 Response by Visit - Clinical Cut-offdate16thJanuary er-protocolPopulation)

<!-- image -->

## SC and IV Arms

Within  the  SC  and  IV  treatment  arms,  ACR20  response  rates  tended  to  be  higher  in  patients weighing &lt;60 kg (78% to 85% SC vs. 82% to 87% IV) and 60 to &lt;100 kg (75% to 76% SC vs. 71% to 78% IV) compared with patients weighing ≥ 100 kg (55% to 58% SC vs. 39% to 59% IV) from Weeks 24 to 49. The same was true for ACR50 and ACR70 response rates.

Within subgroups, ACR20 response rates in the SC and IV arms were comparable at Weeks 24 and 37 in all three body weight categories. The same was true in the &lt;60 and 60 to &lt;100 kg subgroups at Week 49. In the ≥ 100 kg subgroup, the response rate at Week 49 was higher in the  SC  arm  than  in  the  IV  arm  (58%  vs.  39%);  however,  Week  49  data  for  the ≥ 100  kg subgroup should be interpreted with caution due to the low patient numbers (N=19 SC and 13 IV).

More variability was observed for ACR50 and ACR70 responses. Response rates in the SC arm tended to be lower than those of the IV arm in the &lt;60 kg subgroup but comparable with or higher than those of the IV arm in the 60 to &lt;100 kg and ≥ 100 kg subgroups.

## IV-SC and SC-IV Switch Arms

Meaningful analyses of ACR20/50/70 by body weight at baseline were not possible for the switch arms due to the low numbers of patients and responses, particularly at the week 49 time point.

<div style=\"page-break-after: always\"></div>

## Pharmacodynamics

Mean sIL-6R concentrations were generally comparable in the SC and IV arms during both the double-blind  and  open-label  extension  periods,  but  with  an  overall  trend  for  slightly  higher concentrations following SC dosing.

Mean CRP concentrations in the SC arm were lower than in the IV arm at all time points between Week 4 and Week 37. At Week 49, mean concentrations were 0.11 mg/dL in the SC arm and 0.18 mg/dL in the IV arm. The trend for lower mean CRP concentrations in the SC arm compared with the IV arm is consistent with the observed trend for higher sIL-6R concentrations in the SC arm compared with the IV arm.

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 26. Study NA25220

Title: A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome  of  tocilizumab  SC  versus  placebo  SC  in  combination  with  traditional  disease modifying  anti-rheumatic  drugs  (DMARDs)  in  patients  with  moderate  to  severe  active rheumatoid arthritis.

| Study identifier          | NA 25220 / NA 25220 LTE                                                        | NA 25220 / NA 25220 LTE                                                         | NA 25220 / NA 25220 LTE                                                                                                                 |
|---------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Design                    |                                                                                |                                                                                 |                                                                                                                                         |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:  | 24 weeks not applicable 72 weeks (open label)                                                                                           |
| Hypothesis                | Superiority                                                                    | Superiority                                                                     | Superiority                                                                                                                             |
| Treatments groups         | TCZ SC                                                                         | TCZ SC                                                                          | TCZ 162 mg SC q2w in combination with DMARDs                                                                                            |
| Treatments groups         | Placebo                                                                        | Placebo                                                                         | Placebo SC q2w in combination with DMARDs                                                                                               |
| Endpoints and definitions | Primary endpoint                                                               | ACR 20                                                                          | At least a 20% improvement compared with baseline in both TJC68 and SJC66, as well as in three out of five of the additional parameters |
|                           | Secondary endpoints                                                            | ACR 20/50/70 DAS 28 DAS ‹ 2,6 (DAS remission) DAS responder (EULAR) mTSS HAQ-DI |                                                                                                                                         |
| Database lock             | NA25220 (24 Week): completed NA25220LTE (72 week): 28 May 2012                 | NA25220 (24 Week): completed NA25220LTE (72 week): 28 May 2012                  | NA25220 (24 Week): completed NA25220LTE (72 week): 28 May 2012                                                                          |
| Results and Analysis      | Results and Analysis                                                           | Results and Analysis                                                            | Results and Analysis                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Analysis description                                   | Primary Analysis                                                | Primary Analysis                                                | Primary Analysis                                | Primary Analysis                                |
|--------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Analysis population and time point description         | Intent to treat at week                                         | Intent to treat at week                                         | Intent to treat at week                         | Intent to treat at week                         |
| Primary Analysis                                       | Endpoint comparison Treatment group                             | 24                                                              | TCZ SC                                          | Placebo                                         |
| Primary Analysis                                       | Number of subject                                               | n=437                                                           | n=437                                           | n =219                                          |
| Primary Analysis                                       | ACR20 n (%)                                                     | 266 (60.9%)                                                     | 266 (60.9%)                                     | 69 (31.5%)                                      |
| Effect estimate per comparison                         | ACR20 Response                                                  | TCZ SC - Placebo                                                | TCZ SC - Placebo                                |                                                 |
| Effect estimate per comparison                         | ACR20 Response                                                  | Weighted difference                                             | Weighted difference                             | 29.5%                                           |
| Effect estimate per comparison                         | ACR20 Response                                                  | 95%-CI                                                          | 95%-CI                                          | (22.0, 37.0)                                    |
| Effect estimate per comparison                         | ACR20 Response                                                  | P-value                                                         | P-value                                         | p‹ 0.0001                                       |
| Analysis description                                   | Secondary analyses                                              | Secondary analyses                                              | Secondary analyses                              | Secondary analyses                              |
| Results per parameter                                  | Parameter                                                       | Parameter                                                       | TCZ SC                                          | Placebo                                         |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | ACR50 Response rate Weighted difference (95%- CI)               | ACR50 Response rate Weighted difference (95%- CI)               | 39.8% 12.3% 27.9 (21.5, 34.4) p < 0.0001        | 39.8% 12.3% 27.9 (21.5, 34.4) p < 0.0001        |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | ACR70 Response rate Weighted difference (95%- CI) p-value       | ACR70 Response rate Weighted difference (95%- CI) p-value       | 19.7% 5.0% 14.8 (9.8, 19.9) p < 0.0001          | 19.7% 5.0% 14.8 (9.8, 19.9) p < 0.0001          |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | DAS28 Change N Mean Weighted difference (95%- CI)               | DAS28 Change N Mean Weighted difference (95%- CI)               | 344 -3.1 123 -1.7 -1.4 (-1.7, -14.1) p < 0.0001 | 344 -3.1 123 -1.7 -1.4 (-1.7, -14.1) p < 0.0001 |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | p-value TJC change N mean Weighted difference (95%- CI) p-value | p-value TJC change N mean Weighted difference (95%- CI) p-value | 432 -14.2 219 -7.8 6.4 (-8.5, -4.3) p <0.0001   | 432 -14.2 219 -7.8 6.4 (-8.5, -4.3) p <0.0001   |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | SJC change N mean weighted difference (95%- CI) p-value         | SJC change N mean weighted difference (95%- CI) p-value         | 432 -9.3 219 -5.5 -3.7 (-5.1, -2.3) p < 0.0001  | 432 -9.3 219 -5.5 -3.7 (-5.1, -2.3) p < 0.0001  |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | CRP change N mean weighted difference (95%- CI) p-value         | CRP change N mean weighted difference (95%- CI) p-value         | 345 -1.6 124 -0.4 -1.2 (-1.4, -1.0) p < 0.0001  | 345 -1.6 124 -0.4 -1.2 (-1.4, -1.0) p < 0.0001  |
| If not stated otherwise: TCZ: N = 437 Placebo: N = 219 | ESR change N mean                                               | ESR change N mean                                               | 347 -35.6 124 -12.0                             | 347 -35.6 124 -12.0                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| weighted difference (95%- CI) p-value                             | -23.6 (-26.7, -20.5) p < 0.0001                    |
|-------------------------------------------------------------------|----------------------------------------------------|
| DAS LDA (≤ 3.2) N Responder weighted difference (95%- CI) p-value | 374 45.2% 124 15.3% 30.3 (22.0, 38.6) p < 0.0001   |
| DAS Response N Responder p-value                                  | 374 41.7% 138 13.8% p < 0.0001                     |
| mTSS at week 24 N Mean (SD) p-value                               | 391 0.62 (2.69) 186 1.23 (2.82) 0.0149             |
| ACR20 median time to onset Days p-value                           | 57 86 p < 0.0001                                   |
| Change in hemoglobin N Mean Difference (95%-CI) p-value           | 344 8.7 123 0.2 8.5 (6.6, 10.3) p < 0.0001         |
| Patient global VAS change N Mean Difference (95%-CI) p-value      | 346 -29.3 123 -19.8 -9.4 (-14.0, -4.9) p < 0.0001  |
| Pain VAS change N Mean Difference (95%-CI) p-value                | 346 -24.9 123 -13.6 -11.2 (-15.6, -6.9) p < 0.0001 |
| Physician's global VAS change N Mean Difference (95%-CI) p-value  | 348 -34.3 124 -28.7 -5.6 (-9.4, -1.7) p = 0.0048   |
| HAQ-DI change N Mean Difference (95%-CI) p-value                  | 348 -0.4 124 -0.3 -0.2 (-0.3, 0.0) p = 0.0054      |
| Decrease ≥ 0.3 in HAQ N Responder Difference (95%-CI) p-value     | 348 58.0% 124 46.8% 12.1 (2.2, 22.0) p = 0.0170    |
| SF-36 (physical) change N Mean Difference (95%-CI) p-value        | 347 5.3 123 2.9 2.4 (1.0, 3.8) p = 0.0006          |

<div style=\"page-break-after: always\"></div>

| SF-36 (mental) change N Mean Difference (95%-CI) p-value   | 347 6.5 123 2.7        |
|------------------------------------------------------------|------------------------|
| ACR70 median time to onset                                 | 3.8 115                |
|                                                            | (0.7, 4.6)             |
|                                                            | p = 0.0068             |
| ACR50 median time to onset Days p-value Days               | Not reached p < 0.0001 |
|                                                            | 174 Not reached        |
| p-value                                                    | p < 0.0001             |

## Table 27. Study WA22762

Title: A  randomized,  double-blind,  parallel  group  study  of  the  safety  and  effect  on  clinical outcome  of  tocilizumab  SC  versus  tocilizumab  IV,  in  combination  with  traditional  diseasemodifying  anti-Rheumatic  Drugs  (DMARDs),  in  patients  with  moderate  to  severe  active rheumatoid arthritis.

| Study identifier          | WA 22762                                                                                        | WA 22762                                                                                         | WA 22762                                                                                                                                           |
|---------------------------|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    |                                                                                                 |                                                                                                  |                                                                                                                                                    |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                  | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                   | 24 weeks not applicable 72 weeks (open label)                                                                                                      |
| Hypothesis                | Non-inferiority with regard to ACR20 response at week 24 of TCZ SC treatment compared to TCZ IV | Non-inferiority with regard to ACR20 response at week 24 of TCZ SC treatment compared to TCZ IV  | Non-inferiority with regard to ACR20 response at week 24 of TCZ SC treatment compared to TCZ IV                                                    |
| Treatments groups         | TCZ SC                                                                                          | TCZ SC                                                                                           | TCZ 162 mg SC qw in combination with DMARDs                                                                                                        |
| Treatments groups         | TCZ IV                                                                                          | TCZ IV                                                                                           | TCZ 8 mg/kg IV q4w in combination with DMARDs                                                                                                      |
| Endpoints and definitions | Primary endpoint                                                                                | ACR20 response                                                                                   | defined as at least a 20% improvement compared with baseline in both TJC68 and SJC66, as well as in three out of five of the additional parameters |
|                           | Secondary endpoints                                                                             | ACR 50/70 DAS 28 DAS ‹ 2.6 (DAS remission) HAQ-DI Withdrawal due to lack of therapeutic response |                                                                                                                                                    |
| Database lock             | WA22762 (24 Week): completed WA22762 LTE (72 week): 16 January 2012                             | WA22762 (24 Week): completed WA22762 LTE (72 week): 16 January 2012                              | WA22762 (24 Week): completed WA22762 LTE (72 week): 16 January 2012                                                                                |
| Results and Analysis      | Results and Analysis                                                                            | Results and Analysis                                                                             | Results and Analysis                                                                                                                               |
| Analysis description      | Primary Analysis                                                                                | Primary Analysis                                                                                 | Primary Analysis                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description                        | Intent to treat TCZ 162 mg SC q2w = 631 TCZ 8 mg/kg IV q4w = 631 Per-Protocol (PP) population (primary analysis population for non- inferiority) TCZ 162 mg SC q2w = 558 TCZ 8 mg/kg IV q4w = 537                         | Intent to treat TCZ 162 mg SC q2w = 631 TCZ 8 mg/kg IV q4w = 631 Per-Protocol (PP) population (primary analysis population for non- inferiority) TCZ 162 mg SC q2w = 558 TCZ 8 mg/kg IV q4w = 537                         | Intent to treat TCZ 162 mg SC q2w = 631 TCZ 8 mg/kg IV q4w = 631 Per-Protocol (PP) population (primary analysis population for non- inferiority) TCZ 162 mg SC q2w = 558 TCZ 8 mg/kg IV q4w = 537                         | Intent to treat TCZ 162 mg SC q2w = 631 TCZ 8 mg/kg IV q4w = 631 Per-Protocol (PP) population (primary analysis population for non- inferiority) TCZ 162 mg SC q2w = 558 TCZ 8 mg/kg IV q4w = 537                         |
|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary Analysis                                                      |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |
|                                                                       | Treatment group                                                                                                                                                                                                           | TCZ SC                                                                                                                                                                                                                    | TCZ SC                                                                                                                                                                                                                    | TCZ IV                                                                                                                                                                                                                    |
|                                                                       | Number of subject                                                                                                                                                                                                         | 558                                                                                                                                                                                                                       | 558                                                                                                                                                                                                                       | 537                                                                                                                                                                                                                       |
|                                                                       | ACR 20 n(%)                                                                                                                                                                                                               | 387 (69.4 %)                                                                                                                                                                                                              | 387 (69.4 %)                                                                                                                                                                                                              | 394 (73.4 %)                                                                                                                                                                                                              |
| Effect estimate per comparison                                        | ACR20 Response                                                                                                                                                                                                            | TCZ SC - TCZ IV                                                                                                                                                                                                           | TCZ SC - TCZ IV                                                                                                                                                                                                           | TCZ SC - TCZ IV                                                                                                                                                                                                           |
| Effect estimate per comparison                                        | ACR20 Response                                                                                                                                                                                                            | Weighted difference                                                                                                                                                                                                       | Weighted difference                                                                                                                                                                                                       | -4%                                                                                                                                                                                                                       |
| Effect estimate per comparison                                        | ACR20 Response                                                                                                                                                                                                            | 95%-CI                                                                                                                                                                                                                    | 95%-CI                                                                                                                                                                                                                    | (-9.2, 1.2)                                                                                                                                                                                                               |
| Notes                                                                 | As the lower limit of the 95% CI for the difference in response rates (- 9.2) is above the pre-defined non-inferiority margin (-12%), non- inferiority of TCZ SC compared to TCZ IV with regard to ACR20 has been proven. | As the lower limit of the 95% CI for the difference in response rates (- 9.2) is above the pre-defined non-inferiority margin (-12%), non- inferiority of TCZ SC compared to TCZ IV with regard to ACR20 has been proven. | As the lower limit of the 95% CI for the difference in response rates (- 9.2) is above the pre-defined non-inferiority margin (-12%), non- inferiority of TCZ SC compared to TCZ IV with regard to ACR20 has been proven. | As the lower limit of the 95% CI for the difference in response rates (- 9.2) is above the pre-defined non-inferiority margin (-12%), non- inferiority of TCZ SC compared to TCZ IV with regard to ACR20 has been proven. |
| Analysis description                                                  |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           |
| Sensitivity analysis (non-inferiority analysis based on               |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           | TCZ SC N = 631                                                                                                                                                                                                            | TCZ IV N = 631                                                                                                                                                                                                            |
| ITT population)                                                       | ACR20 Response N (%) Weighted difference (95%-CI)                                                                                                                                                                         | ACR20 Response N (%) Weighted difference (95%-CI)                                                                                                                                                                         | 427 (67.7) 443 (70.2) -2.7 (-7.6, 2.2)                                                                                                                                                                                    | 427 (67.7) 443 (70.2) -2.7 (-7.6, 2.2)                                                                                                                                                                                    |
| Secondary analyses                                                    |                                                                                                                                                                                                                           |                                                                                                                                                                                                                           | TCZ SC N = 558                                                                                                                                                                                                            | TCZ IV N = 537                                                                                                                                                                                                            |
| If not stated otherwise secondary analyses are based on PP population | ACR50 Response N (%) Weighted difference (95%-CI)                                                                                                                                                                         | ACR50 Response N (%) Weighted difference (95%-CI)                                                                                                                                                                         | 262 (47.0) 261 (48.6) -1.8 (-7.5, 4.0)                                                                                                                                                                                    | 262 (47.0) 261 (48.6) -1.8 (-7.5, 4.0)                                                                                                                                                                                    |
| If not stated otherwise secondary analyses are based on PP population | ACR70 Response N (%) Weighted difference (95%-CI)                                                                                                                                                                         | ACR70 Response N (%) Weighted difference (95%-CI)                                                                                                                                                                         | 134 (24.0) 150 (27.9) -3.8 (-9.0, 1.3)                                                                                                                                                                                    | 134 (24.0) 150 (27.9) -3.8 (-9.0, 1.3)                                                                                                                                                                                    |
| If not stated otherwise secondary analyses are based on PP population | DAS Remission N (%) Weighted difference (95%-CI)                                                                                                                                                                          | DAS Remission N (%) Weighted difference (95%-CI)                                                                                                                                                                          | 198 (38.4) 184 (36.9) 0.9 (-5.0, 6.8)                                                                                                                                                                                     | 198 (38.4) 184 (36.9) 0.9 (-5.0, 6.8)                                                                                                                                                                                     |
| If not stated otherwise secondary analyses are based on PP population | Decrease ≥ 0.3 in HAQ N (%) Weighted difference (95%-CI)                                                                                                                                                                  | Decrease ≥ 0.3 in HAQ N (%) Weighted difference (95%-CI)                                                                                                                                                                  | 336 (65.2) 337 (67.4) -2.3 (-8.1, 3.4)                                                                                                                                                                                    | 336 (65.2) 337 (67.4) -2.3 (-8.1, 3.4)                                                                                                                                                                                    |
| If not stated otherwise secondary analyses are based on PP population | Withdrawal due to lack of therapeutic response N (%) Weighted difference (95%-CI)                                                                                                                                         | Withdrawal due to lack of therapeutic response N (%) Weighted difference (95%-CI)                                                                                                                                         | 10 (1.8) 5 (0.9) 0.9 (-0.9, 2.7)                                                                                                                                                                                          | 10 (1.8) 5 (0.9) 0.9 (-0.9, 2.7)                                                                                                                                                                                          |

## Analysis performed across trials (pooled analyses and meta-analysis)

A comparative analysis of the week 24 efficacy results from the pivotal SC studies NA25220 and WA22762  were  provided  and  with  the  24-week  historical  IV  data.  The  analysis  is  based  on summary data (ITT population) of:

<div style=\"page-break-after: always\"></div>

- Study WA22762 Week 24
- Study NA25220 Week 24
- 24-week historical Pooled IV

Furthermore long-term maintenance of efficacy for patients treated up to 1 year is analysed. The analysis is based on summary data (ITT population) of:

- Study WA22762-LTE
- Study NA25220-LTE
- All Exposure Historical Pooled IV LTE

## Disposition of patients

A  total  of  1918  patients  were  enrolled  in  the  pivotal  Phase  III  SC  program:  1262  patients  in study WA22762 and 656 in study NA25220. Of the 1918 patients randomized into the two pivotal studies, 1755 patients (92%) completed the 24-week period of the study.

Table 28. Disposition of the pivotal studies (all randomized patients)

| Study    | Treatment Amms                   | Ran- do- mized   | With- drawn Prior to Week24   | Escap- ed Prior to Week 24   | Com- pleted Week 24   | Treatment Ams in LTE Period   | Re-Ran- domized   | Withdrawn During OL LTE up to Clinical Cut- off   | Escaped During OL LTE up to Clinical Cut-off   | Com- pleted OL LTE up to Clinical Cut-off   |
|----------|----------------------------------|------------------|-------------------------------|------------------------------|-----------------------|-------------------------------|-------------------|---------------------------------------------------|------------------------------------------------|---------------------------------------------|
| WA22762  | TCZ162mgSCqW+DMARD               | 631              | 59 (9.4%)                     | NA                           | 572 (91%)             | TCZ 162 mg SC qw (PFS)        | 524               | 21 (4.0%)                                         | NA                                             | 503                                         |
| WA22762  | (PFS)                            | 631              | 59 (9.4%)                     | NA                           | 572 (91%)             | TCZ 8 mg/kg IV q4w            | 48                | 1 (2.1%)                                          | NA                                             | 47                                          |
| WA22762  | TCZ 8 mg/kg IV q4w + DMARD (PFS) | 631              | 67 (10.6%)                    | NA                           | 564 (89%)             | TCZ 8 mg/kg IV q4w            | 377               | 17 (4.5%)                                         | NA                                             | 360                                         |
| WA22762  |                                  | 631              | 67 (10.6%)                    | NA                           | 564 (89%)             | TCZ 162 mg SC qw (PFS)        | 186               | 7 (3.8%)                                          | NA                                             | 179                                         |
| NA25220  | TCZ 162 mg SC q2w + DMARD (PFS)  | 437a             | 26 (5.9%)                     | 72                           | 410b                  | TCZ 162 mg SC q2w (Al)        | 167               | 6 (3.6%)                                          | 2                                              | 161                                         |
| NA25220  |                                  | 437a             | 26 (5.9%)                     | 72                           | (94%)                 | TCZ 162 mg SC q2w (PFS)       | 167               | 3 (1.8%)                                          | 3                                              | 164                                         |
| NA25220  | PBO SC q2W + DMARD (PFS)219      |                  | 7                             | 90                           | 209 b                 | TCZ 162 mg SC q2w (Al)        | 59                | 0 (0.0%)                                          | 1                                              | 59                                          |
| NA25220  |                                  |                  | (3.2%)                        | 90                           | (96%)                 | TCZ 162 mg SC q2w (PFS)       | 60                | 2 (3.3%)                                          | 1                                              | 58                                          |
| MRA229JP | TCZ 162 mg SC q2w (PFS)          | 174              | 12 C                          |                              |                       | NA 161                        | NA 161            | NA 161                                            | NA 161                                         | NA 161                                      |
| MRA229JP | TCZ 8 mg/kg IV q4w               | 174              | 12 C                          |                              |                       | NA 161                        | NA 161            | NA 161                                            | NA 161                                         | NA 161                                      |
| NP22623  | TCZ 162 mg SC qw + MTX           | 14               | 。°                            | NA                           |                       | 14 e                          | 14 e              | 14 e                                              | 14 e                                           | 14 e                                        |

<!-- image -->

The historical 24-week IV data used for comparison included four Phase III studies.

<div style=\"page-break-after: always\"></div>

Table 29. Disposition in historical 24 weeks IV studies (all patients)

|                                                   | WA17822                                           | WA17823                                           | WA18063                                           | WA18062                                           |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Total Randomized                                  | 623                                               | 1196                                              | 1220                                              | 499                                               |
| Placebo + DMARD*                                  | 204                                               | 394                                               | 415                                               | 161                                               |
| TCZ 4 mg/kg + MTX                                 | 214                                               | 401                                               |                                                   | 164                                               |
| TCZ 8 mg/kg + DMARD*                              | 205                                               | 401                                               | 805                                               | 174                                               |
| Received Study Medication                         | 622                                               | 1190                                              | 1216                                              | 498                                               |
| Placebo + DMARD*                                  | 204                                               | 392                                               | 414                                               | 160                                               |
| TCZ 4 mg/kg + MTX                                 | 212                                               | 399                                               |                                                   | 163**                                             |
| TCZ 8 mg/kg + DMARD*                              | 206                                               | 399                                               | 802                                               | 175**                                             |
| Completed 24 weeks (initial therapy)              | Completed 24 weeks (initial therapy)              | Completed 24 weeks (initial therapy)              | Completed 24 weeks (initial therapy)              | Completed 24 weeks (initial therapy)              |
| Placebo + DMARD*                                  | 124 (91%)                                         | 215 (88%)                                         | 325 (78%)                                         | 64 (40%)                                          |
| TCZ 4 mg/kg + MTX                                 | 157 (86%)                                         | 308 (93%)                                         |                                                   | 108 (66%)                                         |
| TCZ 8 mg/kg + DMARD*                              | 174 (93%)                                         | 326 (91%)                                         | 732 (91%)                                         | 132 (76%)                                         |
| Completed 24 weeks (escape therapy)               | Completed 24 weeks (escape therapy)               | Completed 24 weeks (escape therapy)               | Completed 24 weeks (escape therapy)               | Completed 24 weeks (escape therapy)               |
| Placebo + DMARD*                                  | 65 (96%)                                          | 141 (94%)                                         | 45 (100%)                                         | 63 (95%)                                          |
| TCZ 4 mg/kg + MTX                                 | 28 (90%)                                          | 65 (97%)                                          |                                                   | 30 (97%)                                          |
| TCZ 8 mg/kg + DMARD*                              | 18 (95%)                                          | 40 (98%)                                          | 19 (100%)                                         | 20 (100%)                                         |
| Completed 24 weeks (of initial or escape therapy) | Completed 24 weeks (of initial or escape therapy) | Completed 24 weeks (of initial or escape therapy) | Completed 24 weeks (of initial or escape therapy) | Completed 24 weeks (of initial or escape therapy) |
| Placebo + DMARD*                                  | 189 (93%)                                         | 356 (91%)                                         | 370 (89%)                                         | 127 (79%)                                         |
| TCZ 4 mg/kg + MTX                                 | 185 (87%)                                         | 373 (93%)                                         |                                                   | 138 (85%)                                         |
| TCZ 8 mg/kg + DMARD*                              | 192 (93%)                                         | 366 (92%)                                         | 751 (93%)                                         | 152 (87%)                                         |

DMARD = disease modifying anti-rheumatic drug: MTX - methotrexate; TCZ = tocilizumab.

Percentages are based on the number of patients in each randomized treatment group

* In Studies WA17822, WA17823 and WA18062 the DMARD received was MTX.

** In Study WA18062, one patient was randomized to receive TCZ 4 mg/kg + MTX, this patient actually received 6 mg/kg TCZ, and so was included in the TCZ 8 mg/kg + MTX group for all analyses.

Snlrre.WA17822-Finure 2-WA17823Finlre 2-WA18n63·Finure 2-WA18n62·Finure 2

<div style=\"page-break-after: always\"></div>

## Baseline characteristics

Table 30. Key  demographic  parameters  at  baseline  -  Studies  NA  25220  and WA22762 vs. historical pooled IV 24 week data

|                                | StudyWA22762            | StudyWA22762                                    | Study NA25220                       | Study NA25220                   | HistoricalIV Data: Pooled 24-Week Phase Ill Studies   | HistoricalIV Data: Pooled 24-Week Phase Ill Studies   | HistoricalIV Data: Pooled 24-Week Phase Ill Studies   |
|--------------------------------|-------------------------|-------------------------------------------------|-------------------------------------|---------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                | SC qw + DMARD (N = 631) | TCZ 162 mg TCZ 8 mg/kg IV q4w + DMARD (N = 631) | TCZ 162 mg Sc q2w + DMARD (N = 437) | Placebo SC q2w + DMARD (N =219) | TCZ 8 mg/kg IV q4w + DMARD (N = 1576) (N = 773)       | TCZ 4 mg/kg IV q4w + MTX                              | Placebo IV q4w + DMARD (N=1168)                       |
| Sex                            |                         |                                                 |                                     |                                 |                                                       |                                                       |                                                       |
| Male                           | 18%                     | 17%                                             | 14%                                 | 17%                             | 18%                                                   | 17%                                                   | 18%                                                   |
| Female                         | 82%                     | 83%                                             | 86%                                 | 83%                             | 82%                                                   | 83%                                                   | 82%                                                   |
| Race                           |                         |                                                 |                                     |                                 |                                                       |                                                       |                                                       |
| White                          | 77%                     | 76%                                             | 74%                                 | 69%                             | 74%                                                   | 75%                                                   | 75%                                                   |
| Black                          | 5%                      | 4%                                              | 5%                                  | 6%                              | 4%                                                    | 4%                                                    | 4%                                                    |
| Asian                          | 7%                      | 7%                                              | 4%                                  | 6%                              | 8%                                                    | 6%                                                    | 8%                                                    |
| American Indian/ Alaska native | 4%                      | 4%                                              | 0.7%                                | 0.5%                            | 7%                                                    | 6%                                                    | 6%                                                    |
| Other race*                    |                         |                                                 | 15%                                 | 17%                             |                                                       |                                                       |                                                       |
| Other                          | 0.3%                    | 0.2%                                            | 1.4%                                | 0.9%                            | 6%                                                    | 9%                                                    | 7%                                                    |
| Not available **               | 7.3%                    | 8.6%                                            |                                     |                                 |                                                       |                                                       |                                                       |
| Age (mean, years)              | 52.7                    | 52.8                                            | 52.1                                | 52.0                            | 52.9                                                  | 51.3                                                  | 52.3                                                  |
| Weight (mean, kg)              | 74.6                    | 74.4                                            | 70.3                                | 70.0                            | 72.8                                                  | 73.0                                                  | 73.5                                                  |
| Weight category (kg)           |                         |                                                 |                                     |                                 |                                                       |                                                       |                                                       |
| < 60                           | 22.8%                   | 23.1%                                           | 27.2%                               | 26.5%                           | 23.9%                                                 | 23.9%                                                 | 24.4%                                                 |
| 60 -<100                       | 67.4%                   | 66.9%                                           | 66.8%                               | 68.5%                           | 68.1%                                                 | 67.8%                                                 | 66.2%                                                 |
| ≥ 100                          | 9.8%                    | 10.0%                                           | 5.9%                                | 5.0%                            | 7.6%                                                  | 7.8%                                                  | %0'6                                                  |
| Geographic region              |                         |                                                 |                                     |                                 |                                                       |                                                       |                                                       |
| Europe                         | 31.5%                   | 31.4%                                           | 23.1%                               | 22.4%                           | 31.7%                                                 | 40.6%                                                 | 35.7%                                                 |
| North America                  | 28.5%                   | 28.7%                                           | 20.4%                               | 20.5%                           | 37.5%                                                 | 29.1%                                                 | 34.4%                                                 |
| South America                  | 24.6%                   | 24.6%                                           | 40.3%                               | 40.6%                           | 20.3%                                                 | 20.4%                                                 | 19.8%                                                 |
| Rest of World                  | 15.4%                   | 15.4%                                           | 16.2%                               | 16.4%                           | 10.5%                                                 | 9.8%                                                  | 10.1%                                                 |

TCZ = tocilizumab; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug; MTX = methotrexate; qw = once weekly; q2w / q4w = once every 2/ 4 weeks.

* \"Other race\" was not a category in Study WA22762.

** *Not available\" was not a category in Study NA25220.

<div style=\"page-break-after: always\"></div>

Table 31. RA  characteristics  at  baseline  -  Studies  NA  25220  and  WA22762  vs. historical pooled IV 24 week data (ITT population)

|                                         | StudyWA22762          | StudyWA22762                                   | Study NA25220                       | Study NA25220                  | Historical IVData:Pooled 24-WeekPhaseIllStudies   | Historical IVData:Pooled 24-WeekPhaseIllStudies   | Historical IVData:Pooled 24-WeekPhaseIllStudies      |
|-----------------------------------------|-----------------------|------------------------------------------------|-------------------------------------|--------------------------------|---------------------------------------------------|---------------------------------------------------|------------------------------------------------------|
|                                         | SC qw + DMARD (N=631) | TCZ 162 mg TCZ 8 mg/kg IV q4w + DMARD (N =631) | TCZ 162 mg SC q2w + DMARD (N = 437) | Placebo SC q2w + DMARD (N=219) | TCZ 8 mg/kg IV q4w + DMARD                        | TCZ 4 mg/kg IV q4w + MTX                          | PlaceboIV q4w + DMARD (N = 1576) (N= 773) (N = 1168) |
| Duration of RA (mean, years)            | 8.7                   | 8.6                                            | 11.1                                | 11.1                           | 9.7                                               | 9.2                                               | 9.4                                                  |
| No. of previous DMARDs (mean)           | 1.4                   | 1.4                                            | 1.3                                 | 1.4                            | 1.8                                               | 2.1                                               | 1.9                                                  |
| Oral corticosteroid use                 | 55%                   | 54%                                            | 65%                                 | 57%                            | 45%                                               | 37%                                               | 40%                                                  |
| Oral corticosteroid dose (mean, mg/day) | 6.9                   | 6.8                                            | 6.5                                 | 6.3                            | Not available                                     | Not available                                     | Not available                                        |
| RF positive                             | 74%                   | 74%                                            | 81%                                 | 82%                            | 80%                                               | 78%                                               | 77%                                                  |
| Anti-CCP positive                       | 72%                   | 76%                                            | 84%                                 | 83%                            | Not available                                     | Not available                                     | Not available                                        |
| Failed prior anti-TNF treatment         | 23%                   | 22%                                            | 20%                                 | 22%                            | 10.8%                                             | 20.8%                                             | 13.5%                                                |

TCZ = tocilizumab; SC = subcutaneous; IV = intravenous; DMARD = disease modifying antirheumatic drug; MTX = methotrexate; qw = once weekly; q2w / q4w = once every 2/ 4 weeks; RF = rheumatoid factor; cycli citrullinated peptide; TNF = tumor necrosis factor.

Table 32. Mean  ACR/DAS28  characteristics  at  baseline  -  Studies  NA  25220  and WA22762 vs. historical pooled IV 24 week data (ITT population)

|                           | Study WA22762                     | Study WA22762                       | Study NA25220                       | Study NA25220                  | HistoricallvData:Pooled 24-Week Phase Ill Studies   | HistoricallvData:Pooled 24-Week Phase Ill Studies   | HistoricallvData:Pooled 24-Week Phase Ill Studies   |
|---------------------------|-----------------------------------|-------------------------------------|-------------------------------------|--------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                           | TCZ 162 mg SC qw + DMARD (N =631) | TCZ 8 mg/kg IV q4w + DMARD (N =631) | TCZ 162 mg SC q2w + DMARD (N = 437) | Placebo SC q2w + DMARD (N=219) | ZO1 8mg/kg IV q4w + DMARD (N = 1576) (N = 773)      | TCZ 4 mg/kg IV q4w + MTX                            | PlaceboIV q4w + DMARD (N =1168)                     |
| DAS28                     | 6.6                               | 6.7                                 | 6.7                                 | 6.6                            | 6.7                                                 | 6.6                                                 | 6.7                                                 |
| TJC (68 joints)           | 27.3                              | 28.6                                | 28.0                                | 27.4                           | 30.3                                                | 30.1                                                | 29.5                                                |
| SJC (66 joints)           | 15.0                              | 16.5                                | 17.5                                | 17.6                           | 19.0                                                | 18.3                                                | 18.4                                                |
| ESR (mm/hr)               | 51.7                              | 52.0                                | 50.8                                | 49.4                           | 48.2                                                | 47.9                                                | 49.1                                                |
| CRP (mg/dL)               | 2.1                               | 2.2                                 | 2.0                                 | 1.9                            | 2.5                                                 | 2.5                                                 | 2.6                                                 |
| HAQ-DI score (0 - 3)      | 1.6                               | 1.7                                 | 1.6                                 | 1.6                            | 1.5                                                 | 1.6                                                 | 1.6                                                 |
| Patient global VAS (mm)   | 67.0                              | 67.2                                | 63.6                                | 62.1                           | 65.6                                                | 64.2                                                | 65.1                                                |
| Patient pain VAS (mm)     | 59.7                              | 61.5                                | 57.8                                | 56.8                           | 58.6                                                | 57.4                                                | 58.0                                                |
| Physician global VAS (mm) | 61.3                              | 62.5                                | 61.1                                | 61.8                           | 63.7                                                | 63.5                                                | 63.9                                                |

erythrocyte sedimentation rate;CRP=C-reactiveprotein;HAQ-Dl=HealthAssessment Questionnaire Disability Index; VAS = visual analoq scale; TCZ = tocilizumab; SC = subcutaneous; IV=intravenous; DMARD = disease modifying anti-rheumatic drug;MTX = methotrexate; qw = once weekly; q2w / q4w = once every 2/ 4 weeks. Note:n'sforeachparametervariedfrom623to631inStudyWA22762;from434to427fortheTCZ arm andfrom217to219fortheplaceboamofStudyNA25220.Seesourcedocumentsforn's.

<div style=\"page-break-after: always\"></div>

Baseline  RA  characteristics  were  balanced  across the  two  SC  pivotal  studies  and  the  historical pooled IV pooled studies, with the following exceptions:

- The  mean  duration  of  RA  was  longer  in  study  NA25220  (11.1  years)  than  in  Study WA22762 (8.6- 8.7 years) and the IV historical control studies (9.2- 9.7 years).
- The mean number of previous DMARDs was greater in the historical control studies (1.82.1 units) then in the two pivotal SC studies (1.3-1.4 units).
- The proportion of patients who were RF positive was also higher in study NA25220 (81 -82%) compared in study WA22762 (74%) and historical IV control  (77  -80%).  The proportion of patients receiving background oral corticosteroids was higher on both SC pivotal  studies  (54%-  55%  on  Study  WA22762,  65%-  56%  in  study  NA25220) compared with historical IV control (37-45%).

The proportion of patients who were anti-TNF-IRs was 20 - 23% across the four arms in the pivotal studies, reflecting the capping rule (the protocol stipulated the proportion of patients who failed one or more anti-TNF agents should be approximately 20%) but was lower in the historical pooled IV control population (10.8- 20.8% across the arms).

## Outcomes

Table 33. Percentage  with  an  ACR20/50/70  response  at  week  24  baseline  studies  NA  25220  and  WA22762  vs.  historical  pooled  IV  24  week  data  (ITT population)

|       | StudyWA22762                      | StudyWA22762                         | StudyNA25220                        | StudyNA25220                    | Historical V Data Pooled 24-WeekPhaselll Studies   | Historical V Data Pooled 24-WeekPhaselll Studies   | Historical V Data Pooled 24-WeekPhaselll Studies   |
|-------|-----------------------------------|--------------------------------------|-------------------------------------|---------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|       | TCZ 162 mg SC qw + DMARD (N =631) | TCZ 8 mg/kg IV q4w + DMARD (N = 631) | TCZ 162 mg SC q2w + DMARD (N = 437) | Placebo SC q2w + DMARD (N =219) | TCZ 8 mg/kg IV q4w + DMARD (N = 1576)              | TCZ 4 mg/kg IV q4w + MTX (N = 773)                 | Placebo IV q4w + DMARD (N = 1168)                  |
| ACR20 | 67.7%                             | 70.2%                                | 60.9%                               | 31.5%                           | 58.2%                                              | 45.7%                                              | 23.7%                                              |
| ACR50 | 45.5%                             | 46.6%                                | 39.8%                               | 12.3%                           | 36.1%                                              | 25.1%                                              | 8.8%                                               |
| ACR70 | 23.6%                             | 26.5%                                | 19.7%                               | 5.0%                            | 17.8%                                              | 10.1%                                              | 2.2%                                               |

TCZ = tocilizumab; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti- am t  Aaa aouo = mtb / mzb aae ouo = mb :bnp enas

<div style=\"page-break-after: always\"></div>

Figure 10. ACR 20 response to week 24 (ITT population)

<!-- image -->

ACR = American College of Rheumatology; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug; MTX = methotrexate; qw = once weekly; q2w = once everv 2 weeks.

<div style=\"page-break-after: always\"></div>

Figure 11. ACR 50 response to week 24 (ITT population)

<!-- image -->

DMARD = disease modifying anti-rheumatic drug: MTX = methotrexate; qw = once weekly; q2w = once every 2 weeks.

Source:eteprsp01\\_acrsp\\_24\\_1,etsum01\\_acr50\\_1,etacr205070\\_id003\\_pooli

<div style=\"page-break-after: always\"></div>

Figure 12. ACR 70 response to week 24 (ITT population)

<!-- image -->

ACR = American College of Rheumatology; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug: MTX = methotrexate; qw = once weekly; q2w = once every 2 weeks.

Source:eteprsp01\\_acrsp\\_24\\_1, etsum01\\_acr70\\_1, etacr205070\\_id003\\_pooli

Over  time,  the  ACR20/50/70  response  profiles  were  similar  for  the  SC  and  IV  route  of administration. Interestingly, at each time point, response rates for 8 mg/kg IV (WA22762) and placebo  SC  q2w  (study  NA25220)  were  higher  on  the  SC  pivotal  studies  than  the  historical pooled IV data.

The response profile for 162 mg SC qw in study WA22762 was comparable to 8 mg/kg IV.

Taking into account the different placebo rates for study NA25220 vs. historical pooled IV, the response rates for 162 mg SC q2w over time were lower than SC qw and more comparable to 4 mg/kg IV.

The same trend was observed for the DAS28 reduction over time up to week 24. Decreases were similar in the SC qw and IV arms of study WA22762 and greater than those in the q2w arm in study NA25220 at all time points. Compared with the historical IV data, and taking into account the different placebo rates on NA25220 vs. historical pooled IV, the mean changes with SC q2w fell between those from the 4 and 8 mg/kg historical IV groups.

<div style=\"page-break-after: always\"></div>

Figure 13. DAS28 over time to week 24 (ITT population)

<!-- image -->

DAS28 = disease activity score; ITT = intent to treat; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug;: MTX = methotrexate; qw = once weekly; q2w = once every 2 weeks.

Source: WA22762, etsum02\\_dascfb24\\_1; NA25220, etsum02\\_dascfb\\_preesc\\_1; Pooled Historical IV,etsumdas28vis\\_id003\\_pooli

<div style=\"page-break-after: always\"></div>

Table 34. Percentage of ACR response at week 24 by weight - studies NA 25220 and WA22762 vs. historical pooled IV 24 week data (ITT population)

|           | Study WA22762                      | Study WA22762                     | Study NA25220                       | Study NA25220                  | Pooled IVHistorical Data              | Pooled IVHistorical Data          | Pooled IVHistorical Data          |
|-----------|------------------------------------|-----------------------------------|-------------------------------------|--------------------------------|---------------------------------------|-----------------------------------|-----------------------------------|
|           | TCZ 162 mg SC qw + DMARD (N = 631) | TCZ8 mg/kg IV q4w + DMARD (N=631) | TCZ 162 mg SC q2w + DMARD (N = 437) | Placebo SC q2w + DMARD (N=219) | TCZ 8 mg/kg IV q4w + DMARD (N = 1576) | TCZ 4 mg/kg IV q4w + MTX (N =773) | Placebo IV q4w + DMARD (N = 1168) |
| < 60 kg   | (n = 144)                          | (n = 146)                         | (n = 119)                           | (n = 58)                       | (n = 377)                             | (n = 185)                         | (n = 286)                         |
| ACR20     | 74.3%                              | 76.0%                             | 63.0%                               | 29.3%                          | 63.7%                                 | 52.4%                             | 23.4%                             |
| ACR50     | 50.0%                              | 52.7%                             | 43.7%                               | 10.3%                          | 37.7%                                 | 29.7%                             | 8.7%                              |
| ACR70     | 23.6%                              | 35.6%                             | 23.5%                               | 3.4%                           | 19.9%                                 | 13.0%                             | 2.1%                              |
| 60-<100kg | (n = 425)                          | (n = 422)                         | (n = 292)                           | (n = 150)                      | (n = 1073)                            | (n = 524)                         | (n = 773)                         |
| ACR20     | 68.0%                              | 71.1%                             | 62.0%                               | 32.7%                          | 56.9%                                 | 46.0%                             | 24.5%                             |
| ACR50     | 45.6%                              | 48.1%                             | 40.8%                               | 12.7%                          | 36.0%                                 | 24.2%                             | 8.5%                              |
| ACR70     | 25.2%                              | 26.5%                             | 19.5%                               | 5.3%                           | 17.4%                                 | 9.2%                              | 1.9%                              |
| 2 100 kg  | (n = 62)                           | (n = 63)                          | (n = 26)                            | (n = 11)                       | (n = 120)                             | (n = 60)                          | (n = 105)                         |
| ACR20     | 50.0%                              | 50.8%                             | 38.5%                               | 27.3%                          | 53.3%                                 | 25.0%                             | 18.1%                             |
| ACR50     | 33.9%                              | 22.2%                             | 11.5%                               | 18.2%                          | 33.3%                                 | 20%                               | 10.5%                             |
| ACR70     | 12.9%                              | 4.8%                              | 3.8%                                | 9.1%                           | 15%                                   | 10%                               | 4.8%                              |

ACR = American College of Rheumatology: TCZ = tocilizumab; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug: MTX = methotrexate; qw = once weekly; q2w / q4w = once every 2/4 weeks.

Source:WA22762:eteprsp01\\_acrsp\\_wgt\\_24\\_1; NA25220:eteprsp01\\_acrsp\\_wgt\\_wk24\\_1; Pooled 24-Week IV: etsumacr20pool\\_id003\\_wk245; ACR50/70 for historical IV calculated from original filing outputs:etsumacrwgtwk24\\_ah338\\_pool\\_70.rp8,etsumacrwgtwk24\\_ah338\\_pool\\_50.rp8 etsumacrwgtwk24\\_ah338\\_062\\_70.rp8,etsumacrwgtwk24\\_ah338\\_062\\_50.rp8

<div style=\"page-break-after: always\"></div>

Table 35. Percentage  of  ACR  responders  at  week  24  by  geographical  region  studies  NA  25220  and  WA22762  vs.  historical  pooled  IV  24  week  data  (ITT population)

|                         | StudyWA22762            | StudyWA22762                                  | Study NA25220                      | Study NA25220                   | Historical IV Data Pooled 24-Week Phase Ill Studies   | Historical IV Data Pooled 24-Week Phase Ill Studies   | Historical IV Data Pooled 24-Week Phase Ill Studies   |
|-------------------------|-------------------------|-----------------------------------------------|------------------------------------|---------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Region Category         | SC qw + DMARD (N = 631) | TCZ 162 mgTCZ 8 mg/kg + Mb AI DMARD (N = 631) | TCZ 162 mg SC q2w + DMARD (N= 437) | Placebo SC q2w + DMARD (N =219) | TCZ 8 mg/kg IV q4w + DMARD (N= 1576)                  | TCZ 4 mg/kg IV q4w + MTX (N = 773)                    | Placebo IV q4w + DMARD (N= 1168)                      |
| (n = 180) North America | 47.8%                   | (n = 181) 55.2%                               | (m = 89) 38.2%                     | (n = 45) 15.6%                  | (n = 591) 47.5%                                       | (n = 225) 36.4%                                       | (n = 402) 20.4%                                       |
| (n = 155) South America | 74.2%                   | (n = 155) 79.4%                               | (n = 176) 65.3%                    | (n = 89) 36.0%                  | (n = 320) 69.1%                                       | (n = 158) 57.0%                                       | (n = 231) 35.9%                                       |
| (n = 199) 74.9%         | (n = 198) 70.7%         |                                               | (n = 101) 70.3%                    | (n = 49) 42.9%                  | (n = 500) (n =314) 63.6% 46.2%                        | (n = 417) 21.8%                                       | Europe                                                |
| (n = 97) 79.4%          | (n = 97)                | 82.5%                                         | (n = 71) (n = 36) 64.8% 25.0%      | (n = 165) 58.8%                 | (n = 76) 47.4%                                        | (n = 118) 17.8%                                       | Rest of World                                         |

ACR = American College of Rheumatology: TCZ = tocilizumab; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug: MTX = methotrexate; qw = once weekly; q2w / q4w = once every 2/4 weeks.

Source: WA22762:eteprsp01\\_acrsp\\_reg\\_24\\_1; NA25220:eteprsp01\\_acrsp\\_reg\\_wk24\\_1; Pooled 24-Week IV: etsumacr20p0olid003 wk244

<div style=\"page-break-after: always\"></div>

## Persistence of efficacy

Table 36. Percentage of ACR 20/50/70 responders by visit - studies NA 25220 and WA22762 vs. historical pooled IV 24 week data (ITT population)

|                          | StudyWA22762(Open-LabelExtension)   | StudyWA22762(Open-LabelExtension)   | StudyWA22762(Open-LabelExtension)   | StudyNA25220(Open-LabelExtension)   | StudyNA25220(Open-LabelExtension)   | StudyNA25220(Open-LabelExtension)   | HistoricalIVData                       |
|--------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------------------------|
|                          | TCZ 162 mg SC qw + DMARD (N=524)    | TCZ 8 mg/kg IV q4w + DMARD (N=377)  | TCZIV → SC PFS (N=186)              | TCZ 162 mg SC q2w PFS (N=167)       |                                     | TCZ162mgSC q2w PFS →AI (N=167)      | All Exposure PopulationPooled (N=3368) |
|                          | n Responders                        | n Responders                        | n Responders                        | n Responders                        | n                                   | Responders                          | n Responders                           |
| Week12                   | 524                                 | 377                                 | 186                                 | 167                                 | 167                                 |                                     | 3302                                   |
| ACR20 ACR50 ACR70        | 72.7% 40.3% 19.1%                   | 71.4% 39.3% 21.2%                   | 71.5% 43.5% 17.7%                   | 65.9% 37.7% 21.0%                   |                                     | 70.1% 31.7% 12.6%                   | 51.2% 23.8% 9.0%                       |
| Week 24                  | 524                                 | 377                                 | 186                                 | 167                                 | 167                                 |                                     | 3098                                   |
| ACR20 ACR50 ACR70        | 74.8% 50.2% 27.1%                   | 78.0% 52.3% 30.5%                   | 79.6% 52.2% 28.0%                   | 79.0% 53.9% 25.7%                   |                                     | 77.2% 49.1% 24.6%                   | 59.4% 33.7% 15.0%                      |
| Week36/37*               | 309                                 | 225                                 | 113                                 | 74                                  | 77                                  |                                     | 2860                                   |
| ACR20 ACR50 ACR70        | 73.8% 52.8% 30.1%                   | 74.2% 47.1% 29.8%                   | 76.1% 50.4% 26.5%                   | 81.1% 51.4% 39.2%                   |                                     | 67.5% 48.1% 28.6%                   | 64.2% 38.8% 19.7%                      |
| Week 48/49** ACR20 ACR50 | 129                                 | 96                                  | 47                                  | 19 78.9% 52.6%                      |                                     |                                     | 2793                                   |
| ACR70                    | 69.0% 48.1% 32.6%                   | 66.7% 40.6% 28.1%                   | 70.2% 36.2% 19.1%                   | 31.6%                               | 19                                  | 73.7% 57.9% 10.5%                   | 68.3% 43.6% 23.2%                      |

ACR = American College of Rheumatology; TCZ = tocilizumab; SC = subcutaneous; IV = intravenous; DMARD = disease modifying anti-rheumatic drug; qw =

*Week37inStudyWA22762.

**Week49inStudyWA22762.

Source:WA22762-LTE:etacrsp01\\_acrsp\\_1,NA25220-LTE:etsum01\\_acr20\\_nowk24\\_noplc\\_1,etsum01\\_acr50\\_nowk24\\_noplc\\_1, etsum01\\_acr70\\_nowk24\\_noplc\\_1; Allexposure pooled IV: etacr20507090\\_id003i

## Clinical studies in special populations

In  both  studies  NA25220 and  WA22762, efficacy in various subgroups was evaluated. Notable differences in response were seen in both studies in the analysis by bodyweight. ACR 20, 50 and 70 response rates indicated a comparable response rate in the TCZ SC treatment group for all 3 parameters in the &lt; 60 kg and in the 60 to &lt; 100kg, whereas patients in the &gt; 100 kg showed lower  response  rate  for  these  parameters.  Interestingly,  for  ACR  50  and  70  response  in  the highest body weight group was lower for the weight adjusted IV TCZ treatment than for the fixed SC TCZ dose.

<div style=\"page-break-after: always\"></div>

Table 37. Study NA25220 LTE -  ACR20, ACR 50 and ACR 70 response rates at week 36 by bodyweight (ITT population)

|                             | No. (%) of Patients                          | No. (%) of Patients                                       | No. (%) of Patients                                             | No. (%) of Patients                                            |
|-----------------------------|----------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|
| ACR Response by Body Weight | TCZ PFS q2w (N= 167) No. of Responders/n (%) | TCZ PFS q2W → TCZ Al q2w (N= 167) No. of Responders/n (%) | Placebo PFS q2w →→ TCZ PFS q2w (09 = N) No. of Responders/n (%) | Placebo PFS q2w →→ TCZ Al q2w (N = 59) No. of Responders/n (%) |
| ACR20 response              |                                              |                                                           |                                                                 |                                                                |
| ≤60 kg                      | 12/15 (80.0)                                 | 15/20 (75.0)                                              | 7/8 (87.5)                                                      | 5/6 (83.3)                                                     |
| 60 to =c 100 kg             | 46/56 (82.1)                                 | 33/50 (66.0)                                              | 10/17 (58.8)                                                    | 16/21 (76.2)                                                   |
| 2100 kg                     | 2/3 (66.7)                                   | 4/7 (57.1)                                                | 3/3 (100)                                                       | 1/1 (100.0)                                                    |
| ACR50 response              |                                              |                                                           |                                                                 |                                                                |
| <60 kg                      | 9/15 (60.0)                                  | 13/20 (65.0)                                              | 6/8 (75.0)                                                      | 3/6 (50.0)                                                     |
| 60 to < 100 kg              | 29/56 (51.8)                                 | 23/50 (46.0)                                              | 8/17 (47.1)                                                     | 7/21 (33.3)                                                    |
| ≥100 kg                     | 0/3 (0.0)                                    | 1/7 (14.3)                                                | 2/3 (66.7)                                                      | 1/1 (100.0)                                                    |
| ACR70 response              |                                              |                                                           |                                                                 |                                                                |
| <60 kg                      | 6/15 (40.0)                                  | 9/20 (45.0)                                               | 2/8 (25.0)                                                      | 2/6 (33.3)                                                     |
| 60 to ≤ 100 kg              | 23/56 (41.1)                                 | 13/50 (26.0)                                              | 4/17 (23.5)                                                     | 2/21 (9.5)                                                     |
| ≥100 kg                     | 0/3 (0.0)                                    | 0/7 (0.0)                                                 | 2/3 (66.7)                                                      | 1/1 (100.0)                                                    |

ACR20 - American College of Rheumatology 20% response; ACR50-American College of Rheumatology 50% response; ACR70- American College ol Rheumatology 70% response, Al=Autoinjector, CRP=C-reactive protein, PFS=Pre flled syringe; q2w=Every 2 weeks.

Source: page 450.

Table 38. WA 22762 - ACR20, ACR 50 and ACR 70 response rates at week 24 by bodyweight (PP population)

|                                       | No. of Patients (%)        | No. of Patients (%)        |
|---------------------------------------|----------------------------|----------------------------|
| ACR Response by BodyWeight atBaseline | 162 mg SC qw+DMARD (n=558) | 8 mg/kgIVq4w+DMARD (n=537) |
| ACR20 response                        |                            |                            |
| <60 kg                                | 99/131 (75.6)              | 100/129 (77.5)             |
| 60-100 kg                             | 260/374 (69.5)             | 264 358 (73.7)             |
| ≥100 kg                               | 28/53 (52.8)               | 30/50 (60.0)               |
| ACR50response                         |                            |                            |
| 60 kg                                 | 66/131 (50.4)              | 71/129 (55.0)              |
| 60-100 kg                             | 176/374 (47.1)             | 177 358 (49.4)             |
| ≥100 kg                               | 20/53 (37.7)               | 13/50 (26.0)               |
| ACR70 response                        |                            |                            |
| <60 kg                                | 31/131 (23.7)              | 47/129 (36.4)              |
| 60-100 kg                             | 96/374 (25.7)              | 100/358 (27.9)             |
| ≥100 kg                               | 7/53 (13.2)                | 3/50 (6.0)                 |

ACR=American College of Rheumatology; DMARD= disease-modifying anti-rheumatic drug; IV=intravenous; pp=per protocol; q4w=every 4 weeks; qw=once weekly; SC =subcutaneous. Source: page 549.

Analysis  of  ACR  response  by  regions  revealed  comparable  response  rates  across  the  different regions  (Europe,  South  America,  others)  but  North  America.  Irrespective  of  the  treatment

<div style=\"page-break-after: always\"></div>

received, patients in North America demonstrated a lower response to therapy compared with those from other regions. This finding is consistent with the results from the historical IV data.

## Supportive studies

## Study MRA229JP

Study MRA229JP is an ongoing Phase III study comparing TCZ SC with TCZ IV as monotherapy in patients with RA.

The study objectives were to assess:

- The efficacy and safety of TCZ 162 mg SC q2w administered for 24 weeks in patients with RA.
- Efficacy and safety of long-term administration of TCZ SC (up to 108 weeks), including in patients who performed self-injections using either the PFS (same device as in studies WA22762 and NA25220) or the AI (same device as in study NA25220).

The primary endpoint was the ACR20 response rate at Week 24. Non-inferiority of TCZ SC was claimed if the lower bound of the adjusted 95% CI for the difference between the response rates, TCZ SC minus TCZ IV, was not smaller than - 18 percentage points. The non-inferiority limit was defined to ensure maintenance of at least 70% of the ACR20 response seen with TCZ 8 mg/kg IV q4w versus placebo in previous trials conducted by Chugai.

Figure 14. Design of monotherapy study MRA229JP

<!-- image -->

IV=intravenous; q2w / q3w / q4w=every 2/3/4 weeks; qw =once weekly; SC=subcutaneous; TCZ=tocilizumab; PFS =pre-filled syringe; Al=autoinjector.

? Starting after Week 36, at investigator discretion, the dosing interval could be increased to q3w if DAS28&lt; 3.2 for 24 weeks,or could be decreased to qw if a patient had less than a 20% improvement frombaseline in swollen and tender joint count and CRP &gt;0.3 mg/dL and no notable clinically significant AEs.

Starting at Week 36 in approximately 80 patients providing informed consent.

<div style=\"page-break-after: always\"></div>

The study enrolled 348 RA patients who were randomized 1:1 to one of the two treatment arms; 12  patients  in  each  arm  were  prematurely  withdrawn  during  the  double-blind  period  and  one patient  in  each  arm  withdrew  prior  to  administration  of  study  drug.  Withdrawals  for  AEs  were reported in 3 and 9 patients in the TCZ SC and TCZ IV arm, respectively.

Table 39. Primary and secondary efficacy endpoints: ACR20/50/70 response rate at week 24 (PP population)

|                                | TCZ162mgSC q2w N=159   | TCZ8mg/kg IVq4w N=156   |
|--------------------------------|------------------------|-------------------------|
| Primary Efficacy Parameter:    |                        |                         |
| ACR20 responders               | 126 (79.2%)            | 138 (88.5%)             |
| Weighted difference (95% Cl)   | -9.4 (-17.6, -1.2)     | -9.4 (-17.6, -1.2)      |
| Secondary Efficacy Parameters: |                        |                         |
| ACR50 responders               | 101 (63.5%)            | 105 (67.3%)             |
| ACR70 responders               | 59 (37.1%)             | 64 (41.0%)              |

ACR = American College of Rheumatology; Cl = confidence interval; TCZ =

tocilizumab; SC = subcutaneous; IV = intravenous; q2w / q4w = once every 2/4 weeks.

Analysis is adjusted for stratification factors body weight category (&lt; 60 kg; ≥60 kg) and previous treatment with TNF antagonist (Yes, No); Last observation carried forward (LOCF) imputation was used for all ACR core set components. PP = per protocol.

## Study NP22623

Study NP22623 was a Phase Ib, two-arm, randomized, open-label, parallel group, multi-centre 12-week  study  in  patients  with  active  RA  who  had  an  inadequate  response  to  current  MTX therapy. Patients received all SC injections into the abdominal region at the clinic by study site personnel, using a TCZ vial + syringe.

The objectives were to investigate PK, PD, efficacy and safety of in patients with active RA.

A  total  of  24  patients  were  planned  (12  per  group),  however  29  (15  qw  and  14  q2w)  were randomized.

Patients in both groups showed clinical response, with 75% in the qw group and 64% in the q2w group  showing  an  ACR20  response  at  Week  12,  respectively,  while  the  mean  DAS28  score decreased from a value above 5.3 and 6.0 at baseline, respectively, for the qw and q2w groups to 2.9 in both treatment groups at Week 12. At least 50% of patients attained good response according to the EULAR classification at Week 12 in both groups.

<div style=\"page-break-after: always\"></div>

## 2.5.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The  clinical  efficacy  is  supported  by  two  pivotal  Phase  III  trials  (study  NA25220  and  study WA22762). Both of the  pivotal  studies  were  multi-centre,  two-arm,  randomized,  double-blind, controlled trials.

The objectives of the studies were to assess the efficacy and safety of TCZ given subcutaneously.

Study WA22762 was active controlled, the comparator was TCZ IV and in study NA25220, the comparator was placebo. Both studies had 24-week double-blind periods followed by 72-week open-label extensions in which patients were re-randomized to four arms of various treatments.

In both studies, the open-label extensions are on going. The submission of the final clinical study report for study NA25220 and study WA22762 has been included as milestone in the RMP.

Patients  with  moderate  to  severe  active  RA  who  had  an  inadequate  response  to  their  current DMARD, which may have included one or more anti-TNF agents in up to 20% of patients, were enrolled into the study. In general the disease defining inclusion criteria applied for both studies; with the exception of SJC and TJC. Less diseased patients with regard to the number of swollen and tender joints were accepted for study WA 22762. However this had no impact on the disease characteristics; the baseline RA disease characteristics (i.e. baseline ACR and DAS characteristics) were consistent between studies. The study population was consistent with the population included in the Phase III IV TCZ program and represents the patients who receive IV TCZ. The disease duration was slightly longer in study NA25220 than in Study WA22762. Overall, the  demographic  characteristics  and  baseline  criteria  are  well  balanced  between  the  two treatment groups as well as between the two pivotal studies.

In study NA25220, patients received TCZ 162 mg SC q2w or placebo SC q2w. Patients on escape therapy received open-label TCZ 162 mg SC PFS weekly. In study WA22762, patients received TCZ  162  mg  SC  qw  or  TCZ  8  mg/kg  IV  q4w.  In  both  trials,  study  medication  was  given  in combination with DMARD therapy. All patients had received at least one permitted non-biologic DMARD at a stable dose at least 8 weeks prior to baseline and throughout the study. All patients who completed  to  Week  24  were  re-randomized  for  the  open-label  period  (LTE)  at  Week  24. Although  the  applied  SC  TCZ  dose  was  identical  in  both  studies;  the  treatment  schedule  was different.  The  weekly  schedule  chosen  for  study  WA22762  is  supporting  the  claimed  dosing regimen for this extension application. The approach to investigate in the two pivotal trials two different  TCZ  SC  schemes namely TCZ 162 mg SC q2w and TCZ 162 mg SC qw, each tested against a different comparator is not fully comprehensible. The development program would have benefited  from  a  head  to  head  comparison  of  the  TCZ  SC  regime  which  is  intended  to  be recommended for therapeutic  use  i.e.  TCZ  SC  qw  with  placebo,  especially  with  regard  to  the safety evaluation. Furthermore a direct comparison of both TCZ SC schemes with the authorised TCZ  IV  8  mg/kg  q4w  would  have  provided  further  meaningful  results  on  the  comparative efficacy.

For study NA25220 the primary efficacy objective was to demonstrate the superiority of TCZ SC versus  placebo  SC  with  respect  to  ACR20  response  at  Week  24.  For  the  primary  analysis, patients  that  received  escape  therapy  were  considered  non-responders.  Secondary  objectives included prevention of progression of structural joint damage at Weeks 24 and 48; improvement

<div style=\"page-break-after: always\"></div>

of physical function; long-term safety and efficacy; PK and PD of TCZ SC; and immunogenicity of TCZ SC.

The primary efficacy objective of study WA22762 was to demonstrate the non-inferiority of TCZ SC versus TCZ IV with respect to the ACR 20 response rate at Week 24. Secondary objectives included long-term efficacy; as well PK and PD of TCZ SC; immunogenicity of TCZ SC; and the effect of an IV to SC switch on the safety, efficacy, PK, and PD of TCZ. TCZ SC was considered to be non-inferior to TCZ IV if the lower limit of the 95% confidence interval (CI) for the difference in ACR20 response between the two treatment arms was not less than -12% (SC minus IV). If the  primary  hypothesis  was  rejected,  the  95%  CI  calculated  from  the  primary  hypothesis  test was to be used to test against a 10% non-inferiority limit. The MAH was requested during the evaluation to provide a clinical and statistical justification for the non-inferiority margin.

In providing the clinical rationale for the non-inferiority margin (NIM), the MAH considered that if the subcutaneous (SC) and intravenous (IV) doses to be studied in the pivotal study WA22762 were  equivalent,  due  to  natural  variability,  it  is  unlikely  that  the  difference  between  the  two doses in a clinical trial would be exactly equal to zero.

Therefore, assuming that the SC dose is marginally inferior to the IV dose, the MAH considered what treatment difference would be clinically acceptable. Presuming 2 or 3 out of 10 (20-30%) patients  achieve  an  ACR20  response  on  methotrexate  (MTX)  alone,  an  additional  2  out  of  10 patients (20%) achieving an ACR20 response provide a clinically meaningful difference between treatments. Thus, at least 20% more patients would need to achieve an ACR20 response at week 24 with tocilizumab (TCZ), compared to receiving MTX alone to provide a clinically meaningful difference.

To define the NIM, ACR20 response data from the per protocol population (PPP) of three Phase III  studies  of  TCZ  8mg/kg  IV  +  MTX  (WA17823 - LITHE, WA17822 - OPTION and WA18063 TOWARD)  vs.  placebo  +  MTX,  were  used.  The  populations  in  these  three  Phase  III  studies reflected the population in  WA22762,  namely  patients  with  moderate  to  severe,  active rheumatoid arthritis who were MTX-IR / DMARD-IR, with no more than 20% prior anti-TNF use. The TCZ 8mg/kg IV ACR20 responses at week 24 for the studies were 58.5% (WA17823), 63.3% (WA17822)  and  64.3%  (WA18063),  and  28.1%,  29.8%  &amp;  27.6%  for  placebo  +  MTX, respectively. The pooled ACR20 response for TCZ 8mg/kg IV was 62.5%, the pooled placebo + MTX response was 28.2% resulting in a pooled treatment difference of 34.3%.

Given  that  the  treatment  differences  between  placebo  +  MTX  vs.  TCZ  +  MTX  seen  in  the historical IV studies gave a mean treatment difference of 34.3%, a reduction by approximately one third meant a treatment difference greater than the minimum meaningful clinical difference of  20%  would  be  maintained.  Using  a  maximum  reduction  of  this  treatment  effect  of  35%, maintaining 65% of the treatment difference, would retain a treatment effect of 22.3% over MTX alone, keeping a clinically meaningful improvement in signs and symptoms. The NIM of 12% is then defined by 34.3% minus 22.3%, which equals 12.0%.

The  MAH  therefore  believes  that  the  12%  NIM  is  statistically  sound  and  ensured  clinically meaningful  improvements  were  demonstrated  in  the  pivotal  study  WA22762.  The  CHMP concluded  that  the  MAH  provided  a  satisfactory  justification  for  the  non-inferiority  margin  in study WA22762 although done post-hoc.

<div style=\"page-break-after: always\"></div>

The endpoints in both studies reflect study objectives and are in line with development program proposed in the draft Guideline on clinical investigation of medicinal products other than NSAIDs for  treatment  rheumatoid  arthritis  (CPMP/EWP/556/95  Rev.2).  Moreover  the  endpoints  are consistent with the development program of the IV formulation.

## Efficacy data and additional analyses

In study NA25220 the primary objective, demonstrating superiority of TCZ SC q2w over placebo SC q2w with regard to ACR 20 response rate at week 24 was met. The ACR20 response was 60.9% in the TCZ SC arm vs. 31.5% in the placebo SC arm, the weighted difference between the treatment  and  placebo  arm  of  29.5%  (22.0,  37.0)  was  statistically  significant.  The  sensitivity analysis  of  the  ACR  response  rate  in  the  completer  population  (patients  with  a  valid  efficacy assessment at week 24; escape patients are excluded) demonstrated a response rate of 76.7% in the TCZ group vs. 55.6% in the placebo arm, with a weighted difference of 22.2% and thus support the result of the main efficacy analysis. The observed difference can be considered as clinically meaningful.

This result was supported by the analysis of the secondary endpoints e.g. the harder to achieve ACR50/70  response,  DAS28  remission,  and  decrease  in  HAQ-DI  of ≥ 0.3.  The  mTSS  results indicate a greater reduction in the progression of joint damage between baseline and week 24 for the TCZ SC group compared to placebo. The adjusted mean difference of -0.598 was associated with  a  p-value  of  0.0149  or  0.0145  using  the  non-parametric  van  Elteren  test  or  analysis  of variance, respectively.

According the protocol patients who showed less than 20% improvement in their SJC and TJC from  baseline  could  receive  open  label  escape  therapy  (TCZ  162  mg  SC  qw)  from  week  12 onwards.  Placebo  patients  who  switched  to  escape  therapy  showed  12  and  24  weeks  after initiation  of  the  therapy  an  ACR  20  /50/50  response  in  the  same  range  as  patients  in  study WA22762 study (using the same treatment regimen as for escape therapy).

Furthermore, the patients who switched from TCZ SC q2w-to-qw escape therapy showed a lower response  rate  than  the  placebo  patients  but  had  still  a  benefit  from  the  switch  in  treatment schedule. The MAH suggested that the lower response rate for patients in the TCZ SC q2w-to-qw escape  group  compared  to  placebo  patients  switching  to  escape  therapy  probably  reflects  the inclusion patients who  were true TCZ  non-responders. Of note, no differences in the demographics  disease  characteristics  of  the  escape  patients  and  the  overall  safety  population were observed. However, the RA disease characteristics of the escape patients showed that the proportion of patients who were RF positive, anti-CCP positive, and who had failed one or more previous  anti-TNF  therapies  was  higher  among  patients  who  received  escape  therapy  as compared  to  the  overall  safety  population.  The  ACR  core  set  and  DAS28  characteristics  for escape patients at the initiation of escape therapy were generally unchanged from baseline (with the exception of ESR and CRP in the prior TCZ arm) and reflected the inadequate response in these  patients.  The  CHMP  agreed  that  there  might  be  a  true  TCZ  non-responder  population, however to date no robust biomarkers are available to identify these patients.

According  to  the  study  protocol  the  patients  received  concomitant  DMARDs,  the  choice  of  the medication was left to the investigator. It is understood majority of patients received MTX. No analysis if the efficacy result with regard to the concomitant DMARDs is provided.

<div style=\"page-break-after: always\"></div>

During  the  evaluation,  the  MAH  clarified  that  both  Phase  III  studies  WA22762  and  NA25220, required  patients  to  receive  background  stable  doses  of  at  least  one  non-biologic  DMARD. Permitted non-biologic DMARDs were: azathioprine, chloroquine, hydroxychloroquine, leflunomide, MTX and sulfasalazine. DMARDs could be given alone or in combination, except for the combination of MTX and leflunomide which was prohibited due to hepatotoxicity. Data from these two studies were analysed separately: the primary endpoint ACR20 at week 24, and key secondary  endpoints  (which  represented  a  range  of  efficacy  measures  that  had  been  prespecified  in  the  protocols  and  Statistical  Analysis  Plans),  stratified  by  MTX  use  in  a  post  hoc analysis.

In study WA22762, in the Per Protocol (PP) population at baseline, of the TCZ-SC qw group there were 453 (81.2%) patients who received MTX (alone or in combination with other DMARDs) from a total of 558; in the TCZ-IV 8mg/kg every 4 weeks group 444 (82.7%) patients received MTX (alone or in combination with other DMARDs), from a total of 537 patients.

For the primary end point, the proportion of patients achieving an ACR20 response for TCZ-SC qw+MTX  were  comparable  to  those  in  the  overall  study  population  who  were  receiving background  MTX  and/or  other  non-biologic  DMARDs.  ACR20  reponses  were  also  similar  for patients receiving TCZ-IV 8mg/kg every 4 weeks + MTX to those in the overall study population who were receiving background MTX and/or other non-biologic DMARDs. Additonally,responses were  similar  overall  between  TCZ-SC  qw+MTX  a  TCZ-IV  8mg/kg  4  weekly+MTX.  Analyses stratified by MTX use were also performed on the following secondary end points: ACR50 and 70, proportion of patients achieving DAS 28 remission (&lt;2.6), and proportion of patients achieving decrease  in  HAQ-DI  score  of ≥ 0.3.  Across  all  the  secondary  end  points  analysed:  signs  and symptoms (ACR50/70 and DAS28 remission) and physical function (HAQ-DI), efficacy responses were similar between the TCZ-SC qw and TCZ-IV 8 mg/kg groups with background MTX or the overall patient population.

In study NA25220, in the Intent to Treat (ITT) population at baseline, of the 437 patients in the TCZ-SC q2w group, 361 (82.6%) received MTX (alone or in combination with other DMARDs); of the  219  patients  in  the  PBO  group,  174  (79.5%)  patients  were  receiving  MTX  (alone  or  in combination with other DMARDs).

For the primary end point, the proportion of patients achieving an ACR20 response for TCZ-SC q2w  were  comparable  for  patients  receiving  background  MTX  and  those  in  the  overall  study population  who  were  receiving  background  MTX  and/or  other  non-biologic  DMARDs.  ACR20 response rates for TCZ-SC q2w were substantially higher than the rates observed with placebo, for  both  patients  on  background  MTX  and  those  in  the  overall  study  population.  An  analysis stratified by MTX use was also performed on the following key secondary efficacy end points at week 24: proportion of patients achieving ACR50 and 70, proportion of patients achieving DAS 28  remission(  &lt;2.6),  proportion  of  patients  achieving  decrease  in  HAQ-DI  score  of ≥ 0.3,  and mean difference in mTSS from baseline to week 24. As with the overall study population, there was a substantial efficacy advantage for TCZ-SC q2w over PBO for patients on MTX across all key secondary  endpoints,  including  reduction  in  the  signs  and  symptoms  of  RA  (ACR20/50  and DAS28),  improvement  in  physical  function  (HAQDI),  and  reduction  in  progression  of  joint damage (mTSS).

<div style=\"page-break-after: always\"></div>

The  post-hoc  analysis  provided  by  the  MAH  showed  comparable  efficacy  with  regard  to  the primary  and  key  secondary  efficacy  endpoints  in  patients  receiving  TCZ  with  background  MTX and the overall study population.

The clinical study report NA25220-LTE presented data up to the clinical cut-off date of 28 May 2012. The data analysis provides data up to 48 weeks. So far the data indicated that the efficacy of  TCZ  162  mg  SC  q2w  was  maintained  after  the  24-week  double-blind  period  of  the  study. Evaluation  of  the  efficacy  data  in  patients  who  switched  from  PFS  to  AI  showed  in  general comparative efficacy. For the patients who received placebo during the double-blind phase and were then re-randomized at week 24 to receive TCZ 162 mg q2w using either the AI or PFS comparable results were obtained for the PFS vs. AI for ACR20, mean change in HAQ-DI, and decrease  in  HAQ-DI ≥ 0.3,  but  numerically  higher  responses  were  observed  with  the  PFS  for ACR50/70, mean DAS28, mean change in DAS28 from baseline, and DAS28 remission. However no robust conclusion can be drawn since the sample size in these arms is rather small (i.e. 60 and 59 patients per group). Of note, the MAA is limited to the use of PFS.

During the evaluation, the MAH provided further data from ongoing study NA25220-LTE at the clinical cut-off of 29 October 2012. These data indicate that the treatment response was largely maintained. Reduction in progression of joint damage (assessed by change in mTSS and APR) was also maintained through Week 48. The submission of the final clinical study report for study NA25220 has been included as a milestone in the RMP.

In study WA22762 the primary objective demonstrating the non-inferiority of TCZ SC to TCZ IV was met. In the PP population, 69.4% (95% CI: 65.5%, 73.2%) of patients in the TCZ SC arm achieved an ACR20 response at Week 24 compared with 73.4% (95% CI: 69.6%, 77.1%) in the TCZ IV arm, with a weighted difference between the arms of -4.0% (95% CI: -9.2%, 1.2%), the lower limit of the 95%-CI for the difference between arms (-9.2%) was above the pre-defined non-inferiority margin of -12%. These results were confirmed in robustness analyses on the ITT population, ACR20: -2.7% (lower boundary of the 95% CI -7.6%). Again, according the study protocol the patients received concomitant DMARDs. However the choice of the medication was left  to  the  investigator.  During  the  evaluation  the  MAH  provided  a  post-hoc  analysis  on concomitant  DMARDs  use.  For  the  primary  end  point,  the  proportion  of  patients  achieving  an ACR20 response for TCZ-SC qw+MTX were comparable to those in the overall study population who were receiving background MTX and/or other non-biologic DMARDs. ACR20 responses were also similar for patients receiving TCZ-IV 8mg/kg every 4 weeks + MTX to those in the overall study  population  who  were  receiving  background  MTX  and/or  other  non-biologic  DMARDs. Additionally,  responses  were  similar  overall  between  TCZ-SC  qw+MTX  a  TCZ-IV  8mg/kg  4 weekly+MTX.

The clinical cut-off date for the extension phase study WA22762 LTE was 16 January 2012. The efficacy  of  TCZ  162  mg  SC  qw  was  maintained  after  the  24-week  double-blind  period  of  the study.  The  ACR  response  rate  in  the  SC-IV  switch  arm  was  lower  than  in  the  other  arms,  at various time points, including week 24, however the sample size for is limited, thus no robust conclusion can be drawn.

During the evaluation the MAH provided further data from ongoing study WA22762-LTE at the clinical  cut-off  of  12  October  2012.  These  data  indicate  that  the  treatment  response  was maintained in TCZ treated patients. The submission of the final clinical study report for study WA22762 has been included as a milestone in the RMP.

<div style=\"page-break-after: always\"></div>

In  both  studies  efficacy  in  various  subgroups  was  evaluated.  Notable  differences  in  response were  seen  in  both  studies  in  the  analysis  by  bodyweight.  ACR  20,  50  and  70  response  rates indicated a comparable response rate in the TCZ SC treatment group for all 3 parameters in the &lt; 60 kg and in the 60 to &lt; 100kg, whereas patients in the &gt; 100 kg showed lower response rate for  these  parameters.  Interestingly,  for  ACR  50  and  70,  response  in  the  highest  body  weight group was lower for the weight adjusted IV TCZ treatment than for the fixed SC TCZ dose.

Analysis  of  ACR  response  by  regions  revealed  comparable  response  rates  across  the  different regions  (Europe,  South  America,  others)  but  North  America.  Irrespective  of  the  treatment received, patients in North America demonstrated a lower response to therapy compared with those from other regions. This finding is consistent with the results from the historical IV data.

The  applicant  provided  a  comparative  analysis  of  the  week  24  results  for  the  two  pivotal  SC studies  NA25220  and  WA22762  and  a  comparison  of  the  results  with  the  24-week  pooled  IV historical data (TCZ application). In general the baseline demographic characteristics were well balanced  across  the  studies.  Baseline  RA  characteristics  were  also  well  balanced  between  the studies with exception of RA duration which was longer in study NA25220; the proportion of RF positive patients, which was also higher in study NA25220; the proportion of patients receiving background corticosteroids, which was higher in the SC studies and the mean number of previous DMARDS which was higher in the pivotal studies.

TCZ  treated  patients  in  the  SC  studies  had  a  higher  ACR  20/50/70  responses  rate  than  the historical  control,  this  was  also  seen  in  the  placebo  groups.  When  taking  into  account  the difference  in  placebo  response  at  Week  24,  the  ACR20  response  rate  for  TCZ  SC  q2w  fell between that of historical 4 mg/kg IV and 8 mg/kg IV data, whereas for the higher hurdles of ACR50 and ACR70, the SC q2w responses were closer to the response seen with the historical 8 mg/kg IV data.

Analysis of the escape data demonstrated that patients who initially failed to respond adequately to the TCZ SC q2w regimen may benefit from the weekly TCZ SC regimen and thus these data support the dosing regimen claimed by the MAH. However under the light of the comparative data with the historic IV data, one can argue that initiating treatment with a weekly schedule might  be  appropriate.  In  case  of  inadequate  response  the  patient  might  switch  to  a  weekly regimen. Based on the collected clinical evidence supporting TCZ administered SC qw, the MAH believed that 162 mg every week is the most effective dosing regimen for all patients across all body weights and patient subpopulation. According to the MAH, the most important arguments is that  the  PD,  efficacy  and  safety  results  for  TCZ  SC  qw  are  comparable  with  the  approved  IV 8mg/kg every 4 weeks regimen which provides rapid and sustained reduction in disease activity. The MAH therefore concluded that TCZ SC qw is the most appropriate dose regimen to initiate and continue therapy for patients with RA. The CHMP was in agreement with the MAH's position. The preliminary results (24 weeks) of the smaller monotherapy study in Japanese RA patients, comparing  TCZ  162  mg  SC  q2w  or  TCZ  8  mg/kg  IV  q4w  showed  consistent  results  with  the pivotal studies with regard to the ACR20/50/70 response, the primary endpoint demonstrating non-inferiority  between  the  two  arms  with  regard  to  the  proportion  of  ACR20  responders  was met.

On 20 December 2013, the MAH reported a needle clogging issue affecting the new pre-filled syringe  presentation  (see  section  2.2.3  Finished  Medicinal  Product).  To  further  strengthen  the mitigation  statements  already  included  in  the  SmPC  and  PL,  the  MAH  proposed  to  add  some

<div style=\"page-break-after: always\"></div>

further changes to sections 6.3 and 6.6 of the SmPC and sections 5 and 6 of the PL. The CHMP considered the proposed changes suitable to reduce the probability of a clogged syringe due to handling errors. The MAH in addition discussed what happens if a patient uses a pre-filled syringe with such defect. It was clarified that if a patient attempt to administer an injection with a prefilled syringe that is clogged, the patient would unlikely be able to expel any drug product from the syringe. The failure mode is considered highly detectable. Assuming a replacement pre-filled syringe  is  at  hand,  the  dose  would  not  be  missed.  If  no  replacement  pre-filled  syringe  is available,  the  dose  would  be  delayed or  missed.  Results  from  studies  WA22762  and  NA25220 indicate that if a patient on the TCZ QW regimen has a single dose missed or delayed or a partial dose of TCZ SC there would be no impact on efficacy. The probability of receiving a partial dose from a clogged needle is extremely low as a needle clog is more likely to completely block the needle  so  no  injection  can  be  given.  The  CHMP  concluded  that  there  is  no  impact  on  clinical efficacy due to clogging incidents when using the pre-filled syringe.

With regards to the exceeded limit of the injection time with the pre-filled pen reported by the MAH on 31/01/2014, the MAH withdrew this new presentation on 11 February 2014. The MAH also  confirmed  their  ability  to  ensure  commercial  supply  of  the  pre-filled  syringe  to  all rheumatoid arthritis patients once approved and to subjects enrolled in on-going clinical studies.

## 2.5.4. Conclusions on the clinical efficacy

TCZ  IV  in  combination  with  methotrexate  (MTX)  is  an  established  treatment  option  for  adult patients with RA. In study WA22762 the non-inferiority of TCZ 162mg SC qw to TCZ 8mg/kg IV q4w  in  terms  of  efficacy  was  demonstrated.  The  primary  objective  demonstrating  the  noninferiority of TCZ SC qw over TCZ IV q4w with regard to ACR 20 response rate at week 24 was met. These results are supported by the secondary objectives, comparable response rates were observed for e.g. ACR 50/ 70 response.

The  clinical  cut-off  date  of  for  the  extension  phase  study  WA22762  LTE  allowing  for  a  switch between IV and SC application was 16 January 2012. The efficacy of TCZ 162 mg SC qw was maintained after the 24-week double-blind period of the study. However the ACR response rate in the SC-IV switch arm was lower than in the other arms, at various time points, including week 24. Since the sample size is limited, long-term safety in patients in the switcher patient will be further investigated in the BSRBR registry as detailed in the RMP.

Notable  difference  in  response  was  seen  in  the  analysis  by  bodyweight.  ACR  20,  50  and  70 response rates indicated a comparable response rate in the TCZ SC treatment group for all 3 parameters in the &lt; 60 kg and in the 60 to &lt; 100kg, whereas patients in the &gt; 100 kg showed lower  response  rate  for  these  parameters.  Interestingly,  for  ACR  50  and  70  response  in  the highest body weight group was lower for the weight adjusted IV TCZ treatment than for the fixed SC TCZ dose. A statement has been included in section 5.1 of the SmPC regarding the impact of switching from IV to SC on exposure particularly in light and heavy body weight patients

According  to  the  study  protocol  the  patients  received  concomitant  DMARDs,  the  choice  of  the medication was left to the investigator. It is understood that the majority of patients received MTX.  The  post  hoc  analysis  from  study  NA25220  and  study  WA22762  comparing  efficacy  in patients receiving  TCZ  with  background  MTX  with  the  overall  study  population  showed comparable efficacy on the primary and key secondary endpoints.

<div style=\"page-break-after: always\"></div>

Following reports of clogging of the needle with the new pre-filled syringe presentation, the MAH proposed changes to the product information in sections 6.3 and 6.6 of the SmPC as well as in the Package Leaflet. This is supported by CHMP. The CHMP concluded that there is no impact on clinical efficacy due to clogging incidents when using the pre-filled syringe device. With regards to the exceeded limit of the injection time with the pre-filled pen, the MAH withdrew this new presentation.

## 2.6. Clinical safety

The  safety  assessment  of  TCZ  SC  is  based  on  two  pivotal  phase  III  clinical  studies  (studies NA25220 / LTE and WA22762 / LTE).

A safety analysis  from the original Phase III clinical development program for the intravenous (IV) dosage form of TCZ in adult RA following 24 weeks of treatment (data submitted as part of initial MAA) are also summarised.

This data base is further supported by data from the safety analysis analyses on SC TCZ from a completed  Phase  Ib  study  NP22623  in  RA  patients  and  two  Chugai  monotherapy  trials,  the complete Phase I/II study MRA227JP, and the phase III study MRA229JP.

Additionally a summary of safety information from the Phase I clinical development program for SC TCZ in healthy volunteers is also included in the submission.

Table 40. Overview of clinical studies contributing to safety evaluation of TCZ SC

<!-- image -->

| Protocol               | Study Design                                                                                                            | Patient Population                                                                                                                                                                          | Dose,Route,Regimen                                                                                                                                                                                                                          | Number of Patients                                                                                                                                        |
|------------------------|-------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| PivotalPhaseIllStudies | PivotalPhaseIllStudies                                                                                                  | PivotalPhaseIllStudies                                                                                                                                                                      | PivotalPhaseIllStudies                                                                                                                                                                                                                      | PivotalPhaseIllStudies                                                                                                                                    |
|                        | parallel-group non-inferiority study ofTCZ + DMARD 24-week double-blind period followed by 72-week open- labelextension | WA22762Randomized, active-controlled, Adult patients with moderate to severeactiveRAwhohad an inadequateresponse tocurrent DMARD therapy that may have included one or more TNF antagonists | First 24 weeks: 162 mg SC TCZ qw (via PFS) SC TCZ qw: n=631 + placebo IV q4w or Placebo SC qw (via PFS) + 8 mg/kg IV TCZ q4w Open-label extension: 162mg SC TCZ qw(via PFS)SC TCZ qw:n=524 or 8 mg/kg IV TCZ q4w                            | N=1262 IV TCZ q4w: n=631 IV TCZ q4w: n=377 IV TCZ q4w>SC qw: n=186                                                                                        |
| NA25220                | Randomized, placebo- ofTCZ+DMARD 24-week, double-blind period followed by 72-week open- label extension                 | Adult patients with moderate to controlled,parallel-groupstudysevereactiveRAwhohad an inadequateresponsetocurrent DMARD therapy that may have included one or more TNF antagonists          | First 24 weeks: 162mg SC TCZ q2w (viaPFS)SC TCZ q2w PFS: n=438 or Placebo SC q2w (via PFS) Open-label extension: 162 mg SC TCZ q2w (PFS) or 162 mg SC TCZ q2w (Al) Escape therapy (from Week 12): 162 mg SC TCZ qw patients before week 24) | N=656 PISC q2w PFS: n=218 TCZ PFS q2w: n=167 TCZ PFS q2w →Al q2w:n=167 PI PFS q2w→TCZ PFS q2w:n=60 PIPFS q2w→TCZ Al q2w: n=59 n=162 (including 90 placebo |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Protocol           | Study Design                                                                                                                                | Patient Population                                                                     | Dose,Route,Regimen                                                                                                                         | No. of Patients    |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Supportive Studies | Supportive Studies                                                                                                                          | Supportive Studies                                                                     | Supportive Studies                                                                                                                         | Supportive Studies |
|                    | MRA229JP Randomized, double-blind, parallel- (Phase Ill)  group comparative study of SC TCZ monotherapy                                     | Adult patients with RA with inadequate response8 to DMARDs (including TNF antagonists) | 162mg SC TCZ q2w + placebo IV q4w vs 8mg/kgIVTCZq4w+placeboSCq2wfor24 weeksfollowedbyopen-labelSCTCZforupto 84 weeks                       | N=348              |
|                    | MRA227JP Randomized,open-label,multiple-dose,Adult patients withRA (Phase I/l) inter-individual dose escalation study of SC TCZ monotherapy |                                                                                        | 81mgSCTCZq2wfor35weeks vs 162 mg SC TCZ q2w for35 weeks vs 162 mg SC TCZ qw for 28 weeks                                                   | N=32               |
| NP22623 (Phase Ib) | Open-label,randomized,parallel-groupAdult patientswith RA                                                                                   |                                                                                        | Part 1: 7.5-25 mg MTX (PO or IV)plus 162mgSCTCZqworq2wfor12weeks Part 2: (optional post-study phase) 8 mg/kg IV TCZ q4w for up to one year | N=29               |
| WP18097 (Phase I)  | Single-dose, single-blind, randomized, double dummy                                                                                         | Adulthealthyvolunteers                                                                 | 160mgSCTCZ+IVplacebovs 160 mg IVTCZ+ SC placebo                                                                                            | N=20               |
| BP22065 (Phase I)  | Single-dose, open-label, single-center, parallel four-group study of PK, PD, safety of SCTCZvs IV                                           | Adult healthy volunteers                                                               | 81 or162 mg SC TCZ,or81 or 162mg IV TCZ                                                                                                    | N=48               |
| NP25539 (Phase I)  | Single-dose,randomized,open-label, parallel 2-group,2-center relative bioavailability study (PFS vs Al)                                     | Adult healthy volunteers                                                               | 162mgSCTCZviaPFSvs 162 mg SC TCZ via Al                                                                                                    | N=261              |
| BP21894 (Phase I)  | Single-dose, open-label, parallel-group study of PK, PD, safety of SC TCZ                                                                   | Adult healthy volunteers                                                               | single doseof162,324,or648mg with or without rHuPH20                                                                                       | N=48               |

Al=autoinjector; DMARDs=disease-modifying anti-rheumatic drugs; IV=intravenous; MTX=methotrexate; PD=pharmacodynamics; PFS=prefilled syringe; PK=pharmacokinetics; Pl: Placebo; PO=orally; q2w=every two weeks; q4w=every four weeks; qw=every week; RA=rheumatoid arthritis;rHuPH20=recombinant human hyaluronidase;SC=Subcutaneous;TCZ=Tocilizumab;TNF=tumor necrosis factor

## Patient exposure

The safety population included all patients who received at least one dose of TCZ (SC or IV) and had least one post-dose safety assessment.

In the pivotal studies a total of 1465 patients were exposed to TCZ SC. This includes patients treated with TCZ SC during the 24 weeks core and the LTE part of study NA25220 and study WA25220 as well as patients who switched from  placebo to TSZ SC in the LTE part of  study NA25220 and who switched from TCZ IV to TCZ SC in study WA25220 LTE.

Table 41. Clinical studies of TCZ SC in adult RA patients (pivotal studies)

| Core Study Protocol (Number of Patients)                   | Extension Protocol                                         |   Number of Patients Contributing SC TCZ Safety Data |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------|
| WA22672 (N=631)                                            | IV → SC switchers (N =186)                                 |                                                  817 |
| NA25220 (N=438) Placebo Escaper (N=90)                     | Placebo → TCZ PFS (N = 61) Placebo → TCZ PFS (N = 59)      |                                                  648 |
| Total number of patients in SC TCZ All-exposure Population | Total number of patients in SC TCZ All-exposure Population |                                                 1465 |

IV=intravenous; LTE=long-term extension; SC=subcutaneous; TCZ=tocilizumab

<div style=\"page-break-after: always\"></div>

Table 42. Comparison  of  exposure  at  week  24  in  SC  TCZ  and  IV  TCZ  (phase  III pivotal studies)

|                          | StudyWA22762                         | StudyWA22762    | StudyNA25220                         | StudyNA25220   | Week24AnalysesfromIVTCZPhaseIll Clinical Studies   | Week24AnalysesfromIVTCZPhaseIll Clinical Studies   | Week24AnalysesfromIVTCZPhaseIll Clinical Studies   |
|--------------------------|--------------------------------------|-----------------|--------------------------------------|----------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                          | 162mgSCTCZ8mg/kgIVTCZ qW+DMARD N=631 | q4w+DMARD N=631 | Z162mgSCTCZ q2w+DMARDq2w+DMARD N=437 | PISC N=218     | q4w+DMARD N=1582                                   | 8mg/kg IV TCZ4mg/kgIVTCZF q4w+MTX N=774            | PI+DMARD N=1170                                    |
| Duration in study ? (PY) | 289.8                                | 288.3           | 182.68                               | 81.80          | 753.50                                             | 344.74                                             | 507.24                                             |
| Exposure to TCz b        |                                      |                 |                                      |                |                                                    |                                                    |                                                    |
| Mean ±SD (years)         | 0.42±0.093                           | 0.46±0.105      | 0.39±0.100                           |                | 0.43 ± 0.1                                         | 0.41 ± 0.1                                         |                                                    |
| Exposure (PY)            | 267.9                                | 292.8           | 172.1                                |                | 684.7                                              | 320.9                                              |                                                    |
| Exposure toPlacebob      | PIIV                                 | PISC            |                                      | PISC           |                                                    |                                                    | PI IV                                              |
| Mean ±SD (years)         | 0.43 ±0.084                          | 0.41±0.097      |                                      | 0.35±0.107     |                                                    |                                                    | 0.39±0.1                                           |
| Exposure (PY)            | 271.2                                | 260.5           |                                      | 77.2           |                                                    |                                                    | 461.8                                              |

Cl=confidence interval; DMARD=disease-modifying anti-rheumatic drug; IV=intravenous; MTX=methotrexate; Pl=placebo;

PY=patient years; q2w= every two weeks; q4w= every four weeks; qw= every week; SC=subcutaneous; SD=standard deviation; TCZ=tocilizumab.

Dataonescapetherapyisexcluded.

- Date of last assessment - date of first dose + 1 day / 365.25; duration in study is used to calculate rates of AEs per 100 patient years.

Exposure per administration = difference between the dates of a patient's injection and the subsequent injection (capped at length of dosing interval);totalextentofexposure=sumof theexposureforallinjections+dosinginterval.

Source: stextexp\\_sc\\_2, stmeddur\\_2, stextexp\\_iv\\_2, stextexp\\_preesc\\_sc\\_2, staerate01\\_serious\\_wk24\\_2 in WA22762 and NA25520 24-week CSRs, and Table 12 (STmed\\_ext\\_t01), Table 17 (STrate\\_ae Rate) in original submission.

Out of the 1465 patients in the two pivotal studies NA25220 and WA22762 who received SC TCZ treatment; 557 patients received 162 mg q2w treatment and 908 patients received 162 mg qw treatment.

The clinical cut-off dates for the analyses in this summary represent the 24-week cut-off point 28 May 2012 for study NA25220 and 16 January 2012 for study WA22762.

Table 43. Studies NA25520 and WA22767 summary of extend of exposure to TCZ SC (SC all-exposure population)

<!-- image -->

|                                   |   ALL TCZ |
|-----------------------------------|-----------|
| No.Pts Randomized                 |      1465 |
| No. With at Least One Dose        |      1465 |
| No. Completing 12 weeks Treatment |      1308 |
| No. Completing 24 weeks Treatment |      1095 |
| No. Completing 36 weeks Treatment |       650 |
| No. Completing 40 weeks Treatment |       483 |
| No.Completing 44 weeks Treatment  |       357 |
| No. Completing 48weeksTreatment   |       239 |
| No. Completing 60 weeks Treatment |        82 |
| No. Completing 72 weeks Treatment |         4 |

Regarding the Chugai studies one study the Phase I/II study (MRA227JP) is completed. From the ongoing  study  MRA229JP  safety  data  for  the  24-week  double-blind  period  (date  of  the  last assessment was 14 April 2011) are available.

<div style=\"page-break-after: always\"></div>

## Adverse events

Table 44. Overview  of  all  AEs  at  week  24  in  SC  TCZ  and  IV  TCZ  clinical  studies (safety population)n

|                             | StudyWA22762            | StudyWA22762                                    | Study NA25220   | Study NA25220                          | Week24AnalysesfromIVTCZPhaseIll ClinicalStudies   | Week24AnalysesfromIVTCZPhaseIll ClinicalStudies   | Week24AnalysesfromIVTCZPhaseIll ClinicalStudies   |
|-----------------------------|-------------------------|-------------------------------------------------|-----------------|----------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                             | qw+DMARD N=631          | 162mgSCTCZ8mg/kgIVTCZ162mgSCTCZ q4w+DMARD N=631 | N =437          | PISC q2w+DMARDq2w+DMARD N=218          | q4w+DMARD N=1582                                  | 8mg/kgIVTCZ4mg/kgIVTCZPI+DMARD q4w + MTX N =774   | N= 1170                                           |
| Duration in study (PY)      | 289.82                  | 288.39                                          | 182.68          | 81.80                                  | 753.50                                            | 344.74                                            | 507.24                                            |
| Patientswith at least oneAE | 481 (76.2%)             | 486 (77.0%)                                     | 274 (62.7%)     | 126 (57.8%)                            | 1134 (71.7%)                                      | 547 (70.7%)                                       | 733 (62.6%)                                       |
| NumberofAEs                 | 1747                    | 1697                                            | 803             | 283                                    | 3484                                              | 1628                                              | 1914                                              |
| Rateper100PY (95% CI)       | 602.79 (574.85, 631.73) | 588.44 (560.77, 617.12)                         | 439.56          | 345.96 (409.68, 471.04)(306.82,388.71) | 462.37 (447.15, 477.99)                           | 472.24                                            | 377.34 (449.58,495.76) (360.62,394.63)            |

AE = adverse event; Cl = confidence interval; DMARD = disease-modifying anti-rheumatic drug; IV = intravenous; MTX = methotrexate; Pl = placebo; PY = patient years; q2w = every two weeks; q4w = every four weeks; qw = every week; SC = subcutaneous; TcZ = tocilizumab. Durationinstudy=dateoflastassessment-dateoffirstdose+1day/365.25.

Multipleoccurrencesof thesameevent inoneindividualarecounted.

MedDRAversionsusedforanalyses:version10.0forweek24analysesof IVTCZdata;version14.1forstudyWA22762;version15.0forstudyNA25220

Table 45. Overview of all AERs in the pivotal studies until clinical cut-off

|                              | WA22762                            | WA22762                       | NA25220                         |
|------------------------------|------------------------------------|-------------------------------|---------------------------------|
|                              | 162 mg SC TCZ qw (PFS)+DMARD N=631 | 8mg/kg IV TCZ q4w+DMARD N=631 | 162mgSCTCZq2w (PFS)+DMARD N=437 |
| Total duration in study (PY) | 454.20                             | 401.02                        | 222.09                          |
| Patients with AE             | 527 (84%)                          | 502 (80%)                     | 292 (66.8%)                     |
| Number of AEs                | 2501                               | 2137                          | 947                             |
| Rate per 100 PY (95% CI)     | 550.64                             | 532.89                        | 426.40                          |
|                              | (529.27, 572.66)                   | (510.54, 555.98)              | (399.67,454.44)                 |

AE = adverse event; Cl = confidence interval; DMARD = disease-modifying anti-rheumatic Maa = mb rsa  = A aus ad = s tsno = A :n weeks; q4w = every four weeks ; qw = every week; SC = subcutaneous; TCZ = tocilizumab.

SC TCZ arms: Analyses include all patients who received SC TCZ using the PFS in the double-blind period starting from their first dose. Data after switch to IV TCZ (in WA22762) or the Al (in NA25220) in the open-label extension are not included.

IV TCZ arm: Analyses include all patients who received IV TCZ in the double-blind period starting from their first dose. Data after switch to SC TCZ in the open-label extension are not included.

Multiple occurrences of the same AE in one individual are counted.

Source: stae11\\_b LTE CSR WA22762, staerate01\\_all\\_2 LTE CSR WA22762, stae11\\_s\\_pt\\_b LTE CSR NA25220.

<div style=\"page-break-after: always\"></div>

Table 46. Overview of all AEs in pooled TCZ SZ and IV TCZ application all exposure population

|                     | SC Tcz all-exposure N=1465   | IV Tcz all-exposure N=4171   |
|---------------------|------------------------------|------------------------------|
| Total Exposure (PY) | 893.92                       | 16204.77                     |
| Patients with AE    | 1052                         | 3941                         |
| Number of AEs       | 4483                         | 47970                        |
| Rate per 100 PY     | 501.50                       | 296.02                       |
| (95% CI)            | (486.92, 516.40)             | (293.38, 298.68)             |

AE = adverse event; Cl=confidence interval; IV=intravenous; PY=patient years; SC =subcutaneous; TCZ=tocilizumab.

Multiple occurrences of the same AE in one individual are counted.

Source: STae\\_rategp6\\_all and STae\\_rategp6\\_all (IV safety update report)

In study NA25220 the most common SOCs ( ≥ 10% of patients in either arm) in which AEs were reported were:

- Infections and infestations (30.0% TCZ arm vs. 28.0% placebo arm): most commonly, upper respiratory tract infections (6.4% in each treatment arm), urinary tract infections (4.1% vs. 3.2%), and nasopharyngitis (4.3% vs. 2.3%)
- Investigations (16.9% TCZ arm vs. 6.9% placebo arm): most commonly, increased ALT (13.3% vs. 5.0%, respectively) and increased AST (8.2% vs. 3.7%)
- GI  Disorders  (11.9%  TCZ  arm  vs.  10.1%  placebo  arm):  most  commonly,  diarrhoea (1.8% vs. 1.4%), dyspepsia (2.1% vs. 0.9%), and nausea (1.4% vs. 0.9%, respectively)
- Musculoskeletal and connective tissue disorders (8.7% TCZ arm vs. 12.4% placebo arm): most commonly, arthralgia (2.3% vs. 0.5%) and RA (1.1% vs. 1.8%).

A  greater  percentage  of  patients  experienced  injection  site  reactions  (IRS)  in  the  TCZ  arm (7.1%) than in the placebo arm (4.1%). Similarly, a greater percentage of patients in the TCZ arm experienced hypersensitivity events (retrieved events occurring during or within 24 hours of an  injection  or  infusion  (excluding  ISRs)  and  not  deemed  by  the  investigator  as  unrelated  to treatment) compared with patients in the placebo arm, 4.3%  vs. 3.7%, respectively. Musculoskeletal  and  Connective  Tissue  Disorders  was  the  only  SOC  with  a  notably  higher percentage of patients reporting events in the placebo arm (12.4%) compared with the TCZ arm (8.7%), most commonly arthralgia. The majority of AEs in both arms (95% each) were Grade 1 or  2  in  intensity.  The  proportion  of  patients  experiencing  at  least  one  Grade  3  event  was  the same in both arms (5.0% each). In the SC arm, 0.9% of patients experience at least one Grade 4 event, while no patients in placebo had such an event.

<div style=\"page-break-after: always\"></div>

Table 47. NA25220 AEs by weight at baseline (safety population)

|                         | Number of Patients (%)   | Number of Patients (%)   |
|-------------------------|--------------------------|--------------------------|
| Body Weight at Baseline | TCZ PFS q2w (n=437)      | Placebo PFS q2w (n=218)  |
| <60 kg                  | 74/119 (62.2)            | 36/58 (62.1)             |
| 60 to100 kg             | 179/292 (61.3)           | 84/149 (56.4)            |
| 2100 kg                 | 21/26 (80.8)             | 6/11 (54.5)              |

PFS=pre-filled syringe; q2w = twice weekly.

Source:page 848.

Table 48. Study NA25220 LTE adverse event rates until clinical cut-off (all safety population)

staerate01\\_all\\_2 Rate of Adverse Eventsper 100 Patient Years-ClinicalCut-off date 28May 2012 (Safety Population)

|                                                                                                                  | TCZ PFS q2w (N=437)                    | TCZ PFS q2W >TCZAIq2w (N=168)         | Placebo PFS q2w >TCZPFSq2W (N=61)    | Placebo PFS q2w >TCZAIq2w (N=59)     | Placebo PFS q2w (N=218)               |
|------------------------------------------------------------------------------------------------------------------|----------------------------------------|---------------------------------------|--------------------------------------|--------------------------------------|---------------------------------------|
| TotalPatientYears NumberofAdverseEvents AdverseEventsper Patient Year Adverse Events per 1oo Patient Years 95$CI | 222.09 947 4.26 426.40 [399.67;454.44] | 37.20 201 5.40 540.33 [468.21;620.42] | 13.82 56 4.05 405.27 [306.14;526.28] | 13.75 51 3.71 370.85 [276.12;487.60] | 82.12 277 3.37 337.29 [298.74;379.44] |

Multiple occurrences of thesame adverse event inoneindividualare counted.

Duration in study(years)=(date of last assessment-date of first dose + 1)/365.25.

CI is based on events per 1o0patient years.

Escape patients are includeduntil time of escape when theywill be classedas withdrawm.

Program:$PR0D/cs11935c/c25220a/staerate01.sas/0utput:$PR0D/cr11935a/r25220b/reports/staerate01\\_a11\\_2.out 21AUG2012 16:30

Page 1 of 1

In study NA25220 LTE patients were re-randomised at Week 24. Adverse event data in the TCZ PFS Arm included all patient data for patients who received TCZ PFS up to Week 24, data for patients  who  received  TCZ  PFS  up  to  the  time  of  escape  therapy,  and  data  for  patients  who continued to use the PFS during the open label treatment period up to the date of the clinical data cut. In the TCZ PFS Arm a total of 292 patients experienced 947 AEs. The most common SOCs ( ≥ 10.0%) in which AEs were reported were as follows:

- Infections  and  infestations  (34.1%):  most  commonly  upper  respiratory  tract  infections (8.2%), nasopharyngitis (5.3%), urinary tract infection (4.3%), and sinusitis (2.5%).
- Investigations  (16.2%):  most  commonly  increased  ALT  (12.8%)  and  increased  AST (8.5%).
- GI Disorders (14.2%): most commonly diarrhea (3.0%) and dyspepsia (2.3%)
- General Disorders and Administration Site Conditions (10.8%): most commonly injectionsite erythema (2.5%), injection site pain (2.5%), and injection site haematoma (0.7%).

Among the 168 patients in study NA25220 LTE who switched from TCZ PFS to TCZ AI at Week 24, 74 patients had 201 AEs. Most (51/54) of these AEs were Grade 1 or Grade 2 in intensity and resolved  within  7  days,  on  average.  The  most  common  SOCs  ( ≥ 10.0%)  in  which  AEs  were reported were as follows:

- Infections  and  infestations  (22.6%):  most  commonly  upper  respiratory  tract  infections (4.2%), nasopharyngitis (3.0%), urinary tract infection (2.4%), and sinusitis (2.4%).

<div style=\"page-break-after: always\"></div>

- Investigations  (11.3%  AI):  most  commonly  increased  ALT  (8.3%,  respectively)  and increased AST (4.2%).

Sixty  one  patients  switched  from  Placebo to  TCZ  PFS.  Twenty-seven  of  these  patients  had  56 AEs.  The  most  common  AEs  (SOC)  reported  after  the  switch  from  Placebo  to  TCZ  PFS  was infections and infestations (24.6%). The incidence for all other SOCs was ≤ 10.0%. Individual AEs (preferred  terms)  reported  in ≥ 5.0% of  patients  were  ALT  increased  (5  patients;  8.2%),  AST increased  (4  patients;  6.6%),  dyslipidemia  (4  patients;  6.6%),  and  upper  respiratory  tract infection (4 patients; 6.6%).

Among the 59 patients who switched from Placebo to TCZ AI, 25 patients had 51 AEs. The most common  AEs  (SOC)  in  this  treatment  arm  were  investigations  (11.9%)  and  gastrointestinal disorders (10.2%). The incidence for all other SOCs were ALT increased (5 patients; 8.5%), AST increased (4 patients; 6.8%), and hypertriglyceridemia (4 patients; 6.8%).

In the Escape Patients (study NA25220 LTE) the most common AEs (SOC) were infections and infestations (29.2% and 34.4%, respectively]). The next most common AEs were gastrointestinal disorders (16.7%  and  17.8%),  investigations (11.1%  and  21.1%),  musculoskeletal and connective tissue disorders (12.5% and 11.1%), blood and lymphatic system disorders (8.3% and 12.2%), and general disorders and administration site conditions (12.5% and 4.4%). The incidence for all other SOCs was ≤ 10.0%.

In  study  WA22762  the  proportion  of  patients  who  experienced  at  least  one  AE  during  the  24 weeks was 631 patients (76.2%) in the SC arm vs. 486 of 631 patients (77.0%) in the IV arm.

Table 49. Study WA22762 rate of adverse events per 100 Patient-Years (safety population)

<!-- image -->

In study WA22762 the most common SOCs ( ≥ 10% in either arm) in which AEs were reported were:

- Infections and infestations (36.0% SC arm vs. 39.1% IV arm): most commonly, upper respiratory  tract  infections  (7.3%  vs.  11.6%,  respectively),  nasopharyngitis  (5.7%  in each arm), and urinary tract infections (4.1% vs. 5.1%)

<div style=\"page-break-after: always\"></div>

- Investigations  (23.3%  SC  arm  vs.  21.2%  IV  arm):  most  commonly,  increased  ALT (18.7% vs. 16.5%, respectively) and increased AST (13.5% vs. 10.5%)
- GI  Disorders  (19.2%  SC  arm  vs.  18.5%  IV  arm):  most  commonly,  nausea  (4.0%  vs. 4.6%, respectively) and diarrhea (4.3% vs. 4.1%)
- Musculoskeletal and connective tissue disorders (15.4% in each arm): most commonly, arthralgia (1.4% vs. 2.5%, respectively) and back pain (1.3% vs. 2.4%)
- Skin  and  subcutaneous  tissue  disorders  (11.6%  SC  arm  vs.  13.0%  IV  arm):  most commonly, rash (2.9% vs. 2.7%, respectively), and pruritus (2.4% vs. 1.7%)
- General disorders and administration-site conditions (14.9% SC arm vs. 7.0% IV arm): most commonly, injection-site erythema (4.4% vs. 0.8%, respectively), and peripheral edema (1.7% vs. 1.4%, respectively)
- Nervous system disorders (9.4% SC arm vs. 11.6% IV arm): most commonly, headache (4.4% vs. 5.2%, respectively) and dizziness (2.1% vs. 2.4%).

The majority of AEs in both arms (1436 of 1515 events (94.8%) in the SC arm vs. 1387 of 1479 events  (93.8%)  in  the  IV  arm)  were  Grade  1  or  2  in  intensity.  The  proportion  of  patients experiencing  at  least  one  Grade  3  event  was  comparable  for  the  SC  and  IV  arms  (9.4%  vs. 10.0%, respectively), as was the proportion of patients experiencing at least one Grade 4 event (1.0% vs.0.8%, respectively). The most common SOCs in which Grade ≥ 3  AEs  were reported were infections and infestations, with no single event being predominant, and investigations (i.e. increased ALT and AST liver enzymes).

In  study  WA22762  LTE  the  data  based  on  the  safety  population,  this  includes  data  from  the double-blind and open-label periods in the SC and IV arms but only from the open-label period (i.e. after switching) in the IV-SC and SC-IV switch arms.

|                                                                                                                       | +IMARD (N=631)                          | +DMARD (N=631)                          | TOCILIZUMABSC->IV (N=48)             | TOCILIZUMAB IV->SC (N=186)            |
|-----------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|--------------------------------------|---------------------------------------|
| Total Patient Years Number of AdverseEvents AdverseEvents per Patient Year Adverse Events per 100 Patient Years 958CI | 454.20 2501 5.51 550.64 [529.27;572.66] | 401.02 2137 5.33 532.89 [510.54;555.98] | 12.98 39 3.01 300.52 [213.70;410.82] | 58.37 370 6.34 633.88 [570.93;701.87] |

Table 50. Study WA22762 LTE rate of adverse events per 100 patient years (safety population)

<!-- image -->

In  study  WA22762 LTE the incidence of AEs was also similar in both arms; 527/631 (83.5%) patients in the SC arm and 502/631 (79.6%) patients in the IV arm. The most common SOCs ( ≥ 10.0% in either arm) in which AEs were reported were:

<div style=\"page-break-after: always\"></div>

- Infections and infestations (49.4% SC vs. 45.2% IV): most commonly upper respiratory tract infections (11.4% vs. 15.1%, respectively), nasopharyngitis (10.0% vs. 7.9%), and urinary tract infections (7.1% vs. 5.7%).
- Investigations  (27.3%  SC  vs.  23.3%  IV):  most  commonly  increased  ALT  (21.4%  vs. 18.4%, respectively) and increased AST (14.7% vs. 12.0%).
- GI  Disorders  (24.1%  SC  vs.  21.7%  IV):  most  commonly  diarrhea  (6.2%  vs.  4.8%, respectively) and nausea (4.1% vs. 5.2%).
- Musculoskeletal  and  connective  tissue  Disorders  (21.9%  SC  vs.  18.5%  IV):  most commonly RA in the SC arm (3.0% vs. 2.1%) and back pain in the IV arm (2.4% vs. 3.6%).
- General  disorders  and  administration  site  conditions  (17.1%  SC  vs.  7.9%  IV):  most commonly injection site erythema (5.4% vs. 0.8%, respectively), injection site pruritus (2.7% vs. 0.0%), and injection site pain (2.4% vs. 0.8%).
- Skin and subcutaneous tissue disorders (14.7% SC vs. 14.3% IV): most commonly rash (4.3% vs. 3.3%, respectively) and pruritus (2.9% vs. 1.7%).
- Nervous system disorders (12.4% SC vs. 13.5% IV): most commonly headache (5.5% vs. 5.9%, respectively) and dizziness (2.2% vs. 2.9%).
- Injury, poisoning and procedural complications (12.0% SC vs. 9.4% IV): most commonly contusion (2.7% vs. 1.3%, respectively) and fall (1.7% vs. 1.9%).
- Metabolism and Nutrition Disorders (10.1% SC vs. 9.8%  IV): most  commonly hypertriglyceridaemia (2.1% vs. 2.4%, respectively), dyslipidemia (2.5% vs. 1.4%), and hypercholesterolemia (1.4% vs. 2.1%).
- Respiratory, thoracic,  and  mediastinal  disorders  (8.6%  SC  vs.  10.6%  IV):  most commonly cough (2.9% vs. 2.1%, respectively).
- Vascular  Disorders  (8.7%  SC  vs.  10.0%  IV):  most  commonly  hypertension  (5.4%  vs. 7.6%, respectively).

35% of AEs in both the SC and IV arms were reported by the investigator as being related to treatment; 748 of 2128 events [35.2%] vs. 662 of 1863 events [35.5%], respectively. The most common related AEs in both treatment arms were 'infections and infestations' and 'investigations' SOCs (mainly increased liver enzymes).

In study WA22762 LTE 186 patients switched after the 24 weeks period form IV TCZ to TCZ SC. In this IV-SC Switch Arm the rate of AEs was 633.88 (95% CI: 570.93; 701.87) events per 100 PY. The most common AEs (SOC) were infections and infestations (50/186 patients (26.9%)). The  next  most  common  AEs  were  musculoskeletal  and  connective  tissue  disorders  (27/186 (14.5%)). The incidence for all other SOCs was ≤ 8.0%. Individual AEs (preferred terms) with an incidence ≥ 5.0% ( ≥ 10/186 patients) were nasopharyngitis (14/186 (8%)) and upper respiratory tract infection (11/186 (6%)). The proportion of patients with a related AE was 48/186 (25.8%). The most common related AEs were infections.

In the SC-IV Switch Arm the rate of AEs was 300.52 [95% CI: 213.70; 410.82] events per 100 PY. The most common AEs (SOC) were infections and infestations (10/48 patients (20.8%). The

<div style=\"page-break-after: always\"></div>

incidence for all other SOCs was ≤ 10.0%. Individual AEs (preferred terms) with an incidence ≥ 5.0% ( ≥ 3/48 patients) were nasopharyngitis (4/48 (8.3%)) and upper respiratory tract infection (3/48 (6.3%)). A total of 9/48 (18.8%) patients experienced an AE that was reported by the investigator as being related to treatment.

Table 51. Study  WA22762  LTE  summary  of  adverse  events  by  intensity  (safety population)

|            | No. of patients (%)       | No. of patients (%)         | No. of patients (%)   | No. of patients (%)   |
|------------|---------------------------|-----------------------------|-----------------------|-----------------------|
|            | 162 mg SC qw +DMARD n=631 | 8 mg/kg IV q4w +DMARD n=631 | SC-IV n=48            | IV-SC n=186           |
| All grades | 527 (83.5)                | 502 (79.6)                  | 18 (37.5)             | 88 (47.3)             |
| Grade 1    | 431 (68.3)                | 379 (60.1)                  | 14 (29.2)             | 69 (37.1)             |
| Grade 2    | 299 (47.4)                | 297 (47.1)                  | 10 (20.8)             | 33 (17.7)             |
| Grade 3    | 84 (13.3)                 | 81 (12.8)                   | 0 (0.0)               | 11 (5.9)              |
| Grade 4    | 12 (1.9)                  | 5 (0.8)                     | 0 (0.0)               | 2 (1.1)               |
| Grade 5    | 1 (0.2)                   | 2 (0.3)                     | 0 (0.0)               | 0 (0.0)               |

Note: SC-IV and IV-SC switch arms include data from the open label phase only.

Source: page 501.

For study WA22762 LTE the incidence of AEs was analysed by body weight at baseline. In both the SC and IV treatment arms, a higher proportion of heavier patients ( ≥ 100 kg) experienced at least one AE compared with patients in the lighter subgroups.

Table 52. Adverse events by body weight at baseline (safety population)

|             | No. of patients (%)   | No. of patients (%)   | No. of patients (%)   | No. of patients (%)   |
|-------------|-----------------------|-----------------------|-----------------------|-----------------------|
|             | 162mgSCqw +DMARD      | 8mg/kgIVq4w +DMARD    | SC-IV                 | IV-SC                 |
| <60 kg      | n=144 117 (81.3)      | n=146 108 (74.0)      | n=12 3 (25.0)         | n=46 24 (52.2)        |
| 60 to<100kg | n=425 352 (82.8)      | n=422 339 (80.3)      | n=33 14 (42.4)        | n=125 56 (44.8)       |
| ≥100 kg     | n=62 58 (93.5)        | n=63 55 (87.3)        | n=3 1 (33.3)          | n=15 8 (53.3)         |

Note: SC-IV and IV-SC switch arms include data from the open label phase only.

Source:page392

In  study  NP22623, 73 treatment-emergent AEs were reported in 22/29 patients (76%) during the  randomized  SC  treatment  phase.  The  SOC  with  the  highest  frequency  of  AEs  were gastrointestinal disorders (most commonly nausea), infections and infestations (most commonly upper respiratory tract infection) and musculoskeletal and connective tissue disorders SOC (most commonly RA).

<div style=\"page-break-after: always\"></div>

Two AEs (both injection site erythema) in 2 patients were considered as probably related to trial treatment and 19 AEs in 9 patients were considered as possibly related by the investigator. The remaining 52 AEs were classified as either remotely related or unrelated.

In  the  ongoing  supportive  monotherapy  Study  MRA229JP  AEs  were  reported  for  154  patients (89.0%) in the SC TCZ group (q2w) and for 157 patients (90.8%) in the IV TCZ group. The most common SOCs in which AEs were reported were:

- Investigations:  93  patients  (53.8%)  and  89  patients  (51.4%)  (most  commonly  blood cholesterol increased (19.1% vs. 17.9%), low density lipoprotein (LDL] increased (17.3% vs.  13.9%),  blood  triglycerides  increased  (0.4%  in  both  groups),  and  ALT  increased (10.4% vs. 9.8%)
- Infections  and  infestations:  72  patients  (41.6%)  and  78  patients  (45.1%)  (most commonly  nasopharyngitis  (20.8%  vs.  17.9%)  and  upper  respiratory  tract  infection (9.2% vs. 7.5%)
- Skin and subcutaneous tissue disorders: 39 patients (22.5%) and 42 patients (24.3%)
- Gastrointestinal disorders: 34 patients (19.7%) and 43 patients (24.9%)
- General  disorders  and  administration  site  Conditions:  33  patients  (19.1%)  and  13 patients (7.5%)
- Metabolism and nutrition Disorders: 9 patients (5.2%) and 20 patients (11.6%) Nervous System Disorders: 18 patients (10.4%) and 5 patients (2.9%).

Injection site reactions (mostly injection site erythema) at the site of subcutaneous administration (of active substance or placebo) were more frequent in the SC TCZ group with an incidence of 12.1% than in the IV TCZ group (5.2%).

In the dose escalation study MRA227JP (monotherapy) all of the 32 patients experienced AEs By SOC, the most frequently reported AEs included: investigations (with most commonly increased blood  triglycerides,  followed  by  low  density  lipoprotein,  and  increased  ALT);  infections  and infestations (most commonly nasopharyngitis) and gastrointestinal disorders.

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 53. Overview  of  SAEs  at  week  24  in  SC  TCZ  and  IV  TCZ  clinical  studies (safety population)

|                         | StudyWA22762        | StudyWA22762                           | StudyNA25220                    | StudyNA25220         | Week24AnalysesfromIVTCZPhaseIll Clinical Studies   | Week24AnalysesfromIVTCZPhaseIll Clinical Studies   | Week24AnalysesfromIVTCZPhaseIll Clinical Studies   |
|-------------------------|---------------------|----------------------------------------|---------------------------------|----------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                         | qW+DMARD N=631      | 162mgSCTCZ8mg/kg IVTCz q4w+DMARD N=631 | 162 mg SC TCZ q2w+DMARD N = 437 | PISC q2w+DMARD N=218 | q4w+DMARD N=1582                                   | 8 mg/kgIV TCZ4 mg/kgIV TCZ q4w+MTX N=774           | PI+DMARD N=1170                                    |
| Duration in study (PY)  | 289.82              | 288.39                                 | 182.68                          | 81.80                | 753.50                                             | 344.74                                             | 507.24                                             |
| PatientswithSAE         | 29 (4.6%)           | 33 (5.2%)                              | 20 (4.6%)                       | 8 (3.7%)             | 95 (6.0%)                                          | 46 (5.9%)                                          | 62 (5.3%)                                          |
| NumberofSAEs            | 34                  | 43                                     | 25                              | 12                   | 115                                                | 51                                                 | 75                                                 |
| Rate per100 PY (95% CI) | 11.73 (8.12, 16.39) | 14.91 (10.79, 20.08)                   | 13.68 (8.86, 20.20)             | 14.67 (7.58, 25.62)  | 15.26 (12.60, 18.32)                               | 14.79 (11.02, 19.45)                               | 14.79 (11.63, 18.53)                               |

Cl=confidence interval;DMARD=disease-modifying anti-rheumatic drug;IV=intravenous;Pl=placebo;PY=patient years;q2w=every two weeks; q4w = every four weeks; qw = every week; SAE = serious adverse event; SC = subcutaneous; TcZ = tocilizumab.

Durationinstudy=dateoflastassessment-dateoffirstdose+1day/365.25.

In study NA25220 the percentage of patients who experienced at least one SAE during the study was similar in both arms 4.6% of patients in the TCZ arm vs. 3.7% in the placebo arm. The most common SOC in which SAEs were reported was infections/infestations (TCZ 2.1%) and placebo 1.8%.  These  cases  were  all  rated  as  treatment  related.    Three  patients  were  reported  with malignancies (one classified as non-serious AE) during the study, all in the TCZ arm. The events were considered unrelated by the investigator. One SAE of bleeding was reported, an event of haemorrhage in the TCZ arm.

In study WA22762 core the proportion of patients who experienced at least one SAE during the study was similar in both arms (4.6% of patients in the SC arm vs. 5.2% in the IV arm), with the total number of SAEs higher in the IV arm (33 SC arm vs. 41, IV arm). The most common SOC in which SAEs were reported was infections and infestations, which occurred at a similar frequency in both arms (1.4% each), with no specific type of event being predominant. Musculoskeletal and connective tissue disorders were the next most commonly reported SAEs (3 patients in the SC arm vs. 6 patients in the IV arm), followed by nervous system disorders (2 patients SC arm vs. 6 patients  IV  arm),  with  higher  numbers  of  SAEs  in  the  IV  arm.  Two  events  of  haemorrhage (haemorrhoidal  haemorrhage  and  rectal  haemorrhage  were  reported.  The  two  cases  were  not associated with Grade 2 or 3 decreased platelet count. The proportion of SAEs considered by the investigator  to  be  related  to  treatment  was  balanced  across  the  two  arms  at  27%  (9  of  33 events) in the SC arm and 29% (12 of 41 events) in the IV arm. The most frequent treatmentrelated SAEs were from the infections and infestations SOC (5 of 33 events in SC arm vs. 7 of 41 events IV arm).

<div style=\"page-break-after: always\"></div>

Table 54. Overview of SAEs in studies WA22762 and NA25220 until clinical cut-off (safety population)

|                              | WA22762                          | WA22762                       | NA25220                         |
|------------------------------|----------------------------------|-------------------------------|---------------------------------|
|                              | 162mg SC TCZqw (PFS)+DMARD N=631 | 8mg/kg IV TCZ q4w+DMARD N=631 | 162mgSCTCZq2w (PFS)+DMARD N=437 |
| Total duration in study (PY) | 454.20                           | 401.02                        | 222.09                          |
| Patients with SAE            | 50 (7.9%)                        | 47 (7%)                       | 23 (5.3%)                       |
| Number of SAEs               | 66                               | 61                            | 29                              |
| Rateper 100 PY               | 14.53                            | 15.21                         | 13.06                           |
| (95% CI)                     | (11.24, 18.49)                   | (11.64, 19.54)                | (8.74, 18.75)                   |

Cl = confidence interval; DMARD = disease-modifying anti-rheumatic drug;

IV = intravenous; PFS = prefilled syringe; PY = patient years; q4w = every four weeks ;

SC = subcutaneous; TCZ = tocilizumab.

SC TCZ arms: Analyses include all patients who received SC TCZ using the PFS in the double-blind period starting from their first dose. Data after switch to IV TCZ (in WA22762) or the Al (in NA25220) in the open-label extension are not included.

IV TCZ arm: Analyses include all patients who received IV TCZ in the double-blind period starting from their first dose. Data after switch to SC TCZ in the open-label extension are not included.

Multiple occurrences of the same AE in one individual are counted.

Source: stae17\\_s\\_b LTE CSR WA22762,staerate01\\_serious\\_2 LTE CSR WA22762, staerate01\\_serious\\_2 LTE CSR NA25220,stae11\\_s\\_pt\\_b LTE CSR NA25220.

In  the  supportive  monotherapy  study  MRA229JP  SAEs  were  recorded  for  13  of  173  patients (7.5%) in  the  SC  TCZ  group  and  for  10  of  173  patients  (5.8%)  in  the  IV  TCZ  group.  Events classified in the SOC of infections and infestations were reported for 2 patients (1.2%) in the SC TCZ group and for 5 patients (2.9%) in the IV TCZ group. The only types of events reported for more than one patient in a given treatment group were 2 patients each with herpes zoster or pneumonia in the IV TCZ group.

One  SAE  was  reported  in  the  supportive  phase  I/II  study  MRA227JP,  a  causal  relationship between TCZ and the pyelonephritis could not be excluded.

There were no SAEs during the randomized SC treatment phase of the phase Ib study NP22623. In  the  post-study  provisional  care  program,  1  out  of  13  patients)  was  diagnosed  with  lung adenocarcinoma. The SAE was considered unrelated to the study drug.

<div style=\"page-break-after: always\"></div>

Table 55. Overview of death in pooled SC TCZ and IV TCZ (all exposure population)

|                   | SCTcZAll-exposure N=1465   | IVTcZAll-exposure N=4171   |
|-------------------|----------------------------|----------------------------|
| TotalExposure(PY) | 893.92                     | 16204.77                   |
| Deaths            | 5                          | 94                         |
| Rateper100PY      | 0.56                       | 0.58                       |
| (95%CI)           | (0.18,1.31)                | (0.47,0.71)                |

Cl=confidence interval;IV=intravenous;PY=patientyears;SC=subcutaneous; TCz=tocilizumab

Source:STrate\\_dd,andSTrate\\_ddinIVsafetyupdatereport

Table 56. Overview of death in studies WA22762 and NA252220 until clinical cutoff (safety population)

|                              | WA22762                        | WA22762                          | NA25220 (PFS)+DMARD N=437   |
|------------------------------|--------------------------------|----------------------------------|-----------------------------|
|                              | 162mgSCTCZqw (PFS)+DMARD N=631 | 8 mg/kg IV TCZ q4w + DMARD N=631 | 162mgSCTCZq2w               |
| Total duration in study (PY) | 454.20                         | 401.02                           | 182.68                      |
| Patients who died            |                                | 2                                | 4                           |
| Rate per 100 PY              | 0.22                           | 0.50                             | 1.35                        |
| (95% CI)                     | (0.01, 1.23)                   | (0.06, 1.80)                     | (0.28, 3.95)                |

Cl = confidence interval; DMARD = disease-modifying anti-rheumatic drug;

IV = intravenous; PFS = prefilled syringe; PY = patient years; q2w = every two weeks;

q4w = every four weeks; qw = every week; SC = subcutaneous; TCZ = tocilizumab

SC TCZ arms: Analyses include all patients who received SC TCZ using the PFS in the double-blind period starting from their first dose. Data after switch to IV TCZ (in WA22762) or the Al (in NA25220) in the open-label extension are not included.

IV TCZ arm: Analyses include all patients who received IV TCZ in the double-blind period starting from their first dose. Data after switch to SC TCZ in the open-label extension are not included.

Source: staerate01 death 2 LTE CSR WA22762, staerate01 death 2 LTE CSR NA25220.

Three deaths were reported in study NA25220 during 24 weeks period in the TCZ arm, two as a result of a sepsis and one death as result of a lower respiratory tract infection. One additional death due to angina pectoris was reported in study NA25220 LTE.

In study WA22762 one death due to sepsis, secondary to bacterial arthritis of the right tarsus, was reported in the TCZ IV group during the 24 weeks treatment period. Two more deaths were reported in in study WA22762 LTE, one in the SC arm and one in the IV arm. The patient in the SC arm died of shock (unknown cause) associated with pelvic pain 11 days after her last dose of TCZ.  The  investigator  considered  the  death  as  well  as  the  pelvic  pain  and  shock  SAEs  to  be related to study treatment. The patient in the IV arm died approximately 6 months after her last dose of TCZ due to hyperkalaemia and hypocalcaemia AEs. The investigator considered the death

<div style=\"page-break-after: always\"></div>

to be unrelated to study treatment. At the time of the data cut, the cause of death was unknown; however, the death has since been attributed to idiopathic pulmonary fibrosis.

There  were  no  deaths  in  any  of  the  supporting  studies,  including  the  monotherapy  study MRA229JP.

## Immunological events

Table 57. Patients who developed confirmatory or neutralising ant-TCZ antibodies during 24 week period (safety population)

|                                               | WA22762          | WA22762                                 | NA25220                           | NA25220     |
|-----------------------------------------------|------------------|-----------------------------------------|-----------------------------------|-------------|
| Assay                                         | qW+DMARD (N=631) | 162mgSCTCZ8mg/kgTCZIV q4w+DMARD (N=631) | 162mg SC TCZPlaceboSC q2w (N=437) | q2w (N=219) |
| N (%)                                         |                  |                                         |                                   |             |
| Tested by screening assay at any time point   | 625 (99.0)       | 627 (99.4)                              | 434 (99.3)                        | 217 (99.5)  |
| Patients with positive assay post-baseline    |                  |                                         |                                   |             |
| Confirmation assay +                          | 5 (0.8)          | 5 (0.8)                                 | 7 (1.6)                           | 3 (1.4)     |
| Confirmation assay + and Neutralizing assay + | 5 (0.8)          | 5 (0.8)                                 | 6 (1.4)                           | 1 (0.5)     |

IV = intravenous; q2w = every two weeks; q4w = every four weeks; qw = every week; SC = subcutaneous; TCZ = tocilizumab.

Source: Table 105 in NA25220 CSR and Table 8 in WA22762 Immunogenicity Report

Table 58. Study  NA22520  LTE  patients  with  anti-TCZ  results  or  positive  anti-TCZ neutralising assay results (safety population)

| Assay                                            | TCZPFS q2w (N=437)   | TCZ PFS q2w →TCZAI q2w (N=168)   | Placebo PFS q2w→TCZ PFS q2w (N=61)   | Placebo PFS q2w→ TCZ Al q2w (69=N)   |
|--------------------------------------------------|----------------------|----------------------------------|--------------------------------------|--------------------------------------|
| N (%)                                            |                      |                                  |                                      |                                      |
| Tested by screening assay at any time point      | 434 (99.3)           | 167 (99.4)                       | 60 (98.4)                            | 59 (100)                             |
| Patients with positive assay post-baseline       |                      |                                  |                                      |                                      |
| Confirmed assay                                  | 7 (1.6)              | 1 (0.6)a                         | 1 (1.6)                              | 1 (1.7)                              |
| Neutralizing assay + and  Confirmation assay + b | 6 (1.4)              | 1 (0.6)                          | 0                                    | 1 (1.7)                              |

IV = intravenous; q2w = every two weeks; SC = subcutaneous; TCZ = tocilizumab.

Patient counted in both TCZ PFS and TCZ PFS to TCZ Al group

b At any timepoint

<div style=\"page-break-after: always\"></div>

Table 59. Study WA22762 LTE patients with anti-TCZ results or positive anti-TCZ neutralising assay results (safety population)

| Assay                                         | 162mg SCTCZ (N = 631)   | 8mg IV TCZ (N =631)   | SC-to-IV Switch (N=48)   | IV-to-SC Switch (N=186)   |
|-----------------------------------------------|-------------------------|-----------------------|--------------------------|---------------------------|
| N (%)                                         |                         |                       |                          |                           |
| Tested by screening assay at any time point   | 625 (99.0)              | 627 (99.4)            | 48 (100)                 | 185 (99.5)                |
| Patients with positive assay post-baseline    |                         |                       |                          |                           |
| Confirmed assay                               | 6 (1.0)a                | 6 (1.0) b             | 1 (2.1)                  | 1 (0.5)                   |
| Neutralizing assay + and Confirmation assay + | 6 (1.0)a                | 6 (1.0) b             | 1(2.1)                   | 1 (0.5)                   |

IV = intravenous; SC = subcutaneous; TCZ = tocilizumab

Data are cumulative (from baseline to LTE data cutoff) and include results for patients in the SC-to-IV crossover group.

D Data are cumulative (from baseline to LTE data cutoff) and include results for patients in the IV-to-SC crossover group.

Source: Sections 3.3 and 3.4.2 in WA22762 Immunogenicity Report

In patients receiving TCZ SC who developed neutralizing anti-TCZ antibodies post-baseline, there appeared to be no impact on efficacy. None of these patients withdrew for lack of efficacy or loss of efficacy (defined as achieving an ACR50 or DAS28-EULAR good response prior to withdrawal for insufficient therapeutic response).

Of patients treated with TCZ SC who experienced a serious or clinically significant hypersensitivity  reaction,  none  were  positive  for  anti-TCZ  antibodies.  Only  one  patient  who experienced an ISR had a positive ADA result.

## Adverse events of special interest

The  types  of  AEs  were  predefined  based  on  findings  from  nonclinical  and  clinical  studies  with TCZ, safety concerns for the RA population (e.g. cardiovascular risk, malignancies), as well as the  safety  profile  of  other  monoclonal  antibodies  used  in  RA.  These  AEs  of  special  interest (AESIs)  were  defined  using  published  standardized  MedDRA  queries  (SMQs),  SOCs,  high-level terms (HLT), or AE group terms (AEGTs) defined by Roche Drug Safety. No new unexpected AEs occurred in the SC TCZ clinical studies.

<div style=\"page-break-after: always\"></div>

Table 60. Rates of AEs of special interest per 100 Patient Years in pooled SC TCZ and IV TCZ all exposure population

| AE of Special Interest                                                                                             | SC TCZ All-exposure N=1465   | IV Tcz All-exposure N = 4171   |
|--------------------------------------------------------------------------------------------------------------------|------------------------------|--------------------------------|
| Infections (All grades) Rate per 100 PY (95% CI)                                                                   | 1023 114.44 (107.53, 121.67) | 15026 92.73 (91.25, 94.22)     |
| Serious infections Rate per 100 PY (95% CI)                                                                        | 39 4.36 (3.10, 5.96)         | 717 4.42 (4.11, 4.76)          |
| Malignancies Rate per 100 PY (95% CI)                                                                              | 13 1.45 (0.77, 2.49)         | 249 1.54 (1.35, 1.74)          |
| Serious malignancies Rate per 100 PY (95% Cl) Anaphylactic reactions                                               | 8 0.89 (0.39, 1.76)          | 156 0.96 (0.82, 1.13)          |
| Rate per 100 PY (95% Cl)                                                                                           | 0                            | 8 0.05 (0.02, 0.10)            |
| Serious hypersensitivity? Rate per 100 PY (95% Cl)                                                                 | 4                            | 44                             |
| Hypersensitivity leading to withdrawal Rate per 100 PY (95% Cl)                                                    | 10                           | 61                             |
|                                                                                                                    | 0.45 (0.12, 1.15)            | 0.27 (0.20,0.36)               |
| Injection site reactions (SC treatment)                                                                            | 1.12 (0.54, 2.06)            | 0.38 (0.29, 0.48) N/A          |
| Rate per 100 PY (95% CI) Serious hepatic AEs                                                                       | 126 64.55 (59.39, 70.04) 0   | 7                              |
| Rate per 100 PY (95% Cl)                                                                                           | 0                            | 0.04 (0.02,0.09)               |
| Serious ischemic and hemorrhagic cerebrovascular conditions Rate per 100 PY (95% Cl) Serious myocardial Infarction | 4 0.45 (0.12, 1.15) 3        | 52 0.32 (0.24,0.42) 44         |
| Medically confirmed Gl perforation Rate per 100 PY (95% CI)                                                        | 5                            | 33 0.20 (0.14,0.29)            |
|                                                                                                                    | 0 0                          |                                |
| Rate per 100 PY (95% Cl)                                                                                           | 0.56 (0.18, 1.31)            |                                |
| Spontaneous or serious bleeding                                                                                    |                              | 68 0.42 (0.33, 0.53)           |
| Serious demyelinating disorders                                                                                    | 0                            | 3                              |
| Rate per 100 PY (95% CI)                                                                                           |                              | 0.02 (0.00,0.05)               |
|                                                                                                                    | 0                            |                                |

Cl = confidence interval; IV = intravenous; PY = patient years; SC = subcutaneous; TCZ = tocilizumab.

Events reported during or within 24 hours of the injection or infusion (excluding injection site reartinns) and that were nnt deemed hv the investinatnr as linrelated tn treatment

<div style=\"page-break-after: always\"></div>

## Infections

Table 61. Overview of infections at week 24 in SC TCZ and IV TCZ clinical studies (safety population)

|                                  | StudyWA22762              | StudyWA22762                | StudyNA25220               | StudyNA25220          | Week24AnalysesfromIVTCZPhaseIllClinical Studies   | Week24AnalysesfromIVTCZPhaseIllClinical Studies   | Week24AnalysesfromIVTCZPhaseIllClinical Studies   |
|----------------------------------|---------------------------|-----------------------------|----------------------------|-----------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                  | 162mgSCTCZ qw+DMARD N=631 | 8mg/kgIVTCZ q4w+DMARD N=631 | 162mgSCTCZ q2w+DMARD N=437 | PISCq2w +DMARD N=218  | 8mg/kgIVTCZ q4w+DMARD N=1582                      | 4mg/kgIVTCZ q4w+MTX N=774                         | PI+DMARD N=1170                                   |
| Duration in study (PY)           | 289.82                    | 288.39                      | 182.68                     | 81.80                 | 753.50                                            | 344.74                                            | 507.24                                            |
| Patientswithinfections           | 227 (36.0%)               | 247 (39.1%)                 | 131(30.0%)                 | 61 (28.0%)            | 592 (37.4%)                                       | 270 (34.9%)                                       | 374 (32.0%)                                       |
| Numberofevents                   | 348                       | 360                         | 176                        | 82                    | 888                                               | 419                                               | 525                                               |
| Rateper100PY (95%CI）             | 120.07 (107.79,133.38)    | 124.83 (112.27,138.42)      | 96.34 (82.63,111.67)       | 100.24 (79.73,124.43) | 117.85 (110.22,125.86)                            | 121.54 (110.18,133.76)                            | 103.5 (94.84,112.75)                              |
| Patients with serious intections | 9(1.4%)                   | 9(1.4%)                     | 9(2.1%)                    | 4 (1.8%)              | 38(2.4%)                                          | 13(1.7%)                                          | 17 (1.5%)                                         |
| Numberof events                  | 9                         | 10                          | 12                         | 5                     | 39 5.18                                           | 15                                                | 19 3.75                                           |
| Rate per 100 PY (95%CI）          | 3.11 (1.42,5.89)          | 3.47 (1.66,6.38)            | 6.57 (3.39.11.47)          | 6.11 (1.98,14.26)     | (3.68,7.08)                                       | 4.35 (2.44,7.18)                                  | (2.26,5.85)                                       |
| Deathsfrominfections             | 0                         | 1(0.2%)                     | 3 (0.7%)                   | 0                     | 1(0.1%)                                           | 0                                                 | 1(0.1%)                                           |
| Withdrawalforinfections          | 7(1.1%)                   | 8(1.3%)                     | 3(0.7%)                    | 2(0.9%)               | 8(0.5%)                                           | 5 (0.6%)                                          | 7(0.6%)                                           |

DMARD-disease-modifyinganti-rheumaticdrug:IV-intravenousPI-placebo,PY-patient years;q2w-every twoweeks;q4w-every fourweeks qw=every week;SAE=seriousadverseeventSC=subcutaneous;TcZ=tocilzumab.

Durationin study=date of last assessment-date of first dose+1day/365.25.Multiple occurrences of the same event in oneindividual are counted.

AnalysisofSCTCZdatabasedonMedDRAversion15.0SOCInfectionsand Infestations

AnalysisofIVTCZdata basedonMedDRAversion 10.0SOC“Infections andInfestations

Slddo2;STrate\\_ae\\_inf,STrate\\_ae\\_inf\\_sinSafetySummaryoforiginal IVTCZsubmission

Table 62. Overview of infections in studies NA25220 and WA 22762 until clinical cut-off (safety population)

|                                  | WA22762                              | WA22762                         | NA25220                            |
|----------------------------------|--------------------------------------|---------------------------------|------------------------------------|
|                                  | 162 mg SC TCZ qw (PFS)+DMARD N = 631 | 8mg/kgIVTCZ q4w + DMARD N = 631 | 162mg SCTCZq2w (PFS)+DMARD N = 437 |
| Total duration in study (PY)     | 454.20                               | 401.02                          | 222.09                             |
| Patients with infections         | 311 (49.3%)                          | 284 (45.0%)                     | 149 (34.1%)                        |
| Number ofevents                  | 575                                  | 487                             | 218                                |
| Rateper100PY (95% CI)            | 126.60 (116.46, 137.38)              | 121.44 (110.89, 132.72)         | 98.16 (85.56, 112.09)              |
| Patients with serious infections | 16 (2.5%)                            | 11 (1.7%)                       | 9 (2.1%)                           |
| Number of events                 | 16                                   | 12                              | 12                                 |
| Rateper 100PY (95% CI)           | 3.52 (2.01, 5.72]                    | 2.99 (1.55, 5.23)               | 5.40 (2.79, 9.44)                  |
| Deaths from infections           | 0                                    | 1                               | 3 (0.7%)                           |
| Rate per 100 PY (95% CI)         | 0 (0, 0.81)                          | 0.25 (0.006, 1.39)              | 1.35 (0.28, 3.95)                  |

Cl=confidenceinterval;DMARD=disease-modifying anti-rheumaticdrug;PFS=prefilled syringe; IV=intravenous; PY=patient years; q2w=every two weeks; q4w= every four weeks; qw = every week; SC = subcutaneous; TcZ = tocilizumab.

SC TCZ arms: Analyses include all patients who received SC TCZ using the PFS in the double-blindperiodstartingfromtheirfirstdose.Data afterswitchtoIVTCZ(inWA22762)or theAl(inNA25220) intheopen-label extension arenot included.

IV TCZ arm: Analyses include all patients who received IV TCZ in the double-blind period starting from theirfirst dose.Data after switch toSC TCZin the open-label extension arenot included.

Multinleoccurrencesof thesameAFin oneindividual arecounted

<div style=\"page-break-after: always\"></div>

In study NA25220 the rates of infections and serious infections through week 24 were similar in the SC TCZ and the placebo arm. Nine patients in the TCZ arm (2.1%) and four patients in the placebo arm (1.8%) experienced at least one serious infection. Sepsis and lower respiratory tract infection were observed in 2 patients in the TCZ arm, and pneumonia was observed in 2 patients in the placebo arm. None of the serious infections was associated with Grade 3 or 4 neutropenia. One SAE of pulmonary tuberculosis was reported in the SC TCZ arm.

Three deaths were reported as a result of infections, all in the SC TCZ arm (see above).

During  the  long  term  follow  up  in  study  NA25220  LTE  the  rates  of  infections  and  serious infections in the TCZ PFS Arm up to the clinical cut-off were consistent with the rates at week 24. No  additional  serious  infections  were  reported  in  patients  in  the  TCZ  PFS  arm  after  rerandomization.

The rate of infections was higher in the patients who switched from TCZ PFS to TCZ AI (142.48 [95% CI: 106.72, 186.36] per 100 PY) compared to the rate observed in the TCZ PFS Arm up to week  24  (96.34  [95%  CI:  82.63,  111.67]).  One  patient  in  the  TCZ  PFS-to-TCZ  AI  arm experienced  Grade  4  bacterial  arthritis,  considered  by  the  investigator  to  be  related  to  study treatment. No additional serious infections were reported.

The  rate  of  infection  and  infestation  AEs  in  patients  who  switched  from  Placebo-to-TCZ  PFS (144.74 per 100 PY) was higher than the rate in patients who switched from placebo to TCZ AI (43.63 per 100 PY) or the rate in the placebo arm in the 24-week double-blind treatment period (97.41 per 100 PY).

No events of opportunistic infection were reported in patients treated with TCZ up to the clinical cut-off. There were no cases of tuberculosis reported during the LTE at the clinical cut-off.

The  rate  of  infections  in  Escape  Patients  was  similar  in  the  prior  TCZ  arm  (108.23  [95%  CI: 75.80, 149.84] per 100 PY) and the prior placebo arm (114.2 [95% CI: 83.30, 152.81] per 100 PY). The rate of serious infections following escape therapy was 9.02 (95% CI: 1.86, 26.36) per 100 PY in the prior TCZ arm and 7.61 (95% CI: 1.57, 22.25) per 100 PY in the prior placebo arm. Three patients each in the prior TCZ arm (4.2%) and prior placebo arm (3.3%) experienced serious infections. One event of new onset pulmonary tuberculosis (an SAE) occurred in a patient who was on TCZ Escape treatment, and led to discontinuation of treatment.

The  rates  for  all  infections  and  serious  infections  observed  in  the  first  24  weeks  of  study WA22762 were similar between the SC and IV treatment arms. Of a total of 19 serious infections were reported. None of the serious infections were associated with Grade 3 or 4 neutropenia. During the long term extension study WA22762 LTE again, the overall rates of infections and serious  infections  were  similar  between  SC  and  IV  treatment  arms  and  similar  to  the  rates observed in the initial 24 weeks of the study.

There were no cases of tuberculosis reported at the clinical cut-off.

In the monotherapy study MRA229JP AEs classified under the SOC of infections and infestations occurred in 72 patients (41.6%) and 78 patients (45.1%) in the 162 mg SC TCZ q2w and the 8 mg/kg  IV  TCZ  q4w  groups,  respectively.  Serious  infections  were  experienced  by  2  patients (1.2%) and 5 patients (2.9%) in the SC and IV TCZ groups, respectively.

In study MRA2227JP AEs classified under the SOC of infections and infestations occurred in 17 patients (53.1%) in the three treatment groups combined. Although the sample size was small,

<div style=\"page-break-after: always\"></div>

the  incidence  of  Infections  and  Infestations  tended  to  increase  with  dose.  One  infection (pyelonephritis in the 81 mg q2w group) was assessed as severe in intensity; this event was also reported as a SAE. A causal relationship to TCZ could not be excluded for the event. All other infections were mild in intensity

## Malignancies

The rate of malignancies per 100 PY of exposure was comparable between the SC and IV allexposure. The review of the events did not identify any clear pattern of event types.

No malignancies were reported in studies MRA229JP or MRA227JP.

## Anaphylaxis

No events of anaphylaxis related to SC TCZ administration have occurred in the pivotal studies or study MRA229JP.

Two  anaphylactic  reactions  were  reported  in  the  TCZ  IV  arm  in  study  WA22762  LTE.  Both anaphylaxis AEs occurred more than 24 hours after TCZ IV infusion.

In study MRA227JP, one AE of anaphylactoid reaction was reported in 1 of 12 patients (8.3%) in the 162 mg q2w group in Period III.

<div style=\"page-break-after: always\"></div>

## Hypersensitivity

Table 63. Overview of  hypersensitivity  in  the  pivotal  studies  until  clinical  cut-off (safety population)

|                                                               | WA22762                                                   | WA22762                                                   | NA25220 (PFS)+DMARD                                       |
|---------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                               | 162 mg SC TCZ qw (PFS) + DMARD N = 631                    | 8 mg/kg IV TCZ q4w +DMARD N=631                           | 162mg SC TCZ q2w N = 437                                  |
| Total duration in study (PY)                                  | 454.20                                                    | 401.02                                                    | 222.09                                                    |
| All Hypersensitivity Reactions                                | All Hypersensitivity Reactions                            | All Hypersensitivity Reactions                            | All Hypersensitivity Reactions                            |
| Patients with event Number ofevents Rate per 100 PY           | 57 (9.0%) 87 19.15                                        | 75 (11.9%) 125 31.17                                      | 21 (4.8%) 27 12.16                                        |
| Clinically Significant Hypersensitivity Reactions             | Clinically Significant Hypersensitivity Reactions         | Clinically Significant Hypersensitivity Reactions         | Clinically Significant Hypersensitivity Reactions         |
| Patients with event Number of events Rate per 100 PY (95% CI) | 7 (1.1%) 7 1.54 (0.61, 3.18)                              | 12 (1.9%) 13 3.24 (1.73, 5.54)                            | 3 (0.7%) 3 1.35 (0.28, 3.95)                              |
| Serious Hypersensitivity Reactions                            | Serious Hypersensitivity Reactions                        | Serious Hypersensitivity Reactions                        | Serious Hypersensitivity Reactions                        |
| Patients with event                                           | 4 (0.6%)                                                  | 3 (0.5%)                                                  | 0                                                         |
| Number of events                                              | 4                                                         | 3                                                         | 0                                                         |
| Rate per 100 PY (95% CI) (0.24, 2.25) (0.15, 2.19)            | Rate per 100 PY (95% CI) (0.24, 2.25) (0.15, 2.19)        | Rate per 100 PY (95% CI) (0.24, 2.25) (0.15, 2.19)        | Rate per 100 PY (95% CI) (0.24, 2.25) (0.15, 2.19)        |
| Patients with event                                           | 2 (3.2%)                                                  | 1 (0.2%)                                                  |                                                           |
|                                                               | 0.88                                                      | 0.75                                                      |                                                           |
| Serious Clinically Significant Hypersensitivity Reactions     | Serious Clinically Significant Hypersensitivity Reactions | Serious Clinically Significant Hypersensitivity Reactions | Serious Clinically Significant Hypersensitivity Reactions |
|                                                               |                                                           |                                                           | 0                                                         |
| Number of events                                              | 2                                                         | 1                                                         | 0                                                         |
| Rate per 100 PY (95% CI)                                      | 0.44 (0.05, 1.59)                                         | 0.25 (0.01, 1.39)                                         |                                                           |

Cl = confidence interval; DMARD = disease-modifying anti-rheumatic drug; IV = intravenous; PY = patient years; SC = subcutaneous; TCZ = tocilizumab.

Clinical cutoff 16 January 2012 forWA22762and 28 May 2012 for NA25220.

SC TCZ arms: Analyses include all patients who received SC TCZ using the PFS in the double-blind period starting from their first dose. Data after switch to IV TCZ (in WA22762) or the Al (in NA25220) in the open-label extension are not included.

IV TCZ arm: Analyses include all patients who received IV TCZ in the double-blind period starting from their first dose. Data after switch to SC TCZ in the open-label extension are not included.

Multiple occurrences of the same AE in one individual are counted.

<div style=\"page-break-after: always\"></div>

Table 64. Study WA22762 LTE rate of hypersensitivity events per 100 patient years (safety population)

|                                                                                    | 162 mg SC qw +DMARD                                                                | 8 mg/kg IV q4w +DMARD                                                              | SC-IV                                                                              | IV-SC                                                                              |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| PY Exposure                                                                        | 454.20                                                                             | 401.02                                                                             | 12.98                                                                              | 58.37                                                                              |
| All Hypersensitivity Events                                                        | All Hypersensitivity Events                                                        | All Hypersensitivity Events                                                        | All Hypersensitivity Events                                                        | All Hypersensitivity Events                                                        |
| Rate per 100 PY [95% CI]                                                           | 19.15 [15.34; 23.63]                                                               | 31.17 [25.95;37.14]                                                                | 0.00                                                                               | 15.42 [7.05;29.27]                                                                 |
| No. patients                                                                       | 57                                                                                 | 75                                                                                 | 0                                                                                  | 6                                                                                  |
| No. events                                                                         | 87                                                                                 | 125                                                                                | 0                                                                                  | 9                                                                                  |
| Clinically Significant Hypersensitivity Events (leading to withdrawal)             | Clinically Significant Hypersensitivity Events (leading to withdrawal)             | Clinically Significant Hypersensitivity Events (leading to withdrawal)             | Clinically Significant Hypersensitivity Events (leading to withdrawal)             | Clinically Significant Hypersensitivity Events (leading to withdrawal)             |
| Rate per 100 PY [95% CI]                                                           | 1.54 [0.62; 3.18]                                                                  | 3.24 [1.73;5.54]                                                                   | 0.00                                                                               | 0.00                                                                               |
| No. patients                                                                       | 7                                                                                  | 12                                                                                 | 0                                                                                  | 0                                                                                  |
| No.events                                                                          | 7                                                                                  | 13                                                                                 | 0                                                                                  | 0                                                                                  |
| Serious Hypersensitivity Events (reported as an SAE)                               | Serious Hypersensitivity Events (reported as an SAE)                               | Serious Hypersensitivity Events (reported as an SAE)                               | Serious Hypersensitivity Events (reported as an SAE)                               | Serious Hypersensitivity Events (reported as an SAE)                               |
| Rateper 100 PY [95% CI]                                                            | 0.88 [0.24;2.25]                                                                   | 0.75 [0.15;2.19]                                                                   | 0.00                                                                               | 0.00                                                                               |
| No. patients                                                                       | 4                                                                                  | 3                                                                                  | 0                                                                                  | 0                                                                                  |
| No.events                                                                          | 4                                                                                  | 3                                                                                  | 0                                                                                  | 0                                                                                  |
| Serious Clinically Significant Hypersensitivity Events (SAE leading to withdrawal) | Serious Clinically Significant Hypersensitivity Events (SAE leading to withdrawal) | Serious Clinically Significant Hypersensitivity Events (SAE leading to withdrawal) | Serious Clinically Significant Hypersensitivity Events (SAE leading to withdrawal) | Serious Clinically Significant Hypersensitivity Events (SAE leading to withdrawal) |
| Rate per 100 PY [95% CI]                                                           | 0.44 [0.05; 1.59]                                                                  | 0.25 [0.01;1.39]                                                                   | 0.00                                                                               | 0.00                                                                               |
| No. patients                                                                       | 2                                                                                  |                                                                                    | 0                                                                                  | 0                                                                                  |
| No.events                                                                          | 2                                                                                  |                                                                                    | 0                                                                                  | 0                                                                                  |

Note: SC-IV and IV-SC switch arms include data from the open label phase only.

a Hypersensitivity event defined as any AE (excluding ISRs) that occurred during or within 24 Includes all types of AE except ISRs that occurred within 24 hours of study drug administration, regardless of whether or not they were clinically consistent with hypersensitivity.

b Hypersensitivity event that led to withdrawal from treatment.

c Hypersensitivity event reported as an SAE.

d Hypersensitivity event reported as an SAE and leading to withdrawal.

Source:page 787, page 789, page 791; page 793; page 779.

<div style=\"page-break-after: always\"></div>

## Injection site rections

Table 65. Overview of  injection  site  reactions  in  the  pivotal  studies  until  clinical cut-off (safety population)

|                          | StudyWA22762a                                  | StudyWA22762a        | StudyNA25220         | StudyNA25220          |
|--------------------------|------------------------------------------------|----------------------|----------------------|-----------------------|
|                          | 162mgSCTCZ8mg/kgIVTCZ162mgSCTCZ qw+DMARD N=631 | q4w + DMARD N=631    | q2w +DMARD N = 437   | PI SC q2w+DMARD N=218 |
| Duration in study (PY)   | 289.82                                         | 288.39               | 182.68               | 81.80                 |
| Patients with event      | 64 (10.1%)                                     | 15 (2.4%)            | 31 (7.1%)            | 9 (4.1%)              |
| Number of events         | 168                                            | 94                   | 57                   | 10                    |
| Rate per 100 PY (95% CI) | 57.97 (49.53, 67.43)                           | 32.59 (26.34, 39.89) | 31.20 (23.63, 40.43) | 12.22 (5.86, 22.48)   |

Cl = confidence interval; DMARD = disease-modifying anti-rheumatic drug; IV = intravenous;

Pl =placebo; PY = patient years; q2w= every two weeks; q4w = every four weeks; qw= every week,

SC = subcutaneous; TCZ = tocilizumab.

Duration in study = (date of last assessment - date of first dose + 1 day) / 365.25.

Multiple occurrences of the same event in one individual are counted.

Events in the IV TcZ amm refer to ISRs to SC injections of placebo

Source: stae11\\_isr, and taerate01\\_isreact\\_wk24\\_2.

In  study  MRA227JP  and  Study  MRA229JP,  3.1%  and  12.1%  of  patients,  respectively,  who received SC TCZ experienced injection site reactions, as did 5.2% of patients in the IV arm of study MRA229JP.

## Laboratory findings

## Neutropenia and abnormal neutrophil count

Table 66. Incidence of neutropenia by CTC Grade at week 24 (safety population)

|                   | No. of Patients (%)   | No. of Patients (%)      | No. of Patients (%)       | No. of Patients (%)   | No. of Patients (%)       | No. of Patients (%)        | No. of Patients (%)         |
|-------------------|-----------------------|--------------------------|---------------------------|-----------------------|---------------------------|----------------------------|-----------------------------|
|                   | WA22762 (TCZ qw)      | WA22762 (TCZ qw)         | NA25220(TCZq2w)           | NA25220(TCZq2w)       | PooledHistoricalIVTCZData | PooledHistoricalIVTCZData  | PooledHistoricalIVTCZData   |
| Neutropenia Grade | TCZ 162mg SC qw N=631 | TCZ 8 mg/kg IV q4w N=631 | TCZ 162 mg SC q2w N = 437 | Placebo SC q2w N=218  | Placebo IV q4w N = 1170   | TCZ 4 mg/kg IV q4w N = 774 | TCZ 8 mg/kg IV q4w N = 1582 |
| n                 | 631                   | 631                      | 417                       | 196                   | 1170                      | 774                        | 1582                        |
| Normal            | 406 (64.3%)           | 464 (73.5%)              | 334 (80.1%)               | 191 (97.4%)           | 1122 (95.9%)              | 614 (79.3%)                | 1047 (66.2%)                |
| Grade 1           | 126 (20.0%)           | 86 (13.6%)               | 45 (10.8%)                | 5 (2.6%)              | 30 (2.6%)                 | 88 (11.4%)                 | 298 (18.8%)                 |
| Grade 2           | 81 (12.8%)            | 61 (9.7%)                | 22 (5.3%)                 | 0 (0%)                | 10 (<1%)                  | 53 (6.8%)                  | 179 (11.3%)                 |
| Grade 3           | 17 (2.7%)             | 20 (3.2%)                | 15 (3.6%)                 | 0 (0%)                | 0 (0%)                    | 9 (1.2%)                   | 48 (3.0%)                   |
| Grade 4           | 1 (<1%)               | 0 (0.0%)                 | 1 (0.2%)                  | 0 (0%)                | 1 (<1%)                   | 5 (<1%)                    | 6 (<1%)                     |

IV= intravenous;q2w=every two weeks; q4w= every four weeks;qw=every week; SC=subcutaneous;TCZ=tocilizumab

CTC Grade 1: &lt;LLN - 1500/mm²; CTC Grade 2: &lt;1500 - 1000/mm²; CTC Grade 3: &lt;1000 - 500/mm²; CTC Grade 4: &lt;500/mm²

Source:ST1b\\_gradtt inWA22762 and NA25520 24-weekCSRs,and and ST1b+gradtt inSafety Summary of original IVTCZsubmission

<div style=\"page-break-after: always\"></div>

## Study NA25220

Table 67. Neutropenia by worst NCI CTCAE grade (safety population)

|                      | No. of Patients (%)   | No. of Patients (%)     |
|----------------------|-----------------------|-------------------------|
| Baseline Body Weight | TCZ PFS q2w (n=437)   | Placebo PFS q2w (n=218) |
| All body weights     | n=429                 | n=218                   |
| Grade 1              | 49 (11)               | 6 (3)                   |
| Grade 2              | 20 (5)                | 0                       |
| Grade 3              | 13 (3)                | 0                       |
| Grade 4              | 1 (<1)                | 0                       |
| <60 kg               | n=112                 | n=58                    |
| Grade 1              | 16 (14)               | 2(3)                    |
| Grade 2              | 7 (6)                 | 0                       |
| Grade 3              | 1(<1)                 | 0                       |
| Grade 4              | 0                     | 0                       |
| 60 to<100 kg         | n=292                 | n=149                   |
| Grade 1              | 32 (11)               | 4 (3)                   |
| Grade 2              | 13 (4)                | 0                       |
| Grade 3              | 9 (3)                 | 0                       |
| Grade 4              | 0                     | 0                       |
| ≥100 kg              | n=25                  | n=11                    |
| Grade 1              | 1 (4)                 | 0                       |
| Grade 2              | 0                     | 0                       |
| Grade 3              | 3 (12)                | 0                       |
| Grade 4              | 1(<1)                 | 0                       |

<div style=\"page-break-after: always\"></div>

Table 68. Number and percentage of patients with neutropenia (worst neutrophil value from baseline normal value), by observed week 24 Cthrough Quartiles (PKITT population)

|                                 | Q1    | Q2    | Q3      | Q4      |
|---------------------------------|-------|-------|---------|---------|
| Group A (162 mg SC q2w via PFS) | n=81  | n=80  | n=80    | n=80    |
| Grade 1 (%)                     | 5 (6) | 3 (4) | 12 (15) | 18 (23) |
| Grade 2 (%)                     | 0 (0) | 4 (5) | 5 (6)   | 9 (11)  |
| Grade 3 (%)                     | 1 (1) | 2 (3) | 4 (5)   | 1 (1)   |

PFS = pre-filled syringe; q2w = every 2 weeks; SC=subcutaneous.

Note: Quartiles were defined for patients whose values fell within 0 to ≤25%, &gt;25 to ≤50%, &gt;50% to ≤75%, &gt;75 to 100% of exp0sures.

Source: page 792.

Neutropenia (including 'decreased neutrophil count') was reported as an AE for 5% patients in the TCZ arm. One patient was withdrawn because of the event. For an additional 8 patients (2%) of the 437 patients in the TCZ arm, the neutropenia led to dose modification or interruption. Of the 16 patients with NCI CTCAE Grade 3 or 4 non-serious neutropenia, 2 patients in the TCZ arm experienced a non-serious infection with onset after the episode neutropenia.

## Platelet count

In the TCZ arm, mean and median platelet counts decreased within the normal range after the first study drug dose and remained lower for the remainder of the 24-week treatment period

Markedly low platelet counts (&lt; 100 × 10 9 /L and a ≥ 30% change from baseline) were reported in less than 1% of TCZ treated patients. In one patient this resulted in a dose modification.

During  the  long  term  extension  in  study  NA25220  LTE  the  results  on  platelet  counts  were consistent with the week 24 data.

<div style=\"page-break-after: always\"></div>

Table 69. Study WA22762 newly occurring neutropenia, by worst NCI CTCAE grade and baseline body weight (safety population)

|                    | No.ofPatients(%)        | No.ofPatients(%)          |
|--------------------|-------------------------|---------------------------|
| BaselineBodyWeight | 162mgSCqw+DMARD (n=631) | 8mg/kgIVq4w+DMARD (n=631) |
| Allbodyweights     | n-628                   | n-628                     |
| Grade1             | 124(19)                 | 86(14)                    |
| Grade2             | 80(13)                  | 60(10)                    |
| Grade3             | 17(3)                   | 20(3)                     |
| Grade4             | 1（<1）                   | 0(0)                      |
| <60kg              | n=142                   | n=144                     |
| Grade 1            | 29 (20)                 | 18(12)                    |
| Grade2             | 28(20)                  | 16(11)                    |
| Grade3             | 5(4)                    | 6(4)                      |
| Grade4             | 1（<1)                   | 0(0)                      |
| 60-100kg           | n=425                   | n=421                     |
| Grade1             | 85(20)                  | 61(14)                    |
| Grade2             | 50(12)                  | 41(10)                    |
| Grade3             | 10(2)                   | 12(3)                     |
| Grade4             | 0(0)                    | 0(0)                      |
| ≥100kg             | n=61                    | n=63                      |
| Grade1             | 10(16)                  | 7(11)                     |
| Grade2             | 2(3)                    | 3(5)                      |
| Grade3             | 2(3)                    | 2(3)                      |
| Grade4             | 0(0)                    | 0(0)                      |

AE=adverseevents;DMARD-disease-modifying anti-rheumaticdrug;IV-intravenous; NCl CTCAE-National CancerInstituteCommonTerminologyCriteriaforAdverseEvents; q4w-every4weeks;qw-onceweekly;SC-subcutaneous.

<div style=\"page-break-after: always\"></div>

Table 70. Study  WA22762 LTE newly occurring neutropenia by worst NCI CTCAE Grade (ITT population)

|         | No. of Patients (%)        | No. of Patients (%)           | No. of Patients (%)   | No. of Patients (%)   |
|---------|----------------------------|-------------------------------|-----------------------|-----------------------|
|         | 162mg SC qw +DMARD (N=524) | 8 mg/kg IV q4w +DMARD (N=377) | IV-SC (N=186)         | SC-IV (N=48)          |
| Grade 1 | 107 (20.4)                 | 58 (15.4)                     | 30 (16.1)             | 16 (33.3)             |
| Grade 2 | 68 (13.0)                  | 35 (9.3)                      | 25 (13.4)             | 7 (14.6)              |
| Grade 3 | 19 (3.6)                   | 15 (4.0)                      | 5 (2.7)               | 0 (0.0)               |
| Grade 4 | 0 (0.0)                    | 0 (0.0)                       | 0 (0.0)               | 0 (0.0)               |

DMARD =disease-modifying antirheumatic drug; IV=intravenous; NCI CTCAE =National Cancer Weekly; SC=subcutaneous.

Includes data from the double blind and open label phases for all four arms.

Source:page864.

Table 71. Study WA22762 LTE neutropenia adverse events (safety population)

|                            | No. of Patients (%)         | No. of Patients (%)         | No. of Patients (%)   | No. of Patients (%)   |
|----------------------------|-----------------------------|-----------------------------|-----------------------|-----------------------|
|                            | 162 mg SC qw +DMARD (N=631) | 8mg/kg IVq4w +DMARD (N=631) | IV-SC (N=186)         | SC-IV (N=48)          |
| Neutropenia                |                             |                             |                       |                       |
| AE                         | 31 (4.9)                    | 26 (4.1)                    | 2 (1.1)               | 0 (0.0)               |
| Withdrawal                 | 2 (0.3)                     | 1 (0.2)                     | 0 (0.0)               | 0 (0.0)               |
| Dose modification          | 14 (2.2)                    | 14 (2.2)                    | 1 (0.5)               | 0 (0.0)               |
| Decreased neutrophil count |                             |                             |                       |                       |
| AE                         | 8 (1.3)                     | 2 (0.3)                     | 0 (0.0)               | 0 (0.0)               |
| Withdrawal                 | 1 (0.2)                     | 0 (0.0)                     | 0 (0.0)               | 0 (0.0)               |
| Dose modification          | 3 (0.5)                     | 2 (0.3)                     | 0 (0.0)               | 0 (0.0)               |
| Total                      |                             |                             |                       |                       |
| AE                         | 39 (6.2)                    | 28 (4.4)                    | 2 (1.1)               | 0 (0.0)               |
| Withdrawal                 | 3 (0.5)                     | 1 (0.2)                     | 0 (0.0)               | 0 (0.0)               |
| Dose modification          | 17 (2.7)                    | 16 (2.5)                    | 1 (0.5)               | 0 (0.0)               |

AE = adverse event; DMARD= disease-modifying antirheumatic drug; IV =intravenous; q4w=every 4 weeks; qw=once weekly; SC =subcutaneous.

Includes data from the double blind and open label phases for the SC and IV arms but only from the open-label phase for the IV-SC and SC-IV switch arms.

Source: page 282,page 644,and page 652

In  study  MRA229JP,  mean  neutrophil  count  decreased  by  approximately  30%  from  baseline values by 24 weeks. Decreases in neutrophil count were comparable between the SC TCZ and IV

<div style=\"page-break-after: always\"></div>

TCZ groups. In both groups, Grade 3 or 4 decreases in neutrophil count occurred in 5 patients. Among these patients, non-serious infections were recorded for 2 patients in the SC TCZ group and 3 patients in the IV TCZ group; all infections were mild.

In  study  MRA227JP,  mean  neutrophil  count  decreased  by  Week  35,  in  each  of  the  three treatment groups. A reduction in neutrophil count of two or more grades occurred in 1 patient in the 81 mg q2w and in 3 patients in the 162 mg q2w group. Among these patients, non-serious infections of pharyngitis and nasopharyngitis (all mild) and one event of pyelonephritis (severe) were recorded.

## Platelet count

Table 72. Incidence  of  thrombocytopenia  by  CTC  Grade  at  week  24  (safety population)

|                       | No.of Patients (%)    | No.of Patients (%)    | No.of Patients (%)     | No.of Patients (%)   | No.of Patients (%)        | No.of Patients (%)        | No.of Patients (%)          |
|-----------------------|-----------------------|-----------------------|------------------------|----------------------|---------------------------|---------------------------|-----------------------------|
|                       | WA22762 (TCZqw)       | WA22762 (TCZqw)       | NA25220(TCZq2w)        | NA25220(TCZq2w)      | PooledHistoricalIVTCZData | PooledHistoricalIVTCZData | PooledHistoricalIVTCZData   |
| Thrombocyopenia Grade | TCZ162mgSC qw N = 631 | TCZ8mg/kgIV q4w N=631 | TCZ162mgSC q2w N = 437 | PlaceboSC q2w N=218  | PlaceboIV q4w N = 1170    | TCZ 4 mg/kg IV q4w N =774 | TCZ 8 mg/kg IV q4w N = 1582 |
| n                     | 630                   | 630                   | 427                    | 218                  | 1170                      | 774                       | 1582                        |
| Normal                | 575 (91.3%)           | 568 (90.2%)           | 396 (92.7%)            | 215 (100.0%)         | 1144 (97.8%)              | 721 (93.2%)               | 1434 (90.6%)                |
| Grade 1               | 54 (8.6%)             | 59 (9.4%)             | 29 (6.8%)              | 0 (0%)               | 15 (1.3%)                 | 42 (5.4%)                 | 136 (8.6%)                  |
| Grade 2               | 1 (0.2%)              | 2 (0.3%)              | 2 (0.5%)               | 0 (0%)               | 1 (<1%)                   | 3 (<1%)                   | 4 (<1%)                     |
| Grade3                | 0 (0%)                | 1 (0.2%)              | 0 (0%)                 | 0 (0%)               | 1 (<1%)                   |                           | 3 (<1%)                     |
| Grade 4               | 0 (0%)                | 0 (0%)                | 0 (0%)                 | 0 (0%)               | 1 (<1%)                   | 3 (<1%)                   | 2 (<1%)                     |

IV = intravenous; q2w = every two weeks; q4w = every four weeks; qw = every week; SC = subcutaneous; TCZ = tocilizumab.

Platelets:CTCgrade1&lt;LLN-75,000/mm3;CTCgrade2:&lt;75,000-50,000/mm3;CTCgrade3:&lt;50,000-25,000/mm3;CTCgrade 4: &lt;25000/mm3

Source:ST1b\\_gradtt inWA22672andNA25520Week24CSRsandST1b+gradttinSafetySummaryoforiginalIVTCZsubmission

The  data  in  the  long  term  extension  in  study  NA25220  LTE  and  study  WA22762  LTE  were consistent with the 24 weeks data. In study WA22762 LTE one new Grade 3 decreased platelet count  was  observed  in  the  IV-SC  Switch  Arm.  All  other  newly  observed  cases  in  both  studies were Grade 1 or 2.

No association between decreases in platelet counts and serious bleeding events were reported. There was no relationship between body weight and the incidence of thrombocytopenia

In study MRA229JP, mean platelet counts decreased by approximately 25% from baseline values after 4 weeks, and these levels were sustained through 24 weeks. Decreases in platelet count were similar between the SC TCZ and IV TCZ groups. There were no Grade 3 or 4 decreases in platelet  count  in  either  treatment  group.  No  serious  bleeding  events  were  associated  with decreased platelet count.

In study MRA227JP, mean platelet count decreased by Week 35; the reduction in platelet count occurred in each of the three treatment groups.  A reduction in platelet count of two or more grades occurred in 1 patient in the 162 mg q2w group.

## Liver enzymes

The  liver  profile  consisted  of  AST,  ALT,  total  bilirubin,  and  alkaline  phosphatase.  Direct  and indirect bilirubin levels were tested only if total bilirubin was greater than the ULN.

<div style=\"page-break-after: always\"></div>

Table 73. Study NA25220 shifts in ALT and AST from normal at baseline to worst post-baseline value above the ULN (safety population)

|                                        |              | No. of Patients (%)   | No. of Patients (%)              | No. of Patients (%)                    | No. of Patients (%)                   |
|----------------------------------------|--------------|-----------------------|----------------------------------|----------------------------------------|---------------------------------------|
|                                        | Liver Enzyme | TCZ PFS q2w (N = 167) | TCZPFS q2w → TCZ Al q2w (N= 167) | Placebo PFS q2w → TCZ PFS q2w (N = 60) | Placebo PFS q2w → TCZ Al q2w (N = 59) |
| Normal value at BL                     | AST          | 162 (97.0)            | 159 (95.2)                       | 57 (95.0)                              | 58 (98.3)                             |
|                                        | ALT          | 157 (94.0)            | 157 (94.0)                       | 54 (90.0)                              | 57 (96.6)                             |
| Normal value at BL and post-BL         | AST          | 113 (67.7)            | 111 (66.5)                       | 45 (75)                                | 43 (72.9)                             |
|                                        | ALT          | 87 (52.1)             | 80 (47.9)                        | 40 (66.7)                              | 32 (54.2)                             |
| Normal at BL to >ULN-                  | AST          | 47 (28.1)             | 45 (26.9)                        | 12 (20)                                | 14 (23.7)                             |
| 3 x ULN post-BL                        | ALT          | 66 (39.5)             | 72 (43.1)                        | 12 (20.0)                              | 21 (35.6)                             |
| Normal at BL to >3xULN- 5 xULN post-BL | AST          | 2 (1.2)               | 2 (1.2)                          | 0                                      | 1 (1.7)                               |
|                                        | ALT          | 3 (1.8)               | 4 (2.4)                          | 2 (3.3)                                | 4 (6.8)                               |
| normal at BL to >5x ULN post-          | AST          | 0                     | 1 (0.6)                          | 0                                      | 0                                     |
| BLa                                    | ALT          | 1 (0.6)               | 1 (0.6)                          | 0                                      | 0                                     |
| Marked shift                           | AST          | 2 (1.2)               | 3 (1.8)                          | 0                                      | 1 (1.7)                               |
| post-BL b                              | ALT          | 5 (3.0)               | 6 (3.6)                          | 2 (3.3)                                | 4 (6.8)                               |

ALT =alanine aminotransferase; AST =aspartate aminotransferase; BL =baseline; PFS=prefilled syringe; q2w=every 2 weeks; Al=autoinjector; TCZ=tocilizumab; ULN=upper limit of normal.

aExcludes patients with missing values.

b Shift from normal to &gt;3 - 5xULN, from normal to &gt;5xULN, plus from &gt; ULN - 3x ULN to &gt;5xULN).

N used as denominator to calculate percentage.

Source: page 892.

In escape patients a similar proportion of patients in the prior TCZ and placebo arms experienced markedly high AST levels following escape therapy. The incidence of markedly high ALT levels was  higher  in  the  prior  placebo  arm  as  compared  to  the  prior  TCZ  arm  (8/90  (9%)  vs  3/72 (4%)). None of the elevations in transaminases were associated with simultaneous elevations in total  bilirubin  of  &gt;2  ULN.  Following  the  initiation  of  escape  therapy,  the  incidence  of  AEs associated  with  elevated  ALT  and  AST  was  higher  in  the  patients  who  previously  received placebo.

In  study  NA25220 no notable differences in total bilirubin or  alkaline phosphatase  levels  were observed between the TCZ and placebo treatment arms. A greater percentage of patients within the 60 to &lt; 100 kg body weight category in both treatment arms showed an increase in ALT or

<div style=\"page-break-after: always\"></div>

AST as compared with the &lt; 60 kg and ≥ 100 kg categories. There were no patients who met the laboratory criteria for Hy's law, i.e. no patients in this study were identified as having a &gt; 3 × the ULN elevation in AST or ALT and 2 × ULN in total bilirubin.

During the long term extension in study NA25220 LTE the results the results were consistent with the 24 weeks data.

Table 74. Study WA 22762 shifts in ALT and AST from normal at baseline to worst post-baseline value above the ULN (ITT population)

|                                                        |     | 162mg SC qW+DMARD (n=524)   | 8 mg/kg IV 0q4w+DMARD (n=377)   | IV-SC (n=186)   | SC-IV (n=48)   |
|--------------------------------------------------------|-----|-----------------------------|---------------------------------|-----------------|----------------|
| No. (%) patients with a normal value at BL             | ALT | 484 (92.4)                  | 343 (91.0)                      | 169 (93.9)      | 43 (90.0)      |
| No. (%) patients with a normal value at BL             | AST | 497 (94.8)                  | 353 (93.6)                      | 175 (94.1)      | 45 (93.8)      |
| No. (%) patients with a normal value at BL and post-BL | ALT | 197 (37.6)                  | 160 (42.4)                      | 80 (43.0)       | 19 (39.6)      |
| No. (%) patients with a normal value at BL and post-BL | AST | 281 (53.6)                  | 197 (52.3)                      | 108 (58.1)      | 23 (47.9)      |
| No. (%) patients with an increase from normal at BL    | ALT | 264 (50.4)                  | 166 (44.0)                      | 76 (40.9)       | 20 (41.7)      |
| to >ULN to 3 x the ULN                                 | AST | 214 (40.8)                  | 152 (40.3)                      | 64 (34.4)       | 22 (45.8)      |
| No. (%) patients with an increase from normal at BL to | ALT | 20 (3.8)                    | 14 (3.7)                        | 10 (5.4)        | 3 (6.3)        |
| >3 to 5x the ULN a                                     | AST | 1 (0.2)                     | 4 (1.1)                         | 3 (1.6)         | 0 (0.0)        |
| No. (%) patients with an                               | ALT | 3 (0.6)                     | 3 (0.8)                         | 3 (1.6)         | 1 (2.1)        |
| increase from normal at BL to >5x the ULN a            | AST | 1 (0.2)                     | 0 (0.0)                         | 0 (0.0)         | 0 (0.0)        |
| No. (%) of patients with a marked shift b              | ALT | 23 (4.4)                    | 17 (4.5)                        | 13 (7.0)        | 4 (8.3)        |
| No. (%) of patients with a marked shift b              | AST | 2 (0.4)                     | 4 (1.1)                         | 3 (1.6)         | 0 (0.0)        |

ALT =alanine aminotransferase; AST =aspartate aminotransferase; BL =baseline;

IV=intravenous; DMARD=disease-modifying antirheumatic drug; q4w=every 4 weeks; qw=once weekly; SC =subcutaneous; TCZ =tocilizumab; ULN= upper limit of normal.

aExcludes patients with missing values.

b Shift from normal to &gt;3 - 5xULN, from normal to &gt;5x ULN, plus from &gt; ULN - 3x ULN to &gt;5x ULN).

Includes data from the double blind and open label phases for all four arms.

The majority of elevations in both arms occurred at a single time point only: 19 patients (3.6%) in  the  SC  arm  and  15  patients  (4.0%)  in  the  IV  arm.  Non-consecutive  elevations  were experienced by 8 (1.5%) and 6 patients (1.6%) in the SC and IV arms, respectively. One patient in the SC arm experienced a sustained consecutive elevation (i.e. from time of first elevation to the  last  record).  Among  patients  with  an  increased  ALT  and/or  AST  level,  the  majority experienced a Grade 1 elevation at worst; Grade 1 elevations were reported for a slightly higher proportion of patients in the SC arm compared with the IV arm for ALT (48% vs. 42%), whereas no notable difference between arms was seen for AST (38% vs. 37%). No notable differences between arms were observed for Grade 2, 3, or 4 elevations. Grade 3 or 4 elevations in ALT and AST occurred in ~1% of patients.

<div style=\"page-break-after: always\"></div>

Increased ALT and increased AST were reported as AEs for 9 (4.8%) and 7 (3.8%) patients in the  IV-SC  arm,  respectively.  One  patient  was  withdrawn  due  to  increased  ALT  and  AST  AEs. There were no hepatic AEs in the IV-SC Switch Arm.

Table 75. Study WA22762 patients with an increase in AST and Alt from &lt; 3x ULN at baseline to worst value &gt; 3x ULN by weight at baseline (ITT population)

|               | 162 mg SC qw +DMARD N=524   | 8 mg/kg IV q4w +DMARD N=377   | IV-SC N=186   | SC-IV N=48   |
|---------------|-----------------------------|-------------------------------|---------------|--------------|
| ALT           |                             |                               |               |              |
| <60 kg        | 3/120 (2.5)                 | 3/84 (3.6)                    | 3/46 (6.5)    | 0/12 (0.0)   |
| 60 to <100 kg | 22/355 (6.2)                | 18/254 (7.1)                  | 10/125 (8.0)  | 5/33 (15.2)  |
| ≥100 kg       | 4/49 (8.1)                  | 6/39 (15.4)                   | 2/15 (13.3)   | 0/3 (0.0)    |
| AST           |                             |                               |               |              |
| <60 kg        | 1/120 (0.8)                 | 1/84 (1.2)                    | 0/46 (0.0)    | 0/12 (0.0)   |
| 60 to <100 kg | 2/355 (0.6)                 | 4/254 (1.6)                   | 3/125 (2.4)   | 0/33 (0.0)   |
| ≥100 kg       | 1/49 (2.0)                  | 1/39 (2.6)                    | 0/15 (0.0)    | 0/3 (0.0)    |

ALT = alanine aminotransferase; AST = aspartate aminotransferase; DMARD =diseasemodifying antirheumatic drug; IV=intravenous; q4w=every 4 weeks; qw=once weekly; SC=subcutaneous.

Includes data from the double blind and open label phases for all four arms.

Source:page900.

In  both  treatment  arms  of  Study  WA22762  mean  and  median  total  bilirubin  levels  increased within the normal range following initiation of TCZ treatment and remained stable at the higher levels for the duration of treatment. No notable differences were observed between the SC and IV  treatment  arms.  Markedly  high  bilirubin  levels  (&gt;2  ×  ULN)  were  rare,  occurring  in  2%  of patients  in  each  treatment  arm,  and  were  all  elevations  of  indirect  bilirubin.  There  were  no occurrences  of  markedly  high  direct  bilirubin.  The  results  in  the  long  term  extension  study WA22762 LTE were consistent with the week 24 data.

In  study  MRA229JP,  the  time  courses  of  ALT,  AST  and  ALP  levels  were  similar  in  the  two treatment groups. Grade 3 or 4 increases were recorded in the SC TCZ and IV TCZ groups for ALT (1 and 3 subjects, respectively) and AST (1 and 0 patients, respectively). One patient in the IV TCZ group experienced a SAE of hepatic function abnormal.

In study MRA227JP, some fluctuation was noted in the mean values of the liver function-related test  variables,  but  mean  values  remained  within  the  normal  range  for  all  the  liver  function parameters. For ALT, the CTC Grade worsened by at least two grades for 1 patient in each of the 81 mg q2w and 162 mg q2w groups, and for 2 patients in the 162 mg qw group. For AST, the CTC  Grade  worsened  by  at  least  two  grades  for  two  patients  in  the  162  mg  qw  group.  Two patients experienced an AE of hepatic function abnormal.

<div style=\"page-break-after: always\"></div>

## Lipid parameters

Changes in each lipid profile  (total  cholesterol,  low-density  lipoprotein  (LDL)  cholesterol,  highdensity lipoprotein [HDL] cholesterol, and triglycerides) at Week 24 were similar for TCZ SC and TCZ IV in both frequency and grade across SC (qw and q2w) and TCZ IV populations.

At Week 24, the proportion of patients who experienced a sustained elevation in total cholesterol of ≥ 6.2 mmol/L (240 mg/dL), or in LDL of ≥ 4.1 mmol/L (160 mg/dL), was comparable between both TCZ SC dosing regimens (qw and q2w) and TCZ IV populations.

Following an initial increase after the first administration of TCZ SC, the mean values for lipid profile parameters remained stable throughout the remainder of the studies. There was no trend for  an  increased  risk  of  cholesterol  increases  over  time,  which  is  a  known  risk  in  patients receiving TCZ IV. Changes in the lipid profiles for the SC and IV all-exposure populations were comparable.

## Safety in special populations

## Bodyweight

Table 76. Pivotal  studies:  Key  Safety  Parameters  by  body  weight  category  (24 weeks data)

|                    | <60 kg     | <60 kg     | 60-100kg   | 60-100kg    | ≥100 kg    | ≥100 kg    |
|--------------------|------------|------------|------------|-------------|------------|------------|
|                    | TCZ qw     | TCZq2w     | TCZ qw     | TCZ q2w     | TCZ qw     | TCZq2w     |
| Number of patients | N=144      | N=119      | N=425      | N=292       | N=62       | N=26       |
| AEs                | 105 (73%)  | 74(62.2%)  | 322 (76%)  | 179 (61.3%) | 54 (87%)   | 21 (80.8%) |
| Infections         | 49 (34%)   | 41 (34.5%) | 151 (36%)  | 79 (27.1%)  | 27 (44%)   | 11 (42.3%) |
| Serious AE         | 10 (6.9%)  | 8 (6.7%)   | 17 (4.0%)  | 9 (3.1%)    | 2 (3.2%)   | 3 (11.5%)  |
| Serious infections | 5 (3.5%)   | 5 (4.2%)   | 4 (0.9%)   | 3 (1.0%)    | 0          | 1 (3.8%)   |
| Neutropenia        |            |            |            |             |            |            |
| Grade 1            | 29 (20%)   | 17 (11.8%) | 85 (20%)   | 32 (7.5%)   | 10 (16.1%) | 1 (1.6%)   |
| Grade 2            | 28 (19.4%) | 9 (6.3%)   | 51 (12%)   | 13 (3.1%)   | 2 (3.2%)   | 0          |
| Grade 3            | 5 (3.5%)   | 1 (0.7%)   | 10 (2.4%)  | 11 (2.6%)   | 2 (3.2%)   | 3 (4.8%)   |
| Grade 4            | 1 (0.7%)   | 0          | 0          | 0           | 0          | 1 (1.6%)   |

AE: AE; qw weekly; q2w every two weeks; TCZ: tocilizumab.

Source: Sections 7.3, 7.6, 7.9.1 and 7.11.1.1 in the WA22762 24-week CSR, and Sections 7.3, 7.6, and 7.11.1.1 in the NA25520 24-week CSR.

In the long-term extension phases of study NA25520 and study WA22672, subgroup analyses of selected AE parameters by body weight category at baseline (&lt; 60 kg, 60 to &lt; 100 kg, and ≥ 100 kg) indicated a trend for higher incidences of all AEs and SAEs among patients weighing ≥ 100 kg at baseline compared with patients weighing &lt; 100 kg.

<div style=\"page-break-after: always\"></div>

In subgroup analyses of laboratory parameters, the incidence of newly occurring Grade 1 and 2 neutropenia showed a trend for increase with decreasing body weight. However, this effect was not observed with Grade 3 or 4 events.

## Discontinuation due to adverse events

Table 77. Overview of AEs leading to withdrawal at week 24 in SC TCZ and IV TCZ clinical studies (safety population)

|                        | StudyWA22762         | StudyWA22762                          | StudyNA25220                 | StudyNA25220         | Week24AnalysesfromIVTCZPhaseIll ClinicalStudies   | Week24AnalysesfromIVTCZPhaseIll ClinicalStudies   | Week24AnalysesfromIVTCZPhaseIll ClinicalStudies   |
|------------------------|----------------------|---------------------------------------|------------------------------|----------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                        | qW+DMARD N=631       | 162mgSCTCZ8mg/kgIVTCZ q4w+DMARD N=631 | 162mgSCTCZ q2w+DMARD（ N= 437 | PISC q2w+DMARD N=218 | q4w+DMARD N=1582                                  | 8mg/kgIVTCZ4mg/kgIVTCZPI+DMARD q4w+MTX N=774      | N= 1170                                           |
| Duration instudy (PY)  | 289.82               | 288.39                                | 182.68                       | 81.80                | 753.50                                            | 344.74                                            | 507.24                                            |
| PatientswithdrawnforAE | 30 (4.8%)            | 41 (6.5%)                             | 9 (2.1%)                     | 3 (1.4%)             | 11 (3.8%)                                         | 38 (4.9%)                                         | 26 (2.4%)                                         |
| NumberofAEs            | 41                   | 54                                    | 9                            | 3                    | 11                                                | 38                                                | 28                                                |
| Rateper100PY (95% CI)  | 14.15 (10.15, 19.19) | 18.72 (14.07, 24.43)                  | 4.93 (2.25, 9.35)            | 3.67 (0.76, 10.72)   | 1.46 (0.73, 2.61)                                 | 11.02 (7.80, 15.30)                               | 5.70 (3.83, 8.21)                                 |

AE=adverse event;Cl=confidence interval;DMARD=disease-modifying anti-rheumatic drug;IV=intravenous;Pl=placebo;PY=patient years;

q2w=everytwoweeks;q4w=everyfourweeks;qw=everyweek;SC=subcutaneous;TcZ=tocilizumab

Duration instudy=(dateof last assessment-dateof first dose+1day)/365.25.

Multipleoccurrencesofthesameeventinoneindividualarecounted.

Table 78. Overview of AEs leading to withdrawal in pooled SC TCZ and IV TCZ (all exposure population)

|                           | SC Tcz All-exposure N=1465   | IV Tcz All-exposure N = 4171   |
|---------------------------|------------------------------|--------------------------------|
| Total Exposure (PY)       | 893.92                       | 16204.77                       |
| Patients withdrawn for AE | 58                           | 788                            |
| Number of AEs             | 77                           | 793                            |
| Rate per 100 PY           | 8.61                         | 4.89                           |
| (95% CI)                  | (6.80, 10.77)                | (4.56, 5.25)                   |

AE = adverse event; Cl = confidence interval; IV = intravenous; PY = patient years; SC = subcutaneous: TCZ = tocilizumab.

Multiple occurrences of the same AE in one individual are counted.

Source: STae\\_rategp6\\_wd and STae\\_rategp6\\_wd in IV LTE safety update report.

During the 24 weeks treatment period in study NA252209 most common reasons for treatment discontinuation were attributed to infections and infestations (individual events in each arm, with the exception of two cases of lower respiratory tract infection in the TCZ arm) and investigations SOCs  (individual  events  of  elevated  ALT  and  increased  body  weight).  Other  SOCs  included  1 patient  withdrawal  each  because  of  blood  and  lymphatic  system  disorders  (neutropenia); hepatobiliary disorders (hepatic steatosis); neoplasms  benign,  malignant  and  unspecified (including Cysts and Polyps; adenocarcinoma pancreas); and respiratory, thoracic and mediastinal disorders (pulmonary fibrosis).

<div style=\"page-break-after: always\"></div>

In study WA22762 the most common reasons for treatment discontinuation during the 24 weeks period were infections and infestations (individual events in each arm, with the exception of two cases  of  bacterial  arthritis  in  the  IV  arm)  and  investigations  SOCs  (due  to  elevated  liver enzymes).  Other  SOCs  occurring  at  an  incidence  of  1%  in  either  arm  were  immune  system disorders  (hypersensitivity  reactions)  and  skin  and  subcutaneous  tissue  disorders  (including urticaria,  rash,  and  erythema).  Two  patients in  the  SOC  respiratory,  thoracic,  and  mediastinal disorders with interstitial lung disease and pulmonary fibrosis had pre-existing conditions.

In the randomized SC treatment phase of study NP22623, no patients withdrew due to an AE.

In study MRA229JP AEs leading to withdrawal of the investigational product were recorded for 3 patients (1.7%) in the SC TCZ group and 9 patients (5.2%) in the IV TCZ group. The events include  subileus  and  hyponatraemia  in  the  TCZ  SC  group  and  herpes  zoster,  hepatic  function abnormal, colitis ischemic, large intestine perforation, spinal column stenosis, Meniere's disease, spinal compression fracture and anaphylactic reaction in the TCZ IV group.

On patient withdrew from study MRA227JP due to decreases in neutrophils and in white blood cells (two events). A causal relationship to TCZ could not be excluded for either event.

Table 79. Overview of AEs leading to dose modifications at week 24 in the SC TCZ and IV TCZ clinical studies (safety population)

|                                                        | StudyWA22762           | StudyWA22762                          | StudyNA25220                 | StudyNA25220           | Week24AnalysesfromIVTCZPhaseIllClinical Studies   | Week24AnalysesfromIVTCZPhaseIllClinical Studies   | Week24AnalysesfromIVTCZPhaseIllClinical Studies   |
|--------------------------------------------------------|------------------------|---------------------------------------|------------------------------|------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                        | qw+DMARD N= 631        | 162mgSCTCZ8mg/kgIVTCZ q4w+DMARD N=631 | 162mg SC TCZ q2w+DMARD N=437 | PI SC q2w +DMARD N=218 | 8 mg/kg IV TCZ q4w+DMARD N=1582                   | 4mg/kgIVTCZPI+DMARD q4w + MTX N=774               | N= 1170                                           |
| Duration in study (PY)                                 | 289.82                 | 288.39                                | 182.68                       | 81.80                  | 753.50                                            | 344.74                                            | 507.24                                            |
| Patientswith at least one AEleadingtodose modification | 172 (27.3%)            | 170 (26.9%)                           | 59 (13.5%)                   | 18 (8.3%)              | 194 (12.3%)                                       | 103 (13.3%)                                       | 84 (7.2%)                                         |
| NumberofAEsleadingto dosemodification                  | 288                    | 240                                   | 80                           | 28                     | 235                                               | 136                                               | 95                                                |
| AEsper100PY (95% CI)                                   | 104.55 (93.11, 117.01) | 87.38 (76.93, 98.86)                  | 44.34 (35.21, 55.11)         | 34.23 (22.75, 49.47)   | NA                                                | NA                                                | NA                                                |

AE = adverse event; CI = confidence interval; DMARD = disease-modifying anti-rheumatic drug; IV = intravenous; Pl = placebo; PY = patient years; q2w = every two weeks; q4w = every four weeks; qw = every week; SAE = serious adverse event; SC = subcutaneous; TCZ = tocilizumab. Durationinstudy=dateoflastassessment-dateoffirstdose+1day/365.25.

Multipleoccurrencesofthesameeventinoneindividualarecounted.

Source:fromWA22762Week24CSRstae11\\_dm\\_2,fromNA25220Week24\\_2CSR,stae11\\_dmodinSafetySummaryoforiginalIVTCZsubmission.

In the SC all-exposure population, the most common events leading to dose modification were reported  in  the  investigations  (mainly  elevation  in  hepatic  transaminase)  and  Blood  and lymphatic  system  (neutropenia,  leucopaenia  and  thrombocytopaenia)  SOCs.  In  the  IV  allexposure population, the most common AEs leading to dose modifications were in the Infections (most  commonly  URTI,  bronchitis,  nasopharyngitis,  and  sinusitis)  and  Investigations  SOCs (mainly elevation in hepatic transaminase).

In  the  randomized  SC  treatment  phase  of  study  NP22623,  3  patients,  all  in  the  q2w  group, experienced AEs (tracheitis, bronchitis, and diarrhea, respectively) that led to dose modification.

AEs leading to modification of the dosing interval or temporary suspension of treatment occurred in 25 patients (14.5%) in the SC TCZ group and in 22 patients (12.7%) in the IV TCZ group of Study MRA229JP. There were no events with a marked difference in incidence between the two groups.

<div style=\"page-break-after: always\"></div>

AEs  resulting  in  modification  of  the  dosing  interval  occurred  in  5  patients  (15.6%)  in  study MRA227JP. By treatment group, the incidence was 1 patient (12.5%) in the 81 mg q2w group, 1 patient (8.3%) in the 162 mg q2w group and 3 patients (25.0%) in the 162 mg qw group.

## 2.6.1. Discussion on clinical safety

The safety assessment of TCZ SC is based on the two pivotal phase III clinical studies (studies NA25220 and WA22762). This database is further supported by the data from the safety analysis analyses on SC TCZ from a completed Phase Ib study NP22623 in RA patients and two Chugai monotherapy trials, the complete Phase I/II study MRA227JP, and the Phase III study MRA229JP.

Safety  data  from  the  original  Phase  III  clinical  development  program  for  the  intravenous  (IV) dosage form of TCZ in adult RA following 24 weeks of treatment (data submitted as part of initial MAA) are also summarised.

In the pivotal studies a total of 1465 patients were exposed to TCZ SC. This includes patients treated with TCZ SC during the 24 weeks core and the LTE part of study NA25220 and study WA25220 as well as patients who switched from  placebo to TSZ SC in the LTE part of  study NA25220 and who switched from TCZ IV to TCZ SC in study WA25220 LTE. So far 1095 of these patients completed 24 weeks of treatment, 483 patients completed 40 weeks of treatment, and 239 patients have completed 48 weeks of treatment with TCZ SC. This gives a robust database to assess the safety TCZ SC. However the data on the long term safety of TCZ SC are limited, the submission of the final clinical study report for study NA25220 and study WA22762 has been included as milestone in the RMP.

The design of the pivotal study WA22762 further allows a head to head comparison of the safety of  the  requested  dosage  scheme  for  TCZ  SC  and  the  authorised  TCZ  IV  scheme.  In  both treatment groups patients had comparable exposure to the respective treatment. Further, in a smaller population, the preliminary data on the safety of the switch IV-SC and vice versa were provided. Nevertheless the patient population who switched from IV to SC or vice versa is still small. The safety in 'switchers' directly after the switch needs to be further evaluated, especially with regard to hypersensitivity. Long-term safety in patients in the switcher patient population will be further investigated in the BSRBR registry as detailed in the RMP. A statement has also been included in section 4.2 of the SmPC.

In the pivotal studies the overall AE rate until clinical cut-off was comparable in the SC TCZ and TCZ IV groups, and the AE profile of TCZ SC was consistent with the established safety profile of IV TCZ profile with exception of the higher of injection site reaction in the TCZ arm. However the AE rate in Study WA22762 was higher in both groups, TCZ SC and TCZ IV, than in the historical control.

The  MAH  attributed  the  higher  overall  adverse  events  rates  in  study  WA22762  compared  to historical control to partly design issues e.g. open design and thus the knowledge of treatment might have introduced a bias as well as increased interaction between patient and study site due to  weekly  study  drug  applications.  The  second  argument  presented  by  the  MAH  during  the evaluation was not considered acceptable by the CHMP since self-administration of TCZ SC was foreseen if feasible.

The main difference between reported AEs in WA22762 and the historical TCZ IV studies was in the Investigation SOC i.e. ALT increase. Of note, the 24-week analyses of laboratory parameters

<div style=\"page-break-after: always\"></div>

from study WA22672 showed that the shifts in ALT (and similarly AST) were comparable between TCZ SC and TCZ IV treatment arms in study WA22762 and the TCZ IV historical studies. This was considered reassuring by the CHMP.

Another contributing factor to the numerically higher frequency of AEs in study WA22762 versus historical  control  may  be  due  to  AEs  in  the  SOC  General  Disorders  and  Administration  Site Conditions. A higher incidence of these AEs can be expected due to the SC application.

Beyond week 24, at the time of the clinical cut-off of 16 January 2012, the types and overall pattern  of  AEs  occurring  after  SC  TCZ  treatment  were  similar  to  those  for  IV  TCZ  treatment (except for injection site reactions [ISRs]), with no new safety signals identified.

The overall AE rate was higher in the SC TCZ arm of study WA22762 (qw dosing) than in the SC TCZ arm of study NA25220 (q2w dosing). This might be due the higher exposure. Of note, the AE rate in the TCZ SC group in study WA22762 was comparable to the rate in TCZ IV patients. However, comparing all-exposure TCZ SC and all-exposure TCZ IV data a higher incidence of AEs in the TCZ SC patients is observed.

A significant higher AE rate (633.88 (95% CI: 570.93; 701.87) events per 100 PY) was observed in  the  IV-SC  Switch  Arm  as  compared  to  the  SC-IV  Switch  Arm  (300.52  [95%  CI:  213.70; 410.82]  events  per  100  PY).  The  sample  size  however,  is  still  small,  thus  to  data  a  robust conclusion cannot on the clinical significance cannot be drawn.

However, comparing all-exposure TCZ SC and all-exposure TCZ IV data a higher incidence of AEs in the TCZ SC patients is observed.

The most common body system and organ classes in which AEs were reported were: infections and infestations, gastrointestinal disorders and investigations.

The rate of AEs decreases with prolonged treatment duration for both the SC TCZ and the IV TCZ all-exposure populations, however the number of patients completing beyond 36 weeks TCZ SC treatment is still  low.  The  submission  of  the  final  clinical  study  report  for  study  NA25220  and study WA22762 has been included as milestone in the RMP.

According to the study protocol the patients received concomitant DMARDs. However the choice of  the  medication  was  left  to  the  investigator.  It  is  understood  that  the  majority  of  patients received MTX. The MAH was requested during the evaluation to provide an analysis of the safety results regarding concomitant use of DMARDs. The MAH provided post hoc analyses from study NA25220  and  from  study  WA22672  comparing  safety  data  of  patients  taking  TCZ  with  MTX against the overall study population. The safety profile was consistent among patients receiving TCZ with background MTX and the overall study population.

Following 24 weeks of treatment, the incidence of SAEs and the rates of SAEs per 100 PY were very similar between SC TCZ and IV TCZ as well as between the different dose groups (162 mg SC TCZ qw or q2w, IV TCZ doses of 4 or 8 mg/kg q4w) in the pivotal studies and the historical controls.

The  most  common SOC in which SAEs were reported was infections and infestations.  In  both pivotal studies, SAEs in this SOC occurred at similar frequencies in both the SC TCZ and control arms and within the Week 24 analysis and in the long-term extension, with no specific type of event being predominant. However the long term SC exposure is still low, the submission of the

<div style=\"page-break-after: always\"></div>

final  clinical  study  report  for  study  NA25220  and  study  WA22762  has  been  included  as  a milestone in the RMP.

The death rate per 100 PY in the SC TCZ pooled population was 0.56 (95% CI: 0.18, 1.31). This death rate is comparable with the rate observed in the historical IV TCZ all-exposure population of 0.58 (95% CI: 0.41, 0.71).

No patients died during the course of the study MRA227JP, study MRA229JP and study NP22623.

Consistent  with  TCZ  IV,  SC  administration  of  TCZ  induced  a  dose  dependent  decrease  in neutrophil  counts,  with  the  most  notable  change  being  observed  within  the  first  4  weeks  of treatment.

Infections, malignancies,  anaphylaxis, hypersensitivity, ISRs, serious myocardial  infarction events, and serious haemorrhagic and ischemic stroke, were defined as adverse events of special interest. Most of the events occurred with comparable rates in the TCZ SC and TCZ IV group with a few exceptions. The rate of infections was higher under TCZ SC treatment; however the rate for serious infections was comparable. Although the rate of hypersensitivity reactions was low, the rate of serious clinically significant reactions was higher in the TCZ SC group. However no anaphylactic relations occurred under TCZ SC treatment. As expected the in the TCZ SC groups a high rate of injection site reactions were reported.

In both pivotal studies analysis of the key safety parameters by body weight revealed no obvious differences  between  the  treatment  arms  in  the  two  lower  weight  categories,  however  a numerically higher rate of AEs and infections is patients with higher bodyweight of ( ≥ 100kg) was observed in the TCZ SC and IV arms of WA22762 study as well as the historical TCZ IV treatment arm.

Analysis of the baseline and disease characteristics indicated that a higher proportion of patients in the high body weight category have been found to have a history of previous TNF failures, as well as baseline COPD and diabetes contributing to poorer healthy status than in the other weight groups. The CHMP concluded that there is no established exposure-safety relationship between high body weight patients and the occurrence of AEs and SAEs.

Considering the above the analysis suggests that the numerically higher incidence of AEs and infections  is  patients  with  higher  bodyweight  are  triggered  rather  by  comorbidity  than  by  TCZ exposure.

The overall AE rate was higher in the SC TCZ arm of study WA22762 (qw dosing) than in the SC TCZ arm of study NA25220 (q2w dosing) suggesting an exposure related rate of AEs. The MAH was requested during the evaluation to present the AE rates by Cthrough  Quartiles. There was no association between TCZ exposure and AE rates looking at AE rates by Cthrough Quartiles.

Further  events  were  defined  as  events  of  special  interest  such  as  gastrointestinal  perforation, demyelinating  disorders,  serious  hepatic  events,  serious  haemorrhagic  cerebrovascular  events, serious  ischaemic  cerebrovascular  events,  and  serious  bleeding  that  either  did  not  occur  or occurred at a low frequency with TCZ SC.

On 20 December 2013, the MAH reported a needle clogging issue affecting the new pre-filled syringe presentation (see section 2.2.3 Finished Medicinal Product). To further strengthen the mitigation statements already included in the SmPC and PL, the MAH proposed to add some further changes to sections 6.3 and 6.6 of the SmPC and sections 5 and 6 of the PL. The CHMP

<div style=\"page-break-after: always\"></div>

considered the proposed changes suitable to reduce the probability of a clogged syringe due to handling errors. The MAH in addition discussed what happens if a patient uses a pre-filled syringe with such an injection force defect. It was clarified that if a patient attempt to administer an injection with a pre-filled syringe that is clogged, the patient would unlikely be able to expel any drug product from the syringe. The failure mode is considered highly detectable. Assuming a replacement pre-filled syringe is at hand, the dose would not be missed. If no replacement prefilled syringe is available, the dose would be delayed or missed. Results from studies WA22762 and NA25220 indicate that if a patient on the TCZ QW regimen has a single dose missed or delayed or a partial dose of TCZ SC safety would not be affected. The probability of receiving a partial dose from a clogged needle is extremely low as a needle clog is more likely to completely block the needle so no injection can be given. The CHMP concluded that there is no impact on clinical safety due to clogging incidents when using the pre-filled syringe.

With regards to the exceeded limit of the injection time with the pre-filled pen reported by the MAH on 31/01/2014, the MAH withdrew this new presentation on 11 February 2014. The MAH also confirmed their ability to ensure commercial supply of the pre-filled syringe to all rheumatoid arthritis patients once approved and to subjects enrolled in on-going clinical studies.

## 2.6.2. Conclusions on the clinical safety

The safety profile of TCZ SC is comparable with the safety profile of the TCZ IV preparation. No new safety signals were identified.

Comparing  the  two  TCZ  SC  dosage  schemes,  SC  TCZ  q2w  and  SC  TCZ  qw,  the  two  weekly scheme has a slightly favourable safety profile with regard to adverse events, however the rates of adverse events for the SC TCZ qw scheme are still comparable with the rates for the IV TCZ scheme. No such differences were seen with regard to SAEs.

The  data  on  the  long  term  safety  of  TCZ  SC  are  limited  since  only  a  small  patient  number continued treatment beyond week 36. The submission of the final clinical study report for study NA25220 and study WA22762 has therefore been included as milestone in the RMP.

The data suggest that for patients switching from TCZ  IV to TCZ  SC, subcutaneous administration is safe and well-tolerated with the pattern of AEs observed being consistent with the known safety profile of TCZ. However, as the patient population who switched from IV to SC or vice versa is still small, the safety in 'switchers' directly after the switch needs to be further evaluated, especially with regard to hypersensitivity. IgE data following TCZ SC treatment and long-term safety in patients in the switcher patient population will be further investigated in the final CSR for studies NA25220 and WA22762, and in the BSRBR registry respectively as detailed in the RMP.

Following reports of clogging of the needle with the new pre-filled syringe presentation, the MAH proposed changes to the product information in sections 6.3 and 6.6 of the SmPC as well as in the Package Leaflet. This is supported by CHMP. The CHMP concluded that there is no impact on clinical safety due to clogging incidents when using the pre-filled syringe device. With regards to the  exceeded  limit  of  the  injection  time  with  the  pre-filled  pen,  the  MAH  withdrew  this  new presentation.

<div style=\"page-break-after: always\"></div>

## 2.7. Pharmacovigilance

## Detailed description of the Pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

## PRAC Advice

Based on the PRAC review of the Risk Management Plan version 14.2, the PRAC considers by consensus  that  the  risk  management  system  for  tocilizumab  (RoActemra)  in  the  proposed indication:

RoActemra, in combination with methotrexate (MTX), is indicated for the treatment of moderate to  severe  active  rheumatoid  arthritis  (RA)  in  adult  patients  who  have  either  responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoActemra  can  be  given  as  monotherapy  in  case  of  intolerance  to  MTX  or  where  continued treatment with MTX is inappropriate.

RoActemra has been shown to reduce the rate of progression of joint damage as measured by Xray and to improve physical function when given in combination with methotrexate.

could  be  acceptable provided  an  updated  risk  management plan  and  satisfactory  responses  to the questions detailed in this section are submitted.

This advice is based on the following content of the Risk Management Plan:

## · Safety concerns

The MAH identifies the following safety concerns.

<div style=\"page-break-after: always\"></div>

Table 80. Summary of Ongoing Safety Concerns in Adults

| Category                                                                             | Safety Concern                                                                            |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Important Identified Risks                                                           | Serious infection                                                                         |
| Important Identified Risks                                                           | Complications of diverticulitis                                                           |
| Important Identified Risks                                                           | Serious hypersensitivity reactions                                                        |
| Important Identified Risks                                                           | Neutropenia                                                                               |
| Important Potential Risks                                                            | Thrombocytopenia and the potential risk of bleeding                                       |
|                                                                                      | Liver enzyme elevations and bilirubin elevations and the potential risk of hepatotoxicity |
|                                                                                      | Elevated lipid levels and the potential risk of cardiovascular and cerebrovascular events |
|                                                                                      | Neutropenia and the potential risk of infections                                          |
|                                                                                      | Malignancies                                                                              |
|                                                                                      | Demyelinating disorders                                                                   |
|                                                                                      | Immunogenicity                                                                            |
| Important missing information                                                        | Elderly                                                                                   |
| Important missing information                                                        | Paediatric patients                                                                       |
| Important missing information                                                        | Effects during pregnancy                                                                  |
| Important missing information                                                        | Hepatic impairment                                                                        |
| Important missing information                                                        | Renal impairment                                                                          |
| Important missing information                                                        | Combination with biologics                                                                |
| Important missing information                                                        | Safety in patients <60 kg in switcher population                                          |
| Important missing information                                                        | Long-term safety in patients in the switcher patient population                           |
| Important missing information                                                        | lgE data following TCZ SC treatment                                                       |
| Identified and potential interactions including food-drug and drug-drug interactions | CYP450 enzyme normalization                                                               |

<div style=\"page-break-after: always\"></div>

Table 81. Summary of Ongoing Safety Concerns in Paediatric Patients

| Category                   | Safety Concern                     |
|----------------------------|------------------------------------|
| Important Identified Risks | Serious Infection                  |
|                            | Serious hypersensitivity reactions |
|                            | Neutropenia                        |
| Important Potential Risks  | Skeletal development               |
|                            | Immunogenicity                     |
|                            | Malignancies                       |
|                            | CYP450 enzyme normalisation        |

Following the recommendations from the last assessment, the MAH implemented the following measures:

- The MAH addressed the clinical relevance of tocilizumab-specific IgE antibody development following SC administration of tocilizumab as missing information.
- The long-term safety in 'switchers' is included as missing information.
- 'Neutropenia' is classified as an identified risk for all indications.
- The  MAH  does  commit  to  provide  the  final  Clinical  Study  Report  (CSR)  for  study WA22762 in Q2 2014 and for study NA25220 Q3 2014 and has amended the RMP, Part III, Section 10.

The heading 'Important Missing information' must be replaced by 'Missing information'.

## · Pharmacovigilance plans

The following changes of safety concerns were performed:

Table 82. Safety concerns and overview of planned pharmacovigilance actions for All Patients

| Safety Concern   | Proposed Pharmacovigilance Activities (Routine and Additional)                                                                                                                                                                                                                                   | Objective of Proposed Action(s)                                                                                                                                                                                                                                                                                                               |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Neutropenia      | • Study WA29049: a pharmacodynamics study to evaluate neutrophil kinetics and function following tocilizumab treatment in healthy volunteers. • Routine pharmaco- vigilance • Guided questionnaire (post-marketing reports) for events of special interest will collect neutrophil data in cases | Study • To investigate the mechanism whereby the peripheral neutrophil count is reduced Pharmacovigilance • To collect information in a standardized manner and monitor the frequency and nature of neutropenia and the potential risk of serious infection emerging during clinical trials and post-marketing use: • To assess risk compared |

<div style=\"page-break-after: always\"></div>

|                                                                 | of serious infection. • Ongoing clinical trial programme • Epidemiology data: oUS claims database • EU registries (BSRBR, ARTIS, RABBIT)   | with the established safety profile and other conventional and biological DMARDs • To characterize the nature and frequency of the events potentially associated with neutropenia • To assess the effectiveness of risk minimization measures   |
|-----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety of TCZ SC in patients < 60 kg in the switcher population | • Routine pharmacovigilance • Epidemiology data: EU registry (BSRBR)                                                                       | To monitor the safety of TCZ SC in patients < 60 kg                                                                                                                                                                                             |
| Long-term safety in switcher patient population                 | • Routine pharmacovigilance • Epidemiology data: EU registry (BSRBR)                                                                       | To monitor long-term safety in switcher patient population                                                                                                                                                                                      |
| IgE data following TCZ SC treatment                             | • Routine pharmacovigilance • Studies WA22762 and NA25220 • Epidemiology data: EU registry (BSRBR)                                         | To monitor the longer-term immunogenicity following TCZ SC treatment                                                                                                                                                                            |

## · Risk minimisation measures

The changes of the updated RMP version in this section are as follows (see table below):

Table 83. Summary table of Risk Minimisation Measures

| Safety concern   | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Additional risk minimisation measures                                        |
|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Neutropenia      | Identically equal to the potential risk: 'Neutropenia and the potential risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Identically equal to the potential risk: 'Neutropenia and the potential risk |
| Immunogenicity   | of Infection' SPC SPC section 4 .8. Undesirable effects Immunogenicity A total of 2,876 patients have been tested for anti- tocilizumab antibodies in the 6- month controlled clinical trials. Of the 46 patients (1.6%) who developed anti- tocilizumab antibodies, 6 had an associated medically significant hypersensitivity reaction, of which 5 led to permanent discontinuation of treatment. Thirty patients (1.1%) developed neutralising antibodies. In SC-I, a total of 625 patients treated with tocilizumab 162 mg weekly were tested for anti- tocilizumab antibodies in the 6-month controlled period. Five patients (0.8%) developed positive anti-tocilizumab antibodies; of these, all developed neutralizing anti-tocilizumab antibodies. One patient was tested positive for | None proposed                                                                |

<div style=\"page-break-after: always\"></div>

| Safety concern                                      | Routine risk minimisation measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Additional risk minimisation measures   |
|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
|                                                     | IgE isotype (0.2%). In SC-II, a total of 434 patients treated with tocilizumab 162mg every other weekly were tested for anti-tocilizumab antibodies in the 6-month controlled period. Seven patients (1.6%) developed positive anti-tocilizumab antibodies; of these, six (1.4%) developed neutralizing anti- tocilizumab antibodies. Four patients were tested positive for IgE isotype (0.9%). No correlation of antibody development to clinical response or adverse events was observed. IV RoActemra SPC only Immunogenicity sJIA: All 112 patients were tested for anti-tocilizumab antibodies at IV RoActemra SPC only baseline. Two patients developed positive anti-tocilizumab antibodies with one of these patients having a hypersensitivity reaction leading to withdrawal. The incidence of anti-tocilizumab antibody formation might be underestimated because of interference of tocilizumab with the assay and higher drug concentration observed in children compared to adults. pJIA: One patient in the 10 mg/kg < 30kg group developed positive anti-tocilizumab antibodies without developing a hypersensitivity reaction and |                                         |
| Safety in patients <60 kg in switcher population    | subsequently withdrew from the study. SPC SPC section 5.1 Pharmacodynamic properties Subcutaneous Use Clinical efficacy Switching from 8 mg/kg intravenous once every 4 weeks to 162 mg subcutaneous once every week, will alter exposure in the patient. The extent varies with the patient's body weight (increased in light body weight patients and decreased in heavy body weight patients) but clinical outcome is consistent with that observed in intravenous treated patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Not applicable                          |
| Long-term safety in the switcher patient population | subsequently withdrew from the study. SPC SPC section 5.1 Pharmacodynamic properties Subcutaneous Use Clinical efficacy Switching from 8 mg/kg intravenous once every 4 weeks to 162 mg subcutaneous once every week, will alter exposure in the patient. The extent varies with the patient's body weight (increased in light body weight patients and decreased in heavy body weight patients) but clinical outcome is consistent with that observed in intravenous treated patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Not applicable                          |

Following  consideration  of  the  RMP  by  the  PRAC,  the  MAH  provided  an  updated  RMP  (version 14.3) to address the issues that had been identified during the PRAC assessment of the RMP.

This  included  the  following  updated  tables  with  the  summary  of  safety  concerns  and  the proposed risk minimisation measures.

<div style=\"page-break-after: always\"></div>

## · Safety concerns

## Table 84. Summary of Ongoing Safety Concerns in Adults

| Category                                                                             | Safety Concern                                                                            |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Important Identified Risks                                                           | Serious infection                                                                         |
| Important Identified Risks                                                           | Complications of diverticulitis                                                           |
| Important Identified Risks                                                           | Serious hypersensitivity reactions                                                        |
| Important Identified Risks                                                           | Neutropenia                                                                               |
| Important Potential Risks                                                            | Thrombocytopenia and the potential risk of bleeding                                       |
|                                                                                      | Liver enzyme elevations and bilirubin elevations and the potential risk of hepatotoxicity |
|                                                                                      | Elevated lipid levels and the potential risk of cardiovascular and cerebrovascular events |
|                                                                                      | Neutropenia and the potential risk of infections                                          |
|                                                                                      | Malignancies                                                                              |
|                                                                                      | Demyelinating disorders                                                                   |
|                                                                                      | Immunogenicity                                                                            |
| Missing information                                                                  | Elderly                                                                                   |
| Missing information                                                                  | Paediatric patients                                                                       |
| Missing information                                                                  | Effects during pregnancy                                                                  |
| Missing information                                                                  | Hepatic impairment                                                                        |
| Missing information                                                                  | Renal impairment                                                                          |
| Missing information                                                                  | Combination with biologics                                                                |
| Missing information                                                                  | Safety in patients <60 kg in switcher population                                          |
| Missing information                                                                  | Long-term safety in patients in the switcher patient population                           |
| Missing information                                                                  | lgE data following TCZ SC treatment                                                       |
| Identified and potential interactions including food-drug and drug-drug interactions | CYP450 enzyme normalization                                                               |

<div style=\"page-break-after: always\"></div>

## · Pharmacovigilance plan

## Table 85. On-Going and Planned Studies in the Post-Authorisation Pharmacovigilance Development Plan

| Study/activity Type, title and category (1-3)                        | Objectives                                                                                            | Safety concerns addressed                                                                                                           | Status                                              | Date for submission of interim orfinal reports   |
|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------|
| WA22479 (British Society of Rheumatology Biologics Register [BSRBR]) | Prospectiveobservational cohort studiesforsafety datacollection.                                      | GeneralsafetyprofileofTCZ; Safetyof TCZSCinpatients<60kg in the switcher population Long-term safety in switcher patient population | Ongoing                                             | Annual updates to be provided in PSUR            |
| WA22480 (ARTIS) registry study                                       | Toprovidelongtermsafetydatafrom the useof TCZinSwedenforRA patients                                   | GeneralsafetyprofileofTCZ; Safetyof TCZSCinpatients<60kg in the switcher population Long-term safety in switcher patient population | Ongoing                                             | Annual updates to be provided in PSUR            |
| GA28719(RABBIT)                                                      | Thelong-termobservationof treatment with biologics in RA (RABBIT) in German biologics registry        | GeneralsafetyprofileofTCZ; Safetyof TCZSCinpatients<60kg in the switcher population Long-term safety in switcher patient population | Ongoing                                             | Annual updates to be provided in PSUR            |
| Pregnancy registry (GA28720 [0TIS])                                  | To evaluate pregnancy outcomes for womenexposed toTCZduring pregnancy                                 | GeneralsafetyprofileofTCZ; Safetyof TCZSCinpatients<60kg in the switcher population Long-term safety in switcher patient population | Ongoing                                             | Annual updates to be provided in PSUR            |
| Paediatric Registry (name to be confirmed)                           | To be finalized                                                                                       | Safety in pediatric patients                                                                                                        | Protocol of registry to be availableby12 March 2014 | Implementation datetobe confirmed June 2013      |
| WA18696extension                                                     | Longtermextensionstudyofsafety during treatment with TCZ in patients completingtreatmentincorestudies | General safetyprofileof TCZ                                                                                                         | Ongoing                                             | Final CSR Q3 2013                                |

| Study/activity Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Safetyconcernsaddressed       | Status    | Date for submission of interim orfinal reports   |
|-------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-----------|--------------------------------------------------|
| WA18221 (sJIA)                                  | Part l:toevaluatetheefficacy and safetyofTCZinpatientswithactive systemic juvenile idiopathic arthritis (SJIA); Part ll: to examine the effect (in completersofPart I)of longtermuse of TCZ on: ·Safety(including immunogenicity); ·Efficacy(including assessment of joint counts andobjective measurements includinghsCRP, fever, hemoglobin); ·ability to reduce corticosteroid dosage to clinically significant levels; ·Resumption of growth (as determined by growth velocity) | General safety profile of TCZ | Ongoing   | Final CSR Q4 2014                                |
| WA19977 (pJIA)                                  | Toevaluatetheefficacyandsafetyof TCZinpatientswith active polyarticularjuvenilerheumatoid arthritis                                                                                                                                                                                                                                                                                                                                                                                 | General safety profile of TCZ | Ongoing   | Final CSR Q3 2013                                |
| NP22775                                         | To investigate theeffect of TCZonthe pharmacokinetics and pharmacodynamicsofanoral contraceptive infemalepatients with active rheumatoid arthritis                                                                                                                                                                                                                                                                                                                                  | CYP450enzymenormalisation     | Completed | Final CSR August 2012                            |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category(1-3)   | Objectives                                                                                                                                          | Safety concernsaddressed                                   | Status                | Date for submission of interim or final reports              |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|-----------------------|--------------------------------------------------------------|
| WA28029                                        | To evaluate decreased dose frequency in patients with sJIA who experience laboratory abnormalities during treatment with TCZ                        | Safetyinpediatricpatients                                  | Ongoing               | Projected first patient first visit June 2013 Final CSR 2016 |
| NP25737                                        | Apharmacokineticandsafetystudyof TCZ in patients less than 2 years old with active sJIA                                                             | Safety profile in pediatric patients less than 2 years old | Ongoing               | Data available Q32013                                        |
| MA21488RA                                      | Evaluationof threetreatment strategiesbased onTCZand/or methotrexate inpatientswith activeRA whohaveinadequatelyresponded to prior DMARD treatment. | Immunogenicity                                             | Ongoing               | Data available Q42013                                        |
| WA29049                                        | Pharmacodynamicsstudytoevaluate neutrophil kinetics and function following tocilizumabtreatment in healthyvolumteers                                | Neutropenia and thepotential riskof infection              | Study in set up phase | October 2014                                                 |

| Study/activity Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Safetyconcerns addressed                                                                                                                                                                                       | Status   | Date for submission of interim orfinal reports   |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------|
| WA22762                                         | Toassess: Theefficacyof treatmentwith162 mg tocilizumab (TCZ) given subcutaneously(SC)weekly versus8mg/kgTCZgiven intravenously(IV)every4weeks withregard tonon-inferiorityof the proportion ofpatientswho achieve ACR20atWeek24. Thesafetyof treatment with162 mgTCZgivenSCweeklyversus8 mg/kgTCZgiven IVevery4 weeks, with regard to AEs and laboratoryassessments. Secondary Objectives: Long-term safety and efficacy Pharmacokinetics(PK)and pharmacodynamics (PD) of TCZ following SC administration Immunogenicity of TCZ following SC administration Effectof IVtoSCswitchonthe safety,efficacy,PKandPDofTZ | Safetywillbeassessedusingreporting of AEs,clinical laboratoryresults (hematology, chemistry, lipid profiles, liver function, immunogenicity [including IgE data], etc.), physical examination and vital signs. | Ongoing  | Q22014                                           |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Safety concerns addressed                                                                                                                                                                                         | Status   | Date for submission of interim orfinal reports   |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--------------------------------------------------|
| NA25220                                         | Toassess: Efficacy of treatmentwith tocilizumab(TCZ)162mgSC versusplacebogiveneveryother week(q2w),incombinationwith DMARDs, at Week 24 using ACR20. SafetyoftreatmentwithTCZ162 mgSCversusplacebogivenevery other week(q2w),in combination withDMARDs,withregard to adverse events (AEs) and laboratory assessments. SECONDARY Prevention ofprogression of structural joint damage at Week 24 andWeek48 Improvementofphysicalfunction Long-termsafety andefficacy Pharmacokinetics (PK) and pharmacodynamics(PD)of TCZ following SC administration Immunogenicity of TCZ following SC administration. | Safety will be assessed using reporting of AEs,clinical laboratoryresults (hematology, chemistry, lipid profiles, liverfunction,immunogenicity [including IgE data], etc.), physical examination and vital signs. | Ongoing  | Q32014                                           |

The other issues raised in the PRAC assessment of the RMP were also adequately addressed in the updated RMP (version 14.4) provided by the MAH including the removal of new pre-filled pen presentation.

The CHMP endorsed this advice without changes.

The  CHMP,  having  considered  the  data  submitted,  was  of  the  opinion  that  Pharmacovigilance activities in addition to the use of routine Pharmacovigilance are needed to investigate further some of the safety concerns:

| Description                                                                       | Due date          |
|-----------------------------------------------------------------------------------|-------------------|
| Submission of the final clinical study report for study NA25220                   | 30 September 2014 |
| Submission of the final clinical study report for study WA22762                   | 30 June 2014      |
| Submission of a revised protocol for the EU BSRBR registry (study WA22479) study) | 30 June 2014      |

## 2.9. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

TCZ  IV  in  combination  with  methotrexate  (MTX)  is  an  established  treatment  option  for  adult patients with RA. In study WA22762 the non-inferiority of TCZ 162mg SC qw to TCZ 8mg/kg IV q4w  in  terms  of  efficacy  was  demonstrated.  The  primary  objective  demonstrating  the  noninferiority of TCZ SC qw over TCZ IV q4w with regard to ACR 20 response rate at week 24 was met  (study  NA25220).  These  results  are  supported  by  the  secondary  objectives,  comparable response rates were observed for e.g. ACR 50/ 70 response.

## Uncertainty in the knowledge about the beneficial effects

The  clinical  cut-off  date  of  for  the  extension  phase  study  WA22762  LTE  allowing  for  a  switch between IV and SC application was 16 January 2012. The efficacy of TCZ 162 mg SC qw was maintained after the 24-week double-blind period of the study. However the ACR response rate in the SC-IV switch arm was lower than in the other arms, at various time points, including week 24. Since the sample size is limited, no robust conclusion could be drawn. Long-term safety in patients in the switcher patient population will be further investigated in the BSRBR registry as detailed in the RMP.

Notable  difference  in  response  was  seen  in  the  analysis  by  bodyweight.  ACR  20,  50  and  70 response rates indicated a comparable response rate in the TCZ SC treatment group for all 3 parameters in the &lt; 60 kg and in the 60 to &lt; 100kg, whereas patients in the &gt; 100 kg showed lower  response  rate  for  these  parameters.  Interestingly,  for  ACR  50  and  70  response  in  the highest body weight group was lower for the weight adjusted IV TCZ treatment than for the fixed SC TCZ dose.  A statement has been included in section 5.1 of the SmPC regarding the impact of switching from IV to SC on exposure particularly in light and heavy body weight patients.

On 20 December 2013, the MAH reported a needle clogging issue affecting the new pre-filled syringe  presentation  (see  section  2.2.3  Finished  Medicinal  Product).  To  further  strengthen  the mitigation statements already included in the SmPC and PL, the MAH proposed changes to the product information  in  sections  6.3  and  6.6  of  the  SmPC  as  well  as  in  the  Package  Leaflet  in sections 5 and 6 (Instructions for Use Steps 2 and 5). This is supported by CHMP.

Overall  it  was  concluded  that  the  data  indicate  that  clogging  incidents,  including  clogging incidents prior to cap removal, are very rare events. Furthermore, the risk assessment provided by  the  MAH  indicated  that  if  in  the  very  rare  event  a  patient  were  to  attempt  to  perform  an injection using  a pre-filled syringe  or pre-filled pen  with  a  clogged  needle,  it is highly unlikely there would be any impact on clinical efficacy or safety.

The CHMP concluded that there is no impact on clinical efficacy due to clogging incidents when using the pre-filled syringe device.

With regards to the exceeded limit of the injection time with the pre-filled pen reported by the MAH on 31/01/2014, the MAH withdrew this new presentation on 11 February 2014. The MAH also  confirmed  their  ability  to  ensure  commercial  supply  of  the  pre-filled  syringe  to  all rheumatoid arthritis patients once approved and to subjects enrolled in on-going clinical studies.

<div style=\"page-break-after: always\"></div>

## Risks

## Unfavourable effects

The unfavourable effects of TCZ are established and include infection, gastro-intestinal disorders, infusion reactions, skin disorders, neutropenia, elevation in hepatic enzymes and lipid parameters.

No new safety signals were identified with the new route of administration. The AE profiles of TCZ 162 mg SC qw and q2w are consistent with the known safety profile of TCZ IV with a few exceptions.

The  rate  of  infections  was  higher  under  TCZ  SC  treatment;  however  the  rate  for  serious infections was comparable. Although the rate of hypersensitivity reactions was low, the rate of serious clinically significant reactions was higher in the TCZ SC group; however no anaphylactic relations occurred under TCZ SC treatment. As expected high rate of injection site reactions were reported in the TCZ SC groups. A numerically higher incidence of Grade 1 and 2 neutropenia (not Grade 3 or 4) and ALT elevations to  below  3×  ULN  were  found  with the  TCZ  SC  162  mg  qw dosing regimen compared with the TCZ SC 162 mg q2w regimen. However, the rates of these laboratory abnormalities with the qw regimen were comparable to those seen in the pooled TCZ 8 mg/kg IV pivotal data (as well as the 8 mg/kg IV arm of study WA22762).

Injection site reactions (ISRs) were only described in the TCZ SC groups. The incidence of ISRs was also comparable between the TCZ SC qw (10.1%) and q2w (7.1%) regimens and within the range reported for other biologics.

Further events characterising the safety profile of TCZ  e.g. gastrointestinal perforation, demyelinating  disorders,  serious  hepatic  events,  serious  haemorrhagic  cerebrovascular  events, serious  ischaemic  cerebrovascular  events,  and  serious  bleeding  that  either  did  not  occur  or occurred at a low frequency with TCZ SC.

## Uncertainty in the knowledge about the unfavourable effects

The long term safety of TCZ SC is limited. Especially safety regarding potential or identified risks such  as  gastrointestinal  perforation,  demyelinating  disorders,  serious  hepatic  events,  serious haemorrhagic  cerebrovascular  events,  serious  ischaemic  cerebrovascular  events,  and  serious bleeding should be further established (as mentioned in the RMP).

The data suggest that for patients switching from TCZ  IV to TCZ  SC, subcutaneous administration is safe and well-tolerated with the pattern of AEs observed being consistent with the known safety profile of TCZ. However the patient population who switched from IV to SC or vice  versa  is  still  small,  the  safety  in  'switchers'  directly  after  the  switch  needs  to  be  further evaluated, especially with regard to hypersensitivity. Long-term safety in patients in the switcher patient population will be further investigated in the BSRBR registry as detailed in the RMP. A statement has also been included in section 4.2 of the SmPC.

A numerically higher rate of AEs and infections is patients with higher bodyweight of ( ≥ 100kg) was observed in the TCZ SC and IV arms of WA22762 study as well as the historical TCZ IV

<div style=\"page-break-after: always\"></div>

treatment arm. Higher rates for AEs and infections were observed in heavier patients ( ≥ 100 kg), consistent  for  TCZ  SC  and  TCZ  IV,  however,  the  number  of  patients  in  the  highest  weight category was small.

On 20 December 2013, the MAH reported a needle clogging issue affecting the new pre-filled syringe  presentation  (see  section  2.2.3  Finished  Medicinal  Product).  To  further  strengthen  the mitigation statements already included in the SmPC and PL, the MAH proposed changes to the product information  in  sections  6.3  and  6.6  of  the  SmPC  as  well  as  in  the  Package  Leaflet  in sections 5 and 6 (Instructions for Use Steps 2 and 5). This is supported by CHMP.

Overall  it  was  concluded  that  the  data  indicate  that  clogging  incidents,  including  clogging incidents prior to cap removal, are very rare events. Furthermore, the risk assessment provided by  the  MAH  indicated  that  if  in  the  very  rare  event  a  patient  were  to  attempt  to  perform  an injection using  a pre-filled syringe  or pre-filled pen  with  a  clogged  needle,  it is highly unlikely there would be any impact on clinical efficacy or safety.

The CHMP concluded that there is no impact on clinical safety due to clogging incidents when using the pre-filled syringe device.

With regards to the exceeded limit of the injection time with the pre-filled pen reported by the MAH on 31/01/2014, the MAH withdrew this new presentation on 11 February 2014. The MAH also  confirmed  their  ability  to  ensure  commercial  supply  of  the  pre-filled  syringe  to  all rheumatoid arthritis patients once approved and to subjects enrolled in on-going clinical studies.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Rheumatoid  arthritis  is  a  chronic  inflammatory  and  potentially  disabling  chronic  systemic inflammatory  disease,  characterised  by  inflammation  of  the  synovium  leading  to  irreversible destruction of the joints and disability. An established treatment option for patients with adult RA is TCZ IV in combination with MTX. However IV infusion requires administration by a healthcare professional (HCP) in a clinical setting, which affects the quality of life of the patient.

The SC formulation will be a valid option for patients. From the medical point of view, one benefit of  the  SC  route  of  administration  is  that  it  does  not  require  an  IV  access,  which  is  especially important for patients with poor venous access. The shorter administration time and the option to  receive  the  treatment  independent  for  a  HCP  are  additional  advantages  of  the  SC  route compared to the IV route.

The unfavourable effects of TCZ are established and include infection, gastro-intestinal disorders, infusion reactions, skin disorders, neutropenia, elevation in hepatic enzymes and lipid parameters.

Following reports of clogging of the needle with the new pre-filled syringe presentation, the MAH proposed changes to the product information in sections 6.3 and 6.6 of the SmPC as well as in the Package Leaflet in sections 5 and 6 (Instructions for Use Steps 2 and 5). This is supported by CHMP. The CHMP concluded that there is no impact on clinical efficacy or safety due to clogging

<div style=\"page-break-after: always\"></div>

incidents  when  using  the  pre-filled  syringe  device.  With  regards  to  the  exceeded  limit  of  the injection time with the pre-filled pen, the MAH withdrew this new presentation.

## Benefit-risk balance

## Discussion on the benefit-risk balance

TCZ  IV  in  combination  with  methotrexate  (MTX)  is  an  established  treatment  option  for  adult patients with RA. For the proposed dose regimen of TCZ via the SC route, non-inferiority to the established TCZ IV regimen was demonstrated with a comparable safety profile. The risks are well addressed in the SmPC and appropriate additional Pharmacovigilance and risk minimisation activities are included in the RMP.

## 4. Recommendations

## Outcome

Based  on  the  CHMP  review  of  data  on  quality,  safety  and  efficacy,  the  CHMP  considers  by consensus that the risk-benefit balance of RoActemra 162 mg solution for injection in a pre-filled syringe (subcutaneous injection) in the treatment of:

RoActemra, in combination with methotrexate (MTX), is indicated for the treatment of moderate to  severe  active  rheumatoid  arthritis  (RA)  in  adult  patients  who  have  either  responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. In these patients, RoActemra  can  be  given  as  monotherapy  in  case  of  intolerance  to  MTX  or  where  continued treatment with MTX is inappropriate.

## RoActemra has been shown to reduce the rate of progression of joint damage as measured by Xray and to improve physical function when given in combination with methotrexate.

is favourable and therefore recommends  the granting of the marketing authorisation.

## Conditions or restrictions regarding supply and use

Medicinal  products  on  'restricted'  medical  prescription,  reserved  for  use  in  certain  specialised areas (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the Marketing Authorisation

- Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance  with  the  requirements  set  out  in  the  list  of  Union  reference  dates  (EURD  list) provided  for  under  Article  107c(7)  of  Directive  2001/83/EC  and  published  on  the  European medicines web-portal.

## Conditions  or  restrictions  with  regard  to  the  safe  and  effective  use  of  the  medicinal product

- Risk Management Plan (RMP)

<div style=\"page-break-after: always\"></div>

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed  RMP  presented  in  Module  1.8.2  of  the  Marketing  Authorisation  and  any  agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever  the  risk  management  system  is  modified,  especially  as  the  result  of  new information  being  received  that  may  lead  to  a  significant  change  to  the  benefit/risk profile  or  as  the  result  of  an  important  (pharmacovigilance  or  risk  minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

## · Additional risk minimisation measures

The  Marketing  Authorisation  Holder  (MAH)  shall  provide  an  educational  pack  covering  the therapeutic  indications  of  RA,  targeting  all  physicians  who  are  expected  to  prescribe/use RoActemra containing the following:

- Physician Information Pack
- Nurse Information Pack
- Patient Information Pack.

The  MAH  must  agree  the  content  and  format  of  the  educational  material,  together  with  a communication  plan, with the national competent  authority prior to distribution of the educational material.

The Physician Information pack should contain the following key elements:

- The Summary of Product Characteristics
- Risk of serious infections
- The product must not be given to patients with active or suspected infection
- The product may lessen signs and symptoms of acute infection delaying the diagnosis
- Serious injection/infusion reaction and their management
- Serious hypersensitivity reactions and their management
- Risk of gastrointestinal perforations especially in patients with history of diverticulitis or intestinal ulcerations
- Reporting of serious adverse reactions
- The Patient Information Packs (to be given to patients by healthcare professionals).

The Nurse Information Pack should contain the following key elements:

- Prevention of medical errors and injection/infusion reactions
- Preparation of injection/infusion

<div style=\"page-break-after: always\"></div>

- Monitoring of the patient for injection/infusion reactions and hypersensitivity reactions
- Reporting of serious adverse reactions.

The Patient Information Pack should contain the following key elements:

Package leaflet with instructions for use (with instructions for use for SC)

- Patient alert card

-  to  address  the  risk  of  getting  infections  which  can  become  serious  if  not  treated.  In addition, some previous infections may reappear.

-  to  address  the  risk  that  patients  using  RoActemra  may  develop  complications  of diverticulitis which can become serious if not treated.

- to address the risk of allergic reactions.

## Conditions  or  restrictions  with  regard  to  the  safe  and  effective  use  of  the  medicinal product to be implemented by the Member States.

Not applicable.